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Trypanosoma brucei is a protistan parasite of mammals that evades its host’s 
immune responses by antigenic variation, which in T. brucei involves the 
periodic switching of the Variant Surface Glycoprotein (VSG) coat to 
antigenically distinct variants. The T. brucei genome contains a huge archive of 
silent VSG genes that are expressed from specialised expression sites, only one 
of which is actively transcribed at any one time. Copying of silent VSG genes into 
the active expression site has been shown to occur by homologous 
recombination, as mutation of the RAD51 recombinase and a distantly related 
gene, RAD51-3, impairs this process. BRCA2 is a protein that binds and regulates 
the function of Rad51 during homologous recombination. Mutation of BRCA2 in 
bloodstream form T. brucei leads to increased sensitivity to DNA damaging 
agents, and impairments in homologous recombination, RAD51 subnuclear foci 
formation and VSG switching, suggesting that it too acts in recombination-repair 
and antigenic variation. Beyond these phenotypes, an accumulation of putative 
gross chromosomal rearrangements in the megabase chromosomes of the T. 
brucei genome and a novel replication phenotype were also observed, and the 
basis of both these processes was unclear. T. brucei BRCA2 is highly unusual 
relative to orthologues in other eukaryotes, as the protein contains an expansion 
in the number of RAD51-binding BRC repeat motifs, which are arranged in a 
tandem repeat array that has not been observed elsewhere. 
In order to examine the function of BRCA2 in the maintenance of genome 
stability in T. brucei, brca2 homozygous mutants were generated in procyclic 
form TREU 927 and Lister 427 cells. Analysis of genomic stability by Southern 
blotting and pulsed field agarose gel electrophoresis revealed that BRCA2’s 
function in the maintenance of genome stability appears to be either 
bloodstream form-specific, or plays a more substantial role in this life cycle 
stage. To examine the function of the BRC repeat expansion, cell lines 
containing variants of BRCA2 with reduced numbers of BRC repeats were 
generated, expressed in brca2 homozygous mutants and phenotype analysis 
carried out. Growth and DNA repair were restored by the expression of virtually 
all variants, suggesting the BRC repeat expansion is not an adaptation for 
general genome maintenance, though the repair activity of a variant with a 
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single BRC repeat appeared to differ between bloodstream and procyclic form 
parasites. In contrast to this, a striking correlation between BRC repeat number 
and the regulation of RAD51 subnuclear dynamics was observed, showing that 
the BRC array expansion has important functional significance. 
GST pull-down analysis was used to examine the domains of T. brucei BRCA2 that 
interact with RAD51, revealing an extent of interaction not apparent in BRCA2 
orthologues in other organisms. This complexity of interaction was further 
analysed by immunolocalisation of BRCA2 and RAD51, before and after DNA 
damage, which showed potentially dynamic co-localisation of the two repair 
factors. Finally, a putative interaction between T. brucei BRCA2 and CDC45 was 
tested both in vitro and in vivo, but could not be validated, suggesting it does 
not provide an explanation for the replication defects observed in bloodstream 
form brca2-/- mutant cells. All of the analyses above shed light on the function 
of the BRCA2 protein in the regulation of homologous recombination in T. 
brucei. 
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1.1 General Introduction to Trypanosoma brucei 
1.1.1 Phylogeny of Trypanosoma 
Recent advances in molecular phylogenetics have allowed the division of 
Eukaryotes into five supergroups: Excavata, Chromalveolata, Archaeplastida, 
Amoebozoa and Opisthokonta (Adl et al., 2005;Hampl et al., 2009). This new 
grouping places many protistan parasites, including members of the genera 
Trypanosoma, Leishmania, Trichomonas and Giardia, in the Excavata supergroup 
(Figure 1-1;Dacks, Walker, and Field, 2008). Trypanosoma belong to the family 
Trypanosomatidae, which contains at least nine genera, including Leishmania. 
Trypanosomatids are members of the order Kinetoplastidae, which are 
characterised by the possession of a complex catenated network of 
mitochondrial DNA circles organised in a disc-like structure called the 
kinetoplast (Lukes et al., 2002). Kinetoplastids are members of the phylum 
Euglenoza. Thus, the taxonomic ranks for Trypanosoma are as follows: 
supergroup, Excavata; phylum, Euglenozoa; order, Kinetoplastidae; family, 
Trypanosomatidae and genus, Trypanosoma (Simpson, Stevens, and Lukes, 
2006). Much of our understanding of fundamental molecular biology in 
eukaryotes comes from studies of yeasts, metazoa and plants. Relative to this, 
less work has considered protozoan organisms, though it is clear that many key 
processes, such as transcription and mitochondrial biology, are diverged (i.e. 
extensive trans-splicing, multigene transcription units, kinetoplast DNA structure 
and extensive mRNA editing). Given these aspects of divergence, it is of interest 
to consider whether the processes that control genome stability display similar 
divergence, either because of evolutionary distance or because of the needs of a 
parasitic lifestyle. In this regard, Trypanosoma are a key organism of study, as 
extensive tools for genetic manipulation are available. 
The genus Trypanosoma includes both American and African trypanosome 
species. Trypanosoma cruzi is an intracellular parasite of mammals, which 
causes Chagas disease in South America. In contrast, members of the African 
Salivarian branch of trypanosomes are extracellular parasites of mammals mainly 
found in sub-saharan Africa, and include Trypanosoma congolense, Trypanosoma 
vivax and Trypanosoma brucei, which cause Human African Trypanosomiasis 
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(HAT; also called Sleeping Sickness) in humans and Nagana in domestic cattle 
and horses. 
 
Figure 1-1 A phylogenetic tree of the six supergroups that have been proposed within the 
kingdom eukarya. 
The supergroups are named and indicated by shaded lozenges. Taxon supergroups are 
colour-coded and parasitic taxa are in bold. Trypanosoma brucei is indicated by a red circle. 
Taxa represented are Dd; Dictyostelium discoidium, Ec; Encephalitozoon cuniculi, Eg; 
Euglena gracilis, Eh; Entamoeba histolytica, Gi; Giardia intestinalis, Lm; Leishmania major, 
Pf; Plasmodium falciparum, Pr; Phytophthora ramorum, Tb; Trypanosoma brucei, Tg; 
Toxoplasma gondii, Tp; Thalassiosira pseudonana, Tt; Tetrahymena thermophila and Tv; 
Trichomonas vaginalis. Figure reproduced from Dacks, Walker, and Field, 2008. 
1.1.2 Disease, symptoms and treatment  
Trypanosoma brucei is the only African trypanosome that infects humans, and is 
divided into three morphologically identical sub-species: T. b. brucei, T. b. 
gambiense and T. b. rhodesiense. These sub-species classifications are based on 
geographical distribution, host specificity and the course of infection in humans. 
T. b. brucei is unable to establish human infections, in part because it is 
susceptible to lysis by apolipoprotein L1 (ApoL1), a component of trypanolytic 
factor (TLF) found in human serum (Pays et al., 2006). T. b. brucei infects 
domestic cattle and horses causing the wasting disease Nagana. T. b. gambiense 
and T. b. rhodesiense have developed resistance to human trypanolysis; in T. b. 
rhodesiense through the expression of the serum resistance-associated (SRA) 
gene (Xong et al., 1998;Oli et al., 2006), and in T. b gambiense through SRA-
independent resistance to lysis by ApoL1 and, in some strains, reduced uptake of 
TLF (Kieft et al., 2010;Capewell et al., 2011). The clinical course of HAT differs 
depending on which of these sub-species is involved (Turner et al., 2004). T. b. 
gambiense causes a chronic form of HAT in west and central Africa, whereas T. 
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b. rhodesiense causes a more acute form of the disease in east and southern 
Africa (Hoare, 1973). 
African trypanosomes are extracellular parasites, which proliferate in the tissue 
fluids and bloodstream of their mammalian host. The early-stage of the disease 
is characterised by fever, anaemia, lack of appetite and wasting caused by 
inflammation and necrosis within the capillaries of major organs (Vickerman, 
1985). If the infection is allowed to progress, the parasites eventually cross the 
blood brain barrier. This late-stage infection is characterised by motor and 
sensory disorders, sleep disturbances, followed by seizures and finally coma. If 
untreated, Human African Trypanosomiasis is always fatal (Barrett et al., 
2003;Sternberg, 2004;Barrett et al., 2007). 
In 1995, the World Health Organisation (WHO) estimated that 60 million people 
were at risk of HAT, with an estimated 300,000 new cases per year, with fewer 
than 30,000 cases diagnosed and treated (WHO, 1995). In 2004, a review of the 
figures on HAT showed the number of new reported cases falling to 17,616 with 
an estimated cumulative rate of between 50,000 and 70,000 cases (WHO, 2004), 
and this decrease is thought to be due to increased control. 
Only four drugs are registered for the treatment of HAT, and all are associated 
with side effects and an increasing rate of treatment failure (Barrett et al., 
2003;Kennedy, 2004). Pentamidine is used for the treatment of early-stage T. b. 
gambiense infections and is a diamidine compound. Some of the observed side 
effects include nephrotoxicity and pancreatic damage. Suramin is a colourless 
analog of the trypanocidal dye trypan blue and is used for the treatment of 
early-stage T. b. rhodesiense infections. Some of the observed side effects are 
heavy proteinuria, exfoliative dermatitis, severe diarrhoea and prolonged high 
fever. Melarsoprol is an organic arsenical compound that has the ability to enter 
the central nervous system, making it a suitable drug for treating late-stage 
cases of T. b. gambiense and T. b. rhodesiense infections. Fatalities have been 
known to occur in ~ 8% of cases with this treatment, but the most common side 
effects include headache, tremor, slurring of speech and convulsions. Finally, 
eflornithine is used for the treatment of both early- and late-stage T. b. 
gambiense infections. It is an ornithine derivative that acts by inhibiting the 
enzyme ornithine decarboxylase, which is involved in polyamine synthesis in 
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trypanosomes. The most common side effects include diarrhoea, anaemia, 
leukopenia, and convulsions. In 2009, the WHO added the combination therapy 
of eflornithine and nifurtimox, which is used to treat American Trypanosomiasis 
(Chagas disease), to its list of essential medicines. This has reduced the duration 
of eflornithine monotherapy and, hopefully, the onset of drug resistance. 
1.1.3 The life cycle of T. brucei 
T. brucei is transmitted between mammals by the tsetse fly (Glossina sp) (Cross, 
2001;Steverding, 2008), and employs a complex life cycle to allow development 
within both the mammalian host and fly vector. These organisms provide 
contrasting environments and the parasite has evolved several distinct life cycle 
stages adapted to their respective hosts (Figure 1-2). Two main types of life 
cycle stage have been identified: replicative stages and transmission stages. 
Replicative stage parasites include the long slender bloodstream form, the 
procyclic form and the epimastigote form, and their role is to establish and 
maintain infections in their respective environments (Barry and McCulloch, 
2001). Transmission stage parasites include the short stumpy bloodstream form 
and the metacyclic form. These are pre-adapted to their destination host, but 
have a finite half-life if not transmitted as they are non-replicative, cell cycle 
arrested forms (e.g. short stumpy cells lie in G0 phase; Matthews and Gull, 
1997). 
When an infective tsetse fly takes a blood meal from a mammalian host, it 
deposits metacyclic form cells below the skin (Vickerman, 1985). Cells of this 
life cycle stage develop in the salivary glands of the tsetse fly and express a 
Metacyclic Variant Surface Glycoprotein (MVSG) coat (Tetley et al., 1987), which 
serves to protect against the mammalian host’s innate immune system (section 
1.2.1), and also to hide invariant surface molecules from the host’s immune 
surveillance. In the mammal these non-dividing metacyclic form cells 
differentiate into long slender bloodstream form parasites, which can proliferate 
by cell division whilst moving from the site of deposition to the bloodstream 
(Vickerman, 1985;Matthews and Gull, 1994;Matthews, Ellis, and Paterou, 2004). 
In the long slender bloodstream form cells the MVSG coat is replaced by 
Bloodstream Variant Surface Glycoproteins (BVSGs), which involves expression of 
the VSG gene from a distinct genomic location and enables the trypanosome 
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population to evade eradication by the host immune system to establish and 
maintain an infection by a process called antigenic variation (section 1.2.1). In 
the bloodstream, long slender cells can differentiate into a short stumpy 
bloodstream form. This occurs in a density dependent manner due to the 
accumulated secretion of a low molecular weight factor, termed stumpy 
induction factor (SIF), from the long slender bloodstream form trypanosomes. SIF 
induces growth arrest through a cyclic adenosine monophosphate (cAMP) 
signalling pathway (Vassella et al., 1997). Short stumpy form trypanosomes are 
pre-adapted to the tsetse fly environment with metabolic changes that allow 
them to switch from the glucose energy source in the mammalian bloodstream 
to the proline energy source found in the tsetse fly midgut (Hendriks et al., 
2000). Once ingested by a tsetse fly, the short stumpy form cells differentiate 
into replicative procyclic form cells that express a procyclin protein coat on 
their surface. The precise function of the procyclin coat is unknown, though it is 
thought to protect against trypanocidal factors in the tsetse fly midgut (Roditi 
and Liniger, 2002). The procyclic form cells move to the alimentary tract where 
they proliferate by cell division before differentiating into mesocyclic form cells, 
which migrate into the tsetse fly salivary glands (Roditi and Liniger, 2002) . Once 
in the salivary glands, mesocyclic form cells undergo an asymmetrical cell 
division, producing a large daughter cell (that appears to be discarded) and a 
small daughter cell, which is the progenitor of the epimastigote form that 
attaches to the salivary gland wall and multiplies by cell division (Van den 
Abbeele et al., 1999;Fenn and Matthews, 2007). It is here that genetic exchange 
is thought to occur in the life cycle, including between different T. brucei 
strains and sub-species, though it appears to be non-obligatory (Tait and Turner, 
1990;Gibson and Stevens, 1999;Gibson et al., 2008). Analysis of fluorescently 
tagged meiosis-specific proteins has allowed the recent identification of the 
meiotic stage of T. brucei within the tsetse fly (Peacock et al., 2011). This 
morphologically distinct dividing epimastigote form, present in the salivary 
glands, was identified due to strong expression of meiosis-specific proteins in 
the nucleus (Peacock et al., 2011). When the epimastigote form cells detach 
from the salivary gland wall they differentiate into metacyclic form cells and are 
ready to be transmitted to another mammalian host. The life cycle is then 
complete. 
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In the laboratory, two replicative stages of T. brucei are able to be maintained 
and manipulated in culture; these are the procyclic form of the parasite, which 
replicates in the tsetse fly midgut, and the long slender bloodstream form of the 
parasite, which replicates in the blood and tissue fluids of the mammalian host 
(Brun and Schonenberger, 1979;Hirumi and Hirumi, 1989). Some laboratory 
strains, which have been termed monomorphic, have lost the ability to 
differentiate from the long slender bloodstream form to the short stumpy form, 
undermining the natural route of transmission through the fly. Other strains, 
which retain this ability to differentiate are termed pleomorphic (Wijers and 
Willett, 1960;Matthews and Gull, 1994). 
 
Figure 1-2 The life cycle of T. brucei.  
The different life cycle stages shown are scanning electron micrographs, reproduced to 
scale. An erythrocyte is shown next to the long slender bloodstream stage for comparison. 
Curved arrows depict stages capable of replication, whereas straight arrows represent 
differentiation and progression through the life cycle. The host organism and the name of 
the life cycle stage are indicated. Figure reproduced from Barry and McCulloch, 2001. 
1.1.4 The genome of T. brucei 
In 2005, the project to sequence the megabase-sized chromosome DNA of T. 
brucei was completed (Berriman et al., 2005) using the genome of the T. brucei 
strain TREU (Trypanosomiasis Research Edinburgh University) 927/4. The nuclear 
genome of T. brucei contains 11 megabase chromosomes that range in size from 
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~ 0.9 Mb to ~ 5.7 Mb and are named from 1-11 in order of increasing size; their 
total size is ~ 26 Mb (Berriman et al., 2005;Hertz-Fowler, Renauld, and 
Berriman, 2007) The megabase chromosomes contain 9068 predicted genes that 
include ~ 900 pseudogenes and ~ 1700 T. brucei-specific genes (Berriman et al., 
2005). 
The T. brucei megabase chromosomes have been divided into three domains. 
The central core contains most of the housekeeping genes, which are mainly 
transcribed by RNA polymerase II (RNA Pol II) as multigene transcription units. A 
proximal subtelomeric region is also defined that is largely composed of 
transcriptionally silent arrays of tandemly repeated units of variant surface 
glycoprotein (VSG) gene cassettes; interspersed with this are retrotransposon 
and retrotransposon-associated sequences, and some expression site-associated 
genes (ESAGs). Finally, there is a distal subtelomeric region that contains MVSG 
and BVSG expression sites (ESs), which are RNA Pol I transcription units that are 
the sole locations in which VSGs are expressed (Hertz-Fowler, Renauld, and 
Berriman, 2007). It is predicted that up to 55% of the T. brucei megabase 
chromosomes are devoted to subtelomeres, containing ~ 10% of the total 
predicted gene repertoire (Callejas et al., 2006;Hertz-Fowler, Renauld, and 
Berriman, 2007). Since the majority of this subtelomeric repertoire is VSG and 
VSG-associated genes and sequences involved in the evasion of host immune 
destruction, this illustrates the importance of antigenic variation to trypanosome 
survival (section 1.2.1;Barry and McCulloch, 2001;Marcello and Barry, 2007). 
The T. brucei nucleus also contains intermediate- and mini-chromosomes 
(Melville et al., 1998;El Sayed et al., 2000), which appear to have evolved to 
expand the VSG repertoire. In most strains, there are between 1 and 5 
intermediate-chromosomes, of 200-900 kb in size, and numerous (~ 100) mini-
chromosomes of 30-150 kb in size (Melville et al., 1998;Melville et al., 2000;El 
Sayed et al., 2000;Alsford et al., 2003;Wickstead, Ersfeld, and Gull, 2004). The 
intermediate-chromosomes contain VSG expression sites in the subtelomeres and 
a core sequence consisting of many copies of a 177 bp repeat sequence 
(Wickstead, Ersfeld, and Gull, 2004). The mini-chromosomes also contain many 
copies of the 177 bp repeats, arranged in a large repetitive palindrome, as well 
as a repertoire of silent subtelomeric VSG genes (Wickstead, Ersfeld, and Gull, 
2004). It has been suggested that the 177 bp repeat sequences function in the 
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maintenance of mini- and intermediate-chromosomes through mediating 
replication (Weiden et al., 1991). 
Comparison of different T. brucei isolates revealed considerable chromosome 
size polymorphisms between isolates and also between diploid chromosome 
homologs within a single isolate (Melville et al., 1998;Melville, Gerrard, and 
Blackwell, 1999;Melville et al., 2000). This variation in chromosome size is also 
observed in other kinetoplastid parasites, including Leishmania, Trypanosoma 
cruzi and also Plasmodium, although not to the same extent as observed in T. 
brucei (Janse, 1993;Henriksson et al., 1995;Wincker et al., 1996). This variation 
in chromosome and genome size has been attributed, in part, to expansion in 
the many arrays of tandemly repeated gene families (Melville et al., 
2000;Melville, Gerrard, and Blackwell, 1999). The expansion of gene families in 
this manner is thought to be a mechanism to increase gene expression levels and 
therefore the level of protein, due to the lack of transcriptional regulation found 
in T. brucei (section 1.1.5;Ivens et al., 2005;Callejas et al., 2006). However, the 
major size variation appears to arise due to changes in the number and 
organisation of VSGs in the subtelomeric arrays (Callejas et al., 2006), and this 
cannot be driven by gene expression as these sequences are not normally 
transcribed at these locations. 
Analysis of the genome sequences of T. brucei, T. cruzi and L. major (also 
known as the TriTryps) has revealed a striking conservation of gene order 
(synteny), despite high levels of divergence at the sequence level and major 
differences in chromosome numbers and size (Melville et al., 1998;Melville, 
Gerrard, and Blackwell, 1999;Melville et al., 2000;Ghedin et al., 2004;El Sayed 
et al., 2005). The presence of retrotransposon-like elements at the few sites of 
genome rearrangements observed, suggests a role for retrotransposons in 
shaping the genomes of these kinetoplastid organisms (Ghedin et al., 2004). 
1.1.5 Transcription and translation in T. brucei 
The housekeeping genes contained in the central core of the megabase 
chromosomes of T. brucei are arranged in directional gene clusters (DGCs), 
separated by so-called strand switch regions. All genes in a DGC are transcribed 
polycistronically from a single promoter, leading to a lack of control over the 
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transcription of most individual genes (Kooter et al., 1987;El Sayed et al., 
2003;Berriman et al., 2005). In contrast to bacteria, the co-transcribed genes in 
T. brucei are not generally functionally related (Clayton, 2002). A single pre-
mRNA is thought to be generated from each DGC and requires post-
transcriptional modification to generate mature mRNA ready for translation. In 
trans-splicing, a ‘spliced leader’ (SL) RNA is fused to the 5’ end of each mRNA 
(Gunzl, 2010), creating a cap structure that appears unique to kinetoplastids and 
consists of 7-methylguanosine and 4 methylated nucleotides (Bangs et al., 1992). 
The addition of a polyadenylated (PolyA) tail to the 3’ end of the mRNA appears 
to occur in a co-ordinated reaction with trans-splicing, producing mature mRNA 
(Clayton, 2002). The RNA polymerases utilised by trypanosomes for transcription 
are also unusual. In most eukaryotes, transcription is carried out by 3 types of 
RNA polymerase: RNA pol I generates rRNA, RNA pol II produces mRNA, and RNA 
pol III yields tRNA (Rutter et al., 1976;Tamura et al., 1996;Cramer, 2002), 
although additional small RNAs are also produced by RNA pol II and III. In T. 
brucei, RNA pol II is primarily responsible for the transcription of housekeeping 
genes (Devaux et al., 2006). Uniquely, a small number of protein-encoding genes 
are transcribed by RNA pol I, including the VSG expression site and procyclin 
genes (Navarro and Gull, 2001;Gunzl et al., 2003), and this is thought to be an 
adaptation to allow the high level of transcription required for these abundant 
proteins (Gunzl et al., 2003). 
1.2 Antigenic variation 
The survival of pathogens within a host relies on the successful evasion of host 
immune responses and many adaptations to allow persistence and enhanced 
transmission of pathogens have been observed. The invasion of host cells allows 
parasites, such as members of the genera Toxoplasma and Leishmania, an 
environment safe from immune surveillance in which to replicate (Sibley, 2004). 
Parasites that do not invade host cells, such as T. brucei, are constantly exposed 
to host immune defences and may use antigenic variation to evade host immune 
responses. Antigenic variation involves periodic changes in the antigens exposed 
on the pathogen surface to antigenically distinct variants, thus altering their 
appearance to the host immune system (Barbour and Restrepo, 2000;Zambrano-
Villa et al., 2002). 
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Antigenic variation is observed in a diverse array of pathogens with a wide 
variety of underlying mechanisms. For instance, Giardia lamblia, the causative 
agent of Giardiasis, utilises a transcriptional control mechanism to switch 
expression between a repertoire of 150 genes that encode the Variant Surface 
Protein (VSP) (Mowatt, Aggarwal, and Nash, 1991;Kulakova et al., 2006). In 
contrast, some members of the genus Borrelia use a mechanism of gene 
conversion by recombination to switch their surface lipoprotein antigens, called 
variable large protein (vlp) and variable small protein (vsp) (Zhang et al., 1997). 
B. hermsii has been found to contain approximately 60 silent genes present on 
episomes, and gene conversion between fragments of vlp and vsp genes utilise 
this genetic material (Dai et al., 2006). However, in B. burgdorferi homologous 
recombination does not play a role in antigenic variation as mutation of the 
RecA recombinase enzyme in this organism does not impair infection rates 
(Liveris et al., 2008). 
1.2.1 Antigenic variation in T. brucei 
T. brucei was the first organism discovered to undergo antigenic variation as a 
means of escaping the host immune system (Vickerman, 1978;Borst, 
1986;Greaves and Borst, 1987) and remains one of the best-studied examples of 
this process (reviewed in Borst, 2002;Figueiredo, Cross, and Janzen, 
2009;Morrison, Marcello, and McCulloch, 2009;Horn and McCulloch, 
2010;Rudenko, 2010). Infections with T. brucei are characterised by waves of 
parasitaemia (Figure 1-3). In part, these waves are due to the formation of non-
replicating short stumpy cells at high parasiteamias (MacGregor et al., 2011), 
however another major contributing factor is antigenic variation of the major 
surface antigen, the VSG (McCulloch, 2004). The production of specific 
antibodies against the VSG surface coat leads to the destruction of those 
parasites. The avoidance of complete parasite elimination is due to a sub-
population of parasites that have switched to a new, antigenically distinct VSG 
and will be temporarily rendered invisible to the immune system, and so escape 
immune destruction to re-populate the host organism (Morrison et al., 2005). 
Nevertheless, as these VSG-expressing cells outgrow, they too will be targeted 
for immune killing. Thus, antigenic variation succeeds by the continual switching 
to new VSGs, keeping the parasites ‘one step ahead’ of the host immune 
response. 
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Figure 1-3 A parasitaemic profile of a T. brucei infection in a cow. 
The x-axis follows the timeline of infection, from days 0-70. The parasitaemic profile of the 
cow was plotted as measured by the prepatent period in days (y-axis), from inoculating 0.2 
ml cattle blood into an immunosuppressed mouse to achieve a parasitaemia of 1 x 108.1 
trypanosomes.ml−1, a measure that is approximately proportional to the parasite density in 
the cow. Figure reproduced from Morrison et al., 2005. 
1.2.2 The Variant Surface Glycoprotein 
In the mammalian host, 5 x 106 dimers (107 copies) of a VSG form a densely 
packed coat on the parasite surface that performs multiple protective functions 
(Figure 1-4;Cross, 1975). Firstly, the tightly packed VSG coat shields invariant 
surface molecules, such as receptors and transport channels, from immune 
recognition (Ziegelbauer and Overath, 1993;Chung, Carrington, and Field, 
2004;Schwede et al., 2011). Secondly, it protects the parasite from the host’s 
innate and adaptive immune responses, not simply by antigenic variation but 
also due to modulation of these immune responses, the mechanism of which is 
incompletely understood (Leppert, Mansfield, and Paulnock, 2007;Paulnock, 
Freeman, and Mansfield, 2010). Lastly, antibody binding to VSG molecules leads 
to rapid internalisation and degradation of the antibody and recycling of the VSG 
back to the cell surface (Engstler et al., 2007). VSG proteins are anchored to the 
parasite membrane by a glycosylphosphatidylinositol (GPI) anchor at their C-
terminus, which is buried in the coat and is more conserved than the surface 
exposed and highly antigenic N-terminus (Blum et al., 1993;Ferguson, 
1999;Schwede et al., 2011). 
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Figure 1-4 The Variant Surface Glycoprotein (VSG).  
(A) The structure of a VSG homodimer (monomers in light blue and purple) that is attached 
to the T. brucei plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. (B) A 
schematic representation of the cell surface of bloodstream form T. brucei showing the 
densely packed VSG coat bound by IgG and IgM molecules (drawn to scale). Figure 
reproduced from Engstler et al., 2007. 
The T. brucei genome contains ~ 1600 non-expressed VSG genes located in 
subtelomeric tandem arrays in the megabase-chromosomes, containing between 
3 and ~ 250 VSG genes and pseudogenes (Figure 1-5;Berriman et al., 2005). VSGs 
are effectively the only genes found on the mini-chromosomes, and are located 
immediately adjacent to the telomere (Williams, Young, and Majiwa, 
1982;Wickstead, Ersfeld, and Gull, 2004). The gene archives used for antigenic 
variation are commonly found at subtelomeric locations, as observed in 
Pneumocystis carinii (Keely et al., 2005) and Plasmodium falciparum (Scherf, 
Figueiredo, and Freitas-Junior, 2001). It is thought that this is because the 
subtelomeric environment allows for greater ectopic recombination than 
elsewhere in linear chromosomes (Barry et al., 2003). 
VSG genes have a basic ‘cassette’ organisation, comprising in total between 3 
and 4 kb of sequence: one or more 70 bp repeat sequences are normally found at 
the 5’ flank of the cassette, followed downstream by so-called ‘co-transposed 
sequence’ upstream of the VSG open reading frame (ORF), which is then flanked 
by 3’ sequence with limited sequence homology between cassettes (Liu et al., 
1983). The genome sequencing project of T. brucei revealed that the majority of 
VSG genes are defective in some way: only 7% were found to be fully functional, 
9% were atypical, 66% are full-length pseudogenes (with frame shifts and/or in-
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frame stop codons) and 18% are gene fragments (Berriman and Harris, 
2004;Marcello and Barry, 2007). Initially, it was thought that there was no 
organisation of VSG genes according to sequence similarity (Berriman et al., 
2005). However, a more recent study has found that approximately 550 VSGs 
exist in high-identity subfamilies of pairs, triplets and quadruplets, which are 
thought to be important in mosaic gene formation (section 1.2.4.2;Marcello and 
Barry, 2007). This process is a form of antigenic variation that utilises the vast 
archive of VSG pseudogenes and gene fragments to create antigenically novel 
VSG variants (Marcello and Barry, 2007). Indeed, the use of mosaic gene 
formation may be the predominant form of antigenic variation in other 
pathogens such as Borrelia sp, Neisseria sp and Anaplasma sp (Zhang and Norris, 
1998;Hamrick et al., 2001;Brayton et al., 2002). 
 
Figure 1-5 The chromosomal location of silent VSG arrays in T. brucei strain TREU 927.  
The assembled megabase chromosomes are represented by horizontal lines, with the 
chromosome number in a grey box to the left of each chromosome. Arrays of VSGs are 
depicted by black blocks; the orientation of sets of VSGs is shown by the position of the 
box above or below the line. The provisional number of VSGs in each array is shown. 
Breaks in contiguation in chromosome 11 are represented by oblique lines. Figure 
reproduced from Barry et al., 2005. 
1.2.3 VSG expression sites 
A pre-requisite for the success of antigenic variation is that a single VSG is 
expressed at any one time, from a specialised polycistronic transcription unit 
called a VSG expression site (ES) (Figure 1-6;Pays et al., 2001). At least 10 
bloodstream expression sites (BESs) are thought to exist, located at the 
subtelomeres of the megabase- and intermediate-chromosomes (Becker et al., 
2004;Hertz-Fowler et al., 2008;Young et al., 2008). BESs vary hugely in size, 
from 40-100 kb, but have a conserved structure. The VSG gene is invariably 
located closest to the telomere (Berriman et al., 2002), and upstream are the 70 
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bp repeats, which can be present in large arrays containing hundreds of copies. 
Located further upstream of these repeats lie between 8 and 12 expression site 
associated genes (ESAGs) and pseudogenes (Berriman et al., 2002;Hertz-Fowler 
et al., 2008;Young et al., 2008). ESAGs 6 and 7 are the only ESAGs to have been 
found in every BES analysed to date and encode two subunits of the transferrin 
receptor which is required for iron uptake from the host (Schell et al., 
1991;Berriman et al., 2002). Transcription of the active BES is carried out by 
RNA pol I from a single upstream promoter (Gunzl et al., 2003). The parasite 
employs multiple mechanisms to ensure that only a single BES is actively 
transcribed at any one time and accumulating evidence suggests that multiple 
epigenetic phenomena may be involved in maintaining transcriptionally silent 
chromatin at inactive BESs (Rudenko, 2010;Horn and McCulloch, 2010). 
 
Figure 1-6 A schematic representation of a generic bloodstream expression site.  
The diagram shows an example of a T. brucei Lister 427 bloodstream expression site and 
indicates the variant surface glycoprotein (VSG, blue box) and expression-site associated 
genes (ESAG 1, 2, 3, 4, 5, 6, 7, 8, black boxes) separated by a region of 70 bp repeats 
(orange boxes). Also shown are the promoter (red arrow), telomeric repeat region (vertical 
black line), and pseudo-ESAGs (Ψ, grey boxes). Figure adapted from Hertz-Fowler et al., 
2008. 
1.2.4 VSG switching mechanisms 
Antigenic variation relies on the periodic switching of the surface antigen to an 
antigenically distinct variant. In T. brucei this is achieved by utilising the 
multiplicity of the BESs and also the vast archive of silent VSG genes and 
pseudogenes. VSG switching is spontaneous and occurs at a rate of about 10-2 to 
10-3 switches per cell per generation in isolates recently recovered from hosts 
(pleomorphic cells;Lamont, Tucker, and Cross, 1986;Turner and Barry, 1989), 
but at a reduced rate in lab-adapted strains (monomorphic cells, 10-5 to          
10-6;Turner, 1997). VSG switches appear to operate in a hierarchy; telomeric 
VSGs are activated earliest in infections, followed by intact subtelomeric VSGs 
and, lastly, pseudogenes are recombined to form mosaic VSGs (Thon et al., 
1990;Marcello and Barry, 2007;Morrison, Marcello, and McCulloch, 2009). The 
mechanisms that underlie this ordering strategy remain unknown (Capbern et 
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al., 1977;Morrison et al., 2005), and we have only a partial picture of the 
mechanisms that drive VSG switching. 
1.2.4.1 Transcriptional switching 
Only one BES is actively transcribed at any one time, but because there may be 
up to 20 BESs, each containing a different VSG gene, switching to the expression 
of a new VSG can occur by turning off transcription of the active BES and 
activating a previously silent BES (Figure 1-7). This is termed transcriptional, or 
in situ, switching and is thought to occur by epigenetic mechanisms (Rudenko, 
2010;Horn and McCulloch, 2010). However, this only allows access to a 
repertoire of approximately 20 VSG genes, which would rapidly become 
exhausted during the course of an infection. In situ switching is not thought to 
contribute significantly in pleomorphic cell lines (Robinson et al., 1999), though 
it is thought to be the dominant switching mechanism in lab-adapted 
monomorphic cell lines (Barry, 1997). Mutation of a number of genes has been 
shown to result in the loss of singular ES transcription (Rudenko, 2010), and two 
genes, DOT1B and Cohesin, have been implicated in the switch between a silent 
and inactive BES (Figueiredo, Janzen, and Cross, 2008;Landeira et al., 
2009;Frederiks et al., 2010). However, the trigger for such a switch, and the 
mechanisms that are thought to co-ordinate this process are unknown (Chaves et 
al., 1998). Though a putative subnuclear site for BES transcription, termed the 
Expression Site Body (ESB), was described 10 years ago (Navarro and Gull, 2001), 
the nature of this entity remains obscure. 
Chapter 1  37 
 
Figure 1-7 In situ transcriptional VSG switching.  
An in situ transcriptional VSG switching event occurs when the active expression site (red 
dashed arrow) is transcriptionally switched off and a previously silent expression site (blue 
dashed arrow) is transcriptionally switched on. This results in the expression of the green 
VSG being switched off and the initiation of the expression of the blue VSG. Also shown are 
expression site associated genes (ESAG, black boxes), 70 bp repeats (orange boxes), 
promoter (red and blue arrows), and telomeric repeat region (vertical black line). Figure 
adapted from Rachel Dobson, PhD Thesis, 2009. 
1.2.4.2 Recombinational switching 
The most common form of VSG switching requires DNA recombination events. 
Such recombinational switching involves the movement of a VSG from a silent 
location in the genome into the active BES, replacing the existing VSG gene 
(Robinson et al., 1999). There are three different pathways of recombinational 
switching all putatively utilising homologous recombination (HR). HR is 
commonly used by organisms to generate diversity in surface antigens, including 
Candida albicans, Borrellia sp and Neisseria sp (Palmer and Brayton, 2007). 
The first recombinational pathway is gene conversion and involves copying a 
silent VSG gene from the megabase subtelomeric arrays, from a silent BES or 
from the telomere of a mini-chromosome, into the active BES where it replaces 
the existing, previously expressed, VSG (Figure 1-8). The amount of sequence 
copied is variable, but generally extends from the 70 bp repeats to homology in 
the 3’ end of the VSG ORF, although this can extend into the 3’ untranslated 
region (UTR) and beyond into the telomere (Liu et al., 1983;Michels et al., 
1983;Timmers et al., 1987;Matthews et al., 1990). In monomorphic cell lines, 
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gene conversion reactions between BESs can utilise homology from at least 6 kb 
upstream of the VSG, beyond the 70 bp repeats (Lee and Van der Ploeg, 1987). 
Though VSG gene conversion commonly utilises the 70 bp repeats, the deletion 
of these sequences does not inhibit VSG switching (McCulloch, Rudenko, and 
Borst, 1997;Boothroyd et al., 2009). 
The second recombinational pathway is mosaic gene conversion and, as 
previously mentioned, allows the use of the vast archive of VSG pseudogenes and 
gene fragments to form novel VSG variants (Figure 1-9). Mosaic VSG genes are 
assembled using multiple segmental gene conversion reactions, and are distinct 
from the above conversions of intact VSGs because the reaction relies on regions 
of homology within VSG ORFs, rather than flanking homology. Mosaic VSG genes 
generally form and are expressed later in infections, perhaps because the 
reaction is less efficient (Thon et al., 1990;Barbet and Kamper, 1993;Marcello 
and Barry, 2007). Indeed, it is not clear where the novel VSGs are formed, 
though they must eventually be moved to the BES. 
The final recombinational pathway is telomere reciprocal exchange and involves 
a simple cross-over event between two telomeric VSGs, where the chromosome 
ends containing the active BES and a silent telomeric VSG (in an ES or mini-
chromosome) are simply exchanged with no loss of DNA sequence (Figure 1-10). 
This pathway is thought to occur less commonly, as it is limited to telomeric 
VSGs (Pays et al., 1985;Shea et al., 1986). 
Our understanding of the mechanisms of VSG switching by recombination stems 
primarily from the generation and analysis of T. brucei mutants in homologues of 
genes that have been implicated in HR. These are discussed below (section 
1.5.3), but the broad conclusion is that VSG switching exploits HR, rather than 
being a specialised, parasite-specific reaction. Nonetheless, a number of 
questions remain. One question that has recently attracted attention is how the 
reaction is initiated. It has been suggested that a double strand break in the 
region of the BES 70 bp repeats forms a trigger for HR (Liu et al., 
1983;Boothroyd et al., 2009). However, how such a break might form is unclear, 
and it is surprising that the deletion of the 70 bp repeats does not then impair 
VSG switching (McCulloch, Rudenko, and Borst, 1997). Another question 
surrounds mosaic VSG formation and whether it is a related reaction to intact 
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VSG gene conversion. The assays that have been used to examine the impact of 
gene mutation on VSG switching only detect early VSG switch events (McCulloch, 
Rudenko, and Borst, 1997;Kim and Cross, 2010), and no study has asked if mosaic 
VSG formation is similarly impaired. 
 
Figure 1-8 VSG switching utilises silent VSG genes from different genome locations.  
A silent VSG gene (blue boxes) is copied by homologous recombination into the active 
expression site replacing the existing active VSG (red box). Donor VSGs can come from 
subtelomeric silent VSG arrays, telomeric mini-chromosomal VSGs or one of the other 
silent VSG expression sites. Brackets indicate the amount of sequence copied, with dashes 
indicating variation in the amount of sequence that may be copied. Also shown are 
expression site associated genes (black boxes), 70 bp repeats (orange boxes), telomeric 
repeat region (vertical black line). Figure adapted from Rachel Dobson, PhD Thesis, 2009. 
 
Figure 1-9 Mosaic VSG formation by segmental gene conversion.  
A new mosaic VSG gene (red, blue and green box) is formed by segmental gene conversion 
from a number of VSG pseudogenes (Ψ, red, blue and green boxes). Brackets indicate the 
extent of sequence copied. Also shown are expression site associated genes (black boxes), 
70 bp repeats (orange boxes), and telomeric repeat region (vertical black line). Figure 
adapted from Rachel Dobson, PhD Thesis, 2009. 
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Figure 1-10 Telomere reciprocal exchange resulting in a VSG switching event. 
Telomere reciprocal exchange occurs when homologous recombination (crossed lines) 
between two BESs (shown, top) or an active BES and a silent mini-chromosomal VSG (not 
shown) leads to the simple switching of the VSG and/or surrounding sequences. The 
previously silent VSG (blue box) recombines into the active expression site (red dashed 
arrow). There is no loss of DNA during this cross-over event and both VSGs are retained. 
Also shown are expression site associated genes (black boxes), 70 bp repeats (orange 
boxes), promoter (red arrow), and telomeric repeats (vertical black line). Figure adapted 
from Rachel Dobson, PhD Thesis, 2009. 
1.3 DNA repair 
Genomes encode the information required to produce all cellular components 
within the structure of nucleic acid molecules. DNA and RNA allow this 
information to be stored, transferred between generations and read to allow 
protein production. Maintenance of the sequence fidelity of the genome is 
therefore of utmost importance. Many endogenous and exogenous agents, as 
well as the intrinsic instability of DNA molecules and the complex processes it 
undergoes, have the ability to cause damage to DNA (Kuzminov, 1995). The 
consequences of DNA damage include DNA fragmentation and rearrangement, 
which in multi-cellular organisms can lead to cancer and ultimately death 
(Khanna and Jackson, 2001). It is therefore desirable, at least in most settings, 
that DNA damage is repaired as swiftly as possible without the loss of genome 
fidelity. Given the diversity of DNA damage, many different mechanisms of DNA 
repair exist. These mechanisms may be broadly divided into two groups; those 
that join broken DNA molecules by repairing phosphodiester bonds at strand 
breaks, and those that use excision mechanisms to remove damaged bases or 
strands. Three main pathways of excision repair have been described: mismatch 
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repair (MMR), base excision repair (BER) and nucleotide excision repair (NER). All 
three mechanisms have two common properties; the use of a nuclease(s) to 
remove the damaged bases and a DNA polymerase(s) and ligase(s) to fill in the 
resulting gap and repair the DNA backbone. The specific proteins used in the 
three pathways differ greatly and, as these processes are not closely related to 
the subject of this thesis, they will not be discussed further. 
1.3.1 Double strand break repair 
Amongst the lesions that break the phospodiester backbone of DNA molecules, 
those in which both strands are cleaved, termed DNA double strand breaks 
(DSBs), are considered particularly genotoxic. DSBs arise frequently during DNA 
replication and can also be induced by ionising radiation, mutagenic chemicals 
and free radicals. Repair of DSBs occurs primarily by two independent 
mechanisms; non-homologous end joining (NHEJ) and homologous recombination 
(HR) (Figure 1-11). These two pathways of DSB repair are conserved in most 
eukaryotes. However, NHEJ appears to be favoured in mammalian cells, whilst 
HR is favoured by lower eukaryotes (Liang et al., 1998). There are a number of 
determinants that have been shown to affect repair pathway choice, including 
the cell cycle stage at which the DNA damage occurs, the position of the DSB 
along the chromosome and the nature of the DNA substrate (Kass and Jasin, 
2010;Symington and Gautier, 2011;Xu and Price, 2011), however the precise 
mechanism remains to be elucidated. 
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Figure 1-11 Pathways of eukaryotic DNA double strand break repair.  
The two main pathways of eukaryotic DSB repair; non-homologous end joining (A), and 
homologous recombination (B - E). DNA containing a DSB is represented by black lines, 
intact duplex DNA by blue lines, newly synthesised DNA by dashed lines, and NHEJ 
machinery by red circles. (B) Single-strand annealing (SSA) occurs where the boxes 
indicate sequence homology, (C) Break-induced replication (BIR), and (D-E) Gene 
conversion. Figure adapted from Jo Bell, PhD thesis, 2002. 
1.3.2 Non-homologous end joining 
Non-homologous end joining involves the repair of a DSB by re-ligation of the 
DNA ends and frequently results in changes in the DNA sequence at the site of 
the DSB through loss or addition of sequence. No sequence homology is required 
for NHEJ to occur and therefore NHEJ acts on a wide variety of DSB substrates 
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(Lieber et al., 2008;Lieber, 2010). The core proteins that carry out NHEJ consist 
of; the Ku heterodimer (Ku70 and Ku80), the catalytic subunit DNA-PKcs, and the 
DNA ligase IV-XRCC4 complex (Figure 1-12). The Ku heterodimer forms a DNA 
end-binding complex that recognises and binds, with high affinity, to both ends 
of the DSB, forming a bridge and leading to recruitment of other NHEJ factors. 
DNA-PKcs is the first factor to be recruited, and there is some evidence to 
suggest that (auto-) phosphorylation plays a role in the interaction of DNA-PKcs 
at the DSB (Smith and Jackson, 1999;Dobbs, Tainer, and Lees-Miller, 2010). 
However, this phosphorylation is not essential as some eukaryotes, including 
yeast, lack a homolog of DNA-PKcs (Critchlow and Jackson, 1998;Featherstone 
and Jackson, 1999;Parsons et al., 2005). DNA-PKcs is a member of the 
phosphatidylinositol 3-kinase-like kinase (PIKK) family that includes ATM and 
ATR, which are also involved in the response to DNA damage (Smith and Jackson, 
1999). The next factor to be recruited is the DNA ligase complex consisting of 
DNA ligase IV and the XRCC4 protein, a ligase IV-interacting protein (Sibanda et 
al., 2001). The gaps in the DNA are ligated together and the break is repaired. It 
has been shown that NHEJ is the main pathway in V(D)J recombination, which 
creates diversity among the immunoglobulin and T cell receptor genes found in 
the mammalian immune system (Xu et al., 2005). To date, no evidence for NHEJ 
has emerged from studies of DNA repair in T. brucei and related kinetoplastids 
(Conway et al., 2002b;Glover, McCulloch, and Horn, 2008). Indeed, there is no 
bioinformatic evidence for the existence of DNA ligase IV or XRCC4 (Burton et 
al., 2007), though each Ku subunit is present (Conway et al., 2002a;Janzen et 
al., 2004). 
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Figure 1-12 The core proteins involved in non-homologous end joining.  
Black lines represent duplex DNA. Following a DSB the Ku70/80 heterodimer (red and blue 
circles) binds to the DNA ends and recruits the catalytic subunit of the DNA protein kinase 
(DNA-PKcs, green octagon). The DNA ligase IV – XRCC4 complex (purple cyclinder and 
yellow square, respectively) is recruited to complete the ligation reaction. Figure adapted 
from Claire Hartley, PhD Thesis, 2008. 
1.3.2.1 Micro-homology mediated end joining 
A number of reports have shown a distinct form of DSB end-joining that is 
mediated by short, ~ 5-25 bp stretches of sequence homology (Decottignies, 
2007). This pathway was thought to act as a backup to classical NHEJ 
(Nussenzweig and Nussenzweig, 2007), but has been shown to play a prominent 
role in Ig class switch recombination in B cells (Yan et al., 2007) and cancer 
development (Zhu et al., 2002). The micro-homology mediated end joining 
(MMEJ) pathway is independent of core NHEJ factors, such as Ku70 and Ku80, 
but the precise proteins involved are as yet unknown (McVey and Lee, 2008), 
meaning it is unclear if it is distinct from NHEJ or HR, or uses aspects of both 
pathways. Nonetheless, MMEJ has been described in T. brucei both in vivo and in 
vitro (Conway et al., 2002b;Burton et al., 2007;Glover, McCulloch, and Horn, 
2008;Glover, Jun, and Horn, 2011), and may have assumed the role of NHEJ, 
though until catalytic factors can be indentified its functional significance is 
hard to define. 
1.3.3 Homologous recombination 
Homologous recombination involves the repair of a DSB by utilising the 
homologous sequence of an unbroken DNA molecule as a template and therefore 
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generally conserves the sequence fidelity of the genome. HR is conserved in all 
organisms, from bacteria to humans (Cromie, Connelly, and Leach, 2001), and is 
more complex than NHEJ, involving multiple sub-pathways and a greater number 
of factors. HR has been shown to repair DSBs resulting from stalled or collapsed 
replication forks (section 1.3.5) and exposure to DNA damaging agents 
(Petermann and Helleday, 2010;Symington and Gautier, 2011). It also has a role 
in the exchange of genetic material during meiosis, creating genetic diversity 
(Ehmsen and Heyer, 2008), and in antigenic variation of pathogens such as T. 
brucei (Vickerman, 1978). HR can be split into a number of different 
mechanisms, including single-strand annealing (Figure 1-11B), break-induced 
replication (Figure 1-11C) and gene conversion (Figure 1-11D and E). These 
mechanisms appear quite different, and appear to employ subtly differing 
catalytic components, but share the use of a homologous template and the same 
catalytic steps of pre-synapsis, synapsis and post-synapsis (Hamatake, Dykstra, 
and Sugino, 1989;San Filippo, Sung, and Klein, 2008;Holthausen, Wyman, and 
Kanaar, 2010). HR in eukaryotes requires a large number of proteins known as 
the Rad52 epistasis group, which include the proteins Rad50, Rad51, Rad52, 
Rad54, Rad55, Rad57, Rad59, Mre11 and Xrs2 (Symington, 2002). Rad51 is a 
recombinase enzyme and acts by forming a helical nucleoprotein filament on 
single-stranded DNA (ssDNA) to facilitate HR (section 1.6). Rad51 is functionally 
and structurally conserved with RecA and RadA in bacteria and archaea, 
respectively. The other members of the Rad52 epistasis group appear to promote 
Rad51 activity, acting either upstream or downstream of the formation of the 
Rad51 nucleoprotein filament (Symington, 2002). 
1.3.4 Mechanism of homologous recombination 
The proteins involved in the early stages of HR in eukaryotes are displayed in 
Figure 1-13. In pre-synapsis, the DSB is recognised and the DNA ends are 
resected by exonucleases to reveal 3’ ssDNA overhangs which allow the binding 
of the recombinase (Rad51/RadA/RecA in eukaryotes/archaea/bacteria, 
respectively) with the aid of cofactors. DNA end resection is carried out by the 
RecBCD complex in bacteria, the MRX complex in yeast (comprising of Mre11, 
Rad50 and Xrs2) and the MRN complex in mammals (comprising of Mre11, Rad50 
and Nbs1) (Paull, 2010;Longhese et al., 2010;Symington and Gautier 2011). 
These complexes all have helicase and nuclease activity and are responsible for 
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the production of 3’ ssDNA overhangs that can be thousands of bases long (White 
and Haber, 1990;Sun, Treco, and Szostak, 1991). In eukaryotes, the ssDNA 
overhangs are coated with replication protein A (RPA), a homologue of the 
bacterial ssDNA-binding protein (SSB). These proteins have wider roles in the cell 
than simply acting in HR, but protect the ssDNA from nucleases and also remove 
any secondary structure which is inhibitory to nucleoprotein filament formation 
(Sugiyama, Zaitseva, and Kowalczykowski, 1997). Cofactors involved in the 
loading of the recombinase onto the ssDNA overhangs must first remove RPA/SSB 
from the ssDNA (Sung, 1997a;Sung, 1997b). Rad52 has been shown to carry out 
this function in yeast and mammals (Sung, 1997a;Benson, Baumann, and West, 
1998), however, Rad52 is absent from D. melanogaster, C. elegans and T. 
brucei. Evidence exists that the breast cancer susceptibility protein BRCA2 can 
carry out this role (section 1.4). Most eukaryotes express multiple Rad51-related 
proteins, often called Rad51 paralogues, which aid Rad51 function and are 
required for recombinational DNA repair (Thacker, 2005;Lin et al., 2006). Yeast 
utilise a complex of Rad55 and Rad57 to help nucleate the Rad51 nucleoprotein 
filament on ssDNA (Hays, Firmenich, and Berg, 1995;Sung, 1997b). Mammals 
contain five Rad51 paralogues, which form two distinct complexes, the precise 
functions of which have not yet been ascertained (Suwaki et al., 2011). In T. 
brucei, four RAD51 paralogues are found, each of which acts in HR and 
influences the subnuclear mobility of RAD51 (Proudfoot and McCulloch, 
2005;Dobson et al., 2011). In addition, at least three of the RAD51 paralogues 
have been shown to interact and therefore presumably form a complex or 
complexes (Dobson et al., 2011), but the evolutionary relationship between 
these proteins and those present in yeast and mammals remains unclear. 
Once the DNA-recombinase nucleoprotein filament has been assembled synapsis, 
or strand exchange, occurs. This involves the invasion of a homologous duplex 
DNA molecule by the broken DSB end(s) and the formation of a displacement-
loop (D-loop) structure at the point of base-pairing. Strand invasion is aided by 
Rad54, a double-stranded DNA (dsDNA)-dependent ATPase, which is a member of 
the Swi2/Snf2 family of chromatin remodelling factors (Heyer et al., 2006;Mazin 
et al., 2010) Rad54 uses the energy released from the hydrolysis of ATP to 
supercoil and separate the strands of the homologous DNA template and stabilise 
the nucleoprotein filament (Heyer et al., 2006;Mazin et al., 2010). DNA synthesis 
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occurs following the formation of the D-loop structure using the 3’ DSB end as a 
primer and the homologous strand as a template (Paques and Haber, 
1999;Holmes and Haber, 1999). The second 3’ end of the DSB can also invade the 
D-loop in a process called second end capture, this can lead to the formation of 
a four-branched DNA structure called a Holliday Junction (HJ) (Holliday, 1964). 
In post-synapsis the resolution of the strand exchange intermediate takes place. 
Cleavage of the HJ is carried out, at least in humans, by a recently discovered 
resolvase, GEN1 (Ip et al., 2008;Rass et al., 2010), and yields either a crossover 
product (section 1.3.4.3) or a non-crossover product (gene conversion; section 
1.3.4.4). 
 
Figure 1-13 The proteins involved in the early stages of eukaryotic homologous 
recombination. 
Black lines represent duplex DNA and grey lines represent intact duplex DNA used as a 
template for repair. Following a DSB the 5′ ends of the DSB are resected with the aid of the 
MRN complex (purple arrow) to form 3′ ssDNA tails. The ssDNA tails becomes coated with 
RPA (pink squares). The loading of the Rad51 (red circles) nucleoprotein filament is aided 
by Rad52 (light blue cylinder), the Rad51 paralogues (green cylinder) and BRCA2 (orange 
oval). The filament then actively ‘scans’ the genome for homologous sequences in a ‘strand 
invasion’ process that is aided by Rad54 (dark blue squares). Following this, one tail 
invades the homologous DNA duplex forming a displacement (D)-loop, which is then 
extended by DNA synthesis (not shown). Figure adapted from Claire Hartley, PhD Thesis, 
2008. 
1.3.4.1 Single-strand annealing 
Single-strand annealing (Figure 1-11B) occurs on repetitive DNA sequences and is 
a Rad51-independent HR pathway, which usually involves the loss of some 
genetic material (Paques and Haber, 1999). Following the formation of a DSB, 
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the 5’ ends are resected to expose complementary regions within the 3’ strands 
flanking the break site. These complementary sequences are able to anneal to 
each other, eliminating the need for a strand exchange step. The 3’ non-
homologous ends are excised and DNA synthesis and ligation complete the 
repair. Annealing of the complementary sequences is facilitated by accessory 
proteins: Rad52 can act in this way in H. sapiens, U. maydis and S. cerevisiae 
(Sugiyama, New, and Kowalczykowski, 1998;Kojic et al., 2008;Feng et al., 
2011;Liu and Heyer, 2011), and BRCA2 homologues (section 1.4) in U. maydis and 
C.elegans, which lacks a Rad52 homologue, have also been shown to function in 
the SSA pathway (Petalcorin et al., 2006;Mazloum, Zhou, and Holloman, 2007). 
1.3.4.2 Break-induced replication 
Break-induced replication (Figure 1-11C) involves invasion by only one end of the 
DSB and can occur by both Rad51-dependent and Rad51-independent 
mechanisms (McEachern and Haber, 2006;Llorente, Smith, and Symington, 2008). 
Once DNA resection has occurred the 3’ ssDNA overhang invades a homologous 
chromosome. Following this, a replication fork is established and the 
chromosome is copied for long distances, even to the chromosome end. Rad51-
dependent BIR is much more efficient than Rad51-independent, but requires a 
longer length of homologous substrate (Davis and Symington, 2004;Malkova et 
al., 2005). 
1.3.4.3 Gene conversion 
Gene conversion allows the transfer of genetic material from one DNA molecule 
to its homologue in a uni-directional manner, and is the most common 
mechanism of HR in DSB repair (Chen et al., 2007). Gene conversion occurs most 
frequently between newly replicated sister chromatids, in which settings it is 
genetically silent. However, it can also occur between two allelic chromosomes, 
and between homologous sequences on different chromosomes (Chen et al., 
2007). If an HJ is formed following the formation of the strand exchange 
intermediate(Figure 1-11D), the product generated from resolution of this HJ 
depends on the orientation of strand cleavage (Figure 1-14): a non-crossover 
product results from cleavage of the HJ along the one axis and results in gene 
conversion; if the strands are cleaved along different axes, a non-crossover 
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product is generated. This model for DSB repair predicts that HJ resolution 
would lead to an equal number of crossover and non-crossover events. However, 
this is not the case, as mitotic recombination events result in an extremely low 
occurrence of crossover events (Esposito, 1978;Haber and Hearn, 1985;Kupiec 
and Petes, 1988). To account for this, the synthesis-dependent strand annealing 
(SDSA) model was proposed (section 1.3.4.4;Nassif et al., 1994;Paques and 
Haber, 1999). 
 
Figure 1-14 Holliday junction resolution.  
A schematic representation of the two possible products formed following Holliday junction 
resolution. A crossover product occurs when cleavage of both strands of the HJ occurs 
along the same axis (a, red arrows) and a non-crossover event occurs when cleavage of the 
HJ occurs in different axes (b, green arrows). Figure adapted from Rachel Dobson, PhD 
Thesis, 2009. 
1.3.4.4 Synthesis-dependent strand annealing 
In this model (Figure 1-11E), only one 3’ strand invades the homologous DNA 
template, while the other strand remains unengaged (Nassif et al., 1994). 
Following DNA polymerisation, the newly synthesised strand is then displaced 
from the template and anneals to the previously unengaged 3’ strand by a 
second strand annealing step, allowing repair of the DSB (Haber et al., 2004;Ira, 
Satory, and Haber, 2006). The products that arise from this process are 
predominantly non-crossover. However, modification of the pathway can lead to 
crossover events (Ferguson and Holloman, 1996). 
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1.3.5 The role of homologous recombination in 
replication 
As already mentioned, HR has been shown to be involved in the repair of stalled 
replication forks that are often associated with genome rearrangements (Michel 
et al., 2007;Nagaraju and Scully, 2007;Budzowska and Kanaar, 2009;Petermann 
and Helleday, 2010;Branzei and Foiani, 2010). Replication forks may stall and 
collapse for a variety of reasons, including damage to DNA replication 
substrates, DNA-bound proteins blocking replication progression, DNA secondary 
structures and transcription. HR is implicated in at least three pathways of 
replication fork re-start or repair. Firstly, trans-lesion synthesis uses error-prone 
DNA polymerases to by-pass a DNA lesion and enables the progression of 
replication across the lesion (Prakash, Johnson, and Prakash, 2005). The DNA 
lesion remains (called a daughter strand gap) and may be repaired using the 
sister chromatid as a template in an HR mechanism called sister chromatid 
recombination (SCR) (Scully, Puget, and Vlasakova, 2000;Michel et al., 
2004;Nagaraju and Scully, 2007). Secondly, template switching may occur when 
a stalled replication fork switches to using the nascent daughter strand as a 
replication template. HR is implicated in this process that often leads to 
complex genome rearrangements, such as observed in yeast and U. maydis 
(Lambert et al., 2005;Mazloum and Holloman, 2009;Lambert et al., 2010). 
Finally, the HR proteins Rad51 and BRCA2 have been shown to play multiple 
roles during DNA replication, including maintaining replication fork progression 
(Daboussi et al., 2008), stabilisation of stalled replication forks (Lomonosov et 
al., 2003), protection against degradation of nascent DNA (Hashimoto et al., 
2010;Schlacher et al., 2011), direct processing of stalled replication forks into 
DSBs (Michel et al., 2004), and reversal of stalled replication forks to allow 
replication re-start without the occurrence of DNA damage (Michel et al., 2001). 
brca2 mutant phenotypes, which include an accumulation of gross chromosomal 
rearrangements and extensive chromosomal abnormalities (section 1.4;Patel et 
al., 1998;Yu et al., 2000), point to a failure in replication fork rescue by HR 
(Michel, Ehrlich, and Uzest, 1997;Seigneur et al., 1998;Chen and Kolodner, 
1999). 
The repair of DNA structures created during replication has been proposed to 
occur during the G2 gap phase of the cell cycle, prior to entry into mitosis and 
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after S-phase and the completion of DNA replication (Su, Bernal, and 
Venkitaraman, 2008). Microscopically visible focal accumulations containing 
Rad51, BRCA1, BRCA2 and PCNA (proliferating cell nuclear antigen) form in 
undamaged S-phase mammalian cells where they are proposed to be repair 
centres for broken replication forks (Tashiro et al., 1996;Scully et al., 1997;Chen 
et al., 1998). However, the formation of these Rad51 replication-coupled repair 
foci does not require BRCA2 or the Rad51 paralogues (Tarsounas, Davies, and 
West, 2004). The multiple pathways for the bypass and removal of DNA-template 
lesions, and for the restart of stalled replication forks, highlights the importance 
of such mechanisms to ensure that DNA replication is completed faithfully every 
cell cycle (Michel et al., 2004). 
1.4 BRCA2 
1.4.1 The discovery of BRCA2 
Breast cancer is one of the most common causes of cancer-related deaths in 
women and approximately 10% of individuals who develop the disease are 
genetically predisposed to it (Nathanson, Wooster, and Weber, 2001). The first 
breast cancer susceptibility gene, BRCA1, was identified in 1990 by linkage 
analysis and positional mapping (Hall et al., 1990). However, a failure to assign 
all cases of breast cancer to a mutation in BRCA1 led to the search for a second 
breast cancer susceptibility gene and, in 1995, BRCA2 was identified (Wooster et 
al., 1994;Wooster et al., 1995). The products of both these genes function in the 
maintenance of genome stability through HR (Moynahan et al., 1999;Xia et al., 
2001;Moynahan, Pierce, and Jasin, 2001). However, they are remarkably 
different proteins, most notably in terms of their size and the proteins with 
which they interact (Figure 1-15). The following sections will focus on the BRCA2 
protein, which is the subject of this thesis. 
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Figure 1-15 A representation of human BRCA1 and BRCA2 proteins showing their functional 
domains and interacting proteins. 
Both proteins are large polypeptides (1,863 and 3,418 amino acids, respectively) that 
interact with each other and with several other proteins. BRCA1 interacts with BRCA2 and 
the MRN (Mre11/Rad50/Nbs1) complex. The RING finger domain, nuclear localisation signals 
(NLSs) and BRCA1 C-terminal (BRCT) domains are indicated. Similarly, BRCA2 interacts 
with BRCA1, Rad51 (the HR recombinase), DMC1 (the meiosis-specific recombinase), and 
DSS1. The eight BRC repeats, the PhePP motif that interacts with DMC1, the DNA/DSS1-
binding domain (alpha-helical domain, oligonucleotide-binding (OB) domains and tower 
domain) that interacts with ssDNA and DSS1, and the C-terminal NLSs and CDK 
phosphorylation site are indicated. Figure adapted from West, 2003. 
1.4.2 The structure of BRCA2 
The human BRCA2 protein is a large polypeptide, 3418 amino acid residues in 
length, and initial investigations revealed no obvious similarities with other 
published protein sequences (Wooster et al., 1995). Further investigation 
revealed that BRCA2 contains several key motifs, including eight BRC repeats, a 
DNA binding domain (DBD) and two nuclear localisation signals (NLSs). 
1.4.2.1 The BRC repeats 
A series of eight degenerate BRC repeat motifs were discovered in the central 
third of BRCA2, encoded by exon 11 (Bork, Blomberg, and Nilges, 1996). These 
repeated motifs are highly conserved at the sequence level between mammalian 
BRCA2 proteins (Lo et al., 2003). However, a remarkable degree of divergence 
exists between the eight BRC repeats within a single BRCA2 homologue (Figure 
1-20), suggesting that they may have evolved to achieve different functions 
(Bork, Blomberg, and Nilges, 1996;Bignell et al., 1997;Pellegrini and 
Venkitaraman, 2004). The BRC repeat motif is approximately 30 amino acid 
residues in length and separated by linker regions that vary in size from 60 to 
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300 amino acids, which show no sequence conservation (Bork, Blomberg, and 
Nilges, 1996;Bignell et al., 1997). 
The phenotypes of brca2-/- mutants in mammalian cells include early embryonic 
lethality, severe growth retardation, impaired cell division and sensitivity to 
ionising radiation, indicating the essential function of this protein (Sharan et al., 
1997;Ludwig et al., 1997;Suzuki et al., 1997). A major breakthrough occurred 
when it was discovered that BRCA2 binds Rad51, the HR recombinase (Sharan et 
al., 1997;Chen et al., 1998;Marmorstein, Ouchi, and Aaronson, 1998). In 
mammalian cells, it was observed that after the induction of DNA damage BRCA2 
and Rad51 co-localise to form mega-Dalton structures observed microscopically 
as foci, and that these Rad51 foci fail to form in the absence of BRCA2 (Yuan et 
al., 1999;Tarsounas, Davies, and West, 2003). An interaction between BRCA2 and 
monomeric Rad51 was confirmed to occur at the BRC repeats, and six or eight of 
the BRC repeats have been reported to bind Rad51 in vitro, depending on the 
assay used (co-immunoprecipitation or yeast 2-hybrid;Wong et al., 1997;Chen et 
al., 1998;Marmorstein, Ouchi, and Aaronson, 1998). A possible explanation for 
the differences in Rad51 binding observed is that the level of sequence diversity 
across the BRC repeats could produce binding sites with a range of affinities for 
Rad51 (Pellegrini and Venkitaraman, 2004). Indeed, this theory is supported by 
the fact that although all BRC repeats have the ability to bind Rad51 in vitro, 
some bind with a stronger affinity than others (see below;Chen et al., 
1998;Esashi et al., 2005;Thorslund, Esashi, and West, 2007;Carreira and 
Kowalczykowski, 2011). 
The elucidation of the X-ray crystal structure of human BRC repeat 4 bound to 
the core domain of Rad51 led to the identification of a seven amino acid motif 
(F-TASGK) located within the BRC repeat that is critical for making hydrophobic 
and hydrophilic interactions with Rad51 (Pellegrini et al., 2002). These residues 
are conserved in all of the eight BRC repeats in human BRCA2 and form a BRC 
repeat sequence fingerprint (Pellegrini et al., 2002;Lo et al., 2003). Point 
mutations within the BRC repeat fingerprint are associated with an increased 
susceptibility to breast and ovarian cancers and have been shown to be 
sufficient to disrupt the binding of Rad51 to the BRC repeat motif (Chen et al., 
1999), indicating the importance of this motif in the regulation of Rad51 by 
BRCA2 (Gayther et al., 1997;Davies et al., 2001;Pellegrini et al., 2002;Tal, 
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Arbel-Goren, and Stavans, 2009;Ochiai et al., 2011). Further analysis has 
identified a second structural domain of the BRC repeat, within an alpha-helical 
context, that is also essential for the interaction with Rad51 (Rajendra and 
Venkitaraman, 2010). Additionally, it has been shown that an oligomerisation 
motif in Rad51 exists at the subunit-subunit interface (section 1.6), which has 
been shown to function in the assembly of Rad51 into multimeric filament and 
ring forms (Pellegrini et al., 2002;Shin et al., 2003). It is thought that the BRC 
repeat mimics this oligomerisation motif using a β-hairpin structure and so 
regulates the assembly of Rad51 filaments onto DNA (Pellegrini et al., 2002;Lo et 
al., 2003;Shin et al., 2003;Nomme et al., 2008). 
A recent paper has systematically analysed Rad51 binding by each of eight 
peptides corresponding to the BRC repeats in vitro and showed that there are 
two categories of BRC repeat in human BRCA2 (Figure 1-16;Carreira and 
Kowalczykowski, 2011). The first category, consisting of BRC repeats 1 to 4, bind 
with high affinity to monomeric Rad51, reduce its ATPase activity, and maintain 
the recombinase in an active ATP-bound state until required (Carreira et al., 
2009;Carreira and Kowalczykowski, 2011). In addition, members of this category 
of BRC repeats limit the assembly of Rad51 onto dsDNA and have the ability to 
remove RPA from ssDNA, thereby promoting nucleation onto ssDNA (Davies et 
al., 2001;Galkin et al., 2005;San Filippo et al., 2006;Shivji et al., 2009;Carreira 
et al., 2009). BRC4 has also been shown to disrupt Rad51-dsDNA nucleoprotein 
filaments when present in molar excess of Rad51 (Davies et al., 2001;Tarsounas, 
Davies, and West, 2004;Davies and Pellegrini, 2007;Esashi et al., 2007). The 
second category of BRC repeats, consisting of BRC repeats 5 to 8, bind free 
Rad51 with low affinity but bind to Rad51-ssDNA filaments with high affinity and 
function to stabilise these filaments through a reduction in ATP hydrolysis by 
Rad51, thereby promoting nascent filament growth (Galkin et al., 2005;Carreira 
et al., 2009;Carreira and Kowalczykowski, 2011). It is thought that the two 
groups of BRC repeats co-operate in order to bring about delivery of monomeric 
Rad51 to the site of DNA damage, facilitate efficient filament nucleation 
preferentially onto ssDNA whilst impeding nucleation on dsDNA and the 
propagation of filament growth through binding and stabilisation, thereby 
stimulating DNA strand exchange. 
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The requirement for eight copies of the BRC repeat motif observed in human 
BRCA2 was originally postulated to be an adaptation to deliver sufficient Rad51 
molecules to the sites of DNA damage, thereby allowing efficient repair 
(Pellegrini and Venkitaraman, 2004). However, experiments in brca2 mutant cell 
lines expressing a single BRC repeat fused to the ssDNA-binding domain of RPA70 
showed a partial reversal of the brca2 phenotype with substantially improved HR 
and DNA repair, suppression of genome instability and restoration of Rad51 focus 
formation after DNA damage, indicating that BRCA2 with a single BRC repeat can 
function in HR to some extent (Saeki et al., 2006). Also, BRCA2 orthologues in 
Caenorhabditis elegans and Ustilago maydis function with a single BRC repeat 
(section 1.5.1 and 1.5.2, respectively;Kojic et al., 2002;Martin et al., 2005). The 
additional BRC repeats could simply be indicative of the necessity for greater 
control of HR in the putatively more complex biological systems acting in 
mammals. However, if correct, there are exceptions to this rule, most notably 
the T. brucei homologue of BRCA2 that is predicted to contain up to fifteen BRC 
repeats (section 1.5.3.1;Lo et al., 2003;Hartley and McCulloch, 2008). 
1.4.2.2 Rad51 binding at the BRCA2 C-terminus 
Human BRCA2 has also been shown to bind Rad51 at an extreme C-terminal 
motif, encoded by exon 27, that is highly conserved in mammalian BRCA2 and 
distinct from the BRC repeat motif (Mizuta et al., 1997;Sharan et al., 
1997;Esashi et al., 2005;Esashi et al., 2007;Davies and Pellegrini, 2007). This C-
terminal motif has the ability to bind Rad51 in its oligomerised heptameric ring 
form, and also Rad51-DNA nucleoprotein filament form, by binding at the 
interface between two Rad51 monomers. In both settings BRCA2 binding 
functions to stabilise the Rad51 multimeric forms (Davies and Pellegrini, 
2007;Esashi et al., 2007). This C-terminal Rad51 binding motif is phosphorylated 
by unknown cyclin-dependent kinases (CDKs) at Serine 3291 (S3291), and this 
phosphorylation functions to abrogate the interaction of the C-terminal binding 
domain with Rad51 (Esashi et al., 2005). The extent of S3291 phosphorylation 
was shown to decrease after the induction of DNA damage by ionising radiation 
(Esashi et al., 2005), and to increase as cells progress from G2 to M phase. Thus, 
it was postulated S3291 phosphorylation allows BRCA2 to regulate Rad51-
dependent HR to ensure completion of DNA repair before entry into mitosis. In 
addition, induced DNA damage results in increased BRCA2-Rad51 interaction via 
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the C-terminal motif, and perhaps overcomes cell-cycle regulation to allow 
dephosphorylation of S3291, Rad51 filament binding and stabilisation, thereby 
stimulating HR-mediated repair of DNA damage (Lord and Ashworth, 2007). 
Cancer-associated mutations in BRCA2 occur at S3291 and residue 3292, which 
could disrupt the regulation of Rad51 by this C-terminal motif (McAllister et al., 
2002;Donoho et al., 2003;Esashi et al., 2005). The binding and stabilisation of 
Rad51 nucleoprotein filaments by the C-terminus of BRCA2 and was initially 
thought to protect against filament disassembly by BRC repeat 4 (Davies and 
Pellegrini, 2007;Esashi et al., 2007). However, in light of the role of a subset of 
the BRC repeats in the stabilisation of Rad51-ssDNA nucleoprotein filaments, the 
function of the C-terminal Rad51-binding domain has been re-investigated. 
Recent work has suggested that this C-terminal Rad51-binding motif is 
dispensable for DNA repair by HR as a derivative of chicken BRCA2 with the C-
terminal CDK phosphorylation site mutated to mimic the constitutive presence of 
a phosphate group (and therefore unable to bind Rad51) did not show any 
detectable DNA repair or recombination defects (Ayoub et al., 2009). However, 
the disassembly of Rad51 foci after the induction of DNA damage was shown to 
be impaired and linked to a delay in the onset of mitosis (Ayoub et al., 2009). 
The finding that this CDK phosporylation site mutant is capable of supporting 
DNA repair and HR is consistent with earlier work that showed the C-terminus of 
mammalian BRCA2, encompassing all residues downstream of the most C-
terminal BRC repeat, can be replaced with RPA and still function in these 
processes (Saeki et al., 2006); it was not determined if cells expressing such a 
fusion protein display mitosis defects. Very recent work has also indicated that 
the C-terminal Rad51-binding domain of human BRCA2 may be critical for the 
protection of stalled replication forks from degradation (Schlacher et al., 2011), 
and may function through the stabilisation of Rad51 nucleoprotein filaments on 
nascent ssDNA (Figure 1-17;Hashimoto et al., 2010). 
1.4.2.3 Rad51 binding in the context of full-length BRCA2 
The large size of the human BRCA2 protein had precluded the purification of the 
full-length polypeptide until 2010, when three labs published the purification of 
BRCA2 by three distinct methods (Jensen, Carreira, and Kowalczykowski, 
2010;Liu et al., 2010;Thorslund et al., 2010). Initial experiments in vitro 
demonstrate that BRCA2 binds approximately six Rad51 molecules (Liu et al., 
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2010;Jensen, Carreira, and Kowalczykowski, 2010), directs the nucleation of 
Rad51 filaments onto ssDNA in preference over dsDNA (Thorslund et al., 2010;Liu 
et al., 2010;Jensen, Carreira, and Kowalczykowski, 2010), and stimulates the 
displacement of RPA by the Rad51 filament (although a direct interaction with 
RPA was not observed;Liu et al., 2010;Jensen, Carreira, and Kowalczykowski, 
2010). A role for DSS1 (section 1.4.2.4) in the stimulation of BRCA2-mediated 
Rad51 binding to RPA-covered ssDNA was also observed (Liu et al., 2010). BRCA2 
was also shown to stabilise active ATP-bound Rad51-ssDNA nucleoprotein 
filaments by reducing the ATPase activity of Rad51 (Jensen, Carreira, and 
Kowalczykowski, 2010), and thus stimulates DNA strand exchange (Thorslund et 
al., 2010;Liu et al., 2010;Jensen, Carreira, and Kowalczykowski, 2010). No DNA 
polarity preference was detected, with nucleation on both 3’ and 5’ ssDNA tails 
observed, indicating a possible function for BRCA2 in daughter strand gap repair 
during replication (Jensen, Carreira, and Kowalczykowski, 2010). In support of 
this, a binding requirement for the junction between ss- and dsDNA was not 
detected (Jensen, Carreira, and Kowalczykowski, 2010), and binding to 
replication fork structures was observed in vitro (Thorslund et al., 2010). Unlike 
the U. maydis and C.elegans orthologues of BRCA2 (section 1.5.1 and 1.5.2), the 
ability of human BRCA2 to anneal ssDNA-RPA complexes was not detected 
(Jensen, Carreira, and Kowalczykowski, 2010). Uniquely, both monomeric and 
dimeric forms of BRCA2 were observed by electron microscopy (Thorslund et al., 
2010). 
1.4.2.4 The BRCA2 DNA binding domain 
The region of human BRCA2 downstream of the BRC repeats has been shown to 
bind a small, highly acidic protein named DSS1, which is mutated in split 
hand/split foot syndrome (Crackower et al., 1996;Marston et al., 1999). The co-
expression of DSS1 and the C-terminal domain of mouse and rat BRCA2 (~ 800 
amino acids) allowed the elucidation of the X-ray crystal structure of the C-
terminal domain of BRCA2 bound to DSS1 (Yang et al., 2002). Structures were 
determined with and without bound ssDNA, revealing five distinct domains in the 
C-terminal region of BRCA2. The first domain is 190 amino acids in size and 
consists mainly of α helices (α-helical domain). This is followed by three 
oligonucleotide/oligosaccharide-binding folds (OB1, OB2 and OB3), which are 
structurally similar to the OB fold present in most ssDNA binding proteins. 
Chapter 1  58 
Protruding from OB2 is a 130-amino acid insertion that adopts a tower-like 
structure (tower domain), consisting of a pair of long anti-parallel helices that 
support a three-helix bundle, which contains a helix-turn-helix motif (HTH). This 
HTH motif is similar to the DNA-binding domains of bacterial site-specific 
recombinases. ssDNA was observed bound to the OB2 and OB3 domains and the 
presence of the HTH motif analogous to that of bacterial site-specific 
recombinases led to the prediction that the BRCA2 DNA/DSS1-binding domain 
would bind dsDNA, as well as ssDNA. Indeed, when the DNA binding preferences 
of the BRCA2 DNA/DSS1-binding domain were investigated, it was shown to bind 
with high affinity to ssDNA, presumably through the three OB folds, and a role 
for the tower domain in binding to dsDNA was observed, although with much 
lower affinity (San Filippo et al., 2006). In light of these data, it was proposed 
that BRCA2 could be responsible for targeting Rad51 to the ssDNA/dsDNA 
junction at the sites of processed DSBs, and in the removal of RPA from ssDNA to 
facilitate Rad51 nucleoprotein filament formation (Yang et al., 2002;Pellegrini 
and Venkitaraman, 2004). 
Experiments to investigate the function of this conserved C-terminal DBD were 
performed with CAPAN-1 cells, which have lost one BRCA2 allele and the 
remaining allele contains a frame-shift that causes premature termination of 
translation leading to a truncated BRCA2 lacking the entire C-terminal DBD 
(Goggins et al., 1996). CAPAN-1 cells are sensitive to DNA damage, have lost the 
ability to form Rad51 foci and display chromosome instability (Abbott, Freeman, 
and Holt, 1998;Yuan et al., 1999). Analysis of the repair of an I-SceI induced DSB 
lead to the discovery that homology-directed DNA repair was defective in this 
cell line (Moynahan, Pierce, and Jasin, 2001). Culturing of CAPAN-1 cells in the 
presence of Poly ADP-ribose polymerase (PARP) inhibitors, a breast cancer 
therapy that causes lethality in brca2 null cells (Helleday, 2011), lead to the 
occasional resistant clones arising. These resistant cells were active in 
homology-directed repair of DSBs, proficient at Rad51 focus formation and 
recovered chromosome stability, all in the absence of the DBD of BRCA2 
(Edwards et al., 2008). Coupled with the findings from experiments in which the 
BRC repeat region of BRCA2 was fused to the RPA70 ssDNA binding domain, 
leading to attenuation of the brca2-/- phenotype, this indicates that the DBD is 
to some extent expendable for DNA repair (Saeki et al., 2006). As mentioned 
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previously, the BRC repeats of BRCA2 seem to possess an inherent preference for 
facilitating Rad51 nucleation on ssDNA over dsDNA (Carreira and 
Kowalczykowski, 2011), the molecular basis of which has not yet been 
elucidated. 
1.4.2.5 The BRCA2 nuclear localisation signals 
Antibodies against human BRCA2 show it to be localised to the nucleus 
(Bertwistle et al., 1997). Characterisation of the rat and mouse homologues of 
BRCA2 lead to the discovery of two nuclear localisation signals (NLSs) at the 
extreme C-terminus of the protein, which are characterised by a positively 
charged core peptide unit of KKRR (McAllister et al., 1997;Spain et al., 
1999;McAllister et al., 2002). Investigation of the localisation of the smallest 
known cancer-associated truncation of BRCA2, which removes 224 amino acids 
from the C-terminal of the protein (including the two NLSs), demonstrated this 
protein to be cytoplasmically located, indicating that the two NLSs are 
functional and that translocation to the nucleus is required for the normal 
function of BRCA2 in HR (Spain et al., 1999;Davies et al., 2001). 
1.4.3 The function of BRCA2 in homologous 
recombination 
The phenotypes of brca2 null mice demonstrate a critical function for BRCA2 in 
the regulation of homology directed repair of DSBs, and the maintenance of 
genome stability (Sharan et al., 1997;Ludwig et al., 1997;Suzuki et al., 
1997;Connor et al., 1997;Patel et al., 1998;Yu et al., 2000;Moynahan, Pierce, 
and Jasin, 2001;Holloman, 2011). Summaries of current understanding of the 
roles provided by BRCA2 in promoting genome stability via Rad51 are shown in 
Figure 1-16 and Figure 1-17. It is thought that the BRC repeats of mammalian 
BRCA2 provide mediator functions for Rad51 during homology-directed repair of 
DSBs (Holloman, 2011;Carreira and Kowalczykowski, 2011). Specifically, BRC 
repeats 1-4 bind monomeric Rad51 and initiate Rad51 filament nucleation on 
ssDNA, which is then extended by BRC repeats 5-8 through stabilisation of the 
nascent filaments and facilitation of filament growth, therefore promoting DNA 
strand exchange (Figure 1-16;Carreira and Kowalczykowski, 2011). The C-
terminal Rad51-binding site, though dispensable, may play a role in the 
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regulation of this activity, linking it to cell cycle progression, with CDK 
phosphorylation of Serine3291 disrupting Rad51 binding and hastening the 
disassembly of the Rad51 filament (Ayoub et al., 2009;Holloman, 2011). 
Alternatively, or perhaps in addition, the C-terminus of BRCA2 may play a 
critical role in the protection of stalled replication forks from degradation 
(Figure 1-17), via stabilisation of Rad51 filaments on nascent DNA via the BRCA2 
C-terminal Rad51-binding domain, regulation of which is achieved by CDK 
phosphorylation of Serine3291 (Holloman, 2011;Schlacher et al., 2011). What 
seems unclear is how this latter role for the BRCA2 C-terminus, which is not 
proposed to lead to HR (Schlacher et al., 2011), can be reconciled with the 
explicitly HR-promoting role of previous models of BRCA2 function. 
 
Figure 1-16 Proposed model for the role of the BRCA2 BRC repeats in DSB repair. 
Upon formation of a DSB (top), the dsDNA is resected to generate ssDNA tails. (1) BRC 
repeats 1-4 (yellow crescents) bind monomeric Rad51 (blue circles) and enhance binding to 
ssDNA (“locked” Rad51, 2). The binding of BRCA2 directs Rad51 onto the ssDNA of a 
processed DSB and restricts assembly onto the dsDNA nearby. “Locked” Rad51 nucleates 
onto ssDNA and BRC repeats 5-8 (blue crescents) stabilise the nascent nucleoprotein 
filament by limiting ATP hydrolysis by Rad51 (3). The subsequent growth of the Rad51 
nucleoprotein filament displaces RPA (yellow circles) from the ssDNA. At this point, BRCA2 
can be released from the DNA to promote Rad51 nucleation at another DSB (4). The Rad51 
filament continues to grow from the BRCA2-stablised nucleus to form the ATP-bound 
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nucleoprotein filament capable of homologous DNA pairing (5). Figure reproduced from 
Carreira and Kowalczykowski, 2011. 
 
Figure 1-17 Proposed model for role of the BRCA2 C-terminal Rad51-binding motif during 
DNA replication. 
In S-phase, BRCA2 (pink circle) stabilises Rad51 filaments (blue circles) on ssDNA at stalled 
replication forks, thereby preventing fork reversal. Alternatively, stabilised filaments directly 
protect a reversed fork. Once the replication stall is removed, genome duplication can 
proceed until completed. BRCA2 is then no longer required for fork protection, and CDK 
phosphorylation of the BRCA2 C-terminus allows Rad51 filaments to dissociate and 
progression into M phase is initiated. In the absence of BRCA2, nascent strands of the 
stalled fork are unprotected and degraded, possibly by Mre11 (yellow pacman), leading to 
chromosomal instability. Figure reproduced from Schlacher et al., 2011. 
1.4.4 BRCA2 interacting proteins 
Mammalian BRCA2 has been shown to interact with a large number of proteins, 
the first of which to be described was BRCA1, and these two proteins co-localise 
in subnuclear foci following DNA damage (Chen et al., 1998). As mentioned 
above, the C-terminal DNA-binding domain of BRCA2 also binds DSS1, a small 
highly acidic protein that is mutated in split hand/split foot syndrome 
(Crackower et al., 1996). DSS1 is required for recombinational repair but its 
mechanism of action remains to be elucidated (Marston et al., 1999;Kojic et al., 
2003;Gudmundsdottir et al., 2004). The X-ray crystal structure determined of 
the C-terminal ~ 800 residues of BRCA2 showed that DSS1 binds BRCA2 in an 
extended conformation, interacting with the α-helical, OB1 and OB2 domains 
(Yang et al., 2002). The interaction between these two proteins has also been 
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observed in vitro with full-length purified BRCA2, and DSS1 has been shown to 
stimulate Rad51 binding to RPA covered ssDNA (Liu et al., 2010). 
A 2 MDa BRCA2-containing complex was isolated in 2001, within which a 
structural DNA binding component was identified and named BRCA2-associated 
factor 35 (BRAF35;Marmorstein et al., 2001). Since then, BRAF35 (also called 
HMG20b) has been identified as a member of the high-motility group of non-
sequence specific DNA-binding proteins (Wang et al., 1998;Sumoy et al., 
2000;Marmorstein et al., 2001;Lee et al., 2011), and a novel function for BRAF35 
in facilitating the completion of cytokinesis via an interaction with BRCA2 has 
been proposed (Lee et al., 2011). 
BRCA2 has also been shown to be part of the Fanconi Anaemia (FA) pathway 
(section 1.4.5), where it interacts with FANCD2 and FANCG (Hussain et al., 
2003;Hussain et al., 2004). BRCA2 function has also been shown to require the 
protein PALB2/FANCN, another component of the FA pathway (Xia et al., 
2006;Xia et al., 2007), and PALB2 has been demonstrated to co-purify with full-
length BRCA2 (Thorslund et al., 2010). 
Human BRCA2 is required for meiotic recombination, and this function is thought 
to be mediated by its interaction with the meiosis-specific recombinase, DMC1 
(Bishop et al., 1992). DMC1 is a closely related paralogue of Rad51 found widely 
in eukaryotes, capable of promoting strand exchange in similar ways to the 
mitotic recombinase (Masson and West, 2001). Human BRCA2 binds DMC1 at a 
conserved motif called the PhePP motif (KVFVPPFK) that is located downstream 
of the BRC repeats (Thorslund, Esashi, and West, 2007). This PhePP motif is 
distinct from the BRC repeats and promotes specific interactions with DMC1, but 
not with Rad51 (Thorslund, Esashi, and West, 2007). BRCA2 and DMC1 co-localise 
in nuclear foci during meiotic recombination (Bishop, 1994;Tarsounas et al., 
1999), and purified full-length BRCA2 has been shown to interact with DMC1 in 
vitro (Jensen, Carreira, and Kowalczykowski, 2010). 
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1.4.5 Functions of BRCA2 in the Fanconi Anaemia 
pathway 
Fanconi anaemia is an autosomal recessive disorder characterised by bone 
marrow failure, compromised genome stability, and a predisposition to cancer 
(D'Andrea and Grompe, 2003;D'Andrea, 2010). FA is a highly complicated and 
heterogeneous disease caused by mutations in 13 genes, whose products include 
FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ, 
FANCL, FANCM and FANCN, each of which have been demonstrated to function in 
the FA pathway although their precise roles remain unclear (Joenje and Patel, 
2001;Meetei et al., 2005;Levitus, Joenje, and de Winter, 2006;Smogorzewska et 
al., 2007). The hallmark phenotype of FA cells is hypersensitivity to DNA cross-
linking agents, and this lead to the implication of homology-directed DNA repair 
in the FA pathway (Grompe and D'Andrea, 2001;Joenje and Patel, 2001). The 
breast cancer susceptibility proteins have been demonstrated to play integral 
roles in the FA pathway, indeed in 2002 it was concluded that FANCD1 and 
BRCA2 are one and the same (Howlett et al., 2002). This was due to the 
observation that cell lines defective in FANCD1 carry bi-allelic mutations in 
BRCA2 (Howlett et al., 2002), coupled with the discovery that BRCA2 can 
complement for the defect in FANCD1 cell lines (Howlett et al., 2002). BRCA1 is 
known to be required for the efficient foci formation of FANCD2 (Garcia-Higuera 
et al., 2001;Vandenberg et al., 2003), and BRCA2 interacts with FANCD2 and 
FANCN (Hussain et al., 2004;Reid et al., 2007;Xia et al., 2007). Of the remaining 
proteins, it is known that FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL 
and FANCM interact to form a multi-subunit nuclear complex. This core complex 
is known to play multiple roles within the FA pathway, an example of which is 
found following exposure to DNA damage, when the FA core complex 
monoubiquitylates FANCD2, causing it to re-locate to subnuclear foci with BRCA1 
and Rad51 (Garcia-Higuera et al., 2001;Taniguchi and D'Andrea, 2006). Here, 
FANCD2 is thought to promote the loading of BRCA2/FANCD1 into chromatin 
complexes, facilitating the assembly of Rad51 foci and thereby promoting HR 
(Wang, Andreassen, and D'Andrea, 2004;Hussain et al., 2004). 
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1.5 DNA repair in other organisms 
The DNA repair systems in Caenorhabditis elegans, Ustilago maydis and 
Trypanosoma brucei have been characterised and provide an interesting 
comparison with the extensively studied system in mammals. DNA repair in these 
organisms is described with particular emphasis placed on homology-directed 
repair and the BRCA2 orthologues. In some respects, the streamlined machinery 
of HR in these systems may provide insights into the minimum requirements for 
DNA repair. 
1.5.1 Homologous recombination in Caenorhabditis 
elegans 
A BRCA2-related protein, CeBRC-2, was discovered in C. elegans from a yeast 
two-hybrid screen of Rad51 interacting partners (Martin et al., 2005). CeBRC-2 is 
a polypeptide, 394 amino acids in length, and contains a single BRC repeat, a 
single oligonucleotide binding (OB) domain (with similarity to the OB domains 
present in the ssDNA binding protein RPA) and two NLS motifs. CeBRC-2 was 
demonstrated to interact directly with monomeric CeRad51 via the single BRC 
repeat motif present and bind preferentially to ssDNA, in an interaction thought 
to be important for Rad51 filament nucleation onto ssDNA at the site of DNA 
damage (Martin et al., 2005;Petalcorin et al., 2006;Petalcorin et al., 2007). in 
vitro analysis of CeBRC-2 demonstrated an ability to stimulate D-loop formation 
by CeRad51 and, unusually for a BRCA2 orthologue, to promote DNA single-
strand annealing (Petalcorin et al., 2006). The lack of a detectable Rad52 
homologue in this organism may provide an explanation for this unusual 
annealing function of CeBRC-2 (Liu and Heyer, 2011). The single BRC repeat of 
CeBRC-2 has also been shown to stabilise Rad51-DNA filaments via interaction 
with the Rad51 N-terminal domain and may function to promote filament 
propagation (Petalcorin et al., 2007). 
Mutants that contain an N-terminal truncated variant of Cebrc-2, lacking the OB 
domain, display embryonic lethality and meiotic recombination defects (Martin 
et al., 2005). Formation of CeRad51 foci at the sites of DSBs is dependent on 
CeBRC-2 and suggests a requirement for CeBRC-2 for the repair of DSBs by HR 
(Martin et al., 2005). Complementation studies in mammalian cells demonstrate 
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that CeBRC-2 is able to bind directly to mammalian Rad51 and also restore the 
formation of Rad51 foci formation after DNA damage in brca2-/- cells (Min et 
al., 2007). Analysis of differences between the phenotypes of CeRad51 and 
CeBRC-2 mutant cells suggested a role for CeBRC-2 in promoting the use of an 
alternative repair pathway in the absence of CeRad51. CeBRC-2 mutants form 
DNA damage foci in the absence of CeRad51 and the abnormal chromosomal 
aggregates that form in CeBRC-2 mutants can be rescued by blocking NHEJ 
(Martin et al., 2005). 
1.5.2 Homologous recombination in Ustilago maydis 
The yeast-like fungus Ustilago maydis is extremely resistant to killing by ionising 
radiation (Holliday et al., 1971;Resnick, 1978). The homologous recombination 
system in this organism is unusual in containing both a Rad51 orthologue and 
Rec2, an evolutionarily divergent Rad51-paralogue (Rubin, Ferguson, and 
Holloman, 1994). Rec2 has inherent homologous pairing and DNA strand transfer 
activity, unlike Rad51 paralogues in other systems (Bennett and Holloman, 
2001). U. maydis Rad51 and Rec2 appear to have non-redundant roles in DNA 
repair, as mutation of either gene results in radiation sensitivity (Ferguson et 
al., 1997). Rad51 and Rec2 have been shown to interact with each other, and in 
response to DNA damage both Rad51 and Rec2 form intra-nuclear foci thought to 
be the sites of active recombinational repair (Kojic, Thompson, and Holloman, 
2001). Rad51 foci formation is dependent on Rec2 or Brh2 (see below); however, 
Rec2 foci can form in response to DNA damage in the absence of Rad51 and Brh2 
(Kojic et al., 2006). 
A screen for DNA repair-defective mutants in U. maydis identified a BRCA2 
orthologue, Brh2 (Kojic et al., 2002). U. maydis Brh2 is also a simplified version 
of mammal BRCA2, being 1,075 amino acids in length and containing a single BRC 
repeat. Brh2 contains two NLSs, and a highly conserved DBD at the C-terminus 
consisting of a small alpha-helical domain, two OB domains and a tower domain. 
brh2 mutant cells have the same phenotype as rad51 mutant cells, with defects 
in allelic recombination, meiosis, gap repair and repair of ionising radiation 
damage (Bennett and Holloman, 2001;Kojic et al., 2002). However, genomic 
instability and the accumulation of gross chromosomal rearrangements were 
additionally observed in brh2 mutants (Kojic et al., 2002). Interactions between 
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Brh2 and Rad51 were shown to occur at the single BRC repeat motif and also an 
extreme C-terminal motif thought to be analogous to the C-terminal Rad51-
binding motif in mammalian BRCA2 (Kojic et al., 2002;Kojic et al., 2005), though 
no sequence homology can be found. In vitro experiments have shown that Brh2 
nucleates Rad51 filament formation at a dsDNA/ssDNA junction, promotes 
filament elongation and thereby stimulates DNA recombination (Yang et al., 
2005;Mazloum, Zhou, and Holloman, 2007). U. maydis Brh2 is unusual in that the 
N-terminal domain, containing the single BRC repeat, was shown to be sufficient 
for rescue of the brh2 mutant phenotype (Zhou, Kojic, and Holloman, 2009). 
However, the discovery of an additional DNA-binding domain, that was not 
identifiable by sequence analysis, explained this result (Zhou, Kojic, and 
Holloman, 2009). Deletion of this non-canonical N-terminal DNA-binding domain 
creates a requirement for Rad52 for DNA repair activity (Kojic et al., 2011). Brh2 
also possesses inherent DNA annealing activity and an ability to perform second 
end capture; these functions are thought to enable the single-strand annealing 
and synthesis-dependent strand-annealing pathways in this highly radiation 
resistant organism (Mazloum, Zhou, and Holloman, 2007;Mazloum, Zhou, and 
Holloman, 2008;Mazloum and Holloman, 2009). Brh2 has additionally been shown 
to promote template-switching reactions that enable recombinational bypass of 
lesions that occur during DNA replication (Mazloum and Holloman, 2009). 
1.5.3 DNA repair in T. brucei 
Many genes involved in DNA repair mechanisms have been identified in T. 
brucei, most notably RAD51, BRCA2, MRE11, DMC1, KU70/KU80 and four RAD51 
paralogues. T. brucei contains homologues of the KU70 and KU80 proteins, which 
have been shown to function in telomere maintenance in this organism (Conway 
et al., 2002a;Janzen et al., 2004). However, evidence of NHEJ has not been 
obtained and the apparent absence of the key DNA ligase IV and XRCC4 proteins 
may be a possible explanation for this (Burton et al., 2007). Mutation of the 
MRE11 homologue identified in T. brucei has been shown to cause retarded 
growth, impaired HR, an accumulation of gross chromosomal rearrangements 
and increased sensitivity to DNA damaging agents (but not MMS). Despite this, 
evidence for a role in antigenic variation was not seen (Tan, Leal, and Cross, 
2002;Robinson et al., 2002). T. brucei DMC1 has been identified as a close 
homologue of RAD51, which groups with DMC1 from other eukaryotes in 
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phylogenetic analysis (Proudfoot and McCulloch, 2006). Consistent with this, 
mutation of DMC1 does not result in any detectable changes in DNA repair, 
recombination or antigenic variation in bloodstream form cells, which grow 
exclusively by mitotic division (Proudfoot and McCulloch, 2006). The likelihood 
that T. brucei DMC1 contributes to the meiotic genetic exchange that has been 
recorded in the tsetse fly (Tait and Turner, 1990;Gibson and Stevens, 1999) is 
consistent with evidence that expression of the protein appears limited to a 
previously unidentified meiotic life cycle stage in the tsetse salivary glands 
(Peacock et al., 2011), though experiments to show that mutation of the gene 
impairs this process are lacking. Mutation of the RAD51 homologue identified in 
T. brucei has been shown to cause retarded growth, sensitivity to DNA damaging 
agents, impaired homologous recombination and antigenic variation, with down-
regulation of both in situ and transcriptional VSG switching observed (McCulloch 
and Barry, 1999). However, VSG switches were still observed, so alternative, 
RAD51-independent mechanisms for VSG switching must exist. After the 
induction of DNA damage T. brucei RAD51 is detected in clearly visible 
subnuclear foci (Proudfoot and McCulloch, 2005). The levels of RAD51 expression 
upon the induction of DNA damage in T. brucei do not increase, in contrast to 
the up-regulation observed in other closely related organisms, including T. cruzi 
(Regis-da-Silva et al., 2006) and L. major (McKean et al., 2001). T. brucei 
contains four RAD51 paralogues (RAD51-3, RAD51-4, RAD51-5 and RAd51-6), 
which is an unusually large repertoire among protists (Dobson et al., 2011). Each 
of the four paralogues has been systematically mutated and all have been shown 
to cause impaired DNA repair and homologous recombination. However, only one 
paralogue (RAD51-3) has been shown to impair VSG switching (Proudfoot and 
McCulloch, 2005;Dobson et al., 2011). RAD51-3 and RAD51-4 have been shown to 
interact with each other in vivo, and interactions between RAD51-3 and RAD51-
6, and RAD51-4 and RAD51-6 have been detected in vitro (Dobson et al., 2011). 
As mentioned previously (section 1.3.2.1), micro-homology mediated end joining 
has been demonstrated to play a significant, secondary role to HR in DNA repair 
in trypanosomes (Conway et al., 2002b;Burton et al., 2007;Glover, McCulloch, 
and Horn, 2008), and may yet prove to play an important role in genome 
evolution and antigenic variation in this organism (Glover, Jun, and Horn, 2011).  
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1.5.3.1 T. brucei BRCA2 
The T. brucei homologue of BRCA2 (predicted 1,649 amino acids) was identified 
by BLAST searching the T. brucei genome sequence with the sequence of the 
human BRCA2 polypeptide (Lo et al., 2003;Hartley and McCulloch, 2008). The 
most striking feature of T. brucei BRCA2 was the prediction of the presence of 
15 BRC repeat motifs from the genome sequence of TREU 927 (Figure 1-18). This 
number of BRC repeat motifs is a remarkable expansion that is particularly 
noticeable as BRCA2 proteins in other trypanosomatids contain between 1 and 3 
BRC repeats, which is more reminiscent of other unicellular organisms (Figure 
1-19). The BRC repeats of T. brucei BRCA2 display sequence conservation with 
BRC repeats from other organisms, and the sequence fingerprint residues 
identified as critical for Rad51 binding demonstrate this conservation (Figure 
1-20;Lo et al., 2003). However, the organisation of the BRC repeats is unlike 
that seen in multiple BRC repeat BRCA2 homologues in other organisms. In 
contrast with the sequence divergence of the 8 individual BRC repeats of 
mammalian BRCA2, all but the most C-terminal BRC repeat in T. brucei BRCA2 
are identical in sequence. In addition, whereas the human BRC repeats are 
dispersed throughout the middle third of the polypeptide, the T. brucei BRC 
repeats are arranged as a near perfect array close to the N-terminus, with the 
intervening, non-BRC repeat sequences near-perfectly conserved between 
repeat units. Only one other organism is known to contain a BRCA2 with close to 
this number of BRC repeats: Trichomonas vaginalis (14 predicted BRC repeats; 
data not shown). However, here the BRC repeats are not so closely conserved 
relative to each as those in T. brucei, and the inter-BRC repeat sequences are 
not conserved. 
T. brucei BRCA2 displays considerable conservation in the region containing the 
DSS1/DNA-binding domain present in mammalian BRCA2 proteins. Amongst these 
motifs, the α-helical and OB domains 1 and 2 are remarkably conserved, and 
even the more C-terminal tower domain and OB domain 3, though less 
conserved, appear recognisable (Figure 1-21; Claire Hartley, PhD Thesis, 2008). 
Downstream of this DBD is a C-terminal extension, absent in U. maydis Brh2 and 
in A. thaliana BRCA2 (Figure 1-22), which shows limited overall sequence 
homology with human BRCA2. Nevertheless, within this domain a serine residue 
is positionally conserved adjacent to a proline and therefore bears a 
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resemblance to the C-terminal CDK phosphorylation site present at Serine 3291 
in mammalian BRCA2 proteins: in T. brucei BRCA2 this would correspond with 
Serine 1523 (Figure 1-22; Claire Hartley, PhD Thesis, 2008). The same motif, if 
functional, appears conserved also in T. cruzi, but not in L. major. Three 
putative NLS motifs have been proposed in T. brucei BRCA2 (Claire Hartley, PhD 
Thesis, 2008), two upstream of the BRC repeats and a single, bipartite sequence 
present downstream of the last BRC repeat. A divergent PhePP motif may also be 
present just downstream of the bipartite NLS (section 5.2.1). 
brca2-/- mutants in bloodstream form Lister 427 T. brucei cells display DNA 
repair phenotypes characterised by retarded growth, increased DNA damage 
sensitivity, impaired homologous recombination, impaired localisation of RAD51 
to subnuclear foci after DNA damage, and impaired antigenic variation. 
Interestingly, an accumulation of putative gross chromosomal rearrangements 
(GCRs) were observed after prolonged passaging (Hartley and McCulloch, 2008), 
and also a replication phenotype that is manifest as an increase in the number of 
cells with aberrant DNA configurations, as measured by DAPI staining and 
counting of individual cells. Further analysis of these ‘others’ showed they are 
mainly 1N0K and 2N1K cells, suggesting progression through cytokinesis before 
the completion of mitosis. Consistent with this was an observed increase in the 
number of 2N2K cells in which the two nuclei were visibly connected, rather 
than being separate in the cell (Claire Hartley, PhD Thesis, 2008). 
In an attempt to determine the function of the BRC repeat expansion in T. 
brucei BRCA2, brca2-/- mutant cells were complemented with a variant of 
BRCA2 containing a single BRC repeat (the divergent C-terminal repeat), which 
restored the growth, replication, and VSG switching phenotypes to wild-type 
levels, but not the recombination, DNA damage sensitivity, or RAD51 foci 
formation defects (Hartley and McCulloch, 2008;Claire Hartley, PhD Thesis, 
2008). The brca2-/- mutant cells were also complemented with a variant of 
BRCA2 containing the BRC repeat domain fused to the T. brucei RPA50 subunit 
that is homologous to the 70 kDa RPA-1 of eukaryotes, in a recapitulation of 
successful experiments in mammalian and U. maydis cells (Kojic et al., 
2005;Saeki et al., 2006). This led to the restoration of the DNA repair and 
recombination phenotypes and to the conclusion that the C-terminal DBD was 
not required for DNA repair, as seen in other organisms. However, the 
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replication phenotype was not complemented, leading to the conclusion that the 
C-terminal domain of BRCA2 is critical for replication progression, though the 
basis for this was unclear (Claire Hartley, PhD Thesis, 2008). This C-terminal 
domain of BRCA2 has been suggested to interact in vitro with part of the T. 
brucei homologue of CDC45 (Oyola, Bringaud, and Melville, 2009), which is a 
protein essential for the initiation and progression of DNA replication (Chapter 
6;Zou, Mitchell, and Stillman, 1997). The BRC repeats of T. brucei BRCA2 have 
also been suggested to interact with RAD51 and the four RAD51 paralogues by 
yeast 2-hybrid, with a single BRC repeat sufficient for binding to RAD51-3 and 
RAD51-5 (Hall et al., 2011), although the function of these interactions, not seen 
to date in any other organism, remains to be elucidated. 
 
Figure 1-18 A schematic representation of T. brucei BRCA2 and its putative functional 
domains. 
The diagram represents the predicted functional domains of T. brucei BRCA2, including the 
BRC repeats 1-14 (red bars), BRC repeat 15 (dark red bar), NLS (light blue bar), PhePP motif 
(orange bar), alpha helical domain (green oval), OB domains (blue boxes), tower domain 
(purple box), and putative CDK phosphorylation site (light green bar). Figure adapted from 
Claire Hartley, PhD Thesis, 2008. 
 
Figure 1-19 Representation of the number of BRC repeats in BRCA2 proteins from 
trypanosomatids and other eukaryotes. 
BRC repeat motifs are displayed (red bars), and their position within the BRCA2 
polypeptides are shown. Protein sizes in amino acid residues are indicated. Figure 
reproduced from Hartley and McCulloch, 2008. 
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Figure 1-20 Multiple sequence alignment of the BRC repeats from trypansomatids and 
humans. 
The polypeptide sequences of the BRC repeats were taken from T. brucei, T. congolense, T. 
vivax, T. cruzi and H. sapiens. Residues that are identical in greater than 50% of the 
sequences are shaded in black and similarly conserved residues shaded in grey. Figure 
reproduced from Claire Hartley, PhD Thesis, 2008. 
 
Figure 1-21 Alignment of the C-terminal DNA/DSS1-binding domains of BRCA2. 
Multiple sequence alignment of the C-terminal DNA/DSS1-binding domains of the BRCA2 
proteins from T. brucei, T. cruzi, L. major, H. sapiens, G. gallus, A. thaliana and U. maydis. 
Residues that are identical in at least 50% of the proteins are shaded in black and similarly 
conserved residues are shaded in grey. The coloured blocks within the alignment represent 
the corresponding domains in the diagram of BRCA2 shown above. Figure adapted from 
Claire Hartley, PhD Thesis, 2008. 
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Figure 1-22 C-terminal alignment around a CDK phosphorylation site in human BRCA2. 
Multiple sequence alignment of the C-terminus of the BRCA2 proteins from T. brucei, T. 
cruzi, L. major, H. sapiens, G. gallus, A. thaliana and U. maydis. Residues that are identical 
in at least 50% of the proteins are shaded in black and similarly conserved residues are 
shaded in grey. The putative CDK phosphorylation site is highlighted (CDK). Figure adapted 
from Claire Hartley, PhD Thesis, 2008. 
1.6 Rad51 
Rad51, the eukaryotic HR recombinase (Radding, 1991;Sung, 1994;Sung and 
Robberson, 1995), appears to be one of only a small number of proteins that are 
universally conserved, with orthologues named RecA and RadA found in bacteria 
and archea, respectively (Ogawa et al., 1993). This implies that HR is an 
essential process for the propagation of all living cells. Human Rad51 is a protein 
of 37 kDa that possesses a core domain, termed the RecA-fold, which contains 
Walker A and B motifs that are responsible for ATP binding and hydrolysis 
(Walker et al., 1982). In the absence of DNA, Rad51 forms inactive heptameric 
ring structures (Shin et al., 2003). In the presence of DNA, Rad51 forms a highly 
ordered right-handed nucleoprotein filament (Benson, Stasiak, and West, 1994). 
Interactions between Rad51 monomers are thought to occur via an 
oligomerisation motif located at the subunit interface (Shin et al., 2003). The 
Rad51 nucleoprotein filament forms with equal affinity on ss- and dsDNA, with a 
stoichiometry of 3 - 4 bp per protein (Benson, Stasiak, and West, 1994). DNA in 
the nucleoprotein filament is under-wound and extended by ~ 50% relative to B-
form DNA (Ogawa et al., 1993;Arata et al., 2009). These Rad51 nucleoprotein 
filaments are active and possess DNA pairing, strand invasion and strand 
exchange activities (Shinohara, Ogawa, and Ogawa, 1992;Baumann and West, 
1997), which are stimulated by RPA, through removal of secondary structure in 
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the ssDNA tail (McIlwraith et al., 2000), and by Ca2+, through a reduction in the 
ATPase activity of Rad51 thereby maintaining the filament in an active, stable 
state (Bugreev and Mazin, 2004;Chi et al., 2006). No intrinsic polarity preference 
for DNA has been observed, and filaments form on both the 3’ and 5’ ssDNA tails 
produced by the processing of a DSB (McIlwraith et al., 2000). Rad51 
nucleoprotein filament assembly occurs in two steps: nucleation and growth. 2 – 
5 Rad51 monomers are required to form a stable nucleation event and growth 
occurs in vitro to a finite length (Van der Heijden et al., 2007;Mine et al., 
2007;Hilario et al., 2009). It is thought that in vivo Rad51 filaments are made up 
of many small fragments arising from multiple nucleation events, and the highly 
dynamic and flexible nature of this Rad51 filament is thought to facilitate strand 
exchange (Galletto et al., 2006). Filament disassembly after the completion of 
strand exchange requires Rad54, an ATP-dependant DNA translocase, and also 
the hydrolysis of ATP by Rad51 (Amitani, Baskin, and Kowalczykowski, 2006;Li et 
al., 2007). 
When bacteria are exposed to DNA damage, expression of the bacterial 
recombinase (RecA) is induced to increase more than 15 fold in an ‘SOS 
response’ (Little and Mount, 1982;Walker, 1984;Janion, 2008); mammalian cells 
do not exhibit such an induction (Tarsounas, Davies, and West, 2004;Michel, 
2005), but it is common in eukaryotes as diverse as yeast and T. cruzi (Regis-da-
Silva et al., 2006;Putnam, Jaehnig, and Kolodner, 2009), suggesting mammals 
may be the exception. When DNA damage is detected, Rad51 and other repair 
proteins that are normally diffuse throughout the nucleus (Haaf et al., 
1995;Scully et al., 1997) are rapidly relocated and concentrated into subnuclear 
complexes that are microscopically detected as foci. This creates an effect 
whereby the local concentration of repair enzymes is increased, forming what is 
considered a repair centre (Tarsounas, Davies, and West, 2004;Lisby and 
Rothstein, 2009), the precise composition and function of which remains 
unknown. Studies of the nuclear localisation and dynamics of mammalian Rad51 
have identified three pools of Rad51; a large mobile pool of Rad51 exists 
alongside two smaller, relatively immobile pools, one bound by BRCA2 and the 
other self-associated in oligomeric heptamers (Essers et al., 2002;Yu et al., 
2003). 
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1.7 Aims of this thesis 
The initial aim of this thesis was to further investigate the role of BRCA2 in the 
regulation of genome stability in T. brucei, with particular focus on the genetic 
dissection of the chromosomal rearrangements observed in brca2-/- mutants and 
the function of the unusual BRC repeat expansion. 
A second aim of this thesis was to define the interactions between T. brucei 
BRCA2 and RAD51 in the hope this would shed further light on the mechanism of 
the regulation of homology-directed DNA repair by BRCA2 in this organism. 
Finally, the putative function for T. brucei BRCA2 in the repair of stalled 
replication forks was further investigated, focusing on the proposed interaction 
with CDC45. 
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2.1 Trypanosome culture 
2.1.1 Trypanosome strains 
The bloodstream form (BSF) T. brucei strain used in this thesis is Lister 427 
(Rudenko et al., 1996;McCulloch, Rudenko, and Borst, 1997). This is a 
monomorphic strain, which usually only displays the long slender BSF cells. The 
switching frequency of the VSG being expressed is approximately 10-6 - 10-7 
switches/cell/generation (Lamont, Tucker, and Cross, 1986;Turner, 1997). The 
procyclic form (PCF) T. brucei strains used in this thesis are Lister 427 and TREU 
(Trypanosomiasis Research Edinburgh University) 927 (Turner et al., 1990). 
2.1.2 Trypanosome growth 
BSF cell density was determined microscopically using a Bright-Line 
haemocytometer (Hausser Scientific). In a 10 µl aliquot of culture, the number 
of parasites under a 1 mm square area (0.1 µl volume) was counted and 
multiplied by 104 to obtain the number of cells.ml-1 of culture. In vitro growth of 
BSF cells was carried out at 37°C in a humidified 5% CO2 incubator using HMI-9 
growth medium (Hirumi and Hirumi, 1989) supplemented with 20% (v/v) heat-
inactivated foetal calf serum (FCS; Sigma) and 1% (v/v) penicillin/streptomycin 
(Sigma). The population doubling time of this strain is approximately 8 hours 
(Proudfoot and McCulloch, 2006). To keep a working culture of BSF cell lines, 
cells were passaged three times weekly by the addition of 20 µl of a culture 
grown to a density of ~ 4 x 106 cells.ml-1 to 1.5 ml HMI-9 medium in a 24-well 
plate. BSF cultures were grown in petri dishes in volumes of up to 25 mls to 
obtain large numbers of cells. 
PCF cell density was determined using a Z2 Coulter Particle Count and Size 
Analyzer (Beckman Coulter) according to manufacturer’s instructions. 
Background counts due to particles in the culture medium were subtracted from 
readings of cell dilutions into IsoFlow Sheath Fluid (Beckman Coulter), typically 
of 1:1000. Output is given in cells.ml-1 of culture. In vitro growth of PCF cells 
was carried out at 27°C using a derivative of semi-defined medium (SDM-79;Brun 
and Schonenberger, 1979) supplemented with 10% (v/v) heat-inactivated FCS 
(Sigma) and 0.2% (v/v) Haemin (Sigma; diluted from 2 mg.mL-1 solution in 0.2 M 
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NaOH). The population doubling time of the PCF is approximately 10 hours. To 
keep a working culture of PCF cell lines, cells were passaged three times weekly 
by addition of 1 ml of a culture grown to a density of ~ 4 x 107 cells.ml-1 to 9 mls 
SDM-79 medium in a vented 25 cm2 tissue culture flask. PCF cultures were grown 
in vented 75 cm2 tissue culture flasks in volumes of up to 100 mls to obtain large 
numbers of cells. 
2.1.2.1 Stabilate preparation and retrieval 
For the long term storage of trypanosomes, stabilates were prepared by the 
addition of 100 µl of sterile 100% glycerol to 900 µl of culture grown to a density 
of ~ 2 x 106 cells.ml-1 (BSF) or ~ 8 x 106 cells.ml-1 (PCF). These 1 ml aliquots were 
placed in 1.2 ml cryotubes (Nunc), before being wrapped in cotton wool, frozen 
slowly at - 80°C overnight and then transferred to liquid nitrogen storage. For 
retrieval of stabilates from liquid nitrogen storage, frozen cells were defrosted 
at 37°C (BSF) or 27°C (PCF), and placed in 10 mls HMI-9 growth medium (BSF) or 
5 mls SDM-79 growth medium (PCF) overnight; cells were then passaged normally 
as described above. 
2.1.3 Stable, clonal transformation of trypanosomes 
BSF cells were grown to a density of ~ 2 x 106 cells.ml-1 and centrifuged at room 
temperature for 10 minutes at 583 x g. The cells were re-suspended in 
Zimmerman post-fusion medium (ZM; 5 M NaCl, 1 M KCl, 1 M Na2HPO4, 1 M 
KH2HPO4, 1 M MgOAc, 0.2 M CaCl2) supplemented with 1 M D-glucose (ZMG), at a 
concentration of 1 x 108 cells.ml-1. 5 x 107 cells per transformation were 
electroporated in 500 µl ZMG at 1.5 kV and 25 µF capacitance using a BioRad 
Gene Pulser II. Approximately 5 µg of purified DNA in a maximum volume of 10 
µl, that had been restriction digested and ethanol precipitated was routinely 
used for transformations. After electroporation, cells were placed in 10 mls HMI-
9 for 24 hours before being subjected to antibiotic selection. The recovered cells 
were centrifuged at room temperature for 10 minutes at 583 x g and re-
suspended in HMI-9 supplemented with the appropriate antibiotics at a 
concentration of 5 x 105 cells.ml-1. 1-2 x 107 cells were plated out in 1.5 ml 
aliquots over two 24 well plates. Transformants were counted after 7-10 days by 
looking at the plates using a light microscope (Leitz) and counting the number of 
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wells that contained growing cells. The population of cells in a well should have 
descended from a single transformant, and could therefore be considered as 
clonal, so long as less than 80% of the wells contain living cells (Wickstead, 
Ersfeld, and Gull, 2003). Typically six clones were chosen and expanded for 
further analysis. 
PCF cells were grown to a density of ~ 8 x 106 cells.ml-1 and centrifuged at room 
temperature for 10 minutes at 583 x g. The cells were re-suspended in 
Zimmerman post-fusion medium (ZM; 5 M NaCl, 1 M KCl, 1 M Na2HPO4, 1 M 
KH2HPO4, 1 M MgOAc, 0.2 M CaCl2), at a concentration of 1 x 10
8 cells.ml-1. 5 x 
107 cells per transformation were electroporated twice in 500 µl ZM at 1.5 kV 
and 25 µF capacitance using a BioRad Gene Pulser II. Approximately 5 µg of 
purified DNA in a maximum volume of 10 µl, that had been restriction digested 
and ethanol precipitated was routinely used for transformations. After 
electroporation, cells were placed in 10 mls of SDM-79 for 24 hours before being 
subjected to antibiotic selection. The recovered cells were diluted to 
concentrations of 103, 104, 105 and 106 cells in 20 mls of conditioned media (75% 
(v/v) SDM-79, 10% (v/v) FCS, 15% (v/v) SDM-79 conditioned by growth of wild-
type PCF cells to ~ 8 x 106.ml-1, centrifuged and filter sterilised to remove 
trypanosomes) supplemented with the appropriate antibiotics, and plated out 
over four 96-well plates (175 µl per well). Transformants were counted after 10-
14 days by looking at the plates under a light microscope (Leitz) and counting 
the number of wells that contained growing cells. The population of cells in a 
well should have descended from a single transformant, and could therefore be 
considered as clonal, so long as less than 20% of the wells contain living cells. 
Typically six clones were chosen and expanded for further analysis. 
2.1.4 Re-cloning of polyclonal trypanosome populations 
After prolonged passaging of trypanosome cultures, clonal populations were 
obtained by re-cloning the cell cultures prior to further analysis. BSF cells were 
grown to a density of ~ 2 x 106 cells.ml-1 before plating out cells in two 24 well 
plates on HMI-9 supplemented with the appropriate antibiotics at a 
concentration of ~ 12 cells per plate. Clones typically emerged after 7-10 days 
and were counted by looking at the number of wells containing living cells using 
a light microscope (Leitz). The population of cells in a well should have 
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descended from a single cell, and could therefore be considered as clonal, so 
long as less than 80% of the wells contain living cells (Wickstead, Ersfeld, and 
Gull, 2003). Typically six clones were selected and expanded for further 
analysis. 
PCF cells were grown to a density of ~ 8 x 106 cells.ml-1 before plating out cells 
in four 96 well plates on conditioned media supplemented with the appropriate 
antibiotics at concentrations of 103, 104, 105 and 106 cells per plate. Clones 
typically emerged after 10-14 days and were counted by looking at the number 
of wells containing living cells using a light microscope (Leitz). The population of 
cells in a well should have descended from a single cell, and could therefore be 
considered as clonal, so long as less than 20% of the wells contain living cells. 
Typically six clones were selected and expanded for further analysis. 
2.2 Isolation of material from trypanosomes 
2.2.1 Isolation of genomic DNA 
Genomic DNA (gDNA) was prepared using the DNeasy Blood and Tissue kit 
(Qiagen). 10 mls of BSF grown to a density of ~ 4 x 106 cells.ml-1 or 5 mls of PCF 
grown to a density of ~ 2 x 107 cells.ml-1 were harvested by centrifugation at 
1620 x g for 10 minutes at room temperature, washed with 1 ml PBS, before DNA 
extraction according to manufacturer’s protocol. 
Genomic DNA that was to be subsequently used for restriction digestion and 
Southern blot analysis was prepared using the Gentra Puregene cell kit (Qiagen). 
50 mls of BSF grown to a density of ~ 4 x 106 cells.ml-1 or 20 mls of PCF grown to 
a density of ~ 2 x 107 cells.ml-1 were harvested by centrifugation at 1620 x g for 
10 minutes at room temperature. Cell pellets were washed twice with 1 ml PBS 
before DNA extraction according to manufacturer’s protocol. The concentration 
of gDNA extracted was quantified using a spectrophotometer (Eppendorf) to 
measure the absorbance at 260nm, typically using a dilution of 1 µl of gDNA into 
49 µl of dH2O. 
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2.2.2 Genomic plug preparation 
Each genomic agarose plug prepared for the work in this thesis contained ~ 1 x 
108 PCF cells. PCF cells were grown to a density of ~ 8 x 106 cells.ml-1, 
centrifuged at 2500 x g for 5 minutes at room temperature and washed twice in 
25 mls of cold Trypanosome Dilution Buffer (TDB; 120 mM NaCl, 1.2 mM KH2PO4, 
30 mM TES, 40 mM NaH2PO4, 5 mM NaHCO3, 5 mM KCl, 10 mM D-Glucose, 1 µM 
MgSO4.7H2O). The pellet was then re-suspended in 50 µl TDB and warmed at 
37°C for 2 minutes, before adding an equal volume of pre-warmed 1.4% Hi-
strength Low Melting Point (LMP) agarose (Biogene) made with dH2O. This 
mixture was swirled to mix before filling disposable plug moulds (BioRad) with 
100 µl of the agarose/trypanosome solution and leaving for 15 minutes at room 
temperature to set. Plug moulds were submerged in ice cold NDS buffer, pH 9.0 
(0.5 M EDTA, 10 mM Tris and 34.1 mM lauroyl sarcosine) for 10 minutes at 4°C. 
The agarose plugs were then removed from the moulds, incubated in 1 ml NDS 
buffer, pH 9.0 containing 1 mg.ml-1 proteinase K (Invitrogen) at 50°C for ~ 24 
hours and then transferred into 1 ml NDS buffer, pH 8.0 containing 1 mg.ml-1 
proteinase K at 50°C for ~ 24 hours. The plugs were finally transferred into 1 ml 
NDS buffer, pH 8.0 for storage at 4°C indefinetly. 
2.2.3 Isolation of RNA 
2 x 107 BSF or PCF cells from cultures grown to densities of ~ 2 x 106 cells.ml-1 
and ~ 8 x 106 cells.ml-1 respectively, were centrifuged at 583 x g for 10 minutes 
at room temperature. Cell pellets were washed once with 1ml PBS. Cell pellets 
were stored at - 80°C until required. Total RNA was extracted using the RNeasy 
mini kit (Qiagen) according to manufacturer’s instructions. On-column DNase 
treatment (Qiagen) was carried out according to manufacturer’s instructions for 
RNA to be subsequently used for qRT-PCR (section 2.5.5). 
2.2.4 Protein extraction 
2.2.4.1 For SDS-PAGE separation 
25 mls of BSF cells grown to a density of ~ 4 x 106 cells.ml-1, or 10 mls of PCF 
cells grown to a density of ~ 2 x 107 cells.ml-1, were harvested by centrifugation 
at 1620 x g for 10 minutes at room temperature and washed once with 1 ml PBS. 
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The pellet was re-suspended in SDS-PAGE sample buffer (0.5 M Tris-HCL, pH 6.8, 
20% Glycerol, 10% SDS, 5% 2-mercaptoethanol, 0.1% (w/v) bromophenol blue, 
170 mM DTT) to a concentration of 5 x 108 cells.ml-1. Protein extracts were 
denatured at 98°C for 5 minutes prior to electrophoretic separation (section 
2.8.3). 
2.2.4.2 For co-immunoprecipitation 
3 x 108 PCF cells from a culture grown to a density of ~ 8 x 106 cells.ml-1 were 
centrifuged at 1620 x g for 10 minutes at room temperature. The cell pellet was 
washed twice with 1 ml PBS prior to resuspension in 500 µl Trypanosome Lysis 
Buffer (TLB; 20 mM Tris-HCl (pH 8.0), 400 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-
40, 10% Glycerol, 1 mM DTT, 1 x Complete EDTA-free Protease Inhibitor Cocktail 
(Roche)). Cell suspensions were frozen at - 80°C until required. Frozen cell 
suspensions were defrosted on ice and then lysed by vortexing for 30 seconds at 
high speed before incubation on ice for 30 minutes. Cell debris was pelleted by 
centrifugation at 20,000 x g for 20 minutes at 4°C. The supernatant was 
transferred to a clean eppendorf and used immediately for experiments (section 
2.12). 
2.2.5 Aqueous fractionation 
Aqueous fractionation was performed to separate the soluble nuclear and 
cytoplasmic proteins from T. brucei as described in Zeiner et al., (2003). 5 x 108 
PCF cells from a culture grown to a density of ~ 8 x 106 cells.ml-1 were 
centrifuged at 1620 x g and washed twice in 5 ml ice cold Fractionation Buffer A 
(FBA; 150 mM sucrose, 20 mM KCl, 3 mM MgCl2, 20 mM HEPES-KOH (pH 7.9), 1 
mM DTT, and 1 x Complete EDTA-free Protease Inhibitor Cocktail (Roche)). The 
cell pellet was re-suspended in 1 ml of FBA and 0.2% Nonidet P-40 (Calbiochem) 
was added. The cell suspension was passed through a 26-gauge syringe needle 
three times. The suspension was centrifuged at 20,000 x g for 10 minutes at 4°C. 
The supernatant was separated and centrifuged again at 20,000 x g at 4°C. This 
supernatant contains the soluble cytoplasmic proteins. The cell pellet was re-
suspended in 500 µl of FBA and passed through a 26-guage syringe needle 15 
times. The suspension was centrifuged at 20,000 x g at 4°C for 10 minutes. The 
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supernatant was removed and the pellet re-suspended in 500 µl of FBA. This 
suspension contains the soluble nuclear proteins. 
2.3 Phenotype analysis 
2.3.1 In vitro growth and doubling time 
In vitro growth analysis was carried out on BSF cells by inoculating 2 ml cultures 
with 5 x 104 cells.ml-1, from a culture grown to a density of ~ 2 x 106 cells.ml-1. 
The numbers of cells were counted at 24, 48, and 72 hours subsequently using a 
Bright-Line haemocytometer (Hausser Scientific). 
For PCF cells, a 2 ml culture was inoculated with 5 x 105 cells.ml-1, from a 
culture grown to a density of ~ 8 x 106 cells.ml-1. The numbers of cells were 
counted at 24, 48, and 72 hours subsequently using a Z2 Coulter particle count 
and size analyzer (Beckman Coulter). 
Three repetitions of each cell line were carried out and the results plotted on a 
semi-logarithmic scale. The doubling time for the cell populations were 
calculated by comparing the cell count in mid-log phase using the following 
equation: Time Elapsed ÷ (3.3 x Log [Cell count at the end of time elapsed ÷ Cell 
count at the beginning]), where the time elapsed is in hours, and the cell count 
is in cells.ml-1. All population doubling times calculated in this thesis were 
determined using cell counts obtained between 24 and 48 hours. 
2.3.2 DNA damage sensitivity 
The sensitivity of trypanosomes to DNA damaging agents can be analysed using 
the Alamar Blue assay (Raz et al., 1997;Onyango, Burri, and Brun, 2000). Alamar 
Blue (resazurin sodium salt; Sigma) is a blue-coloured, non-fluorescent 
compound. However, in actively metabolising cells, resazurin is reduced to 
resorufin, which is pink and highly fluorescent (Raz et al., 1997;O'Brien et al., 
2000). Cells were grown to a density of ~ 2 x 106 cells.ml-1 (BSF) or ~ 8 x 106 
cells.ml-1 (PCF). First, the 96 well plate (Nunc) was prepared; 100 µl of the 
corresponding media was added to all wells except for the first column. To the 
first column, 200 µl of the stock of MMS or phleomycin were added (0.01% and 4 
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µg.ml-1 respectively for BSF or 0.08% and 32 µg.ml-1 respectively for PCF). A two-
fold serial dilution was made by taking 100 µl from the first column and mixing it 
with the next column. Then 100 µl from the second column was added to the 
third column and mixed, and so on until the last column to which no drug was 
added. To each row, 100 µl of cells at a density of 2 x 105 cells.ml-1 (BSF) or 5 x 
105 cells.ml-1 (PCF) were added, except for the last row which was left with no 
cells as a background control. These cells were allowed to grow for 48 hours at 
their respective normal culture temperatures, after which 20 µl of 0.125 mg.ml-1 
resazurin sodium salt (Sigma) in PBS was added. This was then incubated for 24 
hours and the plate read by a spectrophotometer using filters of 540 nm 
excitation and 590 nm emission (Wallac Envision, 2102 Multi-label reader) and 
the data analysed using Microsoft Office Excel and GraphPad Prism4. In Excel, 
average background counts with no cells added were subtracted from all values 
and percentage survival was calculated relative to no drug controls. In 
GraphPad, these data were transformed using X=Log(X) and nonlinear regression 
(curve fitting) was then performed. EC50 values relative to the wild type cell 
line in each case were plotted with 95% confidence intervals. 
2.3.2.1 Hydroxyurea damage 
Hydroxyurea (HU) inhibits ribonucleotide reductase, an enzyme involved in 
deoxyribonucleotide triphosphate (dNTP) synthesis and thereby causes a stall in 
DNA replication (Hofer et al., 1997). PCF cells grown to a density of ~ 4 x 106 
cells.ml-1 were treated with 0.3 mM HU for 16 hours (2 cell cycles). The effect of 
HU was confirmed by FACS analysis of cells (section 2.3.3;Forsythe, McCulloch, 
and Hammarton, 2009). 
2.3.2.2 Phleomycin damage 
Phleomycin is a group of copper-containing antibiotic peptides of the bleomycin 
family first isolated from Streptomyces verticillus. It has been shown to inhibit 
DNA synthesis by blocking the activity of DNA polymerase and inducing the 
formation of DNA double strand breaks (Falaschi and Kornberg, 1964;Reiter, 
Kelley, and Milewski, 1972). PCF cells grown to a density of ~ 4 x 106 cells.ml-1 
were treated with 1-2 µg.ml-1 phleomycin for 18-24 hours, as indicated. BSF 
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cells grown to a density of ~ 1 x 106 cells.ml-1 were treated with 0.25-1 µg.ml-1 
phleomycin for 18 hours, as indicated. 
2.3.2.3 Methyl methanesulphonate damage 
Methyl methanesulphonate (MMS) is an alkylating agent that methylates DNA to 
produce methylated purines at the 7’ position of guanine residues and the 3’ 
position of adenine residues (Brookes and Lawley, 1961;Reiter et al., 1967). PCF 
cells grown to a density of ~ 4 x 106 cells.ml-1 were treated with MMS as 
indicated. 
2.3.3 Fluorescent Activated Cell Sorting Analysis 
For fluorescent activated cell sorting (FACS) analysis, 1 x 106 cells from a culture 
of PCF cells grown to a density of ~ 8 x 106 cells.ml-1 were pelleted by 
centrifugation at 583 x g for 10 minutes at room temperature, washed once with 
1 ml PBS and re-suspended in cold 70% methanol (v/v) in PBS. The cells were 
fixed by incubation at 4°C overnight. After fixation, cells were washed in 10 ml 
of ice cold PBS, re-suspended in 1 ml of PBS containing 10 µg.ml-1 propidium 
iodide (Sigma) and 10 µg.ml-1 RNase A (Sigma), and incubated at 37°C for 45 
minutes. FACS was performed with a Becton Dickinson FACSCalibur using 
detector FL2-A and an AmpGain value of 1.75. 
2.4 Microscopy 
2.4.1 Cell cycle analysis 
In order to analyse the cell cycle, cells were prepared for microscopy by DAPI 
staining (4, 6-diamidino-2-phenylindole; Vector Laboratories). DAPI stain binds 
preferentially to dsDNA and fluoresces under UV light, allowing the DNA content 
of fixed cells to be analysed. 100 µl of BSF cells grown to a density of ~ 2 x 106 
cells.ml-1 or 50 µl of PCF cells grown to a density of ~ 8 x 106 cells.ml-1 were 
spread thinly on a microscope slide and allowed to air dry. Cells were fixed by 
immersion in methanol at room temperature for 10 minutes. Slides were allowed 
to air dry before placing two drops of vectashield with DAPI (1.5 µg.ml-1; Vector 
Laboratories) onto the slide, positioning a coverslip and sealing the slide with 
clear nail varnish. Differential interface contrast (DIC) was used to visualise 
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intact cells and UV (461 nm) to visualise DAPI using a Zeiss Axioskop microscope. 
Cells were counted according to the number of nuclei and kinetoplasts they 
contained. Cells in G1 phase of the cell cycle contain 1 nucleus and 1 kinetoplast 
(1N1K). Kinetoplast division then occurs resulting in cells with 1 nucleus and 2 
kinetoplasts (1N2K). After this, the nucleus divides leading to cells containing 2 
nuclei and 2 kinetoplasts (2N2K). Completion of cytokinesis forms two daughter 
cells in G1 phase, containing 1 nucleus and 1 kinetoplast (1N1K). Any cells that 
were observed not to be in these cell cycle phases were noted as being aberrant 
cell types and were described as ‘others’. 
2.4.2 Immunolocalisation 
Endogenously expressed epitope-tagged proteins were visualised by 
immunolocalisation using a microscope. 5 x 105 PCF cells from a culture grown to 
a density of ~ 8 x 106 cells.ml-1, or 5 x 106 BSF cells from a culture grown to a 
density of ~ 2 x 106 cells.ml-1, were centrifuged at 735 x g for 5 mins and washed 
in 1 ml ice cold PBS. The cell pellet was re-suspended in 50 µl ice cold PBS 
before being spread thinly on a silane prep glass slide (Sigma) and allowed to air 
dry. Cells were fixed by soaking in cold methanol for 15 minutes. Excess 
methanol was washed off by submersion in ice cold PBS twice before blocking in 
2% FCS in PBS for 1 hour to overnight. Primary antibodies (Table 2-2) were 
diluted to the required concentration in 2% FCS in PBS and incubated on the 
slide for 1 hour. Excess antibody was washed off with 2% FCS in PBS and the 
procedure repeated with the secondary Alexa Fluor-conjugated antibody 
(Invitrogen, Table 2-3). The slides were washed for the final time in ice cold PBS 
and dried to remove excess liquid. One drop of DAPI (Vector laboratories) was 
added to the slide and a coverslip positioned and sealed with clear nail varnish. 
A FITC (520 nm) filter was used to visualise Alexa Fluor 488 conjugated 
antibodies, a Rhodamine (673 nm) filter was used to visualise Alexa Fluor 594 
conjugated antibodies, differential interface contrast (DIC) was used to visualise 
intact cells and UV (461 nm) was used to visualise DAPI using a Zeiss Axioskop 
microscope. High resolution images were obtained with a Deltavision confocal 
microscope using the same slides. De-convolution was carried out and flattened 
projections of the resulting image slices obtained using softWoRx Explorer 
(Applied Precision) are shown. 
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2.5 Molecular biology techniques 
2.5.1 Primer design 
Gene sequences were downloaded from GeneDB (www.genedb.org) using the 
gene accession number. Sequences were viewed in CLC Genomics Workbench 4 
(CLC Bio). Primers were designed using the web-based programme Primer 3 
(http://frodo.wi.mit.edu/primer3/). Restriction sites were added to the 5’ end 
of the primer along with an additional three cytosine bases at the 5’ terminus to 
allow efficient restriction digest of PCR products. Start and stop codons were 
added or removed as required and care was taken to ensure coding sequences 
remained in-frame with fusion tags after cloning. Mutagenesis primers were 
designed with the base pairs to be altered in the centre and 15 to 20 base pairs 
of flanking complementary sequence. Primers for qRT-PCR were designed using 
the Applied Biosystems qRT-PCR primer design programme. All oligonucleotides 
used in this thesis were synthesised by Eurofins MWG Operon 
(www.eurofinsdna.com) and are listed in Table 2-1. Appendix 1 displays the 
location of all primers within the T. brucei BRCA2 gene. 
No Sequence Restriction sites 
1 CCCACTAGTGCTGATACACTTTCACCGTG SpeI  
2 CCCCTCGAGCTACGGGTGCTGCATCGCCA XhoI  
3 CCCCTCGAGGCTACTGTGTCTTCTCGGAC XhoI  
4 CCCGGATCCCAACCGCACGTGCGTCTGGGTACT BamHI  
5 CCCAAGCTTGGCGGGAGCTTCCAGACGATGTG HindIII  
6 CCCTCTAGAGCGCCCGCCAGCGAGGGAGT XbaI  
16 CCCCTCGAGCTATTCTCGCATAAGATCAGCG XhoI  
32 CCCAAGCTTGAAGTGGAAAGTTTGTAGTGTCC HindIII  
33 CCCTCTAGATTCTCGCATAAGATCAGCG XbaI  
37 CCCCTCGAGGTTGAAGTGAGGGGTGGTTAGC XhoI  
40 CCCTCGCGAGGATCCCAACCGCACGTGCGTCTG NruI BamHI 
41 CCCTCGCGAGATATCAAAACATAGATTCACGCACACAC NruI EcoRV 
42 CCCTCTAGAGGACATTGTCATTCGCTGTAG XbaI  
43 CTCAAACCAAGGTAAGAGCTCCTTCCGTGCTTCAT   
44 ATGAAGCACGGAAGGAGCTCTTACCTTGGTTTGAG   
45 CAAAACAATGCGCTCAAACCAAGGTAAGAGAACCTTCCGTGCTTCAT   
46 ATGAAGCACGGAAGGTTCTCTTACCTTGGTTTGAGCGCATTGTTTTG   
48 ATACTTGTTTGCCGACACTGC   
49 TCGAGGACCTTAAATCCTCTACC   
51 CCCGGATCCATCCAAGCTAGCAAGAAAGC BamHI  
59 CGCTAATCAGCATGAAGTCG   
75 CCCGGATCCCACAAGTGCAGCACGTACCTTAAGC BamHI  
76 CCCCTCGAGCTATTCTGAAACCGTAATACTCTGC XhoI  
86 CTTTGTGCGAGCTGATGC   
87 CGTCCGGTGCTTTTCCTG   
88 AGGGTGAAACCCTCACACAG   
89 CTTTGCAGAGACAGCTCGTG   
91 CCCGGATCCCGCTAAGAATAAAGGAGCGGTTGC BamHI  
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93 CCCGGATCCCAGCCACAAAAAAGGAAGAC BamHI  
94 CCCCTCGAGCTATGTACGTGGCGTCCTCTTC XhoI  
97 TTGAAGCAGCGAACAAAGAC   
98 TGCCCCTTGTAGACCTATGC   
99 ACACTCGCAGCAATCCAAG   
100 AAAAAGCAGCAGCATTCACC   
101 TTAGAGAGCGGAACCAAAGC   
102 GCAGATAGCTGCTGCTAGGG   
103 CAAGGTGCCACCCTTAAATG   
104 CCTTTTGTGCCTTGTCCTTG   
112 CCCACTAGTAGCCACAAAAAAGGAAGAC SpeI  
113 CCCTCTAGACTCTTGGCCATTTTCAGTCCCG XbaI  
114 CCCTCTAGAATTCACATCTGCGCTTGTTG XbaI  
115 CCCGGATCCATAATCAGAATTTGACTTCCG BamHI  
116 CCCACTAGTAACACTCGCACCAAAAATAAG SpeI  
117 CCCGGTACCTTCTCAGCCTTTGCCTCAC KpnI  
118 CCCGGTACCACCGAAGTGTGCCTTTTGTC KpnI  
119 CCCGGATCCCCCCTGGTATACGCGTTAAG BamHI  
129 CCCGGATCCGCTGATACACTTTCACCGTG BamHI  
130 CCCCTCGAGTCAGCGCCCGCCAGCGAG XhoI  
133 AAGCGGTGCACCTAACTGAC   
138 GCTGCCTTCCGCTATGGAT   
139 CCACTCGCCCTTTCAAACAA   
140 ATGGCCAAGCCTTTGTCTC   
141 TTAGCCCTCCCACACATAACC   
142 TGGGGAGCAAAGATGAAAAC   
143 CCGTTGCCATAACGGGTCCC   
144 ATGACCGAGTACAAGCCC   
145 TCAGGCACCGGGCTTGCG   
146 TAACCTTTACAACAGAGCGCACAAACTTAA   
147 CGCTGGCTGTGGTGCTCAGAATCATGCAGA   
150 CAGGAGGATCGTTCGGCACCTTGGC   
151 CATGCGCCTGTGGTTCAGCATAGC   
152 CCCTCGAGGACATGACATTTCTTGACCC XhoI  
153 CCTCGCGAGGATCCATAATCAGAATTTGACTTCCG NruI BamHI 
154 TACGGAGTCCATTGTACCTG   
155 TTCAGGCTGGCCAATGCG   
Table 2-1 List of oligonucleotide primers used in this thesis. 
Primer numbers referred to throughout the text are shown, as are the oligonucleotide 
sequences and restriction sites. Base pairs to be mutated during site-directed mutagenesis 
are indicated by underline. 
2.5.2 Polymerase Chain Reaction 
Template DNA used for polymerase chain reactions (PCRs) was typically 0.025 µg 
of gDNA prepared using DNeasy Blood and Tissue kit (Qiagen; section 2.2.1) or 
0.025 ng of circular plasmid prepared by QIAprep spin miniprep kit (Qiagen; 
section 2.7.2). 
For diagnostic PCR reactions Taq DNA polymerase (New England Biolabs [NEB]) 
was used, typically in a reaction of 25 µl containing 0.1 µM 5’ primer, 0.1 µM 3’ 
primer, 1 x ThermoPol Buffer (NEB), 200 µM dNTPs (Invitrogen), 0.5 Units of Taq 
DNA polymerase (NEB), and dH2O to 25 µl. PCRs were conducted in a Robocycler 
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(Stratagene) with typical conditions of 95°C for 5 minutes, followed by 25 to 30 
cycles of 95°C for 1 minute, 50-60°C for 1 minute, 72°C for 1 minute per kb of 
expected product, and a final cycle of 72°C for 10 minutes. 
For PCR reactions where low error rates were required the high fidelity Phusion 
DNA polymerase (Finnzymes) was used, typically in a reaction of 50 µl containing 
0.5 µM 5’ primer, 0.5 µM 3’ primer, 1 x Phusion High Fidelity (HF) buffer 
(Finnzymes), 200 µM dNTPs (Invitrogen), 1 Unit of Phusion DNA polymerase 
(Finnzymes), and dH2O to 50 µl. PCRs were conducted in a Robocycler 
(Stratagene) with typical conditions of 98°C for 5 minutes, followed by 30 to 35 
cycles of 98°C for 1 minute, 50-60°C for 1 minute, 72°C for 1 minute per kb of 
expected product, and a final cycle of 72°C for 10 minutes.  
2.5.2.1 PCR purification 
Specific PCR products required for cloning were routinely cleaned up using the 
QIAquick PCR purification kit (Qiagen) according to the manufacturer’s protocol. 
2.5.3 Site-directed mutagenesis 
Site-directed mutagenesis was carried using KOD hot start DNA polymerase 
(Novagen). Circular plasmid containing the sequence to be mutated was used as 
a template for a 50 µl PCR reaction containing 0.3 µM 5’ primer, 0.3 µM 3’ 
primer, 1 x KOD buffer (Novagen), 0.2 mM dNTPs (Invitrogen), 1.5 mM MgSO4, 1 
Unit of KOD DNA polymerase (Novagen), and dH2O to 50 µl. PCRs were conducted 
in a Robocycler (Stratagene) with typical conditions of 95°C for 5 mins, followed 
by 18 to 20 cycles of 95°C for 30 seconds, 50-60°C for 30 seconds, 70°C for 1 
minute per kb of plasmid. Template DNA was restriction digested with DpnI 
(Promega) for ~ 3 hours prior to transformation into E. coli (section 2.7). Plasmid 
DNA was extracted from E. coli colonies (section 2.7.2) and screened by 
sequencing (Eurofins MWG Operon). 
2.5.4 Reverse Transcription Polymerase Chain Reaction 
Reverse Transcription PCR (RT-PCR) was carried out on 2 µg of the total RNA 
extracted from trypanosomes (section 2.2.3) in order to produce the cDNA 
required for quantitative real-time PCR (qRT-PCR; section 2.5.4). The 
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SuperScript First Strand Reverse Transcription kit (Invitrogen) was used 
according to manufacturer’s protocol. Random hexameric primers (Invitrogen) 
were used and controls without reverse transcriptase were prepared for each 
sample. cDNA was stored at - 20°C until required. PCR was carried out on the 
plus and minus RT cDNA samples generated in order to test for gDNA 
contamination. Primers for DNA polymerase I (150 and 151; Table 2-1) were used 
to amplify from the products of the cDNA reactions and the absence of PCR 
product from the minus RT samples confirms the absence of gDNA 
contamination. 
2.5.5 Quantitative Real-Time Polymerase Chain Reaction 
qRT-PCR was carried out on the cDNA samples generated by RT-PCR (section 
2.5.4). qRT-PCR primers against the gene of interest were used together with 
qRT-PCR primers against an endogenous control gene (tubulin, 154 and 155). 
Power SYBR Green PCR master mix (Applied Biosystems) was used to set up the 
qRT-PCR reactions in a volume of 25 µl in a Micro Amp optical 96-well reaction 
plate (Applied Biosystems) before sealing with clear adhesive film (Applied 
Biosystems). Reactions were carried out in quadruplicate so that outliers could 
be discarded prior to data analysis. Plates were frozen at – 20°C until required. 
qRT-PCR was carried out on a 7500 Real Time PCR System machine (Applied 
Biosystems) using the standard cycling conditions and data was analysed using 
the 7500 System Software (Applied Biosystems). 
2.5.6 Restriction digest 
PCR products and plasmids for cloning were routinely digested by specific 
restriction endonucleases. A typical digest for cloning contained 2 µg of DNA, 1 x 
buffer specific to restriction enzyme (NEB), 100 µg.ml-1 BSA (NEB), up to 10 Units 
of restriction endonuclease enzyme (NEB) and dH2O to 50 µl. Reactions were 
incubated for 2 hours to overnight at 37°C. A typical digest for plasmid screening 
contained 0.25 µg of DNA, 1 x buffer specific to restriction enzyme (NEB), 100 
µg.ml-1 BSA (NEB), up to 2 Units of restriction endonuclease enzyme (NEB) and 
dH2O to 20 µl. Reactions were incubated for 1 hour at 37°C. 
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2.5.7 Phosphatase treatment 
Restriction digests of plasmid backbones subsequently required for ligation 
reactions were treated with Alakaline Phosphatase (Calf Intestinal; CIP [NEB]) in 
order to remove the 5’ phosphate groups from the cut DNA ends and so prevent 
vector re-circularisation during ligation. 5 Units of CIP (NEB) was added to 
restriction digestion reactions and incubated for a further 30 minutes at 37°C 
prior to DNA purification. 
2.5.8 DNA fragment purification 
PCR reactions yielding non-specific products and plasmid restriction digests were 
separated by DNA electrophoresis (section 2.8.1) and visualised on a UV 
transilluminator. The product of interest was excised using a scalpel blade and 
purified using a QIAquick gel extraction kit (Qiagen) according to the 
manufacturer’s protocol. 
2.5.9 DNA fragment blunting 
The blunting of sticky ends produced from restriction digestion was carried out 
using T4 DNA polymerase (NEB) in a 20 µl reaction containing 10 µl of gel 
extracted insert DNA, 1 x T4 DNA ligase buffer (NEB), 1.5 Units of T4 DNA 
polymerase, 0.2 mM dNTPs, 100 µg.ml-1 BSA (NEB) and dH2O to 20 µl. Reactions 
were incubated at 37°C for 1 hour before heat inactivation of the T4 DNA 
polymerase at 75°C for 10 minutes. Ligation reactions were set up directly with 
the resulting insert DNA. 
2.6 Cloning 
2.6.1 T4 DNA ligase 
Insert fragments for cloning were prepared by PCR followed by PCR purification 
(section 2.5.2.1) or DNA fragment purification from an agarose gel (section 
2.5.8). Vector backbones were prepared by restriction digest, Phosphatase 
treatment and DNA fragment purification. The concentration of insert and 
vector DNA was determined by measuring the absorbance at 260 nm using a 
spectrophotometer (Eppendorf). The volume of insert and vector DNA in a 
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ligation reaction was determined by using the equation: [(ng vector x kb 
insert)/kb vector] x ratio insert/vector = ng insert. Ligation reactions were 
carried out in a volume of 20 µl typically containing 100 ng vector, 1 x T4 DNA 
ligase buffer (NEB), 400 Units T4 DNA ligase (NEB), the correct volume of insert 
and dH2O to 20 µl. Reactions were incubated at room temperature for one hour 
to overnight prior to transformation into E. coli (section 2.7). 
2.7 Transformation of E. coli 
All E. coli growth was carried out in Luria-Bertani broth ([LB; 5 g yeast extract 
(Formedium), 10 g tryptone (Formedium), 10 g NaCl in 1 L dH20 pH 7.0 (NaOH)] 
and 20 g agar (Formedium) was added if plates were required). For cloning, 10 µl 
of ligation or 10 ng of circular plasmid was added to a 100 µl aliquot of 
chemically competent DH5α E. coli (Invitrogen). After incubation on ice for 15 
minutes the cells were subjected to heat shock at 42°C for 45 seconds after 
which they were cooled on ice for 5 minutes. 250 µl of super optimal broth (SOB) 
with added glucose (SOC; 20 g tryptone, 5 g yeast extract, 0.5 g NaCl, 10 ml 1 M 
MgCl2, 10 ml 1 M MgSO4, 10 ml 2 M glucose in 1 L dH20) was added and cells 
allowed to recover in a shaking incubator at 37°C for one hour. Cells were 
spread on plates containing the appropriate antibiotic for the plasmid 
transformed. To allow single colonies to grow overnight at 37°C, typically 100 µl 
of cells transformed with a ligation were plated, and only 20 µl of cells 
transformed with a circular plasmid were plated.  
2.7.1 E. coli colony screening  
E. coli colonies transformed with ligation reactions were routinely screened for 
the insert of interest by PCR. Colonies were picked using a pipette tip and 
inoculated into 20 µl of dH2O. 2 µl of this solution was used as a template for a 
PCR reaction (section 2.5.2) using primers specific to the vector insert required. 
Colonies containing the correct insert were inoculated into 5 ml LB containing 
the appropriate antibiotic in a universal vial (Greiner) and DNA extracted 
(section 2.7.2). E. coli colonies transformed with circular plasmid were picked 
using a pipette tip and placed in 5 ml LB containing the appropriate antibiotic in 
a universal vial and grown overnight in a shaking incubator at 37°C. DNA was 
extracted as below (section 2.7.2). 
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2.7.2 DNA extraction from E. coli 
Plasmid DNA was extracted from 5 ml overnight cultures of E. coli using the 
QIAprep spin miniprep kit (Qiagen) according to the manufacturer’s protocol. 
2.7.3 Ethanol precipitation of DNA 
In preparation for transformation into trypanosomes, DNA was cleaned and 
concentrated by ethanol precipitation after restriction digestion. One tenth of 
the total volume of 3 M sodium acetate (pH 5.2) was added along with three 
times the total volume of 100% ethanol. The solution was then incubated at - 
20°C for one hour to overnight, after which the DNA was centrifuged at 20,000 x 
g for 30 minutes at 4°C. The DNA pellet was washed with 1 ml of 70% ethanol 
and re-centrifuged for one minute. The pellet was air dried for 10 minutes and 
re-suspended in the required volume of dH2O. 
2.8 Electrophoresis 
2.8.1 DNA electrophoresis 
Standard DNA separations were performed on 1.0% UltraPure agarose 
(Invitrogen) gels made with 1 x TAE buffer (40 mM Tris, 19 mM acetic acid, 1 mM 
EDTA) and containing 1 x SYBRSafe (Invitrogen). The separations were run in 1 x 
TAE buffer at 100 V for ~ 30 minutes. 1 kb DNA ladder (NEB) was used as a size 
marker and apparatus was supplied by BioRad. Separating gDNA restriction 
digests for Southern blot analysis was carried out as above except they were 
electrophoresed at ~ 30 V overnight. Small DNA products of 500 bp or less was 
separated on 2% agarose gels as above. DNA gels were visualised and 
photographed using a GelDoc (BioRad) machine using UV light with a SYBRSafe 
filter. 
2.8.2 Pulsed field agarose gel electrophoresis 
Prior to electrophoretic separation, the pulsed field agarose gel electrophoresis 
apparatus (CHEF-DR III, BioRad) was cleaned by the circulation of 2 litres of 0.1% 
SDS for 1 hour at 20°C. The tank was then rinsed by circulating dH2O for 1 hour 
at 20°C, and once by circulating the electrophoresis buffer 1 x TB1/10E (90 mM 
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Tris, 90 mM boric acid, 2 mM EDTA) for 1 hour at 15°C. Gels were 
electrophoresed in 2 litres of buffer, which was circulated in the tank for at 
least 30 minutes at 15°C before the gel was run. Separations of megabase-
chromosomes were conducted using 1.2% agarose (Seakem LE). Agarose was 
dissolved in 150 mls of electrophoresis buffer, and 140 mls used to prepare a gel 
using the tray provided with the pulsed field agarose gel electrophoresis system, 
keeping the remainder at 37°C. After the agarose gel had set, the comb was 
removed, agarose genomic plugs placed into the wells, and the wells sealed with 
the remaining agarose. The agarose genomic plugs had been prepared by a 
minimum of three rounds of dialysis for a minimum of 1 hour in the appropriate 
electrophoresis buffer. Gels were electrophoresed at 15°C with an included 
angle of 120°, and 2.5 V.cm-1 for 144 hours with an initial switch time of 1400 
seconds and final switch time of 700 seconds for the separation of megabase-
chromosomes. 
2.8.2.1 Ethidium bromide staining of pulsed field agarose gels 
Chromosomes were visualised by placing agarose gels in 200 mls of 
electrophoresis buffer containing 4 µl ethidium bromide (EtBr) at 10 µg.ml-1 and 
placing on a rocking table for ~ 30 minutes. They were then de-stained in dH2O 
for ~ 30 minutes, or until they could be visualised clearly by UV illumination. 
2.8.3 Protein electrophoresis 
Protein samples were fractionated either on NuPAGE Novex Bis-Tris 10% mini gels 
(Invitrogen) or NuPAGE Novex Tris-Acetate 3-8% mini gels (Invitrogen). The gels 
were electrophoresed at 200 Volts in 1 x MOPS SDS running buffer (Invitrogen) or 
1 x Tris–Acetate SDS running buffer (Invitrogen) respectively, in the XCell 
SureLock Mini-Cell (Invitrogen). Proteins were visualised directly by Coomassie 
staining; gels were placed in Coomassie stain solution (0.25 g Coomassie brilliant 
blue R (Sigma) in 90 ml of methanol: water (1:1, v/v) and 10 mls glacial acetic 
acid), and placed on a rocker for 1 hour to overnight. Visualisation of protein 
bands was achieved by placing the gels in destaining solution (10% glacial acetic 
acid, 40% methanol) for 1-3 hours and viewing on a light box. 
Chapter 2  94 
2.9 Blotting 
2.9.1 Southern blotting 
Agarose gels to be Southern blotted were photographed on a UV transilluminator 
alongside a ruler parallel to the gel in order to allow calculation of the sizes of 
fragments hybridised by radioactively labelled DNA. To depurinate the DNA, the 
gel was soaked in 125 mM HCl for 15 minutes and then rinsed with dH2O. The 
DNA was then denatured by placing the gel in denaturation solution (0.5 M 
NaOH, 1.5 M NaCl) for 30 minutes. Following rinsing with dH2O, the gel was 
placed in neutralisation solution (1 M Tris base, 1.5 M NaCl, 186 mM HCl) for 30 
minutes. The gel was rinsed again in dH2O, before rinsing in 20 x SSC transfer 
buffer (3 M NaCl, 300 mM NaOAc). The DNA was subsequently transferred to a 
nylon membrane (Hybond XL, Amersham Biosciences) by overnight capillary 
blotting (Sambrook, Fritsch, and Maniatis, 1989) using 20 x SSC transfer buffer. 
Following transfer, the DNA was cross-linked to the membrane twice using the 
auto-crosslink setting on a UV Stratalinker (Stratagene). 
Pulsed field gels were Southern blotted essentially as described above, but with 
slightly different wash treatments due to the chromosomes being tightly bound 
within the agarose. After ethidium bromide staining, the chromosomes were 
nicked by soaking the gels twice in 125 mM HCl for 30 minutes. After rinsing in 
dH2O the chromosomes were denatured by soaking in denaturation solution 
twice for 1 hour. The treatment then resumed as the protocol above, apart from 
the capillary blotting, which was usually performed for at least 96 hours with the 
addition of extra transfer buffer after 48 hours. 
2.9.2 Western blotting 
Western blotting of protein gels was carried out using the Mini Trans-Blot Cell 
(Bio-Rad). Gels, Hybond ECL nitrocellulose membrane (Amersham), foam and 
filter paper (BioRad) were equilibrated in transfer buffer (0.19 M Glycine, 0.025 
M Tris base, 20% methanol), before assembling the gel sandwich. The sandwich 
consisted of the gel and the nitrocellulose membrane, surrounded by filter paper 
and foam, sandwiched between plastic cassettes. An ice block was placed 
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alongside the cassette to prevent overheating. Transfer was carried out by 
electrophoresing at 100 Volts for 2 hours. 
2.10 Radiolabelling and hybridisation of DNA 
probes 
2.10.1 Probe manufacture by random primer labelling 
of DNA 
The DNA fragments used for probe manufacture were specific PCR products 
amplified as described previously (section 2.5.2), separated on an agarose gel 
and purified using the QIAquick gel extraction kit (section 2.5.8). Radio-labelling 
of these fragments was performed using the Prime It II kit (Stratagene). 25 ng of 
DNA was mixed with 10 µl random oligonucleotide primers (27 OD units.ml-1) and 
dH20 in a final reaction volume of 36 µl. The DNA was denatured by incubation at 
95°C for 5 minutes. 10 µl of 5 x dATP primer buffer, 3 µl of α32P-labelled dATP (~ 
0.74 MBq; Perkin Elmer) and 1 µl Klenow DNA polymerase (5 U.µl-1) was added 
and the reaction incubated at 37°C for 5 minutes. The reaction was stopped by 
the addition of 2 µl of stop mix (Stratagene). The probes were then purified 
from any unincorporated nucleotides by size exclusion chromatography using 
illustra Probe Quant G-50 Micro columns (GE Healthcare) according to the 
manufacturer’s protocol. After purification, the probes were denatured at 95°C 
for 5 minutes before hybridisation. 
2.10.2 Hybridisation and detection of radiolabelled 
DNA probes 
Nylon membranes blotted with DNA were placed in a hybridisation tube (Hybaid) 
with ~ 50 mls of pre-warmed 0.5 M Church Gilbert solution (342 mM Na2HPO4, 
158 mM NaH2PO4, 7% (w/v) SDS, 1 mM EDTA) and pre- hybridised for a minimum 
of 1 hour typically at 60°C in a rotating hybridisation oven. The denatured, 
radiolabelled probe was then added to the Church Gilbert solution in the 
hybridisation tube and allowed to hybridise to the blot overnight typically at 
60°C in a rotating hybridisation oven. Following hybridisation, the membrane 
was washed in a rotating hybridisation oven with 50 mls of 2 x SSC, 0.1% SDS for 
15 minutes typically at 60°C and then 50 mls of 0.2 x SSC, 0.1% SDS for another 
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15 minutes. After washing, the membranes were sealed in plastic and exposed to 
a Storage Phosphor screen (GE Healthcare) at room temperature for 1-72 hours 
(depending on the strength of the signal). The Storage Phosphor screen was then 
visualised using a Typhoon 8610 phosphorimager (Molecular Dynamics). Washes 
were repeated as necessary. To strip nylon membranes of hybridised probe DNA, 
membranes were placed in a heat-proof container with boiling stripping buffer 
(0.1% SDS, 0.4 M NaOH). After incubation for 10 minutes the solution was poured 
off and the procedure repeated. Successful stripping was checked by exposure to 
a Storage Phosphor screen for 24 hours and visualisation using a Typhoon 8610. 
2.11 Western blot detection 
2.11.1 Hybridisation and detection of antibodies 
Nitrocellulose membranes blotted with protein were placed in blocking buffer 
(PBS, 5% Milk (Marvel), 0.1% Tween 20 (Sigma)), for 1 hour to overnight, on a 
rocker. Membranes were rinsed in blocking buffer before placing in blocking 
buffer containing the primary antibody (Table 2-2) for 1 hour. Membranes were 
rinsed three times in PBST (PBS, 0.1% Tween 20 (Sigma)) for 10 minutes, before 
placing in blocking buffer containing the secondary antibody (Table 2-3) for 1 
hour. In this thesis, all secondary antibodies used for western blot were 
horseradish peroxidise conjugated. Membranes were rinsed three times in PBST 
for 10 minutes before applying the SuperSignal West Pico Chemiluminescent 
Substrate (Pierce). The substrate was applied to the membrane and placed in 
the dark for 5 minutes before exposing the membrane to an X-ray film (Kodak) 
for 5 seconds to overnight. X-ray films were visualised by developing in a Kodak 
M-35-M X-omat processor. To strip the nitrocellulose membranes of bound 
antibodies, membranes were placed in a container with 10 mls of Restore 
Western Blot Stripping Buffer (Pierce) and rocked for 30 minutes. Successful 
stripping was checked by applying SuperSignal West Pico Chemiluminescent 
Substrate (Pierce) to the membrane and exposing it to an X-ray film. Membranes 
were finally rinsed in PBST before being re-probed as above. 
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Name Host animal Company/Laboratory Dilution 
Anti-BRCA2 Chicken Covalab 1:200 
Anti-RAD51 Rabbit R. McCulloch 1:500-1000 
Anti-NOG1 Rabbit M. Parsons 1:5000 
Anti-OPB1 Sheep J. Mottram 1:1000 
Anti-Myc Mouse Millipore 1:7000 
Anti-HA Mouse Sigma 1:10000 
Anti-His Mouse Sigma 1:750 
Anti-GST Mouse Novagen 1:10000 
Table 2-2 List of primary antiserum used in this thesis. 
 
Name Conjugation Company/Laboratory Dilution 
Anti-Chicken HRP Invitrogen 1:200 
Anti-Rabbit HRP Molecular Probes 1:500 
Anti-Sheep HRP Santa Cruz 1:5000 
Anti-Mouse HRP Invitrogen 1:1000 
Anti-Rabbit Alexa Fluor 594 Alexa Fluor 594 Invitrogen 1:7000 
Anti-Myc Alexa Fluor 488 Alexa Fluor 488 Invitrogen 1:7000 
Table 2-3 List of secondary antiserum used in this thesis. 
 
2.11.2 Anti-BRCA2 Antiserum 
Two peptide antigens corresponding to amino acids 105-ARARMNTENGQEST-118 
and 1556-RIKQLEDWQTPHEEC-1570 were inoculated into two chickens with 
complete Freund’s adjuvant at day 0 and with incomplete Freund’s adjuvant at 
days 14, 28 and 63 (Covalab). The final bleeds (day 90) from the two chickens 
were subjected to affinity purification using the two peptides and the resultant 
antisera was pooled. This is referred to as anti-BRCA2 antiserum. 
2.12 In vivo co-immunoprecipitation 
Protein was extracted from PCF cells as above (section 2.2.4.2). A 50 µl aliquot 
of protein extract was taken as an input sample and frozen in SDS-PAGE sample 
buffer until required. The remaining protein extract was split into two 
eppendorfs, ~ 250 µl each. To this was added 50 µl of 50% bead slurry. Beads 
(Anti-Myc agarose (Millipore) and Anti-HA agarose (Roche)) were prepared by 
washing twice with 1 ml Trypanosome Lysis Buffer (TLB) with centrifugation at 
5,000 x g for 1 minute at 4°C and adding an equal volume of TLB to make up to a 
50% slurry. Samples were incubated with end-over-end rotation at 4°C for 1 
hour. Beads were pelleted by centrifugation at 5,000 x g for 1 minute at 4°C and 
washed 5 times with 1 ml TLB. 100 µl of SDS-PAGE sample buffer was added and 
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the sample boiled for 5 minutes at 98°C prior to separation on an SDS-PAGE gel 
and western blotting. 
2.13 In vitro Glutathione S-Transferase pull-down 
Glutathione S-Transferase (GST) pull-down studies in E. coli were carried out as 
co-expression studies, with two complementary plasmids (pGEX-4T-3 (GE 
healthcare) and pRSF-1b (Novagen)) transformed into the same bacterial cell 
line. For each experiment fresh transformations of Rosetta2 BL21 (Novagen) 
chemically competent E. coli were prepared. A single colony was picked from 
the transformation plate, inoculated into 5 ml LB containing the appropriate 
antibiotics and grown at 37°C overnight in a shaking incubator. 1 ml of culture 
was diluted into 50 ml LB containing the appropriate antibiotics in a 250 ml 
conical flask and grown at 37°C until an OD600 nm of ~ 0.5 was reached 
whereupon protein expression was induced by the addition of isopropyl-β-D-
thiogalactopyranoside (IPTG; Melford) at a final concentration of 1 mM. Once 
induced, flasks were transferred to a shaking incubator at 25°C and grown 
overnight. Cells were harvested by centrifugation at 3750 x g for 20 minutes at 
4°C. Cell pellets were re-suspended in 5 ml ice cold Wash/Lysis Buffer (WLB; 1 
mM DTT (Melford), 0.1% (v/v) NP-40, 13 Units.ml-1 DNase1 (Invitrogen), 1 x 
Complete EDTA-free Protease Inhibitor Cocktail (Roche) in PBS) by vortexing. 
Cells were subjected to a cycle of freeze thaw at - 80°C prior to sonication on 
ice for 4 cycles of 10 seconds sonication with 20 seconds rest between pulses 
using a Soniprep 150 (MSE). Insoluble material was removed by centrifugation at 
20,000 x g for 20 minutes at 4°C. A 100 µl aliquot of supernatant (input) was 
frozen in SDS-PAGE sample buffer until required. 
100 µl of bead slurry (Glutathione Sepharose HP (GE Healthcare)) per cell 
extract was prepared by washing twice with 5 ml WLB at 500 x g for 2 minutes at 
4°C. After washing beads, were re-suspended in 10 volumes of WLB and 1 ml of 
bead slurry added to each cell extract. After incubation with end-over-end 
rotation at 4°C for 1 hour beads were pelleted by centrifugation at 500 x g for 2 
minutes at 4°C and the supernatant carefully removed. Beads were washed five 
times with 5 ml WLB. To elute bound proteins, beads were incubated with 500 µl 
elution buffer (50 mM Tris-HCL (pH 8.0), 200 mM NaCl, 20 mM reduced 
glutathione (Sigma), 0.1% NP-40, 1 mM DTT) for 1 hour with end-over-end 
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rotation at 4°C. Beads were pelleted at 500 x g for 2 minutes at 4°C and elution 
buffer removed to a clean eppendorf. A 100 µl aliquot (elution) was frozen in 
SDS-PAGE sample buffer until required. 
2.14 Bioinformatics 
Gene sequences were downloaded from GeneDB (www.genedb.org) and viewed 
in CLC Genomics Workbench (CLC Bio). Sequence alignments were carried out 
and trees generated using CLC Genomics workbench. BLASTn search of the T. 
brucei TREU 927 genome sequence was carried out using the facility at 
www.genedb.org.
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 Chapter 3: The function of T. brucei 
BRCA2 in the maintenance of 
genome stability. 
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3.1 Introduction 
Previous studies on brca2-/- mutants generated in T. brucei bloodstream form 
(BSF) cells in strain Lister 427 demonstrated that they display a genomic 
instability phenotype, detectable by an accumulation of visible karyotype 
changes in the megabase chromosomes (Hartley and McCulloch, 2008), which 
may correspond with gross chromosomal rearrangements (GCRs) observed in 
brca2-/- mutants in other organisms (see below;Yu et al., 2000;Kojic et al., 
2002;Ko, Lee, and Lee, 2008). At least some of the genome rearrangements in T. 
brucei BSF brca2-/- mutant cells appear to arise due to deletions within the 
subtelomeric VSG arrays, as evidenced by the loss of members of the VSG121 
gene family after prolonged passaging (Hartley and McCulloch, 2008). However, 
in the absence of a genome-wide annotation of the VSG repertoire in T. brucei 
Lister 427, indicating their chromosomal locations, it has not been possible to 
determine how widely affected the VSG arrays are by mutation of BRCA2. 
Interestingly, no rearrangements were observed in the intermediate or mini-
chromosomes and, as these chromosomes do not harbour VSG arrays, this lends 
support to the idea that the karyotype changes may be limited to, or at least 
most severely evident as, changes within the VSG arrays. This genomic instability 
phenotype has not been observed in rad51-/- mutants in T. brucei, though the 
experimental procedures adopted were not equivalent to the brca2-/- mutant 
analysis: here, rad51-/- clones were examined after prolonged passaging and 
isolation of VSG switch variants (McCulloch and Barry, 1999), and also after 
transformation to measure recombination events and characterise the 
recombinants (McCulloch and Barry, 1999). A very similar genomic instability 
phenotype is, however, observed in mre11-/- mutants (section 1.5.3; Robinson 
et al., 2002). The function of BRCA2 in the maintenance of genome integrity has 
been well documented in mammals and Ustilago maydis (Moynahan, Pierce, and 
Jasin, 2001;Kojic et al., 2002), and it is possible that this is a function that is 
conserved in the trypanosomatids. However, where GCRs in these organisms are 
manifest as chromosome deletions and translocations, deletion appeared to 
predominate in T. brucei brca2-/-, and mre11-/-, mutants. Whether this is 
because BRCA2 plays subtly different roles in T. brucei, or is due to differences 
in genome composition, is unknown. 
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This chapter aims to understand the precise genetic modifications that occur 
during the genome rearrangements observed in T. brucei brca2-/- mutants. In 
order to achieve this, it was decided to mutate BRCA2 in the genome strain of T. 
brucei, TREU 927. The availability of the complete genome sequence for this 
strain, including annotation of > 800 VSGs (Marcello and Barry, 2007), should 
allow the dissection of the rearrangements at the sequence level, with a focus 
on the subtelomeric VSG archive. TREU 927 is a pleomorphic strain of T. brucei, 
and although gene mutants have been described in the BSF (van Deursen et al., 
2001), due to the difficulties associated with the prolonged passaging of these 
cells, it was decided to analyse brca2-/- mutants in the procyclic form (PCF) 
cells of this strain. 
3.2 Generation of BRCA2 gene disruption mutants 
in PCF TREU 927 T. brucei 
3.2.1 BRCA2 gene deletion constructs 
Homozygous mutants of BRCA2 were generated in PCF TREU 927 T. brucei using 
a classical gene deletion strategy where the entire BRCA2 open reading frame 
(ORF) is removed. The BRCA2 gene deletion constructs that were used, 
∆BRCA2::BSD and ∆BRCA2::PUR, are displayed in Figure 3-1 (gift, Claire Hartley). 
These constructs contain regions of the 5’ and 3’ un-translated regions (UTR) 
flanking the BRCA2 ORF cloned into pBluescript (Stratagene) and used as 
targeting sequence to enable homologous recombination and replacement of the 
entire BRCA2 ORF with antibiotic resistance cassettes, following transformation. 
To allow selection of constructs that have integrated into the genome, one of 
two antibiotic resistance cassettes was cloned between the flanks. The 
blasticidin (BSD) and puromycin (PUR) resistance cassettes each contain 
processing signals derived from actin and tubulin intergenic sequences flanking 
the antibiotic resistance ORFs to allow RNA trans-splicing and polyadenylation, 
respectively. For transformation, the ∆BRCA2::BSD and ∆BRCA2::PUR constructs 
were excised from pBluescript by restriction digestion with XhoI and XbaI, the 
digested DNA was then ethanol precipitated and approximately 5 µg of the 
resuspended DNA was used for each transformation. 
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Figure 3-1 BRCA2 gene deletion constructs. 
Restriction maps of the constructs used for the deletion of BRCA2 are shown, relative to the 
BRCA2 ORF (top). Sizes of the individual components are shown (bp), and are not drawn to 
scale. Constructs were cloned into the pBluescript plasmid and excised using the XhoI and 
XbaI restriction sites shown. 5’ UTR and 3’ UTR correspond to un-translated regions 
upstream and downstream of the BRCA2 ORF, respectively. βα Tub: βα tubulin intergenic 
region. Actin IR: actin intergenic region. BSD: blasticidin resistance ORF. PUR: puromycin 
resistance ORF. 
3.2.2 Generation of BRCA2 mutants in PCF TREU 927 T. 
brucei 
Two separate transformations were carried out in order to generate two 
independent BRCA2 heterozygous (-/+) cell lines using the ∆BRCA2::BSD and 
∆BRCA2::PUR constructs. To do this, wild-type PCF TREU 927 (WT 927) cells 
were transformed using the protocol described in section 2.1.3 and antibiotic 
resistant transformants were selected by placing cells on SDM-79 media (GIBCO) 
supplemented with 10 µg.ml-1 blasticidin (Calbiochem) or 1 µg.ml-1 puromycin 
(Sigma). The generation of BRCA2-/+ mutants was confirmed by PCR analysis 
performed on genomic DNA extracted from six blasticidin resistant clones and six 
puromycin resistant clones. Two independent BRCA2-/+ mutant clones were 
chosen (-/+ BSD and -/+ PUR; Figure 3-2B) and subsequently transformed with 
the complementary BRCA2 gene deletion construct in order to generate 
independent BRCA2 homozygous (-/-) mutant cell lines. Antibiotic resistant 
transformants were selected with 5 µg.ml-1 blasticidin and 0.5 µg.ml-1 
puromycin.  
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3.2.3 Confirmation of BRCA2 mutants by PCR 
The generation of brca2-/- mutants was initially confirmed by PCR performed on 
genomic DNA extracted from seven putative -/- BSD-PUR transformant clones 
and eight putative -/- PUR-BSD transformant clones. PCR was performed using 
primers specific to the BSD (primers 140 and 141) and PUR (primers 144 and 145) 
resistance ORFs, and also a 1.2 kb region of the BRCA2 ORF (primers 48 and 49). 
The location of the primers and expected sizes of the PCR products are displayed 
in Figure 3-2A. The sequences of all primers used in this thesis are displayed in 
Table 2-1 and their location if within the BRCA2 gene sequence can be found in 
Appendix 1. 
The agarose gel in Figure 3-2B demonstrates the presence of the BSD and PUR 
resistance ORFs in all of the putative brca2-/- mutant clones. Some of these 
clones still retained the BRCA2 ORF, and produced a PCR product with the 
primers specific to part of the BRCA2 ORF; whether these had integrated the 
second knockout construct into an unknown genomic location, or were triploid 
for the BRCA2 locus or chromosome, is unknown. These ‘incorrect’ clones were 
discarded. Apart from these, a number of clones were apparent (five -/- BSD-
PUR, and at least one -/- PUR-BSD; indicated by ‘*’ in Figure 3-2B) that failed to 
amplify a PCR product using the primers specific to part of the BRCA2 ORF, and 
had integrated both the BSD and PUR resistance cassettes. Two of these putative 
brca2-/- mutant clones, from distinct BRCA2-/+ antecedents (and thus 
independently derived), were selected for further analysis (from now on, 
referred to as -/- BSD-PUR and -/- PUR-BSD). 
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Figure 3-2 Confirmation of PCF TREU 927 BRCA2 mutants by PCR. 
(A) Primers used to amplify part of the BRCA2 ORF, and the BSD and PUR resistance ORFs 
are indicated (black arrows), with the expected sizes of the resulting PCR products shown 
(bp). (B) An agarose gel of the PCR products obtained using the primers, described above, 
and genomic DNA extracted from wild-type TREU 927 (WT 927), BRCA2 heterozygous (-/+) 
and putative brca2 homozygous (-/-) mutant cell lines. The two independent BRCA2-/+ 
mutants are indicated by -/+ BSD and -/+ PUR, and the putative brca2-/- mutants derived 
from these are indicated by -/- BSD-PUR and -/- PUR-BSD, respectively. Distilled water 
(dH2O) was used as a negative control. The PCR products produced from the BSD, PUR and 
BRCA2 ORFs are indicated (black arrows), and size markers are shown (Ladder, kb). ‘*’ 
indicates brca2-/- mutants that are confirmed by PCR. 
3.2.4 Confirmation of BRCA2 mutants by Southern 
analysis 
To confirm the generation of two independent brca2-/- mutant cell lines, 
Southern analysis was performed. Genomic DNA extracted from wild-type TREU 
927, -/+ and -/- BRCA2 mutant cell lines was digested with SacII and HindIII, 
separated by electrophoresis on a 1% agarose gel, Southern blotted and 
hybridised at 60°C with a DNA probe generated by PCR-amplification with the 
primers 152 and 153, corresponding with the 5’ UTR of the BRCA2 ORF (the 
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region included in the gene deletion constructs). The location of primers, 
predicted restriction enzyme recognition sites and expected DNA fragment sizes 
in this approach are displayed in Figure 3-3A. 
 
 
Figure 3-3 Confirmation of PCF TREU 927 BRCA2 mutants by Southern analysis. 
(A) Restriction maps showing the expected products of restriction digestion, Southern 
blotting and hybridisation with the 5’ UTR of the BRCA2 ORF (black arrows indicate the 
primers used to PCR-amplify this as a DNA probe). The restriction sites are indicated, with 
the expected restriction fragment sizes shown (kb). (B) 5 µg of genomic DNA extracted from 
wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant cell lines was digested with SacII 
and HindIII before being separated by electrophoresis on an agarose gel. The DNA was 
Southern blotted before being hybridised with a DNA probe against the 5’ UTR of the 
BRCA2 ORF. The bands produced from the WT allele and the BRCA2 mutant alleles are 
indicated (black arrows), and size markers are shown (Ladder, kb).  
The Southern blot in Figure 3-3B demonstrates that the intact BRCA2 ORF exists 
in wild-type TREU 927 cells. In this strain no allelic size variation is detectable at 
this gene locus, as observed in wild-type BSF Lister 427 cells where the two 
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alleles of BRCA2 possess different numbers of BRC repeat motifs (Hartley and 
McCulloch, 2008). The BRCA2-/+ mutants have one BRCA2 allele replaced with 
either a BSD or PUR resistance cassette. In the putative brca2-/- mutants, there 
was no evidence for the presence of an intact BRCA2 ORF, suggesting both 
alleles of the gene were deleted, one replaced by the BSD cassette and the 
other replaced by the PUR cassette (though these cannot be distinguished in this 
Southern approach, Figure 3-2B shows that each antibiotic resistance ORF is 
present). 
3.2.5 Confirmation of BRCA2 mutants by western 
analysis 
In order to try and detect BRCA2 protein in T. brucei, antiserum was raised in 
chickens against two peptides that were synthesised based on the predicted T. 
brucei BRCA2 polypeptide (section 2.11.2). One peptide corresponded with the 
BRC repeat domain (amino acids 105 to 118), and the second was derived from 
the C-terminus of the protein (amino acids 1556 to 1570). A number of attempts 
at western blot analyses were performed (data not shown), using whole cell 
extracts from PCF T. brucei cells. This revealed that, on occasion, a band of the 
size expected for T. brucei BRCA2 was observed (176 kDa); however, in all cases, 
significant numbers of further bands were seen, presumably reflecting non-
specific binding of the antiserum to other T. brucei proteins, and in many cases 
the 176 kDa band expected for BRCA2 was not seen. Despite the lack of 
reproducibility of this antiserum, confirmation of the brca2-/- mutants by 
western blot was attempted multiple times using total protein extract from 
wild-type TREU 927, -/+ and -/- BRCA2 mutant cell lines, which was separated 
by SDS-PAGE on a 3-8% Tris-Acetate gel, blotted and probed with anti-BRCA2 
antiserum at a dilution of 1:200. The clearest result of these experiments is 
displayed in Figure 3-4. 
The western blot in Figure 3-4 suggested that BRCA2 protein was visible at 
approximately the expected size (176 kDa) in the wild-type and two BRCA2-/+ 
mutant cell lines, and was absent in the two brca2-/- mutant cell lines. A non-
specific protein band is visible at ~ 58 kDa and, if this is considered as a protein 
loading control, demonstrates approximately equal loading of cell extracts from 
the five cell lines. 
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Figure 3-4 Confirmation of PCF TREU 927 BRCA2 mutants by western analysis. 
Total protein extracts from wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant cell lines 
were separated by SDS-PAGE and western blotted before being probed with anti-BRCA2 
antiserum (1:200 dilution). The band of the size expected for the BRCA2 protein is indicated 
(black arrow), and size markers are shown (kDa). 
3.3  Phenotypic analysis of PCF TREU 927 BRCA2 
mutants 
3.3.1 Analysis of in vitro growth 
brca2-/- mutants in BSF Lister 427 T. brucei display an increased population 
doubling time (approximately 2-fold) when compared to wild-type BSF Lister 427 
cells (Claire Hartley, PhD Thesis, 2008). To determine if the same phenotype is 
observed in PCF TREU 927 brca2-/- mutant cells, in vitro growth was analysed. 2 
ml cultures were inoculated at a density of 5 x 105 cells.ml-1 and counted using a 
Coulter Counter (Beckman) at 24, 48 and 72 hours subsequently. The average 
counts from three experimental repetitions are plotted in Figure 3-5, and 
extrapolated doubling times (calculated as detailed in section 2.3.1) are 
displayed in Table 3-1. 
From the growth curves and doubling times displayed it is apparent that 
disruption of a single BRCA2 allele has no discernible effect on the growth of 
BRCA2-/+ cells when compared to wild-type cells. However, the brca2-/- 
mutants display a slight retardation in growth as evidenced by an increase in 
doubling time from the wild-type value of ~ 11 hours to between 13 and 19 hours 
for the two mutant cell lines. This is an increase in doubling time that is less 
than the observed 2-fold increase of brca2-/- mutants in BSF Lister 427 cells 
(Hartley and McCulloch, 2008). 
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Figure 3-5 Analysis of in vitro growth of PCF TREU 927 BRCA2 mutants. 
2 ml cultures of wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant cell lines were 
inoculated at 5 x 105 cells.ml-1 and cell densities counted 24, 48, and 72 hours subsequently 
are shown. Values are averaged from the counts from three experimental repetitions, and 
vertical lines indicate standard deviation. 
 
Table 3-1 In vitro population doubling times of PCF TREU 927 BRCA2 mutants. 
The mean doubling time for wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant cell 
lines is displayed, in hours, and was calculated from the data displayed in Figure 3-5. 
3.3.2 Analysis of DNA damage sensitivity 
brca2-/- mutants in BSF Lister 427 display increased sensitivity to DNA damaging 
agents, including methyl methanesulphonate (MMS) and phleomycin, when 
compared to wild-type BSF Lister 427 cells (Hartley and McCulloch, 2008). MMS is 
an alkylating agent that methylates DNA to produce methylated purines at the 7’ 
position of guanine residues and the 3’ position of adenine residues (Brookes and 
Lawley, 1961;Reiter et al., 1967). Phleomycin is a group of copper-containing 
antibiotic peptides of the bleomycin family first isolated from Streptomyces 
verticillus. Phleomycin has been shown to inhibit DNA synthesis by blocking the 
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activity of DNA polymerase and inducing the formation of DNA double strand 
breaks (Falaschi and Kornberg, 1964;Reiter, Kelley, and Milewski, 1972). In order 
to determine the sensitivity of the PCF TREU 927 brca2-/- mutant cell lines to 
these DNA damaging agents, the Alamar Blue assay was used. Alamar Blue 
(resazurin sodium salt; Sigma) is a blue-coloured, non-fluorescent compound. 
However, in actively metabolising cells, resazurin is reduced to resorufin, which 
is pink and highly fluorescent (Raz et al., 1997;O'Brien et al., 2000). Monitoring 
the reduction of Alamar Blue can be achieved by measuring the production of 
fluorescent resorufin with a spectrophotometer (Wallac Envision) using filters of 
540 nm excitation and 590 nm emission. By plotting the extent of fluorescence 
against log drug concentration, and performing nonlinear regression on these 
data, a sigmoidal survival curve was generated. Calculation of EC50, the drug 
concentration that causes 50% cell death, allows the metabolic capacity of the 
cells to be quantified, and provides an indirect assessment of cell growth or 
survival. 
The Alamar blue assay was set up as detailed in section 2.3.2 with wild-type 
TREU 927, -/+ and -/- BRCA2 mutant cell lines. The extent of fluorescence for 
each cell line was plotted graphically over the range of log drug concentrations 
(for representative examples see Figure 3-6 and Figure 3-7). From this, EC50s 
were determined from each individual plot and then average EC50s (plus 95% 
confidence intervals) were calculated from the three experimental repetitions. 
The mean EC50s for each cell line were then plotted relative to the wild-type 
EC50, which was taken as 100% (Figure 3-8 and Figure 3-9). Data was presented 
in this way due to the fact that between experimental repetitions variation in 
the absolute EC50 values was observed despite the patterns of relative 
sensitivity between the cell lines being essentially equivalent. 
The survival curves displayed in Figure 3-6 and Figure 3-7 are representative of 
the three experimental repetitions performed. These data demonstrate that as 
the concentration of DNA damaging agent increases the fluorescence, and 
therefore the percentage of surviving cells that are actively reducing Alamar 
blue to fluorescent resorufin, reduces until the concentration at which all cells 
are killed is reached. It is apparent that the brca2-/- cell lines display reduced 
survival in the presence of both MMS and phleomycin, when compared to wild-
type cells. The BRCA2-/+ PUR cell line appeared to demonstrate survival that is 
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intermediate between the wild-type and brca2-/- cell lines for both DNA 
damaging agents and the BRCA2-/+ BSD cell line shows survival essentially 
equivalent to wild-type cells. The extrapolated EC50 values (graphs displayed in 
Figure 3-8 and Figure 3-9) support the graphical observations. In Figure 3-8, 
measuring sensitivity to MMS, the disruption of a single BRCA2 allele in the 
BRCA2-/+ BSD cell line does not detectably alter the sensitivity of the cell line 
to MMS, when compared to wild-type cells. In the same assay, the BRCA2-/+ PUR 
cells appeared to have a lower EC50, suggesting they had increased sensitivity to 
MMS, though this was not statistically significant (see below). In Figure 3-9, 
measuring sensitivity to phleomycin, the BRCA2-/+ PUR cell line again appeared 
to be more sensitive than wild-type cells (though not significantly, see below), 
while the BRCA2-/+ BSD cells were more resistant to this damaging agent 
(although not significantly). Why single gene disruptions of BRCA2 potentially 
display such changes is unclear. Irrespective of this, both brca2-/- mutants 
displayed a greater sensitivity to both DNA damaging agents. 
To evaluate the above data, the EC50 values of the wild-type TREU 927, -/+ and 
-/- BRCA2 mutant cell lines were compared using student’s T-tests, and the 
results of this are displayed in Table 3-2. The statistical analyses largely confirm 
the graphical observations. No statistical difference in the calculated EC50 
values was observed between wild-type cells and BRCA2-/+ mutants (p > 0.05) 
for both DNA damaging agents. However, the BRCA2-/+ BSD cell line was 
statistically different to all cell lines analysed (p ≤ 0.05) after phleomycin 
treatment, apart from wild-type. A statistically significant difference was found 
between wild-type cells and both brca2-/- mutants (p ≤ 0.05) after MMS 
treatment, and one of the brca2-/- mutants (PUR-BSD; p ≤ 0.05) after 
phleomycin treatment. 
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Figure 3-6 A representative survival curve for PCF TREU 927 BRCA2 mutants exposed to 
MMS. 
The extent of fluorescence for each cell line (WT, -/+ and -/-), obtained using the Alamar blue 
assay, is plotted against the log of MMS concentrations. Nonlinear regression was 
performed and fitted curves are shown for each cell line. 
 
Figure 3-7 A representative survival curve for PCF TREU 927 BRCA2 mutants exposed to 
phleomycin. 
The extent of fluorescence for each cell line (WT, -/+ and -/-), obtained using the Alamar blue 
assay, is plotted against the log of phleomycin concentrations. Nonlinear regression was 
performed and fitted curves are shown for each cell line. 
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Figure 3-8 EC50 values of PCF TREU 927 BRCA2 mutants exposed to MMS. 
Wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant cell lines were placed in serially 
decreasing amounts of MMS and allowed to grow for 48 hours, before the addition of 
Alamar Blue. After a further 24 hours, the reduction of Alamar Blue was measured by the 
amount of fluorescent resorufin generated. EC50 values are the mean from three 
experimental repetitions expressed as a percentage relative to wild-type and bars indicate 
95% confidence intervals. 
 
Figure 3-9 EC50 values of PCF TREU 927 BRCA2 mutants exposed to phleomycin. 
Wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant cell lines were placed in serially 
decreasing amounts of phleomycin and allowed to grow for 48 hours, before the addition of 
Alamar Blue. After a further 24 hours, the reduction of Alamar Blue was measured by the 
amount of fluorescent resorufin generated. EC50 values are the mean from three 
experimental repetitions expressed as a percentage relative to wild-type and bars indicate 
95% confidence intervals. 
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Table 3-2 Statistical analysis of Alamar Blue results. 
P values are shown for student’s T-tests comparing the mean EC50 values of wild-type 
TREU 927 (WT 927), -/+ and -/- BRCA2 mutant cell lines grown in the presence of MMS (A) or 
phleomycin (B). Areas shaded in yellow indicate a significant difference (P ≤ 0.05). No 
correction has been made for simultaneous multiple comparisons. 
3.3.3 Analysis of the cell cycle 
brca2-/- mutants in BSF Lister 427 display an unusual replication phenotype 
consistent with the initiation of cytokinesis prior to the completion of nuclear 
DNA replication (Claire Hartley, PhD Thesis, 2008), which is not seen in other 
DNA repair mutants, most notably rad51-/- (McCulloch and Barry, 1999). The cell 
cycle stage of kinetoplastids can be easily defined by visualising the DNA content 
of fixed cells by DAPI staining. In addition to staining the nuclear DNA (nDNA), 
the mitochondrial DNA of kinetoplastids is also visible following DAPI staining, as 
it is organised in a concentrated collection of mini- and maxi-circle DNAs within 
an organelle called the kinetoplast (and hence is called kinetoplast DNA; kDNA) 
(Lukes et al., 2002). The kinetoplast divides slightly ahead of the nucleus in the 
T. brucei cell cycle, and therefore allows the cell cycle stage of individual cells 
within an unsynchronised population to be determined by their N-K ratio (Figure 
3-10;McKean, 2003). 
Following fixation and DAPI staining (section 2.4.1), cells were counted 
according to the number of nuclei and kinetoplasts they contained. Cells in the 
G1 and S phases of the cell cycle contain 1 nucleus and 1 kinetoplast (1N1K). 
Cells in the G2 phase of the cell cycle contain 1 nucleus and 2 kinetoplasts 
(1N2K), as kinetoplast division precedes nuclear division. Following this, the 
nucleus divides and generates cells with 2 nuclei and 2 kinetoplasts (2N2K). Such 
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cells are in the M, mitotic, phase of the cell cycle. Cytokinesis subsequently 
generates two 1N1K cells in G1 phase, re-starting the cell cycle. Any cells that 
were observed not to conform to these standard configurations were noted as 
being aberrant cell types and were described as ‘others’. The data from the cell 
cycle analysis of the PCF TREU 927 BRCA2 mutant cell lines is displayed in Figure 
3-11. 
These data demonstrate that the mutation of one BRCA2 allele has no 
discernible effect on the distribution of cell cycle stages. In contrast, the   
brca2-/- mutants showed an accumulation in the number of ‘others’ and a 
concomitant decrease in the number of 1N1K cells, when compared to wild-type 
cells. The DNA content of these ‘others’ was further analysed (Figure 3-12) and 
the majority (66%) were observed to be anucleate cells (primarily 0N1K; zoids) 
(Figure 3-13). This was subtly different from the distribution of ‘others’ 
observed in the BSF Lister 427 brca2-/- mutants (Claire Hartley, PhD thesis, 
2008): though increased numbers of 0N1K cells were seen in the BSF, these did 
not predominate to the same extent, and the ‘others’ were more evenly split 
between cells with raised kDNA (primarily 0N1K and 0N2K) and raised nDNA 
content (primarily 1N0K and 2N1K). In addition, in the BSF mutants an increase 
in the number of 2N2K cells with attached nuclei were seen, which were not 
observed here in the PCF. Oyola et al., (2009) observed that upon deletion of 
BRCA2 in PCF Lister 427 T. brucei cells approximately 80% of the total cell 
population presented a ‘nundu’ phenotype, characterised by a round, swollen 
DAPI-stained structure situated approximately in the middle of the cell body. No 
cells with this ‘nundu’ morphology were observed in this work. 
 
Figure 3-10 The cell cycle of procyclic form T. brucei. 
The diagram shows the replication and division of the nucleus and kinetoplast during the T. 
brucei cell cycle. During the G1 and S phases of the cell cycle T. brucei contains 1 nucleus 
and 1 kinetoplast (1N1K). Kinetoplast division occurs in G2 phase of the cell cycle before 
nuclear division, resulting in cells containing 1 nucleus and 2 kinetoplasts (1N2K). Nuclear 
mitosis (M) leads to cells having 2 nuclei (2N2K), and occurs prior to cytokinesis, which 
generates two progeny containing 1N1K, which will restart the cell cycle. G1 and G2 
represent cell cycle growth phases. Diagram reproduced from Hammarton, 2007. 
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Figure 3-11 Cell cycle analysis of PCF TREU 927 BRCA2 mutants. 
The DNA content of wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant cell lines were 
visualised by DAPI staining of fixed cells. The numbers of cells with 1 nucleus and 1 
kinetoplast (1N 1K), 1 nucleus and 2 kinetoplasts (1N2K), 2 nuclei and 2 kinetoplasts (2N2K), 
and cells that do not fit into the expected classifications (others), were counted and 
represented by their count as a percentage of the total cells counted (N). 
 
Figure 3-12 DNA content of ‘others’ in PCF TREU 927 brca2-/- mutants. 
Total numbers of cells that do not fit into the expected classifications (others) are 
represented for the PCF TREU 927 brca2-/- mutants. The DNA content is displayed as the 
number of nuclei (N) and the number of kinetoplasts (K). 
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Figure 3-13 Examples of zoids in PCF TREU 927 brca2-/- mutants. 
Each cell is shown after staining with DAPI (DAPI) and in differential interface contrast 
(DIC). Merged images of DAPI and DIC cells are also shown (Merge). 
3.3.4 Analysis of RAD51 focus formation 
brca2-/- mutants in BSF Lister 427 T. brucei display a marked deficiency in the 
ability to form RAD51 foci after DNA damage (Proudfoot and McCulloch, 
2005;Glover, McCulloch, and Horn, 2008;Hartley and McCulloch, 2008). To date, 
the localisation of RAD51 in response to DNA damage in PCF cells has not been 
examined, and so the ability of the PCF TREU 927 BRCA2 mutant cell lines to 
form RAD51 foci was analysed. Cells were treated with phleomycin (1 µg.ml-1 for 
18 hours) before being fixed onto slides and probed with anti-RAD51 antiserum 
at a dilution of 1:1000 and visualised with Alexa Fluor 594 conjugated anti-rabbit 
antiserum (1:7000 dilution, Invitrogen); DNA was visualised with DAPI, and 
control cells without phleomycin treatment were similarly examined. The 
number of RAD51 foci present in the nucleus of the cells were counted for at 
least 200 cells per cell line and represented as a percentage of the total number 
of cells counted in Table 3-3 and plotted graphically (Figure 3-14). 
Representative images of cells are displayed in Figure 3-15. 
In the absence of DNA damage RAD51 foci were seen in ~ 2% of cells (data not 
shown; examples are depicted in Figure 3-15). The small numbers of RAD51 foci 
that are seen in the wild-type TREU 927, -/+ and -/- BRCA2 mutant cell lines 
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without phleomycin treatment may be due to repair at sites of stalled 
replication forks, as these foci have been suggested to able to form in the 
absence of BRCA2 (Tarsounas, Davies, and West, 2004). After the induction of 
DNA damage, the number of wild-type and BRCA2-/+ cells containing no 
detectable RAD51 foci reduced to ~ 25% (Figure 3-14, Table 3-3). These data 
demonstrate that the wild-type and BRCA2-/+ cell lines are efficient at forming 
RAD51 foci following DNA damage. This response is quantitatively very similar to 
that described in BSF T. brucei (Proudfoot and McCulloch, 2005;Hartley and 
McCulloch, 2008;Glover, McCulloch, and Horn, 2008), where 70-80% of cells 
formed foci after the same treatment and most cells, like the PCF cells analysed 
here, had 1-2 detectable foci, although some had more. The brca2-/- mutant 
cell line appeared to have almost completely lost the ability to form RAD51 foci 
after the induction of DNA damage, as almost no foci were visible (only 2 cells 
had a detectable focus out of the 212 analysed). This may, in fact, be a more 
severe defect than observed in BSF cells, where up to 4% of brca2-/- cells 
display RAD51 foci (Hartley and McCulloch, 2008), though it would be preferable 
to analyse greater numbers of cells, and it cannot be excluded that there is 
greater background fluorescence in the BSF cells with this anti-RAD51 antiserum 
possibly causing greater apparent foci. 
 
Table 3-3 RAD51 focus formation in PCF TREU 927 BRCA2 mutants exposed to phleomycin. 
Wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant cell lines were treated with 1 µg.ml-1 
phleomycin for 18 hours and the number of cells with a specific number of subnuclear 
RAD51 foci formed (0, 1, 2, 3, 4, > 4) were counted and are represented as a percentage of 
the total cells counted (N). Boxes shaded in light yellow contain foci, whilst boxes shaded in 
bright yellow contain the highest percentage of foci. 
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Figure 3-14 Graphical representation of RAD51 focus formation in PCF TREU 927 BRCA2 
mutants exposed to phleomycin. 
Wild-type TREU 927 (WT 927), -/+, and -/- BRCA2 mutant cell lines were treated with 1 µg.ml-1 
phleomycin for 18 hours and the number of cells with a specific number of subnuclear 
RAD51 foci formed (0, 1, 2, 3, 4, > 4) were counted and are represented as a percentage of 
the total cells counted (N). 
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Figure 3-15 Representative images of RAD51 focus formation in PCF TREU 927 BRCA2 
mutants exposed to phleomycin. 
(A) Images of wild-type TREU 927 (WT 927) -/+ and -/- BRCA2 mutant cell lines after 
phleomycin treatment (1 µg.ml-1 for 18 hours). Images were similarly prepared from cells 
without phleomycin treatment (B). White arrows indicate RAD51 foci. Each cell is shown in 
differential interface contrast (DIC), after staining with DAPI (DAPI) and after hybridisation 
with anti-RAD51 antiserum (1:1000 dilution) and secondary hybridisation with Alexa Fluor 
594 conjugated anti-rabbit antiserum (RAD51, 1:7000 dilution). Merged images of DAPI and 
RAD51 cells are also shown (Merge). 
To ensure that the observed differences in RAD51 foci were not due simply to a 
difference in the levels of RAD51 in the brca2-/- cells, or that they could be 
accounted for by a loss of RAD51 up-regulation after phleomycin treatment, 
western analysis was carried out. Total protein was extracted from cells before 
and after the same regime of phleomycin treatment as employed above and 
separated by SDS PAGE on a 10% Bis-Tris gel. After blotting, the gel was probed 
with anti-RAD51 antiserum at a dilution of 1:500. The blot was then stripped 
(section 2.11.1) and re-probed with anti-OPB1 antiserum (1:1000 dilution) to 
ensure equal protein loading levels. The western blot in Figure 3-16 
demonstrates that the levels of RAD51 protein remain constant after phleomycin 
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treatment in wild-type, and BRCA2-/+ cell lines, and are unchanged in the 
brca2-/- cells. Thus, BRCA2 is not a determinant of RAD51 stability and the 
recombinase expression levels are not detectably upregulated by phleomycin 
damage, unlike RAD51 in the related parasites T. cruzi and L. major (McKean et 
al., 2001;Regis-da-Silva et al., 2006). 
 
Figure 3-16 Western analysis of RAD51 in PCF TREU 927 BRCA2 mutants exposed to 
phleomycin. 
Total protein extracts from wild-type TREU 927 (WT 927), -/+, and -/- BRCA2 mutant cell lines 
were separated by SDS PAGE and western blotted before being probed with anti-RAD51 
antiserum (1:500 dilution). ‘-’ indicates protein extracts prepared without phleomycin 
treatment and ‘+’ indicates protein extracts prepared after phleomycin treatment (1 µg.ml-1 
BLE for 18 hours). The blots were stripped and re-probed with anti-OPB1 antiserum (1:1000 
dilution) as a loading control. Size markers are shown (kDa). 
3.3.5 Analysis of genomic stability in PCF TREU 927 
BRCA2 mutants 
After prolonged passaging (~ 290 generations) brca2-/- mutants in BSF Lister 427 
T. brucei display genomic instability, detectable by an accumulation of visible 
karyotype changes in the megabase chromosomes, at least some of which arise 
due to deletions within the VSG arrays (Hartley and McCulloch, 2008). In order to 
examine these rearrangements in more detail, the brca2-/- mutant cell lines 
generated here, in PCF TREU 927, were grown for ~ 380 generations before 
analysis of genomic stability by examination of the molecular karyotype in 
multiple clones generated from passaged populations. 
After prolonged passaging, the wild-type TREU 927, -/+ BSD and -/- BSD-PUR 
BRCA2 mutant cell lines were re-cloned as described in section 2.1.4 and a total 
of eight clones were chosen for analysis. The brca2-/- clones were checked by 
PCR, using the primers described in Figure 3-2A, to ensure that they remained 
homozygous mutants, in order to exclude the possibility that cross-
contamination with either wild-type or BRCA2-/+ cells had occurred during the 
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prolonged passaging, as these would likely have a growth advantage. The 
agarose gel in Figure 3-17 demonstrates that the BRCA2 ORF remained absent 
from the six brca2-/- mutant clones, and that both the BSD and PUR ORFs were 
present in each. 
 
Figure 3-17 Screening PCF TREU 927 BRCA2 mutant re-clones by PCR. 
An agarose gel of PCR products obtained using the primers, described in Figure 3-2A, and 
genomic DNA extracted from wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant clonal 
cell lines grown for ~ 380 generations. Distilled water (dH20) was used as a negative control. 
The PCR products produced from the BSD, PUR and BRCA2 ORFs are indicated (black 
arrows), and size markers are shown (Ladder, kb). 
Southern analysis was then performed using DNA probes designed to hybridise to 
multiple members of the ingi retrotransposon family. Retrotransposons 
constitute the most abundant mobile genetic element described in the genome 
of T. brucei, consisting of up to ~ 5% of the haploid genome (Berriman et al., 
2005). The ingi retrotransposon is 5.25 kb in size and composed of a 4.7 kb 
fragment bordered by two separate halves of the ribosomal mobile element 
(RIME) (Kimmel, Olemoiyoi, and Young, 1987;Murphy et al., 1987). If functional, 
it encodes a 1,657 amino acid protein containing a central reverse transcriptase 
domain, a C-terminal DNA-binding domain and an N-terminal 
apurinic/apyrimidinic (AP)-like endonuclease domain (Murphy et al., 
1987;Olivares, Alonso, and Lopez, 1997). The T. brucei genome contains ~ 115 
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copies of the ingi retrotransposon with only three intact copies that potentially 
code for functional retrotransposition machinery (Bringaud et al., 2004;Berriman 
et al., 2005;Bringaud et al., 2008). Ingi retrotransposons are autonomous, which 
means that they encode for their own transposition. It was originally thought 
that they were randomly distributed throughout the genome, but it is now 
known that they show a relative site-specificity for insertion (Bringaud et al., 
2004). The majority of ingi retrotransposons contain a ~ 12 bp direct repeat 
sequence upstream that is thought may be the recognition site of the ingi-
encoded endonuclease (Bringaud et al., 2004). The distribution of 
retrotransposons in the T. brucei genome has been analysed and it was 
discovered that they are over-represented in strand-switch regions (113 
elements per Mb), compared to coding regions (1.8 elements per Mb) and 
subtelomeric regions (26.7 elements per Mb) (Bringaud et al., 2007;Bringaud et 
al., 2008). Ingi retrotransposons in the subtelomeres are interspersed between 
VSG genes located in the silent VSG arrays (Figure 3-18;Berriman et al., 2005). 
The rationale behind using the ingi DNA probes was that it was considered they 
may provide a more complete picture of genetic changes in the genome, and 
more specifically within the subtelomeres, than could be obtained by designing 
DNA probes for a large number of individual VSG genes. 77 of the most complete 
ingi sequences extracted from the TREU 927 genome sequence were aligned 
(Appendix 2) and two DNA probes were designed against relatively conserved 
regions, named INGI-1 and INGI-2, and amplified by PCR using primers 86 and 87, 
and 88 and 89, respectively. The eight clonal cell lines analysed in Figure 3-17 
were used for this analysis. Genomic DNA was extracted from each, digested 
with XhoI or HindIII, separated by electrophoresis on a 1% agarose gel, Southern 
blotted and hybridised at 60°C with the ingi DNA probes. 
The Southern blots in Figure 3-19 demonstrate that this approach revealed no 
obvious ingi rearrangements in the six brca2-/- mutant clones, as the complex 
banding patterns closely resembled each other and that seen in the single wild-
type and BRCA2-/+ clones used for comparison. Though this may indicate an 
absence of ingi-associated rearrangements, it is possible that the complexity of 
the banding pattern masked any subtle changes. 
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Figure 3-18 The location of ingi retrotransposons in the subtelomeres of TREU 927 
chromosome 9. 
The location of VGSs (blue), ESAGs (green) and ingi retrotransposons (purple) are shown 
for the subtelomere of chromosome 9. Reproduced from Berriman et al., 2005. 
 
Figure 3-19 Analysis of genomic stability of PCF TREU 927 BRCA2 mutants by Southern 
analysis using DNA probes against ingi retrotransposons. 
5 µg of genomic DNA extracted from wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant 
clones was digested with XhoI (A) or HindIII (B), before being separated by electrophoresis 
on an agarose gel. The DNA was Southern blotted before being hybridised with a DNA 
probe against ingi (INGI-1 (A) or INGI-2 (B)). Size markers are shown (kb). The clones 
analysed in Figure 3-17 were used for this analysis and grown for ~ 380 generations. 
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In order to test whether the ingi DNA probes are suitable for detecting the 
putative GCRs predicted for T. brucei brca2-/- mutants, the INGI-1 probe was 
used to hybridise at 60°C to a Southern blot of genomic DNA from BSF Lister 427 
brca2-/- mutants that had undergone passaging and cloning, and where genome 
rearrangements had been predicted by the loss of members of the VSG121 family 
(section 3.4;Hartley and McCulloch, 2008). The Southern blot in Figure 3-20 
reveals a similarly complex banding pattern as seen in the PCF TREU 927 cells 
that, again, does not provide clear evidence for GCRs. As such, we can conclude 
that the ingi DNA probes are unsuitable for monitoring the genomic instability 
previously described in BSF Lister 427 brca2-/- mutants. 
 
 
Figure 3-20 Analysis of the suitability of ingi DNA probes for detection of genomic instability 
in BSF Lister 427 BRCA2 mutants. 
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5 µg of genomic DNA extracted from wild-type Lister 427 (WT 427) and brca2-/- mutant 
clones (-/-1 or -/-2) was digested with XmnI, before being separated by electrophoresis on an 
agarose gel. The DNA was Southern blotted before being hybridised with a DNA probe 
against ingi (INGI-1). Size markers are shown (kb). The clones analysed in section 3.4 were 
used for this analysis and grown for ~ 150 generations. 
In order to ask if genome rearrangements occur in the brca2-/- TREU 927 PCF 
mutants, DNA probes were next designed to analyse specific VSGs within the VSG 
arrays in these cells. VSG protein sequences from TREU 927 were aligned and a 
tree generated (Appendix 3). Four VSG families were identified containing 
between 5 and 6 relatively closely related members. The VSG genes of these 
families were aligned (Appendix 4) and primers were designed to amplify DNA 
probes that should hybridise to regions conserved within these VSG family 
members. BLASTn searches of the T. brucei TREU 927 genome were carried out 
using the DNA probe sequences and the results are detailed in Table 3-4. Five 
DNA probes were designed, named VSG1 to VSG5, and amplified using primers 97 
and 98, 99 and 100, 101 and 102, and 103 and 104, and 102 and 133, 
respectively. The eight clonal cell lines analysed in Figure 3-17 were used for 
this analysis. Genomic DNA was extracted, digested with HindIII, separated by 
electrophoresis on a 1% agarose gel, Southern blotted and hybridised at 50°C 
with the VSG1 or VSG2 DNA probes. These Southern blots were then stripped and 
re-probed with the VSG3 or VSG4 DNA probes. 
The Southern blots in Figure 3-21 provide no evidence for karyotype changes in 
the brca2-/- mutant cells, as the banding patterns of the six brca2-/- mutant 
clones closely resemble each other, and that seen in the wild-type and BRCA2-/+ 
mutant clones used for comparison. The Southern blot in Figure 3-21A was 
hybridised with the VSG1 probe that binds predominantly to two restriction 
fragments of ~ 8.5 kb and ~ 10 kb in size. These bands are visible in the wild-
type and BRCA2-/+ cell lines, and are maintained at the same size in all six 
brca2-/- mutant clones analysed. The Southern blot in Figure 3-21B was 
hybridised with the VSG2 probe which displays a much more complex banding 
pattern, with predominant restriction fragments visible at ~ 1.7 kb, ~ 2.7 kb and 
~ 8.0 kb. These bands are present, at the same size, in all clones analysed. The 
Southern blot in Figure 3-21C was hybridised with the VSG3 probe which again 
binds predominantly to two restriction fragments of ~ 5.0 kb and ~ 2.0 kb in size 
that are present at the same size in all the clones analysed. The final Southern 
blot in Figure 3-21D was hybridised with the VSG4 probe and displays two 
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restriction fragments at ~ 1.5 kb and ~ 5.0 kb that are again maintained in size 
across all the clones analysed. Thus, for each VSG analysed, there is no sign of 
gene loss, or of rearrangements that would lead to changes in restriction digest 
patterns. 
 
Table 3-4 BLASTn hits for the five VSG DNA probes. 
The five DNA probes designed were subjected to BLASTn search of the T. brucei TREU 927 
genome and the Gene IDs of the hits returned are shown with their Expect values and 
percentage identities. 
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Figure 3-21 Analysis of genomic stability of PCF TREU 927 BRCA2 mutants by Southern 
analysis using DNA probes against VSGs. 
5 µg of genomic DNA extracted from wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant 
clones was digested with HindIII before being separated by electrophoresis on an agarose 
gel. The DNA was Southern blotted before being hybridised with DNA probes against VSG1 
(A), VSG2 (B), VSG3 (C) or VSG4 (D). Size markers are shown (Ladder, kb). The clones 
analysed in Figure 3-17 were used for this analysis and grown for ~ 380 generations. 
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In order to assay more globally for any genome rearrangements, the molecular 
karyotype of the intact chromosomes in the eight clonal cell lines was analysed 
by pulsed field agarose gel electrophoresis. Genomic plugs containing 1 x 108 
cells of each of the clones derived from the passaged populations were made as 
detailed in section 2.2.2 and the intact chromosomes were separated by 
electrophoresis on a 1.2% agarose gel using conditions detailed in section 2.8.2. 
The ethidium bromide-stained pulsed field agarose gel in Figure 3-22A shows the 
expected karyotype of T. brucei TREU 927 (Melville et al., 1998), and little 
evidence for rearrangements in the brca2-/- mutant clones after prolonged 
passaging. Unlike in BSF Lister 427 brca2-/- mutants (Melville et al., 
2000;Hartley and McCulloch, 2008), substantial reductions in the size of the 
megabase chromosomes, visible as faster migrating bands, were not seen in this 
analysis. Southern blotting of the pulsed field agarose gel was next used to allow 
specific chromosomes to be visualised. DNA probes against VSGs predicted to 
reside on chromosome 5 (VSG5, primers 102 and 133; see Table 3-4) and 
chromosome 9 (VSG1, primers 97 and 98), and against Glucose-6-phosphate 
isomerase (GPI, primers 142 and 143), which is located on chromosome 1, were 
amplified by PCR, and hybridised at 50°C to the pulsed field agarose gel 
Southern blot (Figure 3-22B, C and D). For each DNA probe, hybridisation to a 
chromosome of the expected size was seen in each brca2-/- mutant clone, 
suggesting no loss of the complete genes. In addition, there was no evidence in 
any of the clones for significant reduction (or increase) in the size of 
chromosomes when compared to wild-type and BRCA2-/+ mutant clones, 
suggesting that large-scale genome rearrangements had not occurred. 
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Figure 3-22 Analysis of genomic stability of PCF TREU 927 BRCA2 mutants by pulsed field 
agarose gel electrophoresis. 
(A) Ethidium bromide-stained pulsed field agarose gel electrophoresis separation of intact 
genomic DNA from wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant clones. Lanes 
containing marker DNA molecules are indicated: H. wingei. The clones analysed in Figure 
3-17 were used for this analysis and grown for ~ 380 generations. (B-D) Southern blots of 
the pulsed field agarose gel electrophoresis separation of intact genomic DNA from wild-
type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant clones. The Southern blot was hybridised 
sequentially with DNA probes gainst GPI (Glucose-6-phosphate isomerase, B), VSG5 (C) 
and VSG1 (D). The chromosomes probed for are indicated (black arrows), and size markers 
are shown (Mb). 
Taken together, the above data suggest that brca2-/- mutants in PCF TREU 927 
do not display equivalent levels of putative GCRs to those seen in BSF Lister 427 
brca2-/- mutants, even after more extensive passaging. These data could 
indicate a function for BRCA2 in the maintenance of genome stability that is 
restricted to the BSF of T. brucei. However, an alternative explanation for this 
could be found in the differences in the relative size or composition of the VSG 
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arrays in the TREU 927 and Lister 427 strains. Karyotype analysis has suggested 
that the genome size of TREU 927 is amongst the smallest of the T. brucei 
strains examined (Melville et al., 1998). Microarray analysis suggests that the 
larger size of the genome in Lister 427 is accounted for by significantly larger 
numbers of VSGs in the subtelomeres of the megabase chromosome (Callejas et 
al., 2006). Assuming that the brca2-/- GCRs observed in Lister 427 are 
concentrated in the VSG-containing subtelomeres, the putatively smaller VSG 
repertoire of TREU 927 may mean that these rearrangements are less frequent 
or less detectable. Another plausible explanation is that the composition of the 
VSG arrays in the strain Lister 427 may contribute to the accumulation of 
putative GCRs in BSF Lister 427 brca2-/- mutants, as a large number of families 
of VSGs exist containing multiple members with very high sequence similarity 
(Boothroyd et al., 1982;Carrington et al., 1991). The VSG array of the strain 
TREU 927 does not contain families of VSGs with large numbers of similar genes 
(Marcello and Barry, 2007) and therefore may be less prone to the homologous 
recombination reactions that may lead to an accumulation of GCRs. 
3.4  Analysis of the timescale of genomic 
rearrangements in BSF Lister 427 BRCA2 
mutants 
The timeline over which the putative GCRs occur in the brca2-/- mutants in BSF 
Lister 427 is unknown. Analysis was conducted only after ~ 290 generations of 
growth and revealed rearrangements in the VSG121 gene family (Hartley and 
McCulloch, 2008), which contains five closely related VSG genes, one located at 
the telomere and the other four likely to be located in subtelomeric arrays. Two 
independent BSF Lister 427 brca2-/- mutants were generated previously (-/-1 
and -/-2;Hartley and McCulloch, 2008), and were recovered from frozen storage 
after passaging for ~ 140 generations. To ask if genome rearrangements are 
detectable after this amount of growth, 23 clones of these mutants were 
generated, as described in section 2.1.4, and grown for a mimimal further 
number of generations (~ 10) until sufficient genomic DNA could be recovered 
for Southern analysis. The clones were checked by PCR, using primers described 
in Figure 3-2A, to check the genetic status of the brca2-/- cells. The agarose gel 
in Figure 3-23 demonstrates that the BRCA2 ORF remained absent from the 23 
brca2-/- mutant clones. 
Chapter 3  132 
 
Figure 3-23 Screening BSF Lister 427 brca2-/- mutant re-clones by PCR. 
An agarose gel of the PCR products obtained using the primers, described in Figure 3-2A, 
and genomic DNA extracted from wild-type Lister 427 (WT 427) and brca2-/- mutant clonal 
cell lines. Distilled water (dH2O) was used as a negative control. The PCR products 
produced from the BSD, PUR and BRCA2 ORFs are indicated (black arrows), and size 
markers are shown (Ladder, kb). 
Southern analysis was then performed using a DNA probe specific to a region 
conserved in all five members of the VSG121 family. Genomic DNA was 
extracted, digested with XmnI, separated by electrophoresis on a 1% agarose 
gel, Southern blotted and hybridised at 60°C with the DNA probe for VSG121, 
generated by PCR with primers 146 and 147. The Southern blot in Figure 3-24 
demonstrates that loss of VSG121 occurs at an earlier time-point than thought 
previously (Hartley and McCulloch, 2008). As expected, five copies of VSG121 are 
present in wild-type BSF Lister 427 clones. However, in the majority of brca2-/- 
mutant clones analysed (16 out of 22) one or more copies of VSG121 had been 
lost, consistent with the presence of putative GCRs that result in the loss of non-
essential genetic material. The telomeric copy of VSG121 varies in size, 
presumably due to varying length of the telomere in some clones (lanes 1, 13, 17 
and 24;Van der Ploeg, Liu, and Borst, 1984), but was never lost suggesting that 
such chromosomal rearrangements infrequently affect telomeres.  
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Figure 3-24 Analysis of genomic stability of BSF Lister 427 BRCA2 mutants by Southern 
analysis using a DNA probe against VSG121. 
5 µg of genomic DNA extracted from wild-type Lister 427 (WT 427) and brca2-/- mutant 
clones was digested with XmnI, before being separated by electrophoresis on an agarose 
gel. The DNA was Southern blotted before being hybridised with a DNA probe against 
VSG121. One telomeric (TEL) gene and four genes that are likely to be present in 
subtelomeric arrays (Ii, Iii, Iiii and Iiv) are shown. ‘*’ indicates clones in which an internal 
gene copy has been lost. Size markers are shown (kb). The clones analysed in Figure 3-23 
were used for this analysis and grown for ~ 150 generations. 
3.5 Generation of BRCA2 gene disruption mutants 
in PCF Lister 427 T. brucei 
In order to test further the possibility that the function of BRCA2 in maintaining 
genomic integrity is limited to the BSF parasites, homozygous mutants of BRCA2 
were generated in PCF cells in the Lister 427 strain using the same strategy 
described in section 3.2.1. Ideally, BRCA2 mutants would also have been 
generated in BSF TREU 927 T. brucei, but as this strain is pleomorphic it was 
considered that the generation of homozygous mutants would be problematic, as 
would maintenance in culture during the passaging needed to reveal karyotype 
changes. In order to circumvent some of these difficulties it was attempted to 
transmit the PCF TREU 927 brca2-/- mutants generated here through the tsetse 
fly vector (Craig Lapsley), however no visible metacyclic form trypanosomes 
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were observed in tsetse fly saliva and therefore infection of mammals and 
isolation of BSF TREU 927 brca2-/- mutants was not possible. 
3.5.1 Generation of BRCA2 mutants in PCF Lister 427 T. 
brucei 
Two separate transformations were carried out in order to generate two 
independent BRCA2-/+ cell lines using the ∆BRCA2::BSD and ∆BRCA2::PUR gene 
deletion constructs (Figure 3-1). Wild-type PCF Lister 427 (WT 427) cells were 
transformed and antibiotic resistant transformants were selected by placing cells 
on SDM-79 media supplemented with 10 µg.ml-1 blasticidin or 1 µg.ml-1 
puromycin. Two independent BRCA2-/+ clones were chosen (-/+ BSD and -/+ 
PUR; Figure 3-25) and subsequently transformed with the complementary BRCA2 
gene deletion construct in order to generate two independent brca2-/- mutant 
cell lines. Antibiotic resistant transformants were selected with 5 µg.ml-1 
blasticidin and 0.5 µg.ml-1 puromycin. 
3.5.2 Confirmation of BRCA2 mutants by PCR 
The generation of brca2-/- mutants was initially confirmed by PCR performed on 
genomic DNA extracted from the putative brca2-/- cell lines (six -/- BSD-PUR 
clones and six -/- PUR-BSD clones were chosen). PCR was performed using 
primers specific to the BSD, PUR and BRCA2 ORFs as described in section 3.2.3 
and Figure 3-2A. 
The agarose gel in Figure 3-25 demonstrates the presence of the BSD and PUR 
resistance ORFs in all bar one (BSD-PUR) of the putative brca2-/- mutants. As 
seen in brca2-/- mutants in PCF TREU 927, a number of these clones still 
retained the BRCA2 ORF, producing a PCR product with the primers to amplify 
part of the BRCA2 ORF. These ‘incorrect’ clones were discarded and two 
independent brca2-/- mutant clones were selected from the clones that failed to 
amplify a PCR product using these primers (indicated by ‘*’ in Figure 3-25). The 
two independent brca2-/- mutant clones chosen were referred to as -/- BSD-PUR 
and -/- PUR-BSD. 
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Figure 3-25 Confirmation of PCF Lister 427 BRCA2 mutants by PCR. 
An agarose gel of the PCR products, obtained using the primers, described in Figure 3-2A, 
and genomic DNA extracted from wild-type Lister 427 (WT 427), BRCA2 heterozygous (-/+) 
and putative brca2 homozygous (-/-) mutant cell lines. The two independent BRCA2-/+ 
mutants are indicated by -/+ BSD and -/+ PUR, and the putative brca2-/- mutants derived 
from these are indicated by -/- BSD-PUR and -/- PUR-BSD, respectively. Distilled water 
(dH2O) was used as a negative control. The PCR products produced from the BSD, PUR and 
BRCA2 ORFs are indicated (black arrows), and size markers are shown (Ladder, kb). ‘*’ 
indicates brca2-/- mutants that are confirmed by PCR. 
3.5.3 Confirmation of BRCA2 mutants by Southern 
analysis 
To confirm the generation of two independent brca2-/- mutant cell lines, 
Southern analysis was performed as described in section 3.2.4. The only 
difference was that the genomic DNA extracted was digested with SacII and StuI 
prior to Southern blotting to enable the differentiation between the BSD and 
PUR alleles. The location of primers, predicted restriction enzyme recognition 
sites and expected DNA fragment sizes are displayed in Figure 3-26A. 
The Southern blot in Figure 3-26B demonstrates that the intact BRCA2 ORF exists 
in wild-type Lister 427 cells as two allelic size variants, and these have been 
shown to vary in the number of BRC repeat motifs they encode (Hartley and 
McCulloch, 2008). In each BRCA2-/+ mutant, a distinct BRCA2 allele was 
replaced with either a BSD or PUR resistance cassette. In neither brca2-/- 
mutant could an intact BRCA2 ORF be detected, and instead both alleles of the 
gene were deleted, one replaced by a BSD cassette and the other replaced by a 
PUR cassette. 
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Figure 3-26 Confirmation of PCF Lister 427 BRCA2 mutants by Southern analysis. 
(A) Restriction maps showing the expected products of restriction digestion, Southern 
blotting and hybridisation with the 5’ UTR of the BRCA2 ORF (black arrows indicate the 
primers used to PCR-amplify this as a DNA probe). The restriction sites are indicated, with 
the expected restriction fragment sizes shown (kb). (B) 5 µg of genomic DNA extracted from 
wild-type Lister 427 (WT 427), -/+ and -/- BRCA2 mutant cell lines was digested with SacII 
and StuII before being separated by electrophoresis on an agarose gel. The DNA was 
Southern blotted before being hybridised with a DNA probe against the 5’ UTR of the 
BRCA2 ORF. The bands produced from the WT alleles and the BRCA2 mutant alleles are 
indicated (black arrows), and size markers are shown (Ladder, kb). 
3.5.4 Attempt at confirmation of BRCA2 mutants by 
western analysis 
Attempts at confirmation of the absence of expression of BRCA2 in the PCF 
Lister 427 brca2-/- cells by western blot using anti-BRCA2 antiserum was 
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performed multiple times, including with the addition of 5% chicken serum 
(Sigma) in the blocking solution to reduce non-specific binding of the antibody. 
The result of these attempts was inconclusive due to the extensive nature of the 
non-specific binding of the antiserum and, therefore, is not displayed. 
3.6  Phenotypic analysis of PCF Lister 427 BRCA2 
mutants 
3.6.1 Analysis of in vitro growth 
The in vitro growth of the PCF Lister 427 BRCA2 mutant cell lines was analysed 
and the average counts from three experimental repetitions are plotted in 
Figure 3-27, and extrapolated doubling times are displayed in Table 3-5. 
From the growth curves and doubling times displayed it is apparent that 
disruption of a single BRCA2 allele has no discernible effect on the growth of 
BRCA2-/+ cell lines when compared to wild-type cells. However, the brca2-/- 
mutants display a very slight retardation in growth as evidenced by a slight 
increase in the doubling time from the wild-type value of ~ 11 hours to ~ 13 
hours for the mutants. This minor growth impairment appears to be even slighter 
than that observed for the PCF TREU 927 brca2-/- cells (section 3.3.1). 
 
Figure 3-27 Analysis of in vitro growth of PCF Lister 427 BRCA2 mutants. 
2 ml cultures of wild-type Lister 427 (WT 427), -/+ and -/- BRCA2 mutant cell lines were 
inoculated at 5 x 105 cells.ml-1 and cell densities counted 24, 48, and 72 hours subsequently 
are shown. Values are averaged from the counts from three experimental repetitions, and 
vertical lines indicate standard deviation. 
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Table 3-5 In vitro population doubling times of PCF Lister 427 BRCA2 mutants. 
The mean doubling time for wild-type Lister 427 (WT 427), -/+ and -/- BRCA2 mutant cell 
lines is displayed, in hours, and was calculated from the data displayed in Figure 3-27. 
3.6.2 Analysis of DNA damage sensitivity 
The Alamar blue assay was used to determine the sensitivity of the PCF Lister 
427 BRCA2 mutant cell lines to the DNA damaging agents MMS and phleomycin. 
The Alamar blue assay was set up with wild-type Lister 427, -/+ and -/- BRCA2 
mutant cell lines. The extent of fluorescence for each cell line was plotted 
graphically over the range of log drug concentrations (for representative 
examples see Figure 3-28 and Figure 3-29). From this, EC50s were determined 
from each individual plot and then average EC50s (plus 95% confidence intervals) 
were calculated from the three experimental repetitions. The mean EC50s for 
each cell line were then plotted relative to the wild-type EC50, which was taken 
as 100% (Figure 3-30 and Figure 3-31). 
The survival curves displayed in Figure 3-28 and Figure 3-29 are representative 
of the three experimental repetitions performed. These data demonstrate that 
as the concentration of DNA damaging agent increases the fluorescence, and 
therefore the percentage of surviving cells that are actively reducing Alamar 
blue to fluorescent resorufin reduces, until the concentration at which all cells 
are killed is reached. It is apparent that the brca2-/- cell lines display reduced 
survival in the presence of both compounds, when compared to wild-type cells. 
The BRCA2-/+ cell lines display survival that is essentially equivalent to wild-
type cells, except for the BRCA2-/+ PUR cell line that appears to show a slightly 
greater survival in the presence of phleomycin (although not significantly, see 
below), perhaps similar to the differences in damage sensitivity seen previously 
for a BRCA2-/+ mutant cell line in PCF TREU 927 (section 3.3.2). The graphs of 
relative EC50 values displayed in Figure 3-30 and Figure 3-31 support the 
graphical observations and demonstrate that the disruption of a single BRCA2 
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allele has no discernible effect on the sensitivity of the BRCA2-/+ cell lines to 
the DNA damage caused by either compound when compared to wild-type cells. 
In contrast, the brca2-/- mutants appeared to display a slightly greater 
sensitivity to both DNA damaging agents, though this was very slight and was 
markedly less than the brca2-/- mutants in PCF TREU 927 (section 3.3.2)  
To evaluate the above data the EC50 values of the wild-type Lister 427, -/+ and 
-/- BRCA2 mutant cell lines were analysed using student’s T-tests and the results 
of this are displayed in Table 3-6. The statistical analyses confirm the graphical 
observations. No statistical difference was observed between wild-type, -/+ or -
/- BRCA2 mutant cells (p > 0.05) for both DNA damaging agents, underlining that 
the brca2-/- mutants display at best only a slight phenotype of increased DNA 
damage sensitivity. 
 
Figure 3-28 A representative survival curve for PCF Lister 427 BRCA2 mutants exposed to 
MMS. 
The extent of fluorescence for each cell line (WT, -/+ and -/-) obtained using the Alamar blue 
assay is plotted against the log of MMS concentrations. Nonlinear regression was 
performed and fitted curves are shown for each cell line. 
 
Figure 3-29 A representative survival curve for PCF Lister 427 BRCA2 mutants exposed to 
phleomycin. 
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The extent of fluorescence for each cell line (WT, -/+ and -/-) obtained using the Alamar blue 
assay is plotted against the log of phleomycin concentrations. Nonlinear regression was 
performed and fitted curves are shown for each cell line. 
 
Figure 3-30 EC50 values of PCF Lister 427 BRCA2 mutants exposed to MMS. 
Wild-type Lister 427 (WT 427), -/+ and -/- BRCA2 mutant cell lines were placed in serially 
decreasing amounts of MMS and allowed to grow for 48 hours, before the addition of 
Alamar Blue. After a further 24 hours, the reduction of Alamar Blue was measured by the 
amount of fluorescent resorufin generated. EC50 values are the mean from three 
experimental repetitions expressed as a percentage relative to wild-type and bars indicate 
95% confidence intervals. 
 
Figure 3-31 EC50 values of PCF Lister 427 BRCA2 mutants exposed to phleomycin. 
Wild-type Lister 427 (WT 427), -/+ and -/- BRCA2 mutant cell lines were placed in serially 
decreasing amounts of phleomycin and allowed to grow for 48 hours, before the addition of 
Alamar Blue. After a further 24 hours, the reduction of Alamar Blue was measured by the 
amount of fluorescent resorufin generated. EC50 values are the mean from three 
experimental repetitions expressed as a percentage relative to wild-type and bars indicate 
95% confidence intervals. 
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Table 3-6 Statistical analysis of Alamar Blue results. 
P values are shown for student’s T-tests comparing the mean EC50 values of wild-type 
Lister 427 (WT 427), -/+ and -/- BRCA2 mutant cell lines grown in the presence of MMS (A) or 
phleomycin (B). Areas shaded in yellow indicate a significant difference (P ≤ 0.05). No 
correction has been made for simultaneous multiple comparisons. 
3.6.3 Confirmation of the DNA damage sensitivity of PCF 
Lister 427 BRCA2 mutants 
Due to the lack of statistical significance associated with the DNA damage 
sensitivity of the two PCF Lister 427 brca2-/- mutant cell lines, it was decided to 
analyse the in vitro growth of these cells in the presence of MMS in order to 
confirm the results of the Alamar blue assay. 2 ml cultures were inoculated at 5 
x 105 cells.ml-1 in SDM-79 media supplemented with 0.0004% MMS and counted at 
24, 48 and 72 hours subsequently. The average counts from three repetitions are 
plotted in Figure 3-32. 
From the growth curve displayed it is apparent that the disruption of a single 
BRCA2 allele has no discernible effect on the growth of the cells in the presence 
of MMS, when compared to wild-type cells. However, the brca2-/- mutant cells 
display a visible retardation in growth after 48 hours, indicating that disruption 
of BRCA2 results in an increase in the DNA damage sensitivity of the mutant cell 
lines. For all the cells, the rate of growth was reduced by the presence of MMS, 
but this growth retardation was more pronounced for the brca2-/- mutants 
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Figure 3-32 Analysis of in vitro growth of PCF Lister 427 BRCA2 mutants exposed to MMS. 
2 ml cultures of wild-type Lister 427 (WT 427), -/+ and -/- BRCA2 mutant cell lines were 
inoculated at 5 x 105 cells.ml-1 in media supplemented with 0.0004% MMS, and cell densities 
counted 24, 48, and 72 hours subsequently are shown. Values are averaged from the counts 
from three experimental repetitions, and vertical lines indicate standard deviation. 
3.6.4 Analysis of genomic stability in PCF Lister 427 
BRCA2 mutants 
After prolonged passaging (~ 290 generations) brca2-/- mutants in BSF Lister 427 
T. brucei display evidence for putative GCRs, including gene deletions within the 
subtelomeric VSG arrays (Hartley and McCulloch, 2008). Data displayed in 
section 3.4 demonstrates that these rearrangements can occur earlier than 
previously thought (~ 150 generations), and provided a timescale over which 
analysis of the genomic stability of the brca2-/- mutants generated in PCF Lister 
427 should be considered. The brca2-/- mutants in PCF Lister 427 were initially 
grown for ~ 80 generations before analysis of genomic stability by examination 
of the molecular karyotype. 
Wild-type Lister 427, -/+ and -/- BRCA2 mutant polyclonal cell lines were re-
cloned and a total of 19 clones were chosen for analysis. PCR using primers 
described in Figure 3-2A was carried out to check the genetic status of the 
brca2-/- cells. The agarose gel in Figure 3-33 demonstrates that the BRCA2 ORF 
remained absent from the 12 brca2-/- mutant clones. 
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Figure 3-33 Screening PCF Lister 427 brca2-/- mutant re-clones by PCR. 
An agarose gel of the PCR products obtained using the primers, described in Figure 3-2A, 
and genomic DNA extracted from wild-type Lister 427 (WT 427), -/+ and -/- BRCA2 mutant 
clonal cell lines. Distilled water (dH2O) was used as a negative control. The PCR products 
produced from the BSD, PUR and BRCA2 ORFs are indicated (black arrows), and size 
markers are shown (Ladder, kb). 
Southern analysis was then performed using a DNA probe against members of the 
VSG121 family as described in section 3.4. The Southern blot in Figure 3-34 
demonstrates that no loss of VSG121 was detectable after ~ 80 generations of 
growth in PCF Lister 427 brca2-/- mutant cells. As expected, five copies of 
VSG121 were present in wild-type and BRCA2-/+ clones. However, five copies of 
VSG121 were also present in all of the brca2-/- mutant clones analysed, 
indicating the absence of genome rearrangements affecting the VSG arrays. 
Indeed in the brca2-/- mutant clone in lane 6 a further copy of VSG121 had been 
generated, by an unknown mechanism, and this cell line now contains a sixth 
copy of the gene. Such gene duplication has not been observed before, only 
gene loss. As seen before, the telomeric copy of VSG121 varied in size but was 
never lost. 
 
Figure 3-34 Analysis of genome stability of PCF Lister 427 BRCA2 mutants by Southern 
analysis using a DNA probe against VSG121. 
5 µg of genomic DNA extracted from wild-type Lister 427 (WT 427), -/+ and -/- BRCA2 mutant 
clones was digested with XmnI before being separated by electrophoresis on an agarose 
gel. The DNA was Southern blotted before being hybridised with a DNA probe against 
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VSG121. One telomeric (TEL) gene and four genes that are likely to be present in 
subtelomeric arrays (Ii, Iii, Iiii and Iiv) are shown. Size markers are shown (kb). The clones 
analysed in Figure 3-33 were used for this analysis and grown for ~ 80 generations. 
Because of the discrepancy between the number of passages used here and the ~ 
150 generations after which extensive loss of VSG121 was seen in Lister 427 
brca2-/- mutants (section 3.4), the BRCA2 mutants in PCF Lister 427 were grown 
for a longer period of time and subsequently re-cloned at ~ 230 generations 
growth. Clones were generated from the wild-type Lister 427, -/+ and -/- BRCA2 
mutant polyclonal cell lines and a total of 24 clones were chosen for analysis. 
PCR using primers described in Figure 3-2A was again carried out to confirm the 
absence of BRCA2 ORF in the brca2-/- clones; and Figure 3-35 demonstrates that 
the BRCA2 ORF remained absent from the 15 brca2-/- mutant clones.  
 
Figure 3-35 Screening PCF Lister 427 brca2-/- mutant re-clones by PCR. 
An agarose gel of the PCR products obtained using the primers, described in Figure 3-2A, 
and genomic DNA extracted from wild-type Lister 427 (WT 427), -/+ and -/- BRCA2 mutant 
clonal cell lines. Distilled water (dH2O) was used as a negative control. The PCR products 
produced from the BSD, PUR and BRCA2 ORFs are indicated (black arrows), and size 
markers are shown (Ladder, kb). 
Southern analysis was then performed using a DNA probe against members of the 
VSG121 family, as described in section 3.4. The Southern blot in Figure 3-36 
demonstrates that no loss of VSG121 was detectable in PCF Lister 427 brca2-/- 
mutants, even after ~ 230 generations of growth. The wild-type Lister 427 clones 
in lanes 1, 10 and 11 appeared to have duplicated VSG121 and contain a sixth 
copy of the gene, as seen for one brca2-/- clone at ~ 80 generations (Figure 
3-34, lane 6). As seen before, the telomeric copy of VSG121 varied in size, quite 
considerably in lane 22, but was never lost. 
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Figure 3-36 Analysis of genomic stability of PCF Lister 427 BRCA2 mutants by Southern 
analysis using a DNA probe against VSG121. 
5 µg of genomic DNA extracted from wild-type Lister 427 (WT 427), -/+ and -/- BRCA2 mutant 
clones was digested with XmnI before being separated by electrophoresis on an agarose 
gel. The DNA was Southern blotted before being hybridised with a DNA probe against 
VSG121. One telomeric (TEL) gene and four genes that are likely to be present in 
subtelomeric arrays (Ii, Iii, Iiii and Iiv) are shown. Size markers are shown (kb). The clones 
analysed in Figure 3-35 were used for this analysis and grown for ~ 230 generations. 
In order to confirm the putative absence of genome rearrangements, the 
molecular karyotype of a number of the clones analysed in Figure 3-36 was 
carried out by pulsed field agarose gel electrophoresis. Genomic plugs containing 
1 x 108 cells were made and the intact chromosomes were separated by 
electrophoresis on a 1.2% agarose gel. 
The ethidium bromide-stained pulsed field agarose gel in Figure 3-37A shows the 
expected karyotype of T. brucei Lister 427 (Melville et al., 2000) and indicates 
the absence of clear GCRs in the brca2-/- mutants after prolonged passaging. 
Unlike in BSF Lister 427 brca2-/- cells, where considerable size variation was 
evident in the chromosomes between 1.05-3.13 Mbps, there was a notable 
uniformity in size of the chromosomes in the different PCF Lister 427 brca2-/- 
clones and relative to the wild-type and BRCA2-/+ clones. Only in the brca2-/- 
clone in lane 12 did there appear to be a detectable change, with loss of signal 
for a band of ~ 2.35 Mb.  
A Southern blot was next prepared from the pulsed field agarose gel and 
hybridised with DNA probes against VSG121 and Glucose-6-phosphate isomerase 
(GPI), which is located on chromosome 1, which were amplified by PCR. The 
Southern blots in Figure 3-37B and Figure 3-37C, demonstrate chromosomes at 
the expected sizes for GPI and VSG121 in the strain Lister 427 (Melville et al., 
2000;Hartley and McCulloch, 2008). As observed in the ethidium bromide-stained 
pulsed field agarose gel, the brca2-/- mutant clone in lane 12 contains the only 
Chapter 3  146 
detectable change in karyotype, and appeared to have lost genetic material 
leading to a reduction in size of the chromosome that harbours both GPI and at 
least one of the VSG121 family genes. As only a small number of wild-type and 
BRCA2-/+ clones were analysed for genomic stability in this manner, it is 
possible that the rearrangement in the single brca2-/- clone in lane 12 is simply 
due to changes in chromosome sequences as previously observed after prolonged 
passaging of T. brucei (Anneli Cooper, PhD, Thesis 2010). 
 
 
Figure 3-37 Analysis of genomic stability of PCF Lister 427 BRCA2 mutants by pulsed field 
agarose gel electrophoresis. 
(A) Ethidium bromide-stained pulsed field agarose gel electrophoresis separation of intact 
genomic DNA from wild-type Lister 427 (WT 427), -/+ and -/- BRCA2 mutant clones. Lanes 
containing marker DNA molecules are indicated: H. wingei. The clones analysed in Figure 
3-35 were analysed here and grown for ~ 230 generations. (B-C) Southern blots of the 
pulsed field agarose gel electrophoresis separation of intact genomic DNA from wild-type 
Lister 427 (WT 427), -/+ and -/- BRCA2 mutant clones. The Southern blot was hybridised 
sequentially with DNA probes against GPI (Glucose-6-phosphate isomerase, B) and VSG 
121 (C). The chromosomes probed for are indicated (black arrows), and size markers are 
shown (Mb). 
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3.7 Summary 
In this work, it has been shown that BRCA2 provides a role in the repair of DNA 
damage and in the subnuclear relocalisation of RAD51 after damage in PCF T. 
brucei, which was only previously examined in BSF cells. Despite this, the 
growth impairment and DNA damage sensitivity phenotypes of the PCF brca2-/- 
mutants generated here are slighter than those observed for the BSF brca2-/- 
mutants generated previously (Hartley and McCulloch, 2008). Why this might be 
is unclear, especially as the extent to which the PCF cells formed detectable 
subnuclear RAD51 foci is very comparable to that of the BSF cells (Hartley and 
McCulloch, 2008). One possible explanation is that BRCA2 plays an additional 
role in the BSF life cycle stage, or that it performs dual functions in both life 
cycle stages but one of these is more pronounced in the BSF. What this function 
might be is unclear from these data, but perhaps BRCA2’s role in general repair 
of DNA damage is distinct from another role in the maintenance of genome 
stability. If this stability function required a greater proportion of the available 
BRCA2 in the BSF, then less BRCA2 might be available for general repair and 
mutation of BRCA2 in the BSF stage would then have a much greater impact on 
the general well being of the cells, manifested as a larger growth defect and 
greater sensitivity to exogenously added DNA damaging agents. For this proposed 
dual function of BRCA2, perhaps specific to BSF cells, to be true, it supposes 
that the levels of BRCA2 available for DNA repair may be higher in PCF cells, and 
we have no further evidence for this. It is also not obvious why the levels of 
BRCA2 could not simply be life cycle stage regulated. The only known functions 
of BRCA2 are to aid RAD51-mediated HR (O'Donovan and Livingston, 
2010;Holloman, 2011), so it seems likely that any such dual function for BRCA2 
would be manifest through RAD51. In this regard, it would be intriguing to 
analyse the levels of RAD51 and BRCA2 proteins in the two life cycle stages and 
also to generate and analyse rad51-/- mutants in PCF cells to see if the 
phenotypes of this mutation are comparable in PCF and BSF cells. It is not clear 
whether the observation that T. brucei RAD51 levels do not respond to DNA 
damage, as they do in T. cruzi and L. major (McKean et al., 2001;Regis-da-Silva 
et al., 2006), may be related to this. What is clear though, is that RAD51 is able 
to be relocalised efficiently to induced DNA damage in both PCF and BSF cells 
(Hartley and McCulloch, 2008). 
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A major issue that would need to be addressed in the above hypothesis is the 
nature of the putative dual roles for BRCA2. An obvious possibility is a function 
in VSG switching, which may only occur in the BSF where the VSG ES are actively 
transcribed (Horn and McCulloch, 2010;Rudenko, 2010). Why this should differ 
from general repair by HR is unknown. An alternative is that BRCA2 contributes 
to the maintenance of the subtelomeres, which may have features (such as 
chromatin structure) that differ between the two life cycle stages, rendering 
them more prone to instability in the BSF. This is clearly a possibility, as it would 
explain the observed differences in genome instability described here (see 
below). Nonetheless, we cannot discount more trivial explanations for the 
differences in growth and repair in BRCA2 mutants in BSF and PCF cells. For 
instance, it may be that differences in underlying doubling times of the two life 
cycle stages in culture simply mean that the assays employed here provide less 
discrimination in the PCF, which divide more slowly. It is also possible that the 
PCF cells experience increased oxidative damage, due to the greater 
mitochondrial metabolism in PCF cells relative to BSF cells (Bienen et al., 
1991;Hajduk et al., 1992;Fang and Beattie, 2003) that is likely to yield higher 
levels of reactive oxygen species, which can damage DNA (Kryston et al., 2011). 
Alternatively, previous work has suggested that cell cycle checkpoints differ in 
PCF and BSF cells (Hammarton, 2007), and it may then be that DNA damage is 
recognised, signalled or repaired differently.  
 The observed replication phenotype in BSF brca2-/- mutant cells, consistent 
with the initiation of cytokinesis prior to the completion of DNA replication, 
manifests as an accumulation of cells with aberrant DNA configurations (Hartley 
and McCulloch, 2008). Analysis of the cell cycle in the TREU 927 PCF brca2-/- 
mutants generated here revealed an accumulation of zoids (anucleate cells) and 
this may be due to differences in the cell cycle checkpoints between the two life 
cycle forms; with PCF cells lacking the mitosis to cytokinesis checkpoint that is 
present in BSF cells (Hammarton et al., 2003;Hammarton, 2007), allowing PCF 
cells that have not replicated their nuclear DNA (1N2K) to proceed through 
cytokinesis generating progeny containing 1N1K and 0N1K DNA content 
(Woodward and Gull, 1990). It is also possible that BRCA2 plays a more central 
role in replication progression and/or re-start in the BSF, and this could account 
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for the reduction in the severity of the brca2-/- mutant phenotypes in the PCF 
Lister 427 and TREU 927 strains. 
This work reveals a clear life cycle stage difference in genome stability, which is 
more marked than the repair differences discussed above. It is shown that the 
genomic instability phenotype observed in Lister 427 BSF brca2-/- mutant cells 
cannot be detected in the same brca2-/- mutants generated here in PCF cells of 
both TREU 927 and Lister 427 strains. This surprising finding appears to indicate 
a function of BRCA2 in the maintenance of genome stability that is a BSF-specific 
phenomenon. The differences in the size and composition of the subtelomeric 
VSG arrays in the two strains, TREU 927 and Lister 427, do not appear to account 
for the absence of putative GCRs in the TREU 927 PCF brca2-/- mutants 
generated here, as the Lister 427 PCF brca2-/- mutants also generated do not 
display putative GCRs after prolonged passaging. Though any rearrangements in 
PCF brca2-/- mutant cells may require a longer period of growth before 
accumulating to a level that is detectable, the increased population doubling 
times of this life cycle stage have been taken into account when estimating 
generation times. Thus, the lack of rearrangements in the PCF cells cannot be 
accounted for simply by growth rate differences. In fact, the genome 
rearrangements observed in the BSF brca2-/- mutant cells have been detected at 
an earlier time point (~ 150 generations) than previously examined, and 
significantly earlier than the PCF analyses. The original aim of this chapter was 
to map the genomic rearrangements at the DNA sequence level using the 
assembled genome sequence of strain TREU 927. Due to the absence of genome 
rearrangements in the PCF brca2-/- mutants generated here, this aim could not 
be carried out. Completion of the assembly of the Lister 427 genome, in 
particular the subtelomeres of the megabase chromosomes, and the design of a 
microarray to allow whole genome hybridisation would allow the genetic 
dissection of the rearrangements observed in BSF Lister 427 brca2-/- mutants. In 
the absence of these data, we can only speculate about the reasons for these 
life cycle differences. 
The basis of this function for BRCA2 in the maintenance of genome stability in 
the BSF may be differences in the chromatin structure between the two life 
cycle stages (Schlimme et al., 1993;Burri et al., 1994), possibly due to the 
requirement for antigenic variation and VSG expression in the BSF only (Hughes 
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et al., 2007;Figueiredo, Janzen, and Cross, 2008;Stanne and Rudenko, 
2010;Figueiredo and Cross, 2010). In this regard, there is some evidence to 
suggest that these rearrangements may be specifically targeted to VSGs. The 
large karyotype changes that occur in BSF brca2-/- mutants, that lead to the loss 
of copies of VSG121, do not detectably encompass the ingi retrotransposon 
families (or at least the families analysed here). Many of these ingi 
retrotransposons are located in strand switch regions, and some are distributed 
throughout the VSG arrays in the subtelomeres of the megabase chromosomes. 
This builds upon previous work showing that the intermediate- and mini-
chromosomes, which do not harbour VSG arrays, are not affected by loss of 
BRCA2 (Hartley and McCulloch, 2008). Perhaps, then, the rearrangements are 
even more VSG-localised than previously thought
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 Chapter 4: The function of the 
BRCA2 BRC repeat expansion in T. 
brucei. 
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4.1 Introduction 
The BRCA2 protein in T. brucei contains an unusual number and arrangement of 
the RAD51-binding motif, the BRC repeat, which distinguishes it from BRCA2 
proteins in other species. The human BRCA2 protein contains eight BRC repeats 
(Figure 1-15), all of which have been shown to bind Rad51 in either monomer or 
nucleoprotein filament forms (Wong et al., 1997;Carreira and Kowalczykowski, 
2011). The BRC repeats have been demonstrated to have different affinities for 
binding Rad51 due to the variation in amino acid sequence that is apparent 
across the eight BRC repeats (Chen et al., 1998;Pellegrini and Venkitaraman, 
2004;Esashi et al., 2005;Thorslund, Esashi, and West, 2007;Carreira and 
Kowalczykowski, 2011). The BRC repeats are spread across the central third of 
the BRCA2 protein, with spacer regions between repeats varying from between 
60 and 100 amino acids in length, and showing no sequence conservation (Bork, 
Blomberg, and Nilges, 1996;Bignell et al., 1997). In contrast to this, the BRCA2 
protein identified in T. brucei is unusual in containing an expansion in the 
number of BRC repeats; up to 15 BRC repeat motifs were predicted from the 
TREU 927 genome sequence, and Southern and minisatellite variant repeat (MVR) 
mapping shows that, while this number is variable both between strains and 
between alleles within a strain, BRCA2 always has greater than 8 BRC repeats 
(Lo et al., 2003;Hartley and McCulloch, 2008). If it is assumed that a given 
BRCA2 allele encodes fifteen BRC repeats, sequence analysis revealed that the 
14 most N-terminal motifs are identical in amino acid sequence, while the 
sequence of the most C-terminal motif is slightly diverged in the last 11 amino 
acids. In addition, the BRC repeat motifs are arranged across the N-terminal half 
of the T. brucei BRCA2 protein and exist in a perfect tandem repeated array, 
with exactly 9 amino acids separating each repeat from the next and showing 
complete conservation (Hartley and McCulloch, 2008). This unusual BRC repeat 
expansion and arrangement appears largely unique to T. brucei (Figure 1-19). 
Amongst kinetoplastid parasites, BRCA2 proteins in T. cruzi and Leishmania sp. 
each possess 2 non-identical BRC repeats, while the African trypanosomes T. 
vivax and T. congolense contain 1 and 3 BRC repeats, respectively (Hartley and 
McCulloch, 2008). In other protists, 1-2 BRC repeats appear the norm, though 
larger numbers are found in apicomplexan parasites and in Trichomonas 
vaginalis (6-8 and 14, respectively), though here the repeats do not show the 
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same level of sequence uniformity or array organisation (Hartley and McCulloch, 
2008;Lo et al., 2003). Indeed, only in T. congolense are the repeats arranged 
like the T. brucei tandem repeat array, albeit in a truncated form. 
It has been postulated that this expansion in BRC repeat number in T. brucei 
BRCA2 could be an adaptation for the elevated rates of homologous 
recombination required by T. brucei in order to carry out antigenic variation 
efficiently. However, this appears not to be the case, or at least to be too 
simplistic a hypothesis. In BSF Lister 427 brca2-/- mutant cells the re-expression 
of variants of BRCA2 from T. brucei and T. vivax containing only a single BRC 
repeat restored observed VSG switching frequencies to wild-type levels (Hartley 
and McCulloch, 2008), indicating that 15 BRC repeats are not a requirement for 
efficient antigenic variation in T. brucei, at least as measured by the VSG 
switching assay employed. Despite this, expression of these BRCA2 variants in 
BSF brca2-/- cells did cause detectable impairment in two aspects of 
homologous recombination: homology-directed integration of transformed DNA 
constructs, and re-organisation of RAD51 into detectable subnuclear foci 
following phleomycin-induced DNA damage (Hartley and McCulloch, 2008). 
This chapter aims to characterise the function of the BRC repeat expansion in T. 
brucei BRCA2 further, by investigating the phenotype of T. brucei cells 
expressing a number of variants of BRCA2 with reduced numbers of BRC repeats. 
Full-length BRCA2 was re-expressed in the brca2-/- mutant cell lines in the same 
manner as the BRC variants, in order to determine whether or not the 
phenotypic defects observed were due to loss of BRCA2 (Chapter 3), and not the 
result of secondary mutation(s). 
4.2 Complementation of PCF TREU 927 brca2-/- 
mutant with variants of BRCA2 with reduced 
numbers of BRC repeats 
4.2.1 Generation of constructs containing variants of 
BRCA2 with reduced numbers of BRC repeats 
Constructs to enable the re-expression of variants of BRCA2 with reduced 
numbers of BRC repeats were generated. Re-expression constructs containing 
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the full-length BRCA2 gene (cloned from Lister 427 and estimated to contain 12 
BRC repeats) and a variant containing the single, most C-terminal, degenerate 
BRC repeat motif were generated previously (gift, Claire Hartley). Multiple 
attempts to create variants of BRCA2 with reduced numbers of BRC repeats by 
PCR have failed (data not shown), and therefore the required BRC variant 
domains of BRCA2 were synthesised. The synthesised DNA contained the 216 bp 
of the BRCA2 ORF from the ATG start codon to the start of the first BRC repeat 
sequence, followed by 3, 6 or 9 ‘normal’ BRC repeats, then followed by the 
degenerate BRC repeat and finally 277 bp of sequence extending down to a 
unique MfeI restriction site (2473 bp; Figure 4-1). These BRC variant domains of 
BRCA2 differ from each other only in the number of BRC repeats, since each 
conserved repeat is identical, and were called 4BRC, 7BRC and 10BRC, 
respectively. A restriction digestion-based cloning approach was then used to 
assemble the re-expresser constructs by adding the variant BRC repeat domains 
to the BRCA2 ORF sequence downstream of MfeI, avoiding problematic PCR-
amplification across the BRC repeat sequences. The variant BRC repeat domains 
were synthesised with EcoRV and XhoI sites at the 5’ and 3’ ends, respectively, 
to allow direct cloning into pBluescript. The 2,473 bp C-terminal domain of 
BRCA2, from the unique MfeI restriction site downstream to the stop codon, was 
excised from an existing construct (pRSF1b BRCA2 C-term, section 5.2.1) using 
the restriction endonucleases MfeI and XhoI. This C-terminal BRCA2 DNA 
fragment was then cloned into the pBluescript BRC variant constructs using the 
MfeI and XhoI restriction sites. To create pRM482::BRC re-expression constructs 
(see below), the whole assembly of each variant was then excised from 
pBluescript by digestion with EcoRV and XhoI, and blunt cloned into pRM482 
(gift, Richard McCulloch) prepared by EcoRV restriction digestion. The cloning 
strategy is displayed in Figure 4-2. 
 
Figure 4-1 A diagram of the 7BRC variant domain of T. brucei BRCA2 generated by DNA 
synthesis. 
Indicated are the sequence motifs present including; 6 ‘normal’ BRC repeats (red boxes), 
the C-terminal degenerate BRC repeat (dark red box), the start (ATG), and the restriction 
sites used for cloning. The sizes of the component parts are shown (bp). 4BRC and 10BRC 
variant domains are not shown, but differ from 7BRC only in possessing 3 and 9 ‘normal’ 
BRC repeat-encoding sequences, respectively.  
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Figure 4-2 Cloning strategy used for the assembly of the pRM482::BRC variant re-expresser 
constructs. 
The synthesised BRC repeat variants (top, yellow; only 7BRC is shown) were initially cloned 
into pBluescript using EcoRV and XhoI restriction sites. The C-terminus of BRCA2 (orange) 
was prepared by restriction digestion with MfeI and XhoI, from an existing construct, and 
was ligated into the pBluescript-BRC construct directly downstream of the BRC variant 
insert. The whole insert was then excised using EcoRV and XhoI, and ligated into pRM482 
(bottom) prepared by EcoRV digestion. 
pRM482 is a construct that allows re-expression of a gene from the tubulin array 
in T. brucei (Figure 4-3), where it is transcribed initially as part of the 
endogenous transcript. The mature mRNA produced contains non-endogenous 5’ 
and 3’ UTRs derived from trans-splicing via an upstream actin intergenic 
sequence and polyadenylation from a downstream tubulin intergenic sequence. 
As such, the level of mRNA produced, and its stability, is likely to be altered 
relative to endogenous BRCA2. Nevertheless, re-expression by this strategy was 
successful for BRCA2 in BSF Lister 427 brca2-/- T. brucei leading to significant 
reversion of recombination and RAD51 foci impairment phenotypes (Hartley and 
McCulloch, 2008). pRM482 contains regions derived from tubulin intergenic 
sequences flanking the entire insert in pBluescript that provide targeting 
sequences to enable homologous recombination and replacement of an α tubulin 
ORF with the construct following transformation. To allow selection of 
constructs that have integrated into the genome, pRM482 contains the G418 
antibiotic resistance cassette (NEO) containing processing signals derived from 
tubulin and actin intergenic sequences flanking the antibiotic resistance ORF. 
For transformation, the pRM482::BRC constructs were excised from pBluescript 
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by restriction digestion with XhoI and XbaI, the digested DNA was then ethanol 
precipitated and approximately 5 µg of the resuspended DNA was used for each 
transformation. 
 
Figure 4-3 pRM482::BRC re-expression constructs. 
The full-length BRCA2 ORF and four BRC variant ORFs (1BRC, 4BRC, 7BRC and 10BRC) 
were cloned into an EcoRV site between the actin (Act IR) and αβ tubulin (αβ Tub) intergenic 
sequences of the plasmid pRM482, which contains the antibiotic resistance cassette for 
G418 (NEO). The construct is flanked with tubulin intergenic regions (βα Tub and αβ Tub) 
that allow integration by homologous recombination into the tubulin array (top), replacing 
an α tubulin ORF. Sizes of the BRCA2 variants are shown (bp), and are not drawn to scale. 
Full-length BRCA2 is shown with 12 BRC repeats, as it is cloned from Lister 427 cells and 
estimated to contain 12 BRC repeats. 
4.2.2 Generation of re-expresser cell lines in PCF TREU 
927 
Transformations were carried out in order to generate five re-expresser cell 
lines in PCF TREU 927 brca2-/- cells (section 3.2) containing full-length BRCA2, 
and variants of BRCA2 with 1, 4, 7 and 10 BRC repeats using the pRM482::BRC re-
expresser constructs (section 4.2.1). To do this, PCF TREU 927 brca2-/- BSD-PUR 
mutant cells were transformed and antibiotic resistant transformants were 
selected by placing cells on SDM-79 media supplemented with 20 µg.ml-1 G418 
(Sigma). 
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4.2.3 Confirmation of re-expresser cell lines by PCR 
The generation of BRCA2 re-expresser cell lines was initially confirmed by PCR 
performed on genomic DNA extracted from putative re-expresser clones 
resulting from the five transformations. PCR was performed using primers 
specific to the BSD and PUR resistance ORFs, and also a 1.2 kb region of the 
BRCA2 ORF. The location of the primers and expected sizes of the PCR products 
are displayed in Figure 4-4A. 
 
 
Figure 4-4 Confirmation of PCF TREU 927 BRCA2 re-expresser cell lines by PCR. 
(A) Primers used to amplify part of the BRCA2 ORF, and the BSD and PUR resistance ORFs, 
are indicated (black arrows), with the expected sizes of the resulting PCR products shown 
(bp). (B) An agarose gel of the PCR products obtained using the primers, described above, 
and genomic DNA extracted from wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant, 
and putative BRCA2 re-expresser (-/-/+) cell lines. Distilled water (dH2O) was used as a 
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negative control. The PCR products produced from the BSD, PUR and BRCA2 ORFs are 
indicated (black arrows), and size markers are shown (Ladder, kb). 
The agarose gel in Figure 4-4B demonstrates the presence of the BSD and PUR 
resistance ORFs in all of the putative re-expresser cell lines. All five clones 
analysed here produced a PCR product with the primers specific to part of the 
BRCA2 ORF, indicating they have integrated the re-expression construct. The 
five re-expresser cell lines selected for further analysis are referred to as; -/-/+ 
1BRC, -/-/+ 4BRC, -/-/+ 7BRC, -/-/+ 10BRC and -/-/+ BRCA2. 
4.2.4 Confirmation of re-expresser cell lines by Southern 
analysis 
To confirm the generation of re-expresser cell lines, Southern analysis was 
performed. Genomic DNA extracted from wild-type TREU 927, brca2-/- mutant 
and the five re-expresser (-/-/+) cell lines was digested with HindIII, separated 
by electrophoresis on a 1% agarose gel, Southern blotted and hybridised at 60°C 
with a DNA probe generated by PCR-amplification with the primers 48 and 49, 
corresponding to a 1.2 kb region of the BRCA2 ORF. The location of primers, 
predicted restriction enzyme recognition sites and expected DNA fragment sizes 
in this approach are displayed in Figure 4-5A. 
The Southern blot in Figure 4-5B demonstrates that the intact BRCA2 ORF exists 
as a single size variant in wild-type TREU 927 cells and the brca2-/- mutant cells 
no longer posses a BRCA2 ORF (as described in section 3.2.4). The five re-
expresser cell lines all contained a DNA fragment of the expected size for the 
BRCA2 BRC variants after integration and dependent on the number of BRC 
repeats, which indicates that they have integrated the pRM482::BRC constructs 
correctly into the tubulin array. 
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Figure 4-5 Confirmation of PCF TREU 927 BRCA2 re-expresser cell lines by Southern 
analysis. 
(A) Restriction maps showing the expected products of restriction digestion, Southern 
blotting and hybridisation with 1.2 kb of the BRCA2 ORF (black arrows indicate the primers 
used to PCR-amplify this as a DNA probe). The restriction sites are indicated, with the 
expected restriction fragment sizes shown (kb). (B) 5 µg of genomic DNA extracted from 
wild-type TREU 927 (WT 927), brca2-/- mutant, and BRCA2 re-expresser (-/-/+) cell lines was 
digested with HindIII before being separated by electrophoresis on an agarose gel. The DNA 
was Southern blotted before being hybridised with a DNA probe against 1.2 kb of the 
BRCA2 ORF. Size markers are shown (kb). 
4.2.5 Attempt at confirmation of re-expresser cell lines by 
western analysis 
Attempts at confirmation of the re-expression of the variants of BRCA2 in the 
PCF TREU 927 brca2-/- cells by western blot using anti-BRCA2 antiserum were 
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performed multiple times, including with the addition of 5% chicken serum 
(Sigma) in the blocking solution to reduce non-specific binding of the antibody. 
The clearest result of these experiments is displayed in Figure 4-6. 
The western blot in Figure 4-6 demonstrates a band visible at approximately the 
expected size (176 kDa) for the BRCA2 protein in the wild-type and BRCA2-/+ 
mutant cell lines, which was not present in the brca2-/- cell line. Bands of the 
expected sizes for the BRCA2 BRC variants were not visible in the re-expresser 
cell lines. If the non-specific band visible at ~ 58 kDa is viewed as a loading 
control, it is apparent that although there was significant variation in the 
protein loading between the different cell lines, protein was detectable in all 
samples. This may suggest that the level of expression of the variants of BRCA2 
is reduced relative to the endogenous locus and below the threshold of detection 
of the antiserum. However, one of the peptides recognised by the antiserum is 
the BRC repeat, and it is therefore possible the antiserum does not bind to the 
re-expressed variants as efficiently as full-length BRCA2. 
 
Figure 4-6 Attempt at confirmation of PCF TREU 927 BRCA2 re-expresser cell lines by 
western analysis. 
Total protein extracts from wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant, and 
BRCA2 re-expresser (-/-/+) cell lines were separated by SDS-PAGE and western blotted 
before being probed with anti-BRCA2 antiserum (1:200 dilution). Size markers are shown 
(kDa). 
4.2.6 Analysis of BRCA2 mRNA levels in re-expresser cell 
lines by quantitative RT-PCR 
As the expression of the BRCA2 variants could not be confirmed by western 
analysis, the mRNA levels were analysed by quantitative RT-PCR. Total RNA was 
extracted from wild-type TREU 927, BRCA2-/+ mutant and BRCA2 re-expresser (-
/-/+) cell lines, DNase treated and subsequently cDNA was synthesised by RT-
PCR using the SuperScript First Strand Reverse Transcription Kit (section 2.5.4). 
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To confirm the absence of genomic DNA contamination in the extracted RNA, 
control cDNA reactions were performed without the addition of the reverse 
transcriptase (RT) enzyme. PCR analysis with primers specific for part of an 
endogenous gene, DNA polymerase I (PolI; 150 and 151), was used to test for 
PCR-amplification of cDNA in RT plus and control RT minus samples. The agarose 
gel in Figure 4-7 demonstrates that cDNA had been generated successfully in all 
the RT plus samples, and that genomic DNA contamination was absent from all 
the RT minus samples, as no PCR product was visible. 
Quantitative RT-PCR was carried out (section 2.5.5) on the cDNA produced in the 
RT plus samples using primers specific for part of an endogenous control gene, 
tubulin (154 and 155), and part of the BRCA2 gene (138 and 139). Primer 
annealing was tested after the qRT-PCR reaction by running a dissociation curve 
step (data not shown), which confirmed that that the primers were only 
producing a single product and were not producing primer dimers, which could 
adversely affect the results. The mRNA detected in this and subsequent qRT-PCR 
experiments (section 4.4.2 and section 4.6.5) cannot be absolutely confirmed to 
be BRCA2 mRNA. Analysis of the brca2-/- cell line, and the absence of a product 
could have provided further evidence that this is in fact BRCA2 mRNA. In 
addition, electrophoretic separation of the PCR products would have allowed 
determination of the size of the product and sequencing of the product could 
have been carried out to absolutely confirm the amplification of BRCA2 mRNA. 
However, the data in Figure 4-8 demonstrate that the BRCA2-/+ mutant cell 
lines have a ~ 50% reduced level of BRCA2 mRNA when compared to wild-type 
cells, that is consistent with the deletion of a single BRCA2 allele. However, the 
two different -/+ cell lines analysed showed some inconsistency, with ~ 40% and 
~ 60% reduction. It is possible that a different BRCA2 allele has been deleted in 
each cell line, and the alleles show differences in levels of steady state mRNA, 
though these differences may simply reflect variation in the accuracy of qRT-
PCR measurements. The five BRCA2 re-expresser cell lines had varying levels of 
BRCA2 mRNA, ranging from a ~ 20 - 60% reduced level when compared to wild-
type cells. These variations may be real, and could reflect changes in mRNA due 
to the genes being expressed from variable locations within the tubulin array. 
Nevertheless, the data show a trend not dissimilar to the mRNA levels seen for -
/+ BSD, and suggest that this expression strategy generates BRCA2 mRNA levels 
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close to those of a BRCA2-/+ mutant and slightly less than a wild-type cell line 
with two BRCA2 alleles, consistent with integration of a single gene in each 
case. 
 
Figure 4-7 Testing PCF TREU 927 BRCA2 re-expresser RT-PCR reactions by PCR. 
An agarose gel of the PCR products generated using primers specific to DNA polymerase I 
(PolI), amplified from cDNA generated by RT-PCR reactions containing reverse 
transcriptase (top, + RT). Control cDNA reactions were also analysed, lacking reverse 
transcriptase (bottom, - RT). Distilled water (dH2O) was used as a negative control, and a 
genomic DNA sample (gDNA) as a positive control. Size markers are shown (Ladder, kb). 
 
Figure 4-8 Quantitative RT-PCR analysis of the PCF TREU 927 BRCA2 re-expresser cell 
lines. 
Quantitative RT-PCR was carried out on cDNA generated from wild-type TREU 927 (WT 927), 
BRCA2-/+ mutant (BSD or PUR), and BRCA2 re-expresser (-/-/+) cell lines using primers 
specific for an endogenous control, tubulin, and BRCA2. All samples were normalised to the 
tubulin endogenous control and the level for BRCA2 expressed relative to the WT 927 
sample (which was set as one); values are the average quantification from four repetitions, 
and vertical lines indicate standard deviation. 
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4.3 Phenotypic analysis of PCF TREU 927 BRCA2 
re-expresser cell lines 
4.3.1 Analysis of in vitro growth 
The in vitro growth of the PCF TREU 927 BRCA2 re-expresser cell lines was 
analysed in order to determine if variation in BRC repeat number correlates with 
the extent of the relatively minor growth impairment in TREU 927 brca2-/- cells 
(section 3.3.1). In addition, the re-expression of full-length BRCA2 allows us to 
determine if the impaired growth phenotype of the brca2-/- cell line is due to 
loss of BRCA2, or might result from secondary mutations in the absence of a 
factor needed for repair of DNA damage. The average counts from three 
experimental repetitions are plotted in Figure 4-9, and extrapolated doubling 
times are displayed in Table 4-1. 
From the growth curves and doubling times displayed it is apparent that the re-
expression of BRCA2 with 1, 4, 7 or 10 BRC repeats, or full-length BRCA2, 
restores growth of the brca2-/- mutant cell line to essentially wild-type levels, 
with doubling times of between ~ 10.7 and ~ 11.3 hours for the re-expresser cell 
lines and ~ 11 hours for wild-type cells. It therefore appears that BRCA2 with 
even a single BRC repeat is capable of supporting wild-type rates of growth, at 
least in culture. 
 
Figure 4-9 Analysis of in vitro growth of the PCF TREU 927 BRCA2 re-expresser cell lines. 
Chapter 4  164 
2 ml cultures of wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant, and BRCA2 re-
expresser (-/-/+) cell lines were inoculated at 5 x 105 cells.ml-1 and cell densities counted 24, 
48, and 72 hours subsequently are shown. Values are averaged from the counts from three 
experimental repetitions, and vertical lines indicate standard deviation. 
 
Table 4-1 In vitro population doubling times of PCF TREU 927 BRCA2 re-expresser cell 
lines. 
The mean doubling time for wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant, and 
BRCA2 re-expresser (-/-/+) cell lines is displayed, in hours, and was calculated from the data 
displayed in Figure 4-9. 
4.3.2 Analysis of DNA damage sensitivity 
The Alamar blue assay was used to determine the sensitivity of the PCF TREU 
927 BRCA2 re-expresser cell lines to the DNA damaging agents MMS and 
phleomycin. The Alamar blue assay was set up with wild-type TREU 927, -/+ and 
-/- BRCA2 mutant and BRCA2 re-expresser (-/-/+) cell lines. The extent of 
fluorescence for each cell line was plotted graphically over the range of log drug 
concentrations (for representative examples see Figure 4-10 and Figure 4-11). 
From this, EC50s were determined from each individual plot and then average 
EC50s (plus 95% confidence intervals) were calculated from two experimental 
repetitions. The mean EC50s for each cell line were then plotted relative to the 
wild-type EC50, which was taken as 100% (Figure 4-12 and Figure 4-13). 
The survival curves displayed in Figure 4-10 and Figure 4-11 are representative 
of the two repetitions performed. These data demonstrate that as the 
concentration of DNA damaging agent increases the fluorescence, and therefore 
the percentage of surviving cells that are actively reducing Alamar blue to 
fluorescent resorufin, reduces until the concentration at which all cells are 
killed is reached. It is apparent that the brca2-/- mutant cell line displayed 
reduced survival in the presence of both compounds (section 3.3.2), whilst the 
re-expression of BRCA2 with 1, 4, 7, or 10 BRC repeats in this cell line restored 
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the reduced survival back to at least wild-type levels. Similarly, the full-length 
BRCA2 re-expresser cell line also displayed levels of survival comparable to wild-
type cells when exposed to both MMS and phleomycin. Indeed, in the presence 
of phleomycin, it could be argued that all the re-expresser cell lines displayed 
slightly increased survival compared to wild-type cells. The extrapolated EC50 
values (graphs displayed in Figure 4-12 and Figure 4-13) confirm this, and also 
demonstrate that the re-expression of BRCA2 with 1, 4, 7, or 10 BRC repeats or 
full-length BRCA2 restored the increased sensitivity to MMS observed in the 
brca2-/- cells back to approximately wild-type levels, with calculated EC50s 
being essentially equivalent. These data also appear to confirm that each re-
expresser cell line, with the exception of 7BRC, displayed an increased (though 
not statistically significant, see below) resistance to phleomycin relative to wild-
type and BRCA2-/+ cells, with EC50s between 50 and 100% higher than in wild-
type cells. This increase has also been observed in BSF Lister 427 brca2-/- cell 
lines re-expressing full-length BRCA2 (Hartley and McCulloch, unpublished), 
though the basis for this phenomenon is unknown. Nevertheless, it is striking 
that the number of BRC repeats present in the re-expressed BRCA2 variants does 
not correlate with an increase or decrease in sensitivity to DNA damage, with 
EC50s to both compounds and all variants being essentially equivalent. 
To evaluate the above data further, the EC50 values of wild-type TREU 927, -/+ 
and -/- BRCA2 mutant and BRCA2 re-expresser (-/-/+) cell lines were compared 
using student’s T-tests, and the results of this are displayed in Table 4-2. No 
statistical difference was observed between wild-type, -/+, -/- and BRCA2 re-
expresser cell lines (p > 0.05) for both DNA damaging agents. However, the lack 
of statistical significance may be due to the fact that only two experimental 
repetitions were performed, and further experiments may be needed to clarify if 
the observed trend for greater resistance to phleomycin is real. Indeed, though 
the brca2-/- cells appeared more sensitive to MMS, this too was not seen to be 
statistically significant in these experiments, though it was in previous analysis 
(section 3.3.2). 
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Figure 4-10 A representative survival curve for PCF TREU 927 BRCA2 re-expresser cell lines 
exposed to MMS. 
The extent of fluorescence for each cell line (WT, -/+, -/- and -/-/+) obtained using the Alamar 
blue assay is plotted against the log of MMS concentrations. Nonlinear regression was 
performed and fitted curves are shown for each cell line. 
 
Figure 4-11 A representative survival curve for PCF TREU 927 BRCA2 re-expresser cell lines 
exposed to phleomycin. 
The extent of fluorescence for each cell line (WT, -/+, -/- and -/-/+) obtained using the Alamar 
blue assay is plotted against the log of phleomycin concentrations. Nonlinear regression 
was performed and fitted curves are shown for each cell line. 
 
Figure 4-12 EC50 values of PCF TREU 927 BRCA2 re-expresser cell lines exposed to MMS. 
Wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant, and BRCA2 re-expresser (-/-/+) cell 
lines were placed in serially decreasing amounts of MMS and allowed to grow for 48 hours, 
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before the addition of Alamar Blue. After a further 24 hours the reduction of Alamar Blue 
was measured by the amount of fluorescent resorufin generated. EC50 values are the mean 
from two experimental repetitions expressed as a percentage relative to wild-type, and bars 
indicate 95% confidence intervals. 
 
Figure 4-13 EC50 values of PCF TREU 927 BRCA2 re-expresser cell lines exposed to 
phleomycin. 
Wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant, and BRCA2 re-expresser (-/-/+) cell 
lines were placed in serially decreasing amounts of phleomycin and allowed to grow for 48 
hours, before the addition of Alamar Blue. After a further 24 hours the reduction of Alamar 
Blue was measured by the amount of fluorescent resorufin generated. EC50 values are the 
mean from two experimental repetitions expressed as a percentage relative to wild-type, 
and bars indicate 95% confidence intervals. 
 
Table 4-2 Statistical analysis of Alamar Blue results. 
(A) P values are shown for student’s T-tests comparing the mean EC50 values of wild-type 
TREU 927 (WT 927), -/+ and -/- BRCA2 mutant, and BRCA2 re-expresser (-/-/+) cell lines 
grown in the presence of MMS (A) or phleomycin (B). Areas shaded in yellow indicate a 
significant difference (P ≤ 0.05). No correction has been made for simultaneous multiple 
comparisons. 
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4.3.3 Analysis of RAD51 focus formation 
The ability of PCF TREU 927 BRCA2 re-expresser cell lines to form RAD51 foci 
was next analysed in order to ask about the role of the BRC repeats and their 
expansion in RAD51 function. The numbers of RAD51 foci present in the nucleus 
of each of the cell lines that had been exposed to 1 ug.ml-1 phleomycin for 18 
hours were counted for approximately 200 cells per cell line (Table 4-3) and 
plotted graphically (Figure 4-14). Representative images of cells are displayed in 
Figure 4-15A, and compared with control cells without phleomycin treatment in 
Figure 4-15B. 
In the absence of DNA damage RAD51 foci were rarely seen (~ 2% of cells, Figure 
4-15B), irrespective of the BRC repeat number or the presence or absence of 
intact, full-length BRCA2. As described previously (section 3.3.4), after the 
induction of DNA damage the number of wild-type and BRCA2-/+ cells containing 
no detectable RAD51 foci reduced to ~ 25%, with the majority of cells containing 
1, 2 or 3 foci, while the brca2-/- mutant cells appeared to have lost the ability 
to form RAD51 foci. Comparing the re-expresser cell lines revealed a striking BRC 
repeat number-dependent increase in the ability to form RAD51 foci. The 
number of cells containing no RAD51 foci decreased as the BRC repeat number 
increased, with the full-length BRCA2 re-expresser cell line containing only 13% 
of cells with no detectable RAD51 foci, less than the ~ 25% of wild-type and 
BRCA2-/+ cells containing no RAD51 foci. The number of cells with detectable 
RAD51 foci increased as the BRC repeat number increased, though it appeared 
that under these experimental conditions the relative proportions of cells 
containing 1 or 2 RAD51 foci remained relatively constant as BRC repeat number 
increased, with the largest increases seen in the numbers of cells containing 3 or 
4 RAD51 foci. Indeed, the 1BRC, 4BRC and 7BRC re-expresser cell lines were 
markedly less efficient than wild-type or BRCA2-/+ cells at forming RAD51 foci, 
and it appears that ~ 10 BRC repeats are needed for the cells to respond 
equivalently. Overall, the correlation seen in this phenotype with BRC repeat 
number is quite distinct from the lack of correlation between BRC repeat 
number and cell survival after phleomycin treatment (section 4.3.2). 
Chapter 4  169 
 
Table 4-3 RAD51 focus formation in PCF TREU 927 BRCA2 re-expresser cell lines exposed 
to phleomycin. 
Wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant, and BRCA2 re-expresser (-/-/+) cell 
lines were treated with 1 µg.ml-1 phleomycin for 18 hours and the number of cells with a 
specific number of subnuclear RAD51 foci formed (0, 1, 2, 3, 4, > 4) were counted and are 
represented as a percentage of the total cells counted (N). Boxes shaded in light yellow 
contain foci, whilst boxes shaded in bright yellow contain the highest percentage of foci. 
 
Figure 4-14 Graphical representation of RAD51 focus formation in PCF TREU 927 BRCA2 re-
expresser cell lines exposed to phleomycin. 
Wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant, and BRCA2 re-expresser (-/-/+) cell 
lines were treated with 1 µg.ml-1 phleomycin for 18 hours and the number of cells with a 
specific number of subnuclear RAD51 foci formed (0, 1, 2, 3, 4, > 4) were counted and are 
represented as a percentage of the total cells counted (N). 
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Figure 4-15A Representative images of RAD51 focus formation in PCF TREU 927 BRCA2 re-
expresser cell lines exposed to phleomycin. 
Images of wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant, and BRCA2 re-expresser 
(-/-/+) cell lines after phleomycin treatment (1 µg.ml-1 for 18 hours). Each cell is shown in 
differential interface contrast (DIC), after staining with DAPI (DAPI) and after hybridisation 
with anti-RAD51 antiserum (1:1000 dilution) and secondary hybridisation with Alexa Fluor 
594 conjugated anti-rabbit antiserum (1:7000 dilution, RAD51). Merged images of DAPI and 
RAD51 cells are also shown (Merge). White arrows indicate RAD51 foci. 
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Figure 4-15B Representative images of RAD51 focus formation in PCF TREU 927 BRCA2 re-
expresser cell lines. 
Images of wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant, and BRCA2 re-expresser 
(-/-/+) cell lines without phleomycin treatment. Each cell is shown in differential interface 
contrast (DIC), after staining with DAPI (DAPI) and after hybridisation with anti-RAD51 
antiserum (1:1000 dilution) and secondary hybridisation with Alexa Fluor 594 conjugated 
anti-rabbit antiserum (1:7000 dilution, RAD51). Merged images of DAPI and RAD51 cells are 
also shown (Merge). 
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To ensure that the observed differences in RAD51 focus formation were not due 
simply to a difference in the levels of RAD51 in the BRCA2 re-expresser cell lines 
after phleomycin treatment, western analysis was carried out. The western blot 
in Figure 4-16 demonstrates that the levels of RAD51 protein remain constant 
before and after phleomycin treatment in all cell lines. 
 
Figure 4-16 Western analysis of RAD51 in PCF TREU 927 BRCA2 re-expresser cell lines 
exposed to phleomycin. 
Total protein extracts from wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant, and 
BRCA2 re-expresser (-/-/+) cell lines were separated by SDS PAGE and western blotted 
before being probed with anti-RAD51 antiserum (1:500 dilution). ‘-’ indicates protein extracts 
prepared without phleomycin treatment, and ‘+’ indicates protein extracts prepared after 
phleomycin treatment (1 µg.ml-1 BLE for 18 hours). The blots were stripped and re-probed 
with anti-OPB1 antiserum (1:1000 dilution) as a loading control. Size markers are shown 
(kDa). 
4.3.4 Analysis of the sub-cellular distribution of RAD51 
by aqueous fractionation 
A potential explanation for the above findings is that a primary function of the 
BRC repeats in BRCA2 is to sequester Rad51 until it is required for the repair of 
DNA double strand breaks, at which point it provides a means of transportation 
into the nucleus (Wong et al., 1997;Chen et al., 1998;Lord and Ashworth, 2007). 
In support of this, no nuclear localisation signal has been identified in T. brucei 
RAD51 to date and, in contrast to the clear subnuclear detection of RAD51 in 
foci following damage, the weaker signal detected by anti-RAD51 antiserum 
before damage appears to be distributed throughout the cell (Proudfoot and 
McCulloch, 2005;Hartley and McCulloch, 2008;Glover, McCulloch and Horn, 
2008). In addition, BRCA2 contains three nuclear localisation signals in T. brucei 
(Figure 1-18), and evidence has been presented that BRCA2 carries out this 
nuclear transport of Rad51 in other organisms, as well as facilitating the loading 
of Rad51 onto the processed ssDNA tail and the formation of the nucleoprotein 
filament (Yuan et al., 1999;Davies et al., 2001;Venkitaraman, 2002). However, 
BRCA2-independent mechanisms of Rad51 transport have also been described 
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(Tarsounas, Davies, and West, 2003;Gildemeister, Sage, and Knight, 2009). The 
expansion in the number of BRC repeats in T. brucei could therefore be an 
adaptation to ensure the transport of sufficient RAD51 molecules into the 
nucleus and to the sites of DNA damage, perhaps to ensure general repair occurs 
efficiently whilst antigenic variation takes up a further requirement for RAD51 
(see Chapter 3). In order to test this hypothesis, the distribution of RAD51 
protein between the nucleus and the cytoplasm in the BRC variant re-expresser 
cell lines was analysed. 
Aqueous fractionation was carried out on T. brucei whole cell extracts as 
detailed in section 2.2.5 (Zeiner, Sturm, and Campbell, 2003). Nuclear and 
cytoplasmic protein extracts were prepared from wild-type TREU 927, -/+ and -
/- BRCA2 mutant and BRCA2 re-expresser (-/-/+) cell lines after phleomycin 
treatment (1 µg.ml-1 for 18 hours), and control protein extracts without 
phleomycin treatment were similarly prepared. Protein extracts were separated 
by SDS-PAGE on 10% Bis-Tris gels before western blotting and probing 
sequentially with anti-RAD51 antiserum (1:500 dilution), anti-OPB1 antiserum 
(1:1000 dilution) and anti-NOG1 antiserum (1:5000 dilution). Blots were stripped 
between probings as described in section 2.11.1. 
Anti-OPB1 antiserum (gift, Jeremy Mottram) was raised in sheep against 
Leishmania major recombinant oligopeptidase B and subsequently affinity-
purified. Anti-NOG1 antiserum (gift, Marilyn Parsons) was raised in rabbits 
against T. brucei recombinant NOG1. OPB1 and NOG1 are proteins located in the 
cytoplasm and nucleolus of T. brucei cells, respectively, and were used to check 
that aqueous fractionation was successful (Park et al., 2001;Munday et al., 
2011). 
The western blots probed with NOG1 and OPB1 antiserum in Figure 4-17 
demonstrate that the separation of nuclear and cytoplasmic proteins by aqueous 
fractionation was successful; OPB1 and NOG1 proteins were only present in the 
cytoplasmic and nuclear fractions, respectively. In all cell lines RAD51 was 
detected in both the nuclear and the cytoplasmic fractions, both before and 
after the induction of DNA damage. Notably, RAD51 was found in the nucleus in 
the brca2-/- cells, as also observed in mammalian cells (Orelli and Bishop, 
2001;Yu et al., 2003;Tarsounas, Davies, and West, 2003;Lee et al., 
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2009;Gildemeister, Sage, and Knight, 2009). In addition, there was no strong 
evidence that the number of BRC repeats present in BRCA2 affects the relative 
amount of RAD51 in the nucleus and cytoplasm. In some cell lines there seemed 
to be a slight increase in the RAD51 concentration in the nucleus after the 
induction of DNA damage; for example, in the -/+ and -/- BRCA2 mutants, and 
also the 4BRC and 7BRC re-expresser cell lines. It may be that this small increase 
is present in all nuclear extracts but is more easily detected in the western blots 
with either less total RAD51 present or a reduced X-ray film exposure time. As 
there was no evidence for the up-regulation of RAD51 expression after the 
induction of DNA damage in T. brucei (section 4.3.3), this increase, if real, may 
be due to a cellular re-distribution of RAD51. If correct, this is not inhibited by 
the deletion of BRCA2. The results presented in section 4.3.3 indicate that BRC 
repeat number is important for the ability to form RAD51 foci after DNA damage, 
and from these data it seems likely that this is a reflection of subnuclear 
dynamics, and not transport into the nucleus. 
 
Figure 4-17 Aqueous fractionation of PCF TREU 927 BRCA2 re-expresser cell lines exposed 
to phleomycin. 
Aqueous fractionation was performed to generate protein fractions enriched in soluble 
cytoplasmic proteins (C) and soluble nuclear proteins (N). Fractions were prepared from 
wild-type TREU 927 (WT 927), -/+ and -/- BRCA2 mutant, and BRCA2 re-expresser (-/-/+) cell 
lines. ‘-’ indicates fractions prepared without phleomycin treatment and ‘+’ indicates 
fractions prepared after phleomycin treatment (1 µg.ml-1 BLE for 18 hours). Fractions were 
separated by SDS PAGE and western blotted before being sequentially probed, stripped and 
re-probed with anti-RAD51 antiserum (1:500 dilution), anti-OPB1 antiserum (1:1000 dilution) 
and anti-NOG1 antiserum (1:5000 dilution). Size markers are indicated (kDa). 
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4.4 Complementation of PCF Lister 427 brca2-/- 
mutants with variants of BRCA2 with reduced 
numbers of BRC repeats 
4.4.1 Generation of re-expresser cell lines in PCF Lister 
427 
Given the potential differences in VSG archive size between Lister 427 and TREU 
927 T. brucei strains, and the availability of PCF Lister 427 brca2-/- mutants, the 
same strategy used to re-express the BRC variants described for TREU 927 
(section 4.2) was adopted here with PCF Lister 427. To do this, PCF Lister 427 
brca2-/- BSD-PUR mutant cells were transformed with each of the pRM482::BRC 
re-expresser constructs (section 4.2.1) and antibiotic resistant transformants 
were selected by placing cells on SDM-79 media supplemented with 20 µg.ml-1 
G418. The generation of BRCA2 re-expresser cell lines was initially confirmed by 
PCR performed on genomic DNA extracted from putative re-expresser clones 
resulting from the five transformations, as described in section 4.2.3. The 
agarose gel in Figure 4-18 demonstrates that the BSD resistance ORF was 
detected in the 1BRC, 4BRC, 10BRC and full-length BRCA2 putative re-expresser 
cell lines, while the 7BRC cell line appeared to have lost the BSD resistance ORF 
by an unknown mechanism. The PUR resistance ORF was present in all of the 
putative re-expresser cell lines, and all five clones produced a PCR product with 
the BRCA2 ORF primers, suggesting correct integration of the re-expression 
constructs. The five re-expresser cell lines are referred to as; -/-/+ 1BRC, -/-/+ 
4BRC, -/-/+ 7BRC, -/-/+ 10BRC and -/-/+ BRCA2. 
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Figure 4-18 Confirmation of PCF Lister 427 BRCA2 re-expresser cell lines by PCR. 
An agarose gel of the PCR products obtained using the primers, described in Figure 4-4A, 
and genomic DNA extracted from wild-type Lister 427 (WT 427), -/+ and -/- BRCA2 mutant, 
and putative BRCA2 re-expresser (-/-/+) cell lines. Distilled water (dH2O) was used as a 
negative control. The PCR products produced from the BSD, PUR and BRCA2 ORFs are 
indicated (black arrows), and size markers are shown (Ladder, kb). 
To confirm the generation of re-expresser cell lines, Southern analysis was 
performed as described in section 4.2.4. The Southern blot in Figure 4-19 
demonstrates that the five re-expresser cell lines all contained a BRCA2 DNA 
fragment of the expected size for the pRM482::BRC constructs correctly 
integrated into the tubulin array. The 7BRC re-expresser line also displayed a 
DNA fragment corresponding in size to the larger wild-type allele of BRCA2 (the 
alleles are of distinct sizes in this strain; section 3.5.3;Hartley and McCulloch, 
2008). The reason for this is not known, but it shows that this clone is not 
equivalent in genetic composition to the other BRC variants, and the results 
from this cell line will be included from here on for illustrative purposes only. 
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Figure 4-19 Confirmation of PCF Lister 427 BRCA2 re-expresser cell lines by Southern 
analysis. 
5 µg of genomic DNA extracted from wild-type Lister 427 (WT 427), -/+ and -/- BRCA2 
mutant, and BRCA2 re-expresser (-/-/+) cell lines was digested with HindIII before being 
separated by electrophoresis on an agarose gel. The DNA was Southern blotted before 
being hybridised with a DNA probe against 1.2 kb of the BRCA2 ORF. Restriction maps 
showing the expected products are displayed in Figure 4-5A, and size markers are shown 
(kb). 
4.4.2 Analysis of BRCA2 mRNA levels in re-expresser cell 
lines by quantitative RT-PCR 
As the expression of the BRCA2 variants cannot be confirmed by western 
analysis, the mRNA levels of the genes were analysed by quantitative RT-PCR as 
described in section 4.2.6. The agarose gel in Figure 4-20 shows the PCR 
products produced using primers specific for part of a control gene, DNA 
polymerase I (PolI), used to demonstrate that cDNA has been amplified 
successfully in all the RT plus samples, and that genomic DNA contamination is 
absent from all the RT minus samples. The data in Figure 4-21 demonstrate that 
the BRCA2-/+ mutant cell lines have a ~ 50% reduced level of BRCA2 mRNA when 
compared to wild-type levels, and four of the five re-expresser cell lines (-/-/+ 
1BRC, 4BRC, 10BRC and BRCA2) have varying levels of BRCA2 mRNA (from a ~ 10 
- 40% reduced level compared to wild-type levels), but showed a consistent 
trend suggestive of a single copy gene. In contrast, the 7BRC re-expresser cell 
line displayed a ~ 40% increased level in BRCA2 mRNA when compared to wild-
type levels. This is consistent with the presence of more than one BRCA2 gene 
and confirms the suspicion that a wild-type BRCA2 allele is still present in this 
cell line. 
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Figure 4-20 Testing PCF Lister 427 BRCA2 re-expresser RT-PCR reaction products by PCR. 
An agarose gel of the PCR products generated using primers specific to DNA polymerase I 
(PolI), amplified from cDNA generated by RT-PCR reactions containing reverse 
transcriptase (top, + RT). Control reactions were also analysed, lacking reverse 
transcriptase (bottom, - RT). Distilled water (dH2O) was used as a negative control and a 
genomic DNA sample (gDNA) as a positive control. Size markers are shown (Ladder, kb). 
 
Figure 4-21 Quantitative RT-PCR analysis of the PCF Lister 427 BRCA2 re-expresser cell 
lines. 
Quantitative RT-PCR was carried out on cDNA generated from wild-type Lister 427 (WT 427), 
BRCA2-/+ mutant (BSD or PUR), and BRCA2 re-expresser (-/-/+) cell lines using primers 
specific for an endogenous control, tubulin, and BRCA2. All samples were normalised to the 
tubulin endogenous control and the level for BRCA2 expressed relative to the WT 427 
sample (which was set as one); values are the average quantification from four repetitions 
and vertical lines indicate standard deviation. 
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4.5 Phenotypic analysis of PCF Lister 427 BRCA2 
re-expresser cell lines 
The in vitro growth of the PCF Lister 427 BRCA2 re-expresser cell lines was first 
analysed. These data are plotted in Figure 4-22, and extrapolated doubling times 
are displayed in Table 4-4. As seen previously, re-expression of BRCA2 with 1, 4 
or 10 BRC repeats, or full-length BRCA2, restored the growth of the brca2-/- 
mutant cell line to essentially wild-type levels, with doubling times of ~ 10.5 
hours for the re-expresser cell lines, ~ 11 hours for wild-type cells, and ~13 
hours for the brca2-/- cells. The 7BRC re-expresser displays an increased 
doubling time of ~ 9.6 hours, which is faster than that observed for wild-type 
cells. 
 
Figure 4-22 Analysis of in vitro growth of the PCF Lister 427 BRCA2 re-expresser cell lines. 
2 ml cultures of wild-type Lister 427 (WT 427), -/+ and -/- BRCA2 mutant, and BRCA2 re-
expresser (-/-/+) cell lines were inoculated at 5 x 105 cells.ml-1 and cell densities counted 24, 
48, and 72 hours subsequently are shown. Values are averaged from the counts from three 
experimental repetitions, and vertical lines indicate standard deviation. 
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Table 4-4 In vitro population doubling times of PCF Lister 427 BRCA2 re-expresser cell 
lines. 
The mean doubling time for wild-type Lister 427 (WT 427), -/+ and -/- BRCA2 mutant, and 
BRCA2 re-expresser (-/-/+) cell lines is displayed, in hours, from data displayed in Figure 
4-22. 
To measure sensitivity of these cell lines to DNA damage, the Alamar blue assay 
was set up with wild-type Lister 427, -/+ and -/- BRCA2 mutant, and BRCA2 re-
expresser (-/-/+) cell lines. Survival curves displayed in Figure 4-23 and Figure 
4-24 are representative of the two repetitions performed, and show again that 
brca2-/- cell lines display reduced survival in the presence of both MMS and 
phleomycin, when compared to the wild-type and BRCA2-/+ cell lines. All the re-
expresser cell lines displayed increased survival in the presence of both 
compounds, to levels above that of wild-type cells, and to essentially equivalent 
amounts. This is similar to that observed previously for TREU 927 PCF cells 
(section 4.3.2), but appears more marked in the Lister 427 PCF cells. The 
extrapolated EC50 values for MMS in Figure 4-25 is consistent with this: re-
expression of BRCA2 with 1, 4, 7 or 10 BRC repeats or full-length BRCA2 restores 
the sensitivity to MMS observed in the brca2-/- cell line to values slightly above 
wild-type levels (10 – 20% increased). However, these data did not display 
statistical significance (Table 4-5). The EC50 data for phleomycin sensitivity, 
Figure 4-26, displays a more pronounced increase in survival, with EC50 values 
between 25% and 100% increased relative to wild-type cells. However, these 
were not seen as statistically significant differences (Table 4-5) between the 
wild-type cells and the 1BRC, 4BRC, 7BRC and full-length BRCA2 re-expresser 
cell lines (p > 0.05), though it was for the 10BRC re-expresser cell line (p ≤ 
0.05). Overall, the behaviour of the Lister 427 PCF cells is very comparable with 
the TREU 927 PCF cells, with the number of BRC repeats in the BRCA2 variants 
being indistinguishable in terms of their ability to support survival after DNA 
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damage, and even 1 BRC repeat being capable of reverting the small sensitivity 
of the brca2-/- mutants. Given this, RAD51 foci formation was not examined. 
 
Figure 4-23 A representative survival curve for PCF Lister 427 BRCA2 re-expresser cell lines 
exposed to MMS. 
The extent of fluorescence for each cell line (WT, -/+, -/- and -/-/+) obtained using the Alamar 
blue assay is plotted against the log of MMS concentrations. Nonlinear regression was 
performed and fitted curves are shown for each cell line. 
 
Figure 4-24 A representative survival curve for PCF Lister 427 BRCA2 re-expresser cell lines 
exposed to phleomycin. 
The extent of fluorescence for each cell line (WT, -/+, -/- and -/-/+) obtained using the Alamar 
blue assay is plotted against the log of phleomycin concentrations. Nonlinear regression 
was performed and fitted curves are shown for each cell line. 
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Figure 4-25 EC50 values of PCF Lister 427 BRCA2 re-expresser cell lines exposed to MMS. 
Wild-type Lister 427 (WT 427), -/+ and -/- BRCA2 mutant, and BRCA2 re-expresser (-/-/+) cell 
lines were placed in serially decreasing amounts of MMS and allowed to grow for 48 hours, 
before the addition of Alamar Blue. After a further 24 hours the reduction of Alamar Blue 
was measured by the amount of fluorescent resorufin generated. EC50 values are the mean 
from two experimental repetitions expressed as a percentage relative to wild-type and bars 
indicate 95% confidence intervals. 
 
Figure 4-26 EC50 values of PCF Lister 427 BRCA2 re-expresser cell lines exposed to 
phleomycin. 
Wild-type Lister 427 (WT 427), -/+ and -/- BRCA2 mutant, and BRCA2 re-expresser (-/-/+) cell 
lines were placed in serially decreasing amounts of phleomycin and allowed to grow for 48 
hours, before the addition of Alamar Blue. After a further 24 hours the reduction of Alamar 
Blue was measured by the amount of fluorescent resorufin generated. EC50 values are the 
mean from two experimental repetitions expressed as a percentage relative to wild-type and 
bars indicate 95% confidence intervals. 
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Table 4-5 Statistical analysis of Alamar Blue results. 
P values are shown for student’s T-tests comparing the mean EC50 values of wild-type 
Lister 427 (WT 427), -/+ and -/- BRCA2 mutant, and BRCA2 re-expresser (-/-/+) cell lines 
grown in the presence of MMS (A) or phleomycin (B). Areas shaded in yellow indicate a 
significant difference (P ≤ 0.05). No correction has been made for simultaneous multiple 
comparisons. 
4.6 Complementation of BSF Lister 427 brca2-/- 
mutants with variants of BRCA2 with reduced 
numbers of BRC repeats 
4.6.1 Generation of re-expresser cell lines in BSF Lister 
427 
In Chapter 3, it was demonstrated that mutation of BRCA2 appeared to have 
more profound consequences in BSF than in PCF cells, with visible chromosome 
rearrangements and more severe sensitivity to DNA damaging agents. To see if 
this may be a consequence of the BRCA2 BRC repeat expansion being a selection 
for a BSF-specific process, the BRC variants were functionally examined in Lister 
427 BSF T. brucei cells. As before (section 4.2), transformations were carried out 
in order to generate re-expresser cell lines in BSF Lister 427 brca2-/- cells 
(generated previously; brca2-/-1;Hartley and McCulloch, 2008) containing 
variants of BRCA2 with 1, 4, 7 and 10 BRC repeats using the pRM482::BRC re-
expresser constructs (section 4.2.1). Antibiotic resistant transformants were 
selected by placing cells on HMI-9 media supplemented with 2.5 µg.ml-1 G418. 
The full-length BRCA2 re-expresser BSF Lister 427 cell line generated previously 
(Hartley and McCulloch, 2008) was recovered from frozen storage. 
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4.6.2 Confirmation of re-expresser cell lines by PCR 
PCR was performed on genomic DNA extracted from putative BRCA2 re-expresser 
clones resulting from the four transformations, and also the full-length BRCA2 
re-expresser cell line, using primers specific to the BSD, PUR and BRCA2 ORFs as 
described in section 4.2.3. The agarose gel in Figure 4-27 shows that the BSD and 
PUR resistance ORFs are present in all of the putative re-expresser cell lines, 
and that all five clones analysed here produced a PCR product with the primers 
specific to part of the BRCA2 ORF. The cell lines are referred to as; -/-/+ 1BRC, -
/-/+ 4BRC, -/-/+ 7BRC, -/-/+ 10BRC and -/-/+ BRCA2. 
 
Figure 4-27 Confirmation of BSF Lister 427 BRCA2 re-expresser cell lines by PCR. 
An agarose gel of the PCR products obtained using the primers, described in Figure 4-4A, 
and genomic DNA extracted from wild-type Lister 427 (WT 427), brca2-/- mutant, and 
putative BRCA2 re-expresser (-/-/+) cell lines. Distilled water (dH2O) was used as a negative 
control. The PCR products produced from the BSD, PUR and BRCA2 ORFs are indicated 
(black arrows), and size markers are shown (Ladder, kb). 
4.6.3 Confirmation of re-expresser cell lines by Southern 
analysis 
Southern analysis was next performed, as described in section 4.2.4, to check 
integration of the pRM482::BRC constructs. The Southern blot in Figure 4-28 
demonstrates that the BRCA2 ORF is present in two allelic size variants in wild-
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type Lister 427 cells, as was seen for the PCF cells of this strain (section 3.5.3), 
and the brca2-/- mutant cell line no longer possesses a BRCA2 ORF, as previously 
observed (Hartley and McCulloch, 2008). The four re-expresser cell lines 
analysed here demonstrate a DNA fragment of the expected size for their BRC 
repeat variant BRCA2 ORF, which indicates the constructs had integrated 
correctly into the tubulin array. The full-length BRCA2 re-expresser cell line, 
which was generated previously and independently verified (Hartley and 
McCulloch, 2008), demonstrated a DNA fragment that was slightly smaller than 
expected, although this could be explained by irregularities in the 
electrophoresis separation of the genomic DNA due the presence of a large 
amount of DNA. 
 
Figure 4-28 Confirmation of BSF Lister 427 BRCA2 re-expresser cell lines by Southern 
analysis. 
5 µg of genomic DNA extracted from wild-type Lister 427 (WT 427), brca2-/- mutant, and 
BRCA2 re-expresser (-/-/+) cell lines was digested with HindIII before being separated by 
electrophoresis on an agarose gel. The DNA was Southern blotted before being hybridised 
with a DNA probe against 1.2 kb of the BRCA2 ORF. Restriction maps showing the expected 
fragment sizes are displayed in Figure 4-5A, and size markers are shown (kb). 
4.6.4 Attempt at confirmation of re-expresser cell lines by 
western analysis 
Multiple attempts were made at confirmation of the re-expression of the 
variants of BRCA2 in the BSF Lister 427 brca2-/- cells by western blot using anti-
BRCA2 antiserum, as before (section 4.2.5). The western blot in Figure 4-29 is 
the clearest of these experiments and demonstrates the presence of two faint 
bands at approximately the expected size for the BRCA2 protein (176 kDa) in all 
cell lines, including the brca2-/- mutant cell line, suggesting that it is not BRCA2 
but results from non-specific binding of the antiserum to other parasite proteins, 
such as also seen at ~ 58 kDa. 
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Figure 4-29 Attempt at confirmation of BSF Lister 427 BRCA2 re-expresser cell lines by 
western analysis. 
Total protein extracts from wild-type Lister 427 (WT 427), brca2-/- mutant, and BRCA2 re-
expresser (-/-/+) cell lines were separated by SDS-PAGE and western blotted before being 
probed with anti-BRCA2 antiserum (1:200 dilution). Size markers are shown (kDa). 
4.6.5 Analysis of BRCA2 mRNA levels in re-expresser cell 
lines by quantitative RT-PCR 
As the western analysis was unsuccessful, BRCA2 mRNA levels in the re-expresser 
cell lines were analysed by quantitative RT-PCR as described in section 4.2.6. 
The agarose gel in Figure 4-30 shows the PCR products produced using primers 
specific for part of a control gene, DNA polymerase I (PolI), used to demonstrate 
that cDNA could be PCR-amplified successfully in all the RT plus samples, and 
that genomic DNA contamination was absent from all the RT minus samples. The 
qRT-PCR data in Figure 4-31 demonstrate greater variation of BRCA2 mRNA 
levels in the five BSF re-expresser cell lines than was seen for either of the PCF 
analyses (sections 4.2.6 and 4.4.2). The -/-/+ 1BRC, 4BRC, 7BRC and 10BRC cell 
lines each displayed ~ 10 - 30% reduced levels compared with wild-type cells, 
which could be consistent with a lower copy number of the gene, but in all cases 
the level appeared higher than seen in PCF re-expresser cell lines, which was 
closer to 50% of wild-type (Figure 4-8 and Figure 4-21). Unusually, the full-length 
BRCA2 re-expresser cell line displayed a ~ 20% increased level of BRCA2 mRNA 
compared to wild-type cells, which could be more consistent with the presence 
of two copies of the BRCA2 gene, which we cannot evaluate from the Southern 
data available. The reason for this increase is therefore not known, and nor is 
the reason for the increased BRCA2 mRNA variation in BSF cells. 
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Figure 4-30 Testing BSF Lister 427 BRCA2 re-expresser RT-PCR reaction products by PCR. 
An agarose gel of the PCR products generated using primers specific to DNA polymerase I 
(PolI), amplified from cDNA generated by RT-PCR reactions containing reverse 
transcriptase (top, + RT). Control reactions were also analysed, lacking reverse 
transcriptase (bottom, - RT). Distilled water (dH2O) was used as a negative control and a 
genomic DNA sample (gDNA) as a positive control. Size markers are shown (Ladder, kb). 
 
Figure 4-31 Quantitative RT-PCR analysis of the BSF Lister 427 BRCA2 re-expresser cell 
lines. 
Quantitative RT-PCR was carried out on cDNA generated from wild-type Lister 427 (WT 427) 
and BRCA2 re-expresser (-/-/+) cell lines using primers specific for an endogenous control, 
tubulin, and BRCA2. All samples were normalised to the tubulin endogenous control and 
the level for BRCA2 expressed relative to the WT 427 sample (which was set as one); values 
are the average quantification from four repetitions and vertical lines indicate standard 
deviation. 
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4.7 Phenotypic analysis of BSF Lister 427 BRCA2 
re-expresser cell lines 
4.7.1 Analysis of in vitro growth 
The in vitro growth of the BSF Lister 427 BRCA2 re-expresser cell lines was 
analysed, the results of which are plotted in Figure 4-32 and extrapolated 
doubling times displayed in Table 4-6. As described previously (Claire Hartley, 
PhD thesis, 2008), the BSF brca2-/- mutants displayed substantial growth 
impairment relative to wild-type cells. Figure 4-32 clearly shows that the re-
expression of of BRCA2 with 1, 4, 7 or 10 BRC repeats, or full-length BRCA2, 
restored the impaired growth of the brca2-/-mutant cell line to levels above 
that observed for wild-type cells. The calculated doubling times were less clear 
with the values obtained for the re-expresser cell lines varing between ~ 11 to ~ 
14.5 hours compared to the wild-type doubling time of ~ 10.5 hours, while 
brca2-/- cells doubled in ~ 12.6 hrs. The reliability of these data could have 
been improved by measuring growth over a longer timescale using linear 
regression. 
 
Figure 4-32 Analysis of in vitro growth of the BSF Lister 427 BRCA2 re-expresser cell lines. 
2 ml cultures of wild-type Lister 427 (WT 427), brca2-/- mutant, and BRCA2 re-expresser (-/-
/+) cell lines were inoculated at 5 x 104 cells.ml-1 and cell densities counted 24, 48, and 72 
hours subsequently are shown. Values are averaged from three experimental repetitions 
and vertical lines indicate standard deviation. 
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Table 4-6 In vitro population doubling times for BSF Lister 427 BRCA2 re-expresser cell 
lines. 
The mean doubling time for wild-type Lister 427 (WT 427), brca2-/- mutant, and BRCA2 re-
expresser (-/-/+) cell lines is displayed, in hours, and was calculated from the data displayed 
in Figure 4-32. 
4.7.2 Analysis of DNA damage sensitivity 
The Alamar blue assay was set up with wild-type Lister 427, brca2-/- mutant and 
BRCA2 re-expresser (-/-/+) cell lines. As before, the extent of fluorescence for 
each cell line was plotted graphically over the range of MMS and phleomycin 
concentrations (for representative examples see Figure 4-33 and Figure 4-34), 
and average EC50s (plus 95% confidence intervals) calculated from the three 
experimental repetitions were plotted relative to the wild-type EC50, which was 
taken as 100% (Figure 4-35 and Figure 4-36). From the survival curves, it was 
clear that BSF brca2-/- mutants were significantly more sensitive to both DNA 
damaging agents, and this was confirmed by analysing the data with student’s T-
tests; displayed in Table 4-7. The re-expression of BRCA2 with 1BRC repeat 
produced a cell line that alleviated some of the decreased survival observed in 
the brca2-/- mutant cell line, but was still more sensitive than wild-type cells to 
both compounds. In contrast, the re-expression of BRCA2 with 4, 7, or 10 BRC 
repeats, or re-expression of full-length BRCA2, restored survival of the brca2-/- 
mutants to essentially wild-type levels. The extrapolated EC50 values displayed 
in Figure 4-35 and Figure 4-36 confirm these findings. The -/-/+1BRC cell line 
displayed a 30% and 40% reduction in survival relative to wild-type cells for MMS 
and phleomycin, respectively, compared with a 70% and 80% reduction in 
survival for the brca2-/- mutants. Furthermore, this increased sensitivity of the -
/-/+1BRC cells relative to wild-type cells was found to be statistically significant 
in both cases (p ≤ 0.05, Table 4-7). The 4, 7 and 10 BRC repeat and full-length 
re-expresser cell lines displayed EC50 values essentially indistinguishable from 
the wild-type EC50, and no statistically significant differences were observed (p 
> 0.05). 
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Taken together, these data reveal a difference between BRCA2 function in BSF 
and PCF T. brucei cells. In both life cycle stages, reducing the number of BRC 
repeats in BRCA2 from 12-15 to 4, 7, 10 did not have any effect on sensitivity to 
DNA damaging agents. In contrast, whereas expression of a BRCA2 variant with 1 
BRC repeat (the divergent, C-terminal repeat) has no effect on DNA damage 
sensitivity in PCF cells, it displays significantly increased sensitivity in BSF cells. 
 
Figure 4-33 A representative survival curve for BSF Lister 427 BRCA2 re-expresser cell lines 
exposed to MMS. 
The extent of fluorescence for each cell line (WT, -/- and -/-/+) obtained using the Alamar 
blue assay is plotted against the log of MMS concentrations. Nonlinear regression was 
performed and fitted curves are shown for each cell line. 
 
Figure 4-34 A representative survival curve for BSF Lister 427 BRCA2 re-expresser cell lines 
exposed to phleomycin. 
The extent of fluorescence for each cell line (WT, -/- and -/-/+) obtained using the Alamar 
blue assay is plotted against the log of phleomycin concentrations. Nonlinear regression 
was performed and fitted curves are shown for each cell line. 
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Figure 4-35 EC50 values of BSF Lister 427 BRCA2 re-expresser cell lines exposed to MMS. 
Wild-type Lister 427 (WT 427), brca2-/- mutant, and BRCA2 re-expresser (-/-/+) cell lines were 
placed in serially decreasing amounts of MMS and allowed to grow for 48 hours, before the 
addition of Alamar Blue. After a further 24 hours the reduction of Alamar Blue was 
measured by the amount of fluorescent resorufin generated. EC50 values are the mean from 
three experimental repetitions expressed as a percentage relative to wild-type and bars 
indicate 95% confidence intervals. 
 
Figure 4-36 EC50 values of BSF Lister 427 BRCA2 re-expresser cell lines exposed to 
phleomycin. 
Wild-type Lister 427 (WT 427), brca2-/- mutant, and BRCA2 re-expresser (-/-/+) cell lines were 
placed in serially decreasing amounts of phleomycin and allowed to grow for 48 hours, 
before the addition of Alamar Blue. After a further 24 hours the reduction of Alamar Blue 
was measured by the amount of fluorescent resorufin generated. EC50 values are the mean 
from three experimental repetitions expressed as a percentage relative to wild-type and bars 
indicate 95% confidence intervals. 
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Table 4-7 Statistical analysis of Alamar Blue results. 
P values are shown for student’s T-tests comparing the mean EC50 values of wild-type 
Lister 427 (WT 427), brca2-/- mutant, and BRCA2 re-expresser (-/-/+) cell lines grown in the 
presence of MMS (A) or phleomycin (B). Areas shaded in yellow indicate a significant 
difference (P ≤ 0.05). No correction has been made for simultaneous multiple comparisons. 
4.7.3 Analysis of RAD51 focus formation 
The ability of the BSF Lister 427 BRCA2 re-expresser cell lines to form RAD51 foci 
was next analysed. In this life cycle stage, the methanol fixation procedure used 
appears to result in greater background staining with the anti-RAD51 antiserum 
than is seen with formaldehyde fixation (Dobson et al., 2011), but subnuclear 
foci were nevertheless detectable after 18 hrs growth in the presence of 
phleomycin; representative images of cells are displayed in Figure 4-38, and the 
numbers of RAD51 foci present in the nucleus of each cell line are shown in 
Table 4-8 and Figure 4-37. The brca2-/- cells were analysed after growth in a 
reduced concentration of phleomycin (0.25 µg.ml-1) due to their increased 
sensitivity to this compound (section 4.3.2 and section 4.7.2 ). 
In the absence of DNA damage clearly discernible RAD51 foci were rarely seen (~ 
2% of cells), despite the greater amount of background staining (Figure 4-38B). 
After the induction of DNA damage with phleomycin, the number of wild-type 
cells containing no detectable RAD51 foci reduced to ~ 30%, a quantitatively 
similar response to that observed in PCF TREU 927 cells (section 4.3.3) and 
reported previously in Lister 427 BSF cells (Hartley and McCulloch, 2008). The 
BSF brca2-/- mutant cell line had greatly reduced ability to form RAD51 foci 
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after the induction of DNA damage, as a single focus was detected in only 3.3% 
of cells. Again, this is a quantifiably similar finding to that described previously 
in the same mutants (Hartley and McCulloch, 2008). Though PCF TREU 927 brca2-
/- mutants appear even more impaired in RAD51 foci formation (only 0.9% 
displayed a detectable focus; Figure 4-14), it may be that this reflects the lesser 
background staining with anti-RAD51 antiserum in the tsetse fly stage. Hartley 
and McCulloch (2008) showed that BRCA2 with 1 BRC repeat is impaired in RAD51 
foci formation in BSF cells, and these data confirm that finding; ~ 90% of the 
1BRC re-expresser cells contained no detectable foci after phleomycin 
treatment. The number of cells containing at least one detectable focus (~ 10%) 
appears greater than that observed for BSF Lister 427 brca2-/- mutants, but 
remains a substantial impairment. Indeed, this impairment is more severe than 
that seen in the PCF TREU 927 -/-/+1BRC re-expresser cell line, where 45% of 
cells displayed RAD51 foci, consistent with the difference in phleomycin 
sensitivity detailed in the two cells lines (section 4.7.2).  
The previous analysis of BRCA2 BRC repeat function in the contribution to RAD51 
focus formation in BSF T. brucei was limited to BRCA2 variants with a single BRC 
repeat (Hartley and McCulloch, 2008). This work builds on that analysis by 
examining BRCA2 variants with increasing numbers of BRC repeats (4, 7 and 10) 
that are still reduced relative to full-length BRCA2, which has 12 BRC repeats in 
this T. brucei strain. Like the findings in TREU 927 PCF cells, a BRC-repeat 
number-dependent increase in the ability to form RAD51 foci was found. The 
number of cells containing no detectable RAD51 foci decreased as the BRC 
repeat number increased, with the full-length BRCA2 re-expresser cell line 
containing ~ 30% of cells without RAD51 foci, which is essentially equivalent to 
wild-type cells. In contrast to TREU 927 PCF cells, where the 10BRC variant re-
expresser appeared to display an equivalent number and pattern of RAD51 foci 
to wild-type cells (Figure 4-14), here the 10BRC variant did not respond to the 
same extent as wild-type cells (> 40% of cells did not display foci). Indeed, it is 
apparent that, overall, each BRC variant generates a greater proportion of cells 
with RAD51 foci in PCF cells compared with BSF. Moreover, the proportion of 
cells with larger numbers of RAD51 foci are consistently higher in PCF BRC 
variant re-expresser cell lines than in BSF BRC variants. Taken together, this 
appears to suggest that BRCA2 is more effective at re-distributing RAD51 to sites 
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of damage in PCF cells than in BSF cells, which may explain the difference in 
DNA damage sensitivities in the two life cycle stages (Chapter 3), both in wild-
type cells and in BRC variant re-expresser cell lines (sections 4.3.2 and 4.7.2).  
 
Table 4-8 RAD51 focus formation in BSF Lister 427 BRCA2 re-expresser cell lines exposed 
to phleomycin. 
Wild-type Lister 427 (WT 427) and BRCA2 re-expresser (-/-/+) cell lines were treated with 1 
µg.ml-1 phleomycin for 18 hours and the brca2-/- mutant cell line was treated with 0.25 µg.ml-
1 phleomycin for 18 hours. The number of cells with a specific number of subnuclear RAD51 
foci formed (0, 1, 2, 3, 4, > 4) were counted and are represented as a percentage of the total 
cells counted (N). Boxes shaded in light yellow contain foci, whilst boxes shaded in bright 
yellow contain the highest percentage of foci. 
 
Figure 4-37 Graphical representation of RAD51 focus formation in BSF Lister 427 BRCA2 re-
expresser cell lines exposed to phleomycin. 
Wild-type Lister 427 (WT 427) and BRCA2 re-expresser (-/-/+) cell lines were treated with 1 
µg.ml-1 phleomycin for 18 hours and the brca2-/- mutant cell line was treated with 0.25 µg.ml-
1 phleomycin for 18 hours. The number of cells with a specific number of subnuclear RAD51 
foci formed (0, 1, 2, 3, 4, > 4) were counted and are represented as a percentage of the total 
cells counted (N). 
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Figure 4-38A Representative images of RAD51 focus formation in BSF Lister 427 BRCA2 re-
expresser cell lines exposed to phleomycin. 
Images of wild-type Lister 427 (WT 427) and BRCA2 re-expresser (-/-/+) cell lines after 
phleomycin treatment (1 µg.ml-1 BLE for 18 hours) and brca2-/- mutant cell line after 
phleomycin treatment (0.25 µg.ml-1 BLE for 18 hours). Each cell is shown in differential 
interface contrast (DIC), after staining with DAPI (DAPI) and after hybridisation with anti-
RAD51 antiserum (1:1000 dilution) and secondary hybridisation with Alexa Fluor 594 
conjugated anti-rabbit antiserum (1:7000 dilution, RAD51). Merged images of DAPI and 
RAD51 cells are also shown (Merge). White arrows indicate RAD51 foci. 
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Figure 4-38B Representative images of RAD51 focus formation in BSF Lister 427 BRCA2 re-
expresser cell lines. 
Images of wild-type Lister 427 (WT 427), brca2-/- mutant and BRCA2 re-expresser (-/-/+) cell 
lines without phleomycin treatment. Each cell is shown in differential interface contrast 
(DIC), after staining with DAPI (DAPI) and after hybridisation with anti-RAD51 antiserum 
(1:1000 dilution) and secondary hybridisation with Alexa Fluor 594 conjugated anti-rabbit 
antiserum (1:7000 dilution, RAD51). Merged images of DAPI and RAD51 cells are also shown 
(Merge). 
Finally, to ensure that the observed differences in RAD51 foci formation are not 
due to differences in the levels of RAD51 in the BRCA2 re-expresser cell lines 
before or after phleomycin treatment, western analysis was carried out. As was 
seen in PCF cells, the western blot in Figure 4-39 demonstrates that the levels of 
RAD51 protein remain constant before or after phleomycin treatment in all cell 
lines. 
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Figure 4-39 Western analysis of RAD51 in BSF Lister 427 BRCA2 re-expresser cell lines 
exposed to phleomycin. 
Total protein extracts from wild-type Lister 427 (WT 427), brca2-/- mutant and BRCA2 re-
expresser (-/-/+) cell lines were separated by SDS PAGE and western blotted before being 
probed with anti-RAD51 antiserum (1:500 dilution). ‘-’ indicates protein extracts prepared 
without phleomycin treatment and ‘+’ indicates protein extracts prepared after phleomycin 
treatment (1 µg.ml-1 BLE for 18 hours), except for the brca2-/- mutant which was additionally 
treated with 0.25 µg.ml-1 BLE for 18 hours. The blots were stripped and re-probed with anti-
OPB1 antiserum (1:1000 dilution) as a loading control. Size markers are shown (kDa). 
4.8 Summary 
The data presented in this chapter indicate that the phenotypes associated with 
the brca2-/- mutants generated in the PCF TREU 927 and Lister 427 cells of T. 
brucei are due to the absence of BRCA2, and not a secondary mutation, as the 
re-expression of full-length BRCA2 in these cell lines restores the wild-type 
growth, DNA damage sensitivity and RAD51 foci formation phenotypes. This also 
confirms the data observed previously with the full-length BRCA2 re-expresser 
cell line generated in BSF Lister 427 brca2-/- cells (Hartley and McCulloch, 
2008). 
Here, the importance of BRC repeat number in T. brucei BRCA2 has been 
systematically analysed by varying the number of BRC repeat motifs from 1 to 12 
(the ‘natural’ repertoire); previously the function of a single BRC repeat was 
examined in T. brucei (Claire Hartley, PhD Thesis, 2008;Hartley and McCulloch, 
2008). Indeed, in no other organism with BRCA2 possessing multiple BRC repeats 
has such an analysis been attempted. The data associated with the re-expression 
of variants of BRCA2 with varying numbers of BRC repeats reveals a number of 
things about BRCA2 function. Virtually all the BRC repeat variant re-expresser 
cell lines generated in all three strains demonstrated restored growth and DNA 
damage sensitivity when compared to the brca2-/- mutant cell lines. The sole 
exception to this was the 1BRC re-expresser cell line in BSF Lister 427, which 
displayed greater DNA damage sensitivity than wild-type cells and all the other 
BRC variant expressers. Though the 1 BRC variant appeared less sensitive to DNA 
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damage than the parental brca2-/-1 cell line, it was still detectably repair-
deficient, which is consistent with previous findings (Claire Hartley, PhD Thesis, 
2008). The first thing these data show is that the strong growth impairment in 
BSF brca2-/- mutants, and the weaker growth impairment in PCF mutants, is 
complemented irrespective of the BRC complement of BRCA2. This indicates that 
BRC repeat number is not a determinant of the role BRCA2 plays in promoting 
effective growth, and perhaps cell division or replication, in T. brucei. The 
second, more striking, finding is that these data demonstrate that it is not 
necessary for BRCA2 to have 12-15 BRC repeats in order to carry out efficient 
DNA damage repair in T. brucei. In the PCF re-expresser cell lines, a single BRC 
repeat is sufficient for maximal detectable levels of DNA repair, whereas 3 BRC 
repeats are required in BSF. An important caveat is that this finding is limited to 
the ability to repair damage to the extent measured by the assays adopted here, 
which is based on growth. More detailed analysis of lesion numbers, if this were 
possible, would be useful. Despite this, it is important to note that the BSF and 
PCF cells are not equivalent in terms of DNA repair; in Chapter 3 it was shown 
that PCF brca2-/- mutants are less sensitive to DNA damage. Here, we show that 
the PCF cells expressing BRCA2 variants with reduced BRC repeat numbers form 
RAD51 foci after DNA damage more readily than the equivalent proteins in BSF, 
and greater numbers of foci are detected (see below). This could be an 
explanation as to why BRCA2 with a single BRC repeat is functional in DNA repair 
in PCF cells, but impaired in BSF cells. 
Analysis of the ability of the re-expresser cell lines to form RAD51 foci 
demonstrated a striking concordance between BRC repeat number and the 
ability to form RAD51 subnuclear foci, in both life cycle stages. This is not 
because BRCA2 transports RAD51 to the nucleus (see below), but clearly 
demonstrates a functional and quantitative interaction between BRCA2 and 
RAD51. This is the first time that a biological process has been identified that is 
determined by multiple BRC repeats. However, the composition of these repair 
foci is unknown, in any organism (Lisby and Rothstein, 2009), as is the 
requirement for the multiple foci observed here during DNA repair (for instance, 
it is unclear if each foci represents a single site of DNA damage, or an 
accumulation of DNA breaks into a repair centre). These data require further 
verification, as a number of potential problems exist. For instance; the 
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detection threshold of RAD51 foci using fluorescence microscopy could be higher 
than expected, and therefore the absence of detectable foci may not necessarily 
correlate with the absence of RAD51-dependent DNA repair. It is also surprising 
that the sensitivity of the re-expresser cell lines to exogenous DNA damage does 
not display a BRC-repeat number dependence, as would be expected from the 
RAD51 foci formation data. However, the Alamar blue assay employed here is a 
secondary assay, which measures the metabolic capacity of the cells in the 
presence of DNA damaging agents, not directly the repair of the induced DNA 
damage, and could therefore be masking a more subtle phenotype revealed by 
the immunofluorescence. 
These data also demonstrate the functionality of the ‘degenerate’ C-terminal 
BRC repeat, that was not clear from previous data (Claire Hartley, PhD Thesis, 
2008), which showed that the 1BRC variant was deficient in HR and RAD51 focus 
formation. The demonstration that the 1BRC variant can support DNA repair, and 
to some extent RAD51 foci formation, in PCF cells shows that it is not 
degenerate, but can support RAD51-associated functions. It would be interesting 
to determine if there are differences in the mode and function of RAD51 binding 
between the conserved BRC repeats and the degenerate BRC repeat, as observed 
in mammalian BRCA2 where BRC 1 to 4 bind with high affinity to monomeric 
Rad51, bring about delivery to ssDNA at the site of DNA damage and facilitate 
efficient nucleation onto ssDNA, and BRC 5 to 8 bind to the nucleoprotein 
filament and stabilise it ensuring filament growth, thereby co-operating to bring 
about efficient DNA strand exchange (Carreira and Kowalczykowski, 2011). It 
would also be valuable to determine if the T. brucei 1BRC variant is capable of 
supporting HR in the PCF cells, since it is not in BSF cells (Hartley and 
McCulloch, 2008). 
Aqueous fractionation indicates that RAD51 is found both in the nucleus and the 
cytoplasm of brca2-/- cells to the same extent as in wild-type cells. This 
indicates that BRCA2 is either not responsible for nuclear transport of T. brucei 
RAD51, is one of a number of transporters, or that RAD51 mediates its own 
transport into the nucleus (Tarsounas, Davies, and West, 2003;Tarsounas, 
Davies, and West, 2004). In order to try and address this question further, site-
directed mutants of the three putative T. brucei BRCA2 nuclear localisation 
signal sequences were generated, and re-expression in brca2-/- mutant cells was 
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attempted (van den Hoek, Trenaman and McCulloch, data not shown). The 
supposition behind this analysis was that if BRCA2 was present, and able to bind 
RAD51, but unable to translocate to the nucleus this might reveal a transport 
function (for instance, alternate RAD51 transporters may be activated in the 
complete absence of BRCA2). For unknown reasons, these cell lines could not be 
generated, despite being based on precisely the same pRM482 re-expression 
system used here. It is possible that an ‘untransportable’ BRCA2 mutant acts in a 
dominant negative manner and leads to an impairment in DNA repair that is 
worse than a knockout of brca2 or rad51, however an alternative approach will 
be required to investigate this further.
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5.1 Introduction 
In mammalian cells, it has been demonstrated that BRCA2 interacts directly with 
the Rad51 recombinase via multiple BRC repeat motifs, and also through a 
distinct C-terminal Rad51-binding motif (Wong et al., 1997;Mizuta et al., 
1997;Chen et al., 1998;Sharan et al., 1997;Marmorstein, Ouchi, and Aaronson, 
1998;Esashi et al., 2005;Esashi et al., 2007). Two classes of BRC repeat motifs 
have been described and it is proposed that they have evolved to promote Rad51 
nucleation on single-stranded DNA resulting from the processing of a DSB and 
also to stabilise nascent Rad51-ssDNA filaments, facilitating propagation and 
thereby stimulating DNA strand exchange (Tarsounas, Davies, and West, 
2003;Bugreev and Mazin, 2004;Esashi et al., 2005;Esashi et al., 2007;Shivji et 
al., 2009;Carreira et al., 2009;Carreira and Kowalczykowski, 2011). The first 
group of BRC repeats, consisting of repeats 1 to 4, bind with high affinity to 
monomeric Rad51 and reduce its ATPase activity, thereby maintaining Rad51 in 
an active ATP-bound state until required for filament nucleation (Carreira and 
Kowalczykowski, 2009;Carreira and Kowalczykowski, 2011). The second group, 
consisting of BRC repeats 5 to 8, bind free Rad51 with low affinity but bind to 
Rad51-ssDNA filaments with high affinity and function to stabilise them, thereby 
promoting filament growth (Galkin et al., 2005;Carreira and Kowalczykowski, 
2009;Carreira and Kowalczykowski, 2011). The BRCA2 C-terminal Rad51-binding 
motif is unrelated to the BRC repeat motif and, although highly conserved 
among vertebrate BRCA2 proteins, appears to be absent from BRCA2 orthologues 
in other taxa. The C-terminal motif binds and stabilises Rad51 in the multimeric 
filament, but not monomeric form (Davies and Pellegrini, 2007;Esashi et al., 
2007), and binding is cell cycle regulated by cyclin dependent kinase (CDK) 
phosphorylation of Serine3291 (Esashi et al., 2005). Phosphorylation of 
Serine3291 in response to DNA damage inhibits binding by Rad51 at this site 
(Ayoub et al., 2009). However, this C-terminal Rad51-binding motif appears to 
be dispensable for recombination and DNA repair; as a constitutively 
phosphorylated mutant that cannot bind Rad51 expressed in Chicken DT40 cells 
did not produce any detectable recombination or DNA repair defects (Ayoub et 
al., 2009). A function for the C-terminal Rad51-binding motif in the protection of 
stalled replication forks from degradation has been described (Schlacher et al., 
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2011) and may operate via stabilisation of Rad51 filaments on nascent DNA 
(Hashimoto et al., 2010). 
The BRCA2 orthologues identified in C. elegans and U. maydis, CeBRC-2 and Brh2 
respectively, also demonstrate binding to Rad51, although with different 
mechanisms to that observed with mammalian BRCA2. C. elegans CeBRC-2 
contains a single N-terminal BRC repeat that interacts directly with monomeric 
Rad51 (Martin et al., 2005;Petalcorin et al., 2006). No evidence of binding in the 
C-terminal region of CeBRC-2 has been found to date, though the region directly 
downstream of, and distinct from, the BRC repeat has been shown to bind Rad51 
in filament form, inhibit ATP hydrolysis and so function to stabilise the 
nucleoprotein filament in a possibly analogous mechanism (Petalcorin et al., 
2007). U. maydis Brh2 also contains a single, N-terminal BRC repeat motif which 
binds monomeric Rad51 (Kojic et al., 2002) and also a distinct C-terminal Rad51-
binding domain, in the region downstream of the conserved DNA-binding domain 
(Kojic et al., 2005). However, the N-terminal domain of Brh2 has been shown to 
rescue the brh2-/- mutant phenotype, and this was due to the presence of a 
non-canonical DNA-binding domain that was not identifiable from sequence data 
(Zhou, Kojic, and Holloman, 2009). 
This chapter aims to investigate the interactions between T. brucei BRCA2 and 
RAD51, including during repair of DNA damage, using in vitro GST pull-down and 
in vivo co-immunolocalisation approaches. These data will allow us to ask if the 
mode of BRCA2-RAD51 interaction in T. brucei is conserved with that seen in 
other organisms, and should deepen our understanding of the regulation of 
RAD51-mediated homologous recombination by BRCA2. 
5.2 In vitro GST pull-down 
In vitro GST pull-down was performed order to define the domains of the T. 
brucei BRCA2 protein that mediate its interaction with RAD51 during DNA repair. 
This experiment was carried out using tagged fusion proteins co-expressed in E. 
coli, in an approach previously successful in detecting interactions between T. 
brucei RAD51 paralogue proteins (Dobson et al., 2011). The GST pull-down 
strategy is displayed in Figure 5-1. GST-tagged RAD51 was expressed in E. coli 
and captured from whole cell lysates (input) using glutathione conjugated to 
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sepharose beads. After extensive washing, co-expressed His-tagged variants of 
BRCA2 that interacted with GST-RAD51 were detected in elution samples by 
western blot and hybridisation with anti-His antiserum. 
 
Figure 5-1 GST pull-down strategy. 
GST RAD51 (GST, blue circle) and His BRCA2 variants (His, red circle) were co-expressed in 
E. coli. Whole cell lysates were prepared and incubated with Glutathione (Glu) conjugated to 
sepharose beads (S, green circle). Beads and bound protein complex were captured by 
centrifugation and washed extensively. His BRCA2 variants were detected after elution with 
20 mM glutathione followed by SDS PAGE, blotting and hybridisation with anti-His 
antiserum. 
5.2.1 Generation of bacterial fusion protein over-
expression constructs 
Two compatible bacterial protein over-expression constructs were used; pGEX-
4T-3 (Amersham) and pRSF-1b (Novagen). T. brucei RAD51 was over-expressed in 
E. coli using the pGEX-4T-3 construct, which results in RAD51 being expressed as 
an N-terminal Glutathione S-Transferase (GST) fusion; the construct also 
contains an ampicillin (AMP) resistance cassette for selection (Figure 5-2). The 
pGEX-4T-3 construct containing the full-length RAD51 gene was generated 
previously (gift, Chris Stockdale). Multiple variants of T. brucei BRCA2 were 
over-expressed in E. coli as N-terminal hexa-Histidine (His) fusions using the 
pRSF-1b construct; in each case, the constructs were maintained via a 
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kanamycin (KAN) resistance cassette for selection (Figure 5-3). The variants of 
BRCA2 (Figure 5-4) were generated by PCR using primers containing a BamHI 
restriction site in the forward primer and an XhoI restriction site in the reverse 
primer to enable cloning into the pRSF-1b construct. The two empty vectors 
were used to express the His and GST tags (not fused to a protein) for control 
purposes. 
The BRCA2 variants generated are grouped into the two ‘halves’ of the BRCA2 
protein: the N-terminal and the C-terminal. The N-terminal half contains two 
putative nuclear localisation signal (NLS) sequences and the BRC repeat motifs; 
N-terminal BRCA2 variants were cloned with 1, 4, 7 or 10 BRC repeats, and were 
PCR-amplified using primers 93 and 94 from the pRM482::BRC re-expression 
constructs (section 4.2.1). The expressed BRC variant polypeptides were called 
His 1BRC, His 4BRC, His 7BRC and His 10BRC. The C-terminal half of BRCA2 
contains all motifs present in the region downstream from the last BRC repeat 
motif. The His BRCA2 C-term variant contains this complete portion of the 
protein, including a putative PhePP motif (see below), the DNA/DSS1-binding 
domain (consisting of the alpha-helical domain, the three oligonucleotide-
binding (OB) domains and the tower domain), and a putative CDK 
phosphorylation site at Serine1523 (section 1.4.2.4). This sequence was PCR-
amplified from genomic DNA extracted from PCF TREU 927 cells using the 
primers 16 and 51. Site-directed mutagenesis (section 2.5.3) was then carried 
out on this construct to mutate the putative CDK phosphorylation site at 
Serine1523 to determine if the binding of RAD51 to the C-terminus of BRCA2 
might be regulated by phosphorylation, as reported in mammalian cells (Mizuta 
et al., 1997;Sharan et al., 1997;Esashi et al., 2005;Esashi et al., 2007). The 
Serine residue at position 1523 was mutated to a Glutamine residue (Ser1523Glu) 
in order to mimic the presence of a phosphate group (using primers 45 and 46). 
As a control for any side effects due to manipulation of the Serine residue, an 
Alanine mutant (Ser1523Ala) was similarly generated (using primers 43 and 44). 
These variants were called His BRCA2 C-term Glu and His BRCA2 C-term Ala, 
respectively. 
In order to determine if RAD51 binding localises to the region of BRCA2 
downstream from the end of the DNA/DSS1-binding domain and containing the 
putative Serine1523 phosphorylation residue, truncated variants of His BRCA2 C-
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term were constructed. Firstly, the His BRCA2 C-term variant was modified, 
using primers 51 and 76, to remove the sequence downstream from the end of 
the DNA/DSS1-binding domain, and this variant was called His BRCA2 DBD + 
PhePP. Secondly, the region downstream of the DNA/DSS1-binding domain was 
cloned, using primers 16 and 75, allowing the small, extreme C-terminus 
containing Serine1523 to be expressed as a fusion protein called His BRCA2 C-
tail. To allow comparison with the Serine1523 mutants of His BRCA2 C-term, 
constructs were derived from each of the putative phosphorylation mutant 
variants described above (generating the proteins His BRCA2 C-tail Glu, and His 
BRCA2 C-tail Ala). 
It has been previously reported that mammalian BRCA2 binds DMC1, the meiosis-
specific recombinase, at a conserved motif called the PhePP motif (KVFVPPFK) 
that is located just downstream of the BRC repeats (Thorslund, Esashi, and 
West, 2007). GST pull-down experiments with a fragment of human BRCA2 
corresponding to the PhePP motif did not demonstrate binding to Rad51 
(Thorslund, Esashi, and West, 2007). However, both the U. maydis and C. 
elegans orthologues of BRCA2, Brh2 and CeBRC-2 respectively, display binding 
between a PhePP motif, albeit slightly diverged in sequence (Figure 5-5), and 
Rad51 (Petalcorin et al., 2007;Kojic et al., 2011). A sequence of substantial 
similarity (KPFVVPFA) was identified in T. brucei BRCA2 located immediately 
downstream of the central bi-partite NLS sequence at amino acids 764 to 771 
(Figure 5-5). A function for T. brucei DMC1 in DNA repair has not been detected 
to date (Proudfoot and McCulloch, 2006), and due to the similarity between 
DMC1 and RAD51 (Proudfoot and McCulloch, 2005;Proudfoot and McCulloch, 
2006), it was considered that this putative DMC1-binding site might be capable 
of binding RAD51. In order to test this, the His BRCA2 DBD + PhePP variant was 
modified, using primers 76 and 91, to remove the putative DMC1/RAD51-binding 
site to create His BRCA2 DBD - PhePP. 
Finally, in order to test if the DNA/DSS1-binding domain interacts with RAD51, 
expression of a variant of BRCA2 consisting of the DNA/DSS1-binding domain was 
attempted. In mammalian cells, this region has been shown to interact with 
DSS1, a small, highly acidic protein which is mutated in split hand/split foot 
syndrome (Crackower et al., 1996;Marston et al., 1999), but there has been no 
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evidence for interaction with Rad51 to date. Unfortunately, expression of the T. 
brucei BRCA2 DNA/DSS1-binding domain in E. coli was unable to be detected. 
 
Figure 5-2 Construct used for N-terminal GST tagging of RAD51 for over-expression in E. 
coli. 
The RAD51 ORF (blue) was cloned into BamHI and XhoI restriction sites downstream of the 
GST tag (red). AMP: ampicillin resistance ORF (grey). LacI: lac repressor ORF (green). Sizes 
are shown (bp). 
 
Figure 5-3 Construct used for N-terminal His tagging of BRCA2 variants for over-expression 
in E. coli. 
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The BRCA2 variant ORFs (yellow, only BRCA2 C-term is shown) were cloned into BamHI 
and XhoI restriction sites downstream of the His tag (orange). KAN: kanamycin resistance 
ORF (grey). LacI: lac repressor ORF (green). Sizes are shown (bp). 
 
Figure 5-4 A schematic diagram of the His-tagged BRCA2 variant proteins over-expressed in 
E. coli. 
Full length BRCA2 is shown (top) with protein domains indicated; nuclear localisation 
signals (light blue bars), ‘normal’ BRC repeats (red boxes), degenerate BRC repeat (dark red 
box), PhePP motif (orange bar), α helical domain (green oval), oligonucleotide binding 
domains (blue boxes), tower doman (purple bar) and putative CDK phosphorylation site (S, 
light green bar). The His-tagged BRCA2 variants generated are shown with the domains 
present. Mutation of the putative CDK phosphorylation site is indicated; Ser1523Ala (A) and 
Ser1523Glu (Q), and amino acid positions are numbered. 
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Figure 5-5 Sequence alignment of putative PhePP motifs from BRCA2 orthologues. 
BRCA2 from a variety of organisms; At (A): Arabidopsis thaliana BRCA2 homologue A. Ce: 
Caenorhabditis elegans. Um: Ustilago maydis. Tc: Trypanosoma cruzi. Tb: Trypanosoma 
brucei. Amino acids indicated in red are fully conserved in mammalian species. Figure 
adapted from Thorslund, Esashi, and West, 2007. 
5.2.2 Generation of co-expressing bacterial cultures 
Competent cells of the Rosetta2 E. coli bacterial strain (Novagen) were 
transformed with the constructs generated in section 5.2 to produce bacterial 
cultures co-expressing GST RAD51 and each of the His BRCA2 variants. Rosetta2 
cells contain the pRare construct, which was maintained via a chloramphenicol 
(CHL) resistance cassette. Control cultures co-expressing GST RAD51 and the His 
tag alone (from construct pRSF-1b), His 10BRC and the GST tag alone (pGEX-4T-
3), and His BRCA2 C-term and the GST tag alone were also generated to control 
for binding of the T. brucei proteins to the His or GST tags, rather than to each 
other. The competent E. coli cells were co-transformed, as detailed in section 
2.7, with two constructs and selected on LB agar supplemented with 100 µg.ml-1 
ampicillin (Sigma), 50 µg.ml-1 kanamycin (Sigma) and 34 µg.ml-1 chloramphenicol 
(Sigma). 
5.2.3 GST pull-down using co-expressing bacterial 
cultures 
50 ml cultures of the bacterial cell lines were grown in LB media supplemented 
with antibiotics (see above) and protein expression induced with 1 mM IPTG as 
described in section 2.13. After growth for 16 hours at 25°C the bacterial cells 
were then harvested by centrifugation, lysed by sonication and the soluble 
proteins retained after the removal of insoluble cell debris by further 
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centrifugation as described in section 2.13; this is referred to as the input. GST 
and GST RAD51 were then recovered from the lysates using Glutathione 
conjugated to sepharose beads (Amersham) as described in section 2.13; protein 
recovered is referred to as the elution. The input and elution protein samples 
were separated by SDS PAGE on 10% Bis-Tris gels, western blotted and first 
probed with anti-His antiserum (Sigma) at a dilution of 1:750. The blots were 
then stripped and re-probed with anti-GST antiserum (Novagen) at a dilution of 
1:10000. For unknown reasons the expressed GST-tagged RAD51 protein was not 
able to be detected by western blot in these conditions, despite the GST tag 
alone being detected (data not shown). Coomassie stained protein gels of the 
same elution samples showed clearly visible protein of the expected sizes for 
GST (28 kDa) and a prominent band at just under 80 kDa in size that is thought 
to be GST RAD51, for unknown reasons running at higher than its expected size 
of 67 kDa. Due to the problems with western blot detection, eluted GST RAD51 is 
shown as a coomassie-stained gel. 
Interaction between RAD51 and the BRCA2 N-terminal BRC repeat region is 
shown in Figure 5-6. The western blot in Figure 5-6A shows the N-terminal BRCA2 
variant input samples probed with anti-His antiserum and demonstrates the 
expression of His-tagged proteins at approximately the expected sizes for the His 
BRC variants; 1BRC (16 kDa), 4BRC (34 kDa), 7BRC (52 kDa) and 10BRC (66 kDa). 
The coomassie stained protein gel (Figure 5-6B) of the separated elution samples 
demonstrates that the GST and GST RAD51 proteins were successfully recovered 
by the GST pull-down approach. The western blot in Figure 5-6C shows the 
elution samples probed with anti-His antiserum and demonstrates the presence 
of only a very faint band corresponding to the His 10BRC variant (lane 4), which 
was not seen when 10BRC was co-expressed with GST alone (lane 5). This 
indicates that while 10BRC binds GST-RAD51, the 1BRC, 4BRC and 7BRC variants 
either do not bind, or bind so weakly that they cannot be detected under these 
experimental conditions. These data may indicate that binding between the BRC 
repeats of T. brucei BRCA2 and RAD51 is surprisingly weak and, at least in this 
experimental system, 10 BRC repeats must be present to detect this. 




Figure 5-6 GST pull-down analysis of the interactions between RAD51 and the N-terminal 
domain of BRCA2. 
(A) A western blot of the separated input samples probed with anti-His antiserum (1:750 
dilution). His tagged proteins are indicated (black arrows), and the GST-tagged proteins that 
were co-expressed are indicated (top). (B) A coomassie stained gel of the separated elution 
samples showing GST RAD51 and the GST tag (black arrows). His-tagged proteins that were 
co-expressed are indicated (top). (C) A western blot of the separated elution samples 
probed with anti-His antiserum (1:750 dilution). GST-tagged proteins used for the pull-down 
are indicated (top). In each panel, size markers are shown (kDa). 
Figure 5-7 shows analysis of interaction between RAD51 and the C-terminal 
BRCA2 variants. The western blot in Figure 5-7A shows input samples probed 
with anti-His antiserum and demonstrates expression of His-tagged proteins of 
the expected sizes for each of the variants; four His BRCA2 C-term variants (100 
kDa; lanes 1, 3-5), His BRCA2 DBD + PhePP ( 75 kDa; lane 6), His BRCA2 DBD – 
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PhePP ( 73.5 kDa; lane 7), three His BRCA2 C-tail variants (28 kDa; lanes 8-10), 
and also the His tag (7 kDa; lane 2). The coomassie stained protein gel (Figure 
5-7B) of the separated elution samples demonstrates the presence of the GST 
and GST RAD51 proteins, indicating they were successfully recovered by the GST 
pull-down approach. The western blot in Figure 5-7C shows the elution samples 
probed with anti-His antiserum to detect the His BRCA2 variants. The first 
control culture, where GST RAD51 was co-expressed with the His tag (lane 2), 
displayed some binding of the anti-His antiserum in the elution sample (see 
below). The second control culture, with His BRCA2 C-term co-expressed with 
GST did not display His tagged protein in the elution sample, indicating that no 
binding between the His BRCA2 C-term variant and GST has occurred (lane 3). 
Strong bands corresponding to each of the three His BRCA2 C-term variants were 
seen in each eluate (Figure 5-7C. lanes 1, 4-5). This indicates that all of the His 
BRCA2 C-term variants have bound to GST RAD51, irrespective of whether or not 
this was the wild-type sequence or the Ser1523Ala or Ser1523Glu mutants, 
indicating that RAD51 can bind T. brucei BRCA2 in the region downstream of the 
BRC repeats. Each of the His BRCA2 C-tail variants were also recovered by the 
GST pull-down (lanes 8-10), indicating that RAD51 can bind to the region C-
terminal of the DNA/DSS1-binding domain. Though this appears analogous to 
Rad51-BRCA2 C-terminal interaction in mammals (Mizuta et al., 1997;Sharan et 
al., 1997;Esashi et al., 2005;Esashi et al., 2007;Davies and Pellegrini, 2007), the 
status of Serine1523 in T. brucei BRCA2 had no influence on RAD51 binding, 
suggesting binding to the C-tail region is not regulated by phosphorylation on 
this residue. Surprisingly, the His BRCA2 variant encompassing only the region 
between the BRC repeats and the C-tail (mainly composed of DNA/DSS1-binding 
domain) was also pulled down by GST RAD51 (lane 6), and this was unaffected by 
removal of the putative PhePP motif (lane 7). This suggests, firstly, that this 
PhePP motif is not a mediator of T. brucei RAD51 interaction and, secondly, that 
T. brucei BRCA2 possesses a binding site for RAD51 in the vicinity of the 
DNA/DSS1-binding domain that has not been observed in any other BRCA2 
orthologue. Taken together, these data suggest that T. brucei RAD51 binds to at 
least two regions in the BRCA2 C-terminus downstream from the last BRC repeat: 
one region is found in or around the DNA/DSS1-binding domain, and the other in 
the poorly conserved C-tail. Thus, BRCA2-RAD51 interaction in T. brucei appears 
extensive, including these C-terminal regions and the BRC repeats. 
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As mentioned above, problems were encountered with the detection of the His 
tag alone due to its small size (7 kDa). The control input sample in Figure 5-7A 
(lane 2), with GST-RAD51 co-expressed with the His tag, shows a clearly visible 
band of the expected size for the His tag. In the corresponding elution sample in 
Figure 5-7C (lane 2) it appears that binding of the His antiserum was observed at 
just above the expected size for the His tag. Due to this, a coomassie stained gel 
of the input and elution samples containing GST-RAD51 co-expressed with the 
His tag were also analysed (Figure 5-7D). The input sample (lane 1) in Figure 
5-7D shows the expression of a protein of the expected size for the His tag, and 
this band is not visible in the elution sample (lane 2), confirming that GST RAD51 
has not bound to the His tag. In addition, no binding between the His tagged 
1BRC, 4BRC and 7BRC variants of BRCA2 and GST RAD51 was detected in the 
previous experiment (Figure 5-6C lanes 1-3) and this acts as a negative control 
for this experiment also. 
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Figure 5-7 GST pull-down analysis of the interactions between RAD51 and the C-terminal 
domain of BRCA2. 
(A) A western blot of the separated input samples probed with anti-His antiserum (1:750 
dilution). His tagged proteins are indicated (black arrows), and the GST-tagged proteins that 
were co-expressed are indicated (top). (B) A coomassie stained gel of the separated elution 
samples showing GST Rad51 and the GST tag (black arrows). His-tagged proteins that were 
co-expressed are indicated (top). Lanes 4 and 9 contain the Ser1523Ala mutants, and lanes 
5 and 10 the Ser1523Glu mutants. (C) A western blot of the separated elution samples 
probed with anti-His antiserum (1:750 dilution). GST-tagged proteins used for the pull-down 
are indicated (top). (D) A coomassie stained gel of the separated input and elution samples 
from GST Rad51 co-expressed with the His tag (black arrows). In each panel, size markers 
are shown (kDa). 
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5.3 Co-immunolocalisation of RAD51 and BRCA2 
The GST pull-down analysis above indicates extensive BRCA2-RAD51 interaction 
in vitro. However, it does not tell us how the proteins might interact in the cell 
and in response to DNA damage. For this reason, co-immunolocalisation using 
epitope tagged BRCA2 and anti-RAD51 antiserum was carried out in order to 
investigate the cellular localisation of BRCA2 and RAD51 before and after the 
induction of DNA damage, and to test for co-localisation. Though a number of T. 
brucei factors, including BRCA2 and RAD51 paralogues (Hartley and McCulloch, 
2008;Dobson et al., 2011), have been shown to influence the ability of RAD51 to 
form subnuclear foci after damage, it is not clear if the proteins physically 
interact in these putative repair structures. Epitope tagged BRCA2 was used in 
this approach due to the lack of reproducibility and specificity of the anti-BRCA2 
antiserum. A tag consisting of twelve copies of the c-myc epitope was added to 
the C-terminus of BRCA2 in PCF TREU 927 cells in a strategy previously used for 
PTP tagging and purification of T. brucei proteins (Schimanski, Nguyen, and 
Gunzl, 2005). 
5.3.1 Endogenous C-terminal epitope tagging strategy 
A construct (pNAT x12myc) that enables the fusion of a C-terminal 12myc epitope 
tag at the endogenous loci of a gene of interest was modified to target BRCA2 
(Figure 5-8;Alsford and Horn, 2008). The strategy to enable the C-terminal 
tagging of T. brucei proteins at their endogenous loci is displayed in Figure 5-9. 
The C-terminal epitope tagging construct uses a region of the 3’ end of the ORF 
to enable homologous recombination and integration into the genome. Selection 
of clones is enabled by the presence of a blasticidin (BSD) resistance cassette 
flanked by tubulin and actin processing sequences. After integration of the 
construct, endogenous upstream gene sequences are used for RNA trans-splicing, 
while the downstream integrated BSD cassette provides polyadenylation signals 
for the tagged gene, meaning that the 3’ UTR is non-endogenous. For BRCA2, a 
491 bp region of the 3’ end of the BRCA2 ORF was amplified by PCR using 
primers 32 and 33, which contained HindIII and XbaI restriction sites, 
respectively. The PCR-amplified region includes all ORF sequence up to, but 
omitting the stop codon to allow translational read-through into the epitope tag. 
This region also contains a unique restriction site (SphI) to allow linearisation of 
Chapter 5  217 
the construct prior to transformation. The DNA fragment was cloned into the 
construct upstream of the epitope tag using the HindIII and XbaI restriction sites. 
For transformation, the construct was linearised by restriction digestion with 
SphI, the digested DNA was then ethanol precipitated and approximately 5 µg of 
the resuspended DNA was used for each transformation. 
 
Figure 5-8 Construct used for C-terminal 12myc tagging of T. brucei BRCA2. 
491 bp of the 3’ end of the BRCA2 ORF (orange) containing a unique restriction site (SphI) 
was cloned into HindIII and XbaI restriction sites. The 12myc epitope tag (green) consists of 
12 tandemly repeated copies of the c-myc epitope. The BSD resistance cassette is shown 
(red) flanked by the tubulin (βα Tub, blue) and actin (Act IR, purple) intergenic sequences. 
AMP: Ampicillin resistance ORF (grey). Sizes are shown (bp). 
 
Figure 5-9 Strategy for C-terminal 12 myc tagging of T. brucei proteins at their endogenous 
loci. 
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A schematic of the C-terminal 12myc tagging construct, described in Figure 5-8, is shown 
(top). Linearisation of the construct using a unique restriction site, within the 3’ end of the 
ORF (orange), allows integration into the genome by homologous recombination (HR). This 
produces the endogenous ORF fused with the C-terminal 12myc tag (green, bottom). 
5.3.2 Generation of C-terminal 12myc tagged BRCA2 cell 
line 
A transformation was carried out in order to generate a C-terminal 12myc tagged 
BRCA2 cell line. To do this, wild-type PCF TREU 927 cells were transformed with 
the BRCA2 12myc tagging construct and antibiotic resistant transformants were 
selected by placing cells on SDM-79 media supplemented with 10 µg.ml-1 
blasticidin. The clones obtained from transformation were screened by western 
blot performed on total protein extracted from six blasticidin resistant clones. 
The total protein extracts were separated by SDS PAGE on a 3-8% Tris-Acetate 
gel before western blotting and probing with anti-myc antiserum at a dilution of 
1:7000. The western blot in Figure 5-10 demonstrates that four of the six 
putative BRCA2 12myc cell lines contained a protein band of the expected size 
for BRCA2 12myc (193 kDa). One of these was taken forward for further analysis. 
 
Figure 5-10 Confirmation of expression of C-terminal 12myc tagged BRCA2 by western 
analysis. 
Total protein extract from wild-type TREU 927 (WT 927) and putative BRCA2 12myc tagged 
cell lines were separated by SDS-PAGE and western blotted before being probed with anti-
myc anti-serum (1:7000 dilution). A band of the size expected for BRCA2 12myc tagged 
protein is indicated (black arrow), and size markers are shown (kDa). 
5.3.3 Co-immunolocalisation of BRCA2 and RAD51 
Fluorescence microscopy was performed (section 2.4.2) using the BRCA2 12myc 
cell line; anti-myc antiserum conjugated to Alexa Fluor 488 (1:7000 dilution, 
Invitrogen) was used to detect 12myc tagged BRCA2, and anti-RAD51 antiserum 
(1:1000 dilution), in conjunction with Alexa Fluor 594 conjugated anti-rabbit 
secondary antiserum (1:7000 dilution, Invitrogen), to detect RAD51. Cells were 
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treated with 2 µg.ml-1 phleomycin and slides prepared 5 hours and 24 hours 
subsequently (Figure 5-11 and Figure 5-12, respectively). Control slides were 
similarly prepared without phleomycin treatment (Figure 5-13). Images were 
captured using a Zeiss Axioskop microscope with DAPI, DIC, Rhodamine and FITC 
filters. These images were used for quantification of the various categories of 
localisation observed (Table 5-1). The images presented in Figure 5-11, Figure 
5-12 and Figure 5-13 were obtained from the same slides, but using a Deltavision 
confocal microscope (Volodymyr Nechyporuk-Zloy), and were subjected to 
deconvolution. 
The localisation of BRCA2 in the absence of DNA damage appeared to be largely 
nuclear. In most cells (58 of 87), concentration of BRCA2 in multiple, discrete 
foci-like punctate structures was clearly visible, either around the nuclear 
periphery or throughout the nucleus (examples are shown in Figure 5-13). In a 
smaller, but still substantial number of cells (24 out of 87), BRCA2 localisation 
was less focal, either because staining was visible throughout the nucleus or 
because no clear subcellular staining was apparent. In a very small proportion of 
cells (~ 6%) BRCA2 was seen in peripheral nuclear ‘rings’ (see below). As has 
been seen previously (Chapter 3 and Chapter 4) in the absence of damage 
detectable RAD51 localisation was negligible (indeed, in this analysis, no RAD51 
signal was detected). 
After the induction of DNA damage, as has been described previously (Chapter 3 
and Chapter 4) RAD51 formed clear subnuclear foci, the numbers of which 
increased between 5 and 24 hours (40% and 62% of total cells, respectively). The 
localisation of BRCA2 and RAD51 in these conditions can be broadly classified 
into several distinct types. Firstly, BRCA2 was seen much more frequently to be 
forming distinctive, generally continuous, rings around the edge of the DAPI 
stained DNA (Figure 5-11A and Figure 5-12A). The numbers of cells displaying 
this localisation increased with time, and in many cases no RAD51 foci were 
observed in these cells. When cells were seen with both RAD51 foci and BRCA2 
rings, the RAD51 foci were observed in the nucleus within the BRCA2 ring (Figure 
5-11B and Figure 5-12B), and the signals did not overlap. Secondly, there 
appeared to be little change, between 5 and 24 hours, in the numbers of cells 
with punctate BRCA2 rings around the DAPI stained DNA; again, these cells were 
seen both with and without the presence of subnuclear RAD51 foci (Figure 5-11C 
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and Figure 5-12C). Co-localisation was observed in ~ 50% of cells that had 
multiple BRCA2 and RAD51 foci, but in no cases was there complete co-
localisation of all foci as observed in mammalian cells. Instead, it appeared that 
this colocalisation was essentially always between a single BRCA2 ‘focus’ that 
made up part of the punctate ring and a single RAD51 focus (Figure 5-11D and 
Figure 5-12D). Thirdly, BRCA2 was observed as focal accumulations spread 
throughout the nucleus, rather than being concentrated in the periphery (Figure 
5-11E and Figure 5-12E). In some cases, however, predominantly peripheral foci 
were seen, with one or two more central foci (Figure 5-11B and D for examples), 
suggesting that the distinction between peripheral and subnuclear localisation, 
and perhaps also with rings, may be less clear-cut than presented here. 
Nevertheless, in the cells with BRCA2 subnuclear foci, some displayed no RAD51 
foci, while others displayed both BRCA2 and RAD51 foci. Where BRCA2 and 
RAD51 foci were both present, most did not co-localise, though overlap in the 
signals between single BRCA2 and RAD51 foci were common (Figure 5-11F and 
Figure 5-12F). 
 
Table 5-1 Quantification of the localisation of BRCA2 and RAD51 in PCF TREU 927 T. brucei 
before and after exposure to phleomycin. 
(A) Quantification of BRCA2 localisation without phleomycin treatment and after 5 or 24 
hours growth in phleomycin (2 µg.ml-1); cells in which BRCA2 localises in peripheral nuclear 
rings (BRCA2 rings), in more punctuate peripheral rings (BRCA2 punctate rings), in 
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subnuclear foci (BRCA2 foci), or where clear localisation of BRCA2 was not apparent 
(Diffuse/no BRCA2), are distinguished. Numbers indicate total number of cells observed and 
N indicates the total number of cells counted. Quantification of the number of cells that 
display RAD51 foci, and whether any of these foci co-localise with BRCA2; this is separated 
into cells with BRCA2 rings (B), BRCA2 punctate rings (C) and BRCA2 foci (D). 
 
Figure 5-11 Representative images of BRCA2 and RAD51 localisation in PCF TREU 927 T. 
brucei exposed to phleomycin for 5 hours. 
Images of BRCA2 12myc cells after phleomycin treatment (2 µg.ml-1 BLE for 5 hours). Each 
cell is shown after staining with DAPI (DAPI), after hybridisation with anti-myc Alexa Fluor 
Chapter 5  222 
488 conjugated antiserum (1:7000 dilution, BRCA2) and after hybridisation with anti-RAD51 
antiserum (1:1000 dilution) and secondary hybridisation with Alexa Fluor 594 conjugated 
anti-rabbit antiserum (1:7000 dilution, RAD51). Merged images of DAPI, BRCA2 and RAD51 
cells are also shown (Merge). White arrows indicate co-localisation between BRCA2 and 
RAD51. A: BRCA2 ring, B: BRCA2 ring with RAD51 foci, C: Punctate BRCA2 ring with 
RAD51 foci, D: Punctate BRCA2 ring with RAD51 co-localisation, E: BRCA2 foci, F: BRCA2 
foci with RAD51 co-localisation. 
 
Figure 5-12 Representative images of BRCA2 and RAD51 localisation in PCF TREU 927 T. 
brucei exposed to phleomycin for 24 hours. 
Images of BRCA2 12myc cells after phleomycin treatment (2 µg.ml-1 BLE for 24 hours). Each 
cell is shown after staining with DAPI (DAPI), after hybridisation with anti-myc Alexa Fluor 
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488 conjugated antiserum (1:7000 dilution, BRCA2) and after hybridisation with anti-RAD51 
antiserum (1:1000 dilution) and secondary hybridisation with Alexa Fluor 594 conjugated 
anti-rabbit antiserum (1:7000 dilution, RAD51). Merged images of DAPI, BRCA2 and RAD51 
cells are also shown (Merge). White arrows indicate co-localisation between BRCA2 and 
RAD51. A: BRCA2 ring, B: BRCA2 ring with RAD51 foci, C: Punctate BRCA2 ring with 
RAD51 foci, D: Punctate BRCA2 ring with RAD51 co-localisation, E: BRCA2 foci, F: BRCA2 
foci with RAD51 co-localisation. 
 
Figure 5-13 Representative images of BRCA2 and RAD51 localisation in PCF TREU 927 T. 
brucei in the absence of DNA damage. 
Images of BRCA2 12myc cells without phleomycin treatment. Each cell is shown after 
staining with DAPI (DAPI), after hybridisation with anti-myc Alexa Fluor 488 conjugated 
antiserum (1:7000 dilution, BRCA2) and after hybridisation with anti-RAD51 antiserum 
(1:1000 dilution) and secondary hybridisation with Alexa Fluor 594 conjugated anti-rabbit 
antiserum (1:7000 dilution, RAD51). Merged images of DAPI, BRCA2 and RAD51 cells are 
also shown (Merge). 
Having performed the above immunofluorescence, western analysis was next 
carried out in order to check that the differences in localisation observed were 
not simply due to changes in protein expression levels after DNA damage. Total 
protein extracts were prepared before and after phleomycin treatment (2 µg.ml-
1 for 24 hours), separated by SDS PAGE on 3-8% Tris-Acetates gels and western 
blotted. The blot was probed with anti-myc antiserum (1:7000 dilution), anti-
RAD51 antiserum (1:1000 dilution), and anti-OPB1 antiserum (1:1000 dilution) as 
a loading control. The blot was stripped between probings (section 2.11.1). The 
western blot in Figure 5-14 demonstrates that the levels of RAD51 and BRCA2 
12myc remained constant after phleomycin treatment. 
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Figure 5-14 Western analysis of BRCA2 12myc and RAD51 in PCF TREU 927 T. brucei after 
exposure to phleomycin. 
Total protein extracted from BRCA2 12myc tagged cells was separated by SDS PAGE and 
western blotted before being probed with anti-myc antiserum (1:7000 dilution) and anti-
RAD51 antiserum (1:500 dilution). ‘-’ indicates protein extracts prepared without phleomycin 
treatment, and ‘+’ indicates protein extracts prepared after phleomycin treatment (2 µg.ml-1 
BLE for 24 hours). The blots were stripped and re-probed with anti-OPB1 antiserum (1:1000 
dilution) as a loading control. Size markers are shown (kDa). 
5.3.4 Analysis of the sub-cellular distribution of BRCA2 
by aqueous fractionation 
In order to examine further the subcellular distribution of BRCA2, aqueous 
fractionation was carried out on T. brucei whole cell extracts as detailed in 
section 2.2.5 (Zeiner, Sturm, and Campbell, 2003). Nuclear and cytoplasmic 
protein extracts were prepared from BRCA2 12myc cells after phleomycin 
treatment (1 µg.ml-1 for 18 hours), and control protein extracts without 
phleomycin treatment were similarly prepared. Protein extracts were separated 
by SDS-PAGE on 3-8% Tris-Acetate gels before western blotting and probing 
sequentially with anti-myc antiserum (1:7000 dilution), anti-RAD51 antiserum 
(1:500 dilution), anti-OPB1 antiserum (1:1000 dilution) and anti-NOG1 antiserum 
(1:5000 dilution). Blots were stripped between probings as described in section 
2.11.1. The western blot probed with NOG1 and OPB1 antiserum in Figure 5-15 
demonstrates that the separation of nuclear and cytoplasmic proteins by 
aqueous fractionation was successful; OPB1 and NOG1 proteins were only 
present in the cytoplasmic and nuclear fractions, respectively. BRCA2 12myc was 
detected in both the nuclear and the cytoplasmic fractions, both before and 
after the induction of DNA damage. This is in agreement with the images 
obtained by fluorescence microscopy that were not subjected to deconvolution 
(data not shown) which show BRCA2 localised predominantly nuclearly in the 
formations discussed in section 5.3.3, but also present at low levels throughout 
the cytoplasm of the parasite. As seen previously (section 4.3.4), RAD51 was 
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detected in both nuclear and cytoplasmic fractions both with and without 
phleomycin treatment. 
 
Figure 5-15 Aqueous fractionation of PCF TREU 927 BRCA2 12myc tagged cell line exposed 
to phleomycin. 
Aqueous fractionation was performed to generate protein fractions enriched in soluble 
cytoplasmic proteins (C) and soluble nuclear proteins (N). Fractions were prepared from the 
BRCA2 12myc cell line. ‘-’ indicates fractions prepared without phleomycin treatment and ‘+’ 
indicates fractions prepared after phleomycin treatment (1 µg.ml-1 BLE for 18 hours). 
Fractions were separated by SDS PAGE and western blotted before being sequentially 
probed, stripped and re-probed with anti-myc antiserum (1:7000), anti-RAD51 antiserum 
(1:500 dilution), anti-OPB1 antiserum (1:1000 dilution) and anti-NOG1 antiserum (1:5000 
dilution). Size markers are indicated (kDa). 
5.4 Summary 
The results from the in vitro GST pull-down experiment to identify the domains 
of T. brucei BRCA2 that interact with RAD51 are summarised in Figure 5-16, 
which also shows the protein interacting domains of BRCA2 orthologues from H. 
sapiens, U. maydis and C.elegans. Perhaps the most surprising finding from the 
GST pull-down analysis is that these data indicate that T. brucei RAD51 
interaction with the N-terminal BRC repeat domain of BRCA2 is not observed 
until 10 BRC repeat motifs are present, at least in this experimental system. This 
is in direct contrast to in vitro observations with the BRC repeats of mammalian 
BRCA2, where a single repeat is sufficient to bind Rad51 (Wong et al., 1997;Chen 
et al., 1998;Carreira and Kowalczykowski, 2011), and the BRCA2 orthologues in 
C. elegans and U. maydis that only possess a single BRC repeat that is also 
sufficient to bind Rad51 and function in DNA repair (Figure 5-16;Kojic et al., 
2002;Martin et al., 2005;Petalcorin et al., 2006). However, it is hard to evaluate 
just how weak the observed binding of RAD51 to the BRC repeats of T. brucei 
BRCA2 is in comparison to the equivalent in vitro experiments performed with 
BRC repeat fragments of mammalian BRCA2 (Carreira and Kowalczykowski, 
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2011). It is possible that the T. brucei BRC repeats are simply poor at binding 
monomeric RAD51, and that in vivo they bind predominantly, or with higher 
affinity, to RAD51-ssDNA nucleoprotein filaments that may not be present in this 
experimental system. This is supported by the fact that the T. brucei BRC 
repeats most closely resemble the human BRC repeat 7 (with 48.6% similarity for 
the ‘normal’ T. brucei BRC repeat and 51.4% similarity for the ‘degenerate’ T. 
brucei BRC repeat), which is a member of the second group of human BRC 
repeats that are thought to bind with high affinity to Rad51 nucleoprotein 
filaments and function to stabilise them (Carreira and Kowalczykowski, 2011). If 
the BRC repeat expansion in T. brucei is an adaptation in order to bind with high 
affinity and stabilise RAD51-ssDNA nucleoprotein filaments, then it is possible 
that the perfect tandem repeat organisation of the array is critical in this 
function. The demonstration of binding of the BRC repeat array to RAD51 
filaments using electrophoretic mobility shift assays (EMSAs) could be used to 
test this. It would also be interesting to investigate the DNA repair function of a 
variant of T. brucei BRCA2 with the BRC repeats dispersed, as in mammalian 
BRCA2. The BRC repeats of T. brucei BRCA2 have also been suggested to bind to 
the five RAD51 paralogues by yeast 2-hybrid analysis (Hall et al., 2011), and 
these interactions were shown to be stronger than the observed interaction with 
RAD51 (Hall et al., 2011). However, to date there is no report of an interaction 
between a BRCA2 orthologue and Rad51 paralogues in any other organism. 
Binding of T. brucei RAD51 to the C-terminal domain of BRCA2 was observed 
with all of the BRCA2 variants tested here. RAD51 was shown to bind to the C-
tail of BRCA2, the region downstream of the DNA/DSS1-binding domain, and this 
binding was not affected by mutation of a putative CDK phopshorylation site. 
RAD51 binding to this C-tail region may be analogous to the discrete C-terminal 
Rad51-binding site displayed by mammalian BRCA2 and U. maydis Brh2 (Esashi et 
al., 2005;Kojic et al., 2005;Esashi et al., 2007). However, the mammalian 
Rad51-binding motif is not conserved across the BRCA2 orthologues, and notably 
not in U. maydis, so its functional significance outside mammals is unclear (Kojic 
et al., 2005). Nonetheless, it would also be interesting to determine if T. brucei 
BRCA2 is indeed phosphorylated, how this phosphorylation changes throughout 
the cell cycle and the effect of phosphorylation on RAD51 binding (including at 
the C-terminus). It is highly likely that cell cycle-dependent phosphorylation is a 
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universal mechanism for the regulation of RAD51 binding and therefore function 
by BRCA2, as observed in mammalian cells (Esashi et al., 2005;Ayoub et al., 
2009), due to the requirement of a homologous template that is most likely 
present after nuclear DNA replication has been completed. There is some 
evidence to suggest that the C-terminal Rad51-binding motif present in 
mammalian BRCA2 plays a critical role in replication by stabilising Rad51 
filament formation on nascent DNA, preventing its degradation (Hashimoto et 
al., 2010;Schlacher et al., 2011). The mapping of the replication phenotype in T. 
brucei to the C-terminus of BRCA2 is consistent with this function (Claire 
Hartley, PhD Thesis, 2008) and a role for the observed multiple sites of RAD51 
binding to the C-terminal region of BRCA2 in the maintenance of replication 
could be interesting to investigate. 
T. brucei RAD51 was also shown to interact with a region of BRCA2 upstream of 
the C-tail, containing the DNA/DSS1-binding domain and including a putative 
DMC1 interaction motif (PhePP). Removal of this PhePP motif did not affect 
RAD51 binding, indicating that binding is occurring downstream of this motif, 
possibly within the DNA/DSS1-binding domain. DMC1 binding to the putative 
PhePP motif has not been demonstrated in T. brucei, and cannot be ruled out. 
However, the observed binding of Rad51 by the U. maydis orthologue of BRCA2 
via the putative PhePP motif (Kojic et al., 2011) does not appear to be 
conserved in T. brucei BRCA2. Further fine mapping of the interaction between 
RAD51 and the C-terminus of T. brucei BRCA2 is required to determine if indeed 
Rad51 binds to the DNA/DSS1-binding domain, which has not been detected to 
date in any organism. However, the possibility remains that an uncharacterised 
RAD51-binding domain exists in the region between the PhePP motif and the 
DNA/DSS1-binding domain. 
The in vivo immunolocalisation of BRCA2 and RAD51 has produced a complex 
picture of the distribution of these proteins in T. brucei. BRCA2 appears to be a 
largely nuclearly located protein both before and after the induction of DNA 
damage, though subcellular fractionation does detect extra-nuclear protein. 
Focal accumulations of BRCA2 are clearly visible in the absence of DNA damage. 
However, once DNA damage has been induced a more complex distribution of 
BRCA2 is observed. Rings of BRCA2 around the DAPI stained DNA are observed 
more frequently, both ‘smooth’ and ‘punctate’ in nature, as well as BRCA2 foci 
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distributed throughout the nucleus and at the periphery. Co-localisation with 
RAD51 foci is observed, but at a much lower frequency than observed in 
mammalian cells (Mizuta et al., 1997;Tarsounas, Davies, and West, 2003). 
However, BRCA2 and RAD51 do bind and interact with each other in T. brucei, as 
demonstrated by in vivo co-immunoprecipitation in Chapter 6 and the GST pull-
down analysis here. RAD51 and BRCA2 localisation has been investigated in 
multiple systems. In mammalian cells multiple Rad51 foci are observed after 
DNA damage, the majority of which co-localise with BRCA2 (Mizuta et al., 
1997;Tarsounas, Davies, and West, 2003), which is similar to that observed in 
Drosophila (Brough et al., 2008). Localisation of Rad51 in C. elegans is observed 
as multiple subnuclear foci during meiosis, and in Cebrc-2 null mutants this 
localisation of Rad51 is dramatically reduced (Martin et al., 2005). Bimolecular 
fluorescence complementation analysis in C. elegans using fluorescently labelled 
Cebrc-2 and mammalian Rad51 indicates that Cebrc-2 binds mammalian Rad51 
and forms multiple discrete foci that increase in size after DNA damage (Min et 
al., 2007). Co-localisation of Rad51 and Brh2 has not been studied in U. maydis, 
but the formation of Rad51 foci is observed after DNA damage in this organism, 
and is co-incident with the formation of Brh2 foci (Kojic et al., 2006). The 
composition of DNA repair foci is not known, though it is assumed that they 
contain multiple copies of DNA repair factors and form a highly efficient DNA 
repair factory (Lisby and Rothstein, 2009). The relatively low occurrence of 
RAD51 and BRCA2 co-localisation in T. brucei when compared to mammalian 
cells could point to a role for BRCA2 in establishing the RAD51 foci and then 
moving away, leaving the RAD51 foci in place. It may also be consistent with 
BRCA2 acting in DNA damage and an additional role, as discussed in Chapter 4. 
The most striking observation from the imunolocalisation images are the ‘rings’ 
of BRCA2 that are observed in a small percentage of cells after DNA damage. It 
may be possible that this ring structure represents sites of replication located at 
the periphery of the nucleus (Elias et al., 2002;Calderano et al., 2011), or even 
binding to chromosome telomeres, which have been demonstrated to be located 
at the nuclear periphery (Chung et al., 1990). A role in VSG switching can 
probably be discarded as this analysis was carried out in PCF cells that 
presumably do not undergo VSG switching. 
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Taken together, these data reveal a complex picture of T. brucei BRCA2 
subnuclear behaviour, with a perhaps dynamic redistribution between general 
peripheral nuclear localisation and accumulation into more discrete foci both at 
the nuclear periphery and in the interior. Furthermore, this localisation shows 
surprisingly little overlap with RAD51, which is only seen in subnuclear foci after 
damage. In contrast to the extensive co-localisation seen between BRCA2 and 
RAD51 in the nuclei of mammals and Drosophila (Mizuta et al., 1997;Tarsounas, 
Davies, and West, 2003;Brough et al., 2008) after damage, here we see frequent 
examples where there is no such co-localisation. In addition, when T. brucei 
BRCA2 and RAD51 do localise it appears to be nearly always in a single focus 
amongst many foci. 
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Figure 5-16 A representation of BRCA2 orthologues showing their functional domains and 
interacting proteins. 
BRCA2 orthologues from H. sapiens, T. brucei, U. Maydis and C. elegans are shown with the 
protein domains indicated; BRC repeats (red bars), ‘degenerate’ BRC repeat (dark red bar), 
PhePP motif (orange line), alpha-helical domain (green oval/semi-circle), oligonucleotide-
binding domain (blue box), and tower domain (purple bar). Interacting proteins and their 
sites of binding are indicated below the protein, and ‘?’ indicates predicted binding sites. 
Not to scale.
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 Chapter 6: Does T. brucei BRCA2 
interact with CDC45? 
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6.1 Introduction 
In mammalian cells, it has been demonstrated that BRCA2 plays multiple roles to 
ensure faithful genome replication, although the precise mechanisms remain to 
be elucidated (Michel et al., 2004;Nagaraju and Scully, 2007;Constanzo, 2011). A 
number of publications have begun to implicate BRCA2 in the maintenance of 
replication fork progression (Daboussi et al., 2008), the stabilisation of DNA 
structures at stalled replication forks (Lomonosov et al., 2003) and, in some 
cases, DNA replication directly (Michel et al., 2001;Michel et al., 2004). A 
function for the BRCA2 C-terminal Rad51-binding motif in the protection of 
stalled replication forks from degradation by Mre11 has been described 
(Schlacher et al., 2011), and may operate via stabilisation of Rad51 filaments on 
nascent DNA (Hashimoto et al., 2010). Mutation of the BRCA2 C-terminal CDK 
phosphorylation site at Serine 3291 to Alanine, which does not support Rad51 
binding to this motif, was shown to be deficient in this protection function, 
despite being HR proficient (Schlacher et al., 2011). Mutation of the equivalent 
C-terminal Rad51-binding motif in avian BRCA2, which also ablates Rad51 
binding, has been demonstrated to link the observed faster disassembly of Rad51 
subnuclear complexes to the early onset of mitosis, despite having no effect on 
HR-mediated DNA repair (Ayoub et al., 2009). BRCA2 has also been shown to 
interact with BRAF35 (also called HMG20b), a member of the high-motility group 
of non-sequence specific DNA-binding proteins (Wang et al., 1998;Sumoy et al., 
2000;Marmorstein et al., 2001;Lee et al., 2011). This interaction was localised 
to the BRC repeats of BRCA2, and BRAF35 displays the highest affinity for BRC 
repeat 5, a motif that binds poorly to Rad51 (Lee et al., 2011;Carreira and 
Kowalczykowski, 2011). Depletion of BRAF35 by RNAi delays and disrupts the 
completion of cell division by cytokinesis (Lee et al., 2011) in a phenotype 
previously detected in BRCA2-deficient cells (Daniels et al., 2004). Therefore, a 
novel function of BRAF35 in facilitating the completion of cytokinesis via an 
interaction with the BRC repeats of BRCA2 has been proposed (Lee et al., 2011). 
A role for BRCA2 in facilitating the completion of cell division by cytokinesis has 
also been observed (Daniels et al., 2004;Jonsdottir et al., 2009;Vinciguerra et 
al., 2010;Rowley et al., 2011), though doubt has been cast due to the absence of 
hallmarks of a failure to complete cytokinesis in HeLa cells depleted of BRCA2 by 
RNAi and a lack of BRCA2 localisation to cytokinetic structures (Lekomtsev et 
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al., 2010). BRCA2 has also been shown to associate with telomeres in mouse 
embryonic fibroblasts during the S and G2 phases of the cell cycle (Badie et al., 
2010), and is proposed to act in loading Rad51 to facilitate telomere replication 
and protection by capping (Badie et al., 2010). Finally, in the highly radiation 
resistant fungus U. maydis, the BRCA2 orthologue Brh2 has been show to 
promote template switching reactions that enable HR-mediated bypass of DNA 
replication blocking lesions (Mazloum and Holloman, 2009). 
brca2-/- mutants in BSF Lister 427 T. brucei display a replication phenotype that 
is not observed in other DNA repair mutants, most notably rad51-/- (Claire 
Hartley, PhD Thesis, 2008), which is consistent with the initiation of cytokinesis 
prior to the completion of nuclear DNA replication (Claire Hartley, PhD Thesis, 
2008). There is evidence to suggest that the C-terminal region of T. brucei 
BRCA2 may function in this replication role. Firstly, DAPI analysis of brca2-/- 
cells in which the C-terminal region of BRCA2 in isolation was re-expressed 
suggested partial complementation of the replication defect observed in the 
brca2-/- mutant cells, as the number of aberrant cells was more comparable 
with wild-type and full-length BRCA2 re-expresser cell lines (Claire Hartley, PhD 
Thesis, 2008). Secondly, the re-expression of a variant of BRCA2 consisting of the 
BRC repeat region fused to the RPA50 subunit continued to generate aberrant 
cells, indicating that C-terminal-specific functions underlie this replication 
phenotype (Claire Hartley, PhD Thesis, 2008). The publication of an observed 
interaction between the C-terminal domain of BRCA2 and a region of the T. 
brucei homologue of CDC45 (Oyola, Bringaud, and Melville, 2009), a protein 
essential for DNA replication (see below;Zou, Mitchell, and Stillman, 
1997;Tercero, Labib, and Diffley, 2000), presented a possible novel mechanism 
for the involvement of BRCA2 in DNA replication. This publication did not 
explore this question, but perhaps the interaction with CDC45 allows homology-
directed DNA repair of stalled replication forks in a mechanism to ensure that 
replication stalls are overcome in T. brucei. 
CDC45 is a protein originally identified in Saccharomyces cerevisiae (Hardy, 
1997) that is essential for the initiation and progression of DNA replication (Zou, 
Mitchell, and Stillman, 1997;Tercero, Labib, and Diffley, 2000). CDC45 localises 
to the nucleus (Hopwood and Dalton, 1996) and has been shown to bind to the 
minichromosome maintenance (MCM2-7) and GINS complexes to form the 
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replicative helicase, the CMG complex (CDC45-MCM-GINS; Aparicio, Ibarra, and 
Mendez, 2006;Aparicio et al., 2009;Ilves et al., 2010;Costa et al., 2011). CDC45 
is thought to play a critical role in firing assembled pre-replication complexes to 
allow the start of DNA replication (Zou, Mitchell, and Stillman, 1997), and has 
also been shown to move with replication forks, presumably functioning during 
fork progression (Aparicio, Weinstein, and Bell, 1997). The MCM2-7 proteins have 
weak DNA helicase activity on their own, and binding to CDC45 and GINS 
stimulates this helicase activity (Aparicio et al., 2009;Ilves et al., 2010;Costa et 
al., 2011), allowing unwinding of DNA at the origin of replication. The 
components of the CMG complex have recently been identified in T. brucei and 
depletion of CDC45 by RNAi was observed to be lethal (Dang and Li, 2011). 
Further observations indicate that CDC45 is excluded from the nucleus after the 
completion of nuclear DNA replication (Dang and Li, 2011), and may suggest a 
possible role for CDC45 in a mechanism to prevent re-replication of nuclear DNA 
during the cell cycle in trypanosomes (Dang and Li, 2011). 
Oyola et al., (2009) used a T. brucei cDNA library in a yeast 2-hybrid screen to 
detect potential BRCA2 interactors. A homologue of T. brucei CDC45 was 
identified in approximately one-third of colonies analysed. Further yeast 2-
hybrid analysis was carried out with the two ‘halves’ of BRCA2, and positive 
colonies were only obtained with the C-terminal half of BRCA2. The interaction 
was quantitatively much stronger than that observed with a positive control, and 
only a medium strength interaction was observed between BRCA2 and RAD51 
using the same assay. Co-immunoprecipitation analysis was carried out using 
full-length BRCA2 over-expressed in T. brucei or the C-terminal half of BRCA2 
over-expressed as a hexa-histidine fusion in E. coli. Interaction with a fragment 
of CDC45 (residues 371-523) over expressed in E. coli as a GST fusion was tested 
for and observed with both the full-length and the C-terminal fragment of 
BRCA2. The detection of this interaction between the C-terminal half of BRCA2 
and CDC45 in T. brucei was interesting as a potential explanation for the 
replication phenotype observed in BSF brca2-/- mutants (Hartley and McCulloch, 
2008), and is consistent with the location of the replication phenotype to the C-
terminus of BRCA2 (Claire Hartley, PhD Thesis, 2008). 
This chapter aims to test the validity of the putative interaction between BRCA2 
and CDC45 in T. brucei. Two approaches were taken. Firstly, the interaction was 
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investigated in vivo by co-immunoprecipitation using epitope-tagged proteins 
expressed from their endogenous loci in T. brucei. Secondly, in vitro GST pull-
down was performed using fusion proteins over-expressed in E. coli. Both of 
these approaches have been used successfully to identify interacting proteins in 
T. brucei (Dobson et al., 2011;Calvin Tiengwe, PhD Thesis, 2010), and GST pull-
down was used to examine BRCA2-RAD51 interaction in this work (Chapter 5). 
6.2 In vivo co-immunoprecipitation 
The lack of antiserum against T. brucei CDC45 meant that in order to detect the 
presence of this protein a tag consisting of twelve copies of the c-myc epitope 
was added to the C-terminus in PCF TREU 927 cells, as described previously 
(section 5.3.1). This epitope tag allowed the immunoprecipitation of CDC45 
using antiserum against the c-myc epitope. 
6.2.1 Endogenous C-terminal epitope tagging strategy 
The pNAT x12myc construct, which enables the fusion of a C-terminal 12myc 
epitope tag at the endogenous loci of a gene of interest, was modified to target 
CDC45 (Figure 6-1;Alsford and Horn, 2008). The epitope tagging strategy is 
described in section 5.3.1. A 925 bp region of the 3’ end of the CDC45 ORF was 
PCR-amplified using primers 5 and 6, which contained HindIII and XbaI restriction 
sites, respectively, to allow cloning into the construct upstream of the epitope 
tag. The DNA fragment contained a unique restriction site (EcoRV) to allow 
linearisation prior to transformation. For transformation, the construct was 
linearised by restriction digestion, the digested DNA was then ethanol 
precipitated and approximately 5 µg of the resuspended DNA was used for each 
transformation. 
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Figure 6-1 Construct used for C-terminal 12myc tagging of T. brucei CDC45. 
925 bp of the 3’ end of the CDC45 ORF (orange) containing a unique restriction site (EcoRV) 
was cloned into HindIII and XbaI restriction sites. The 12myc epitope tag (green) consists of 
12 tandemly repeated copies of the c-myc epitope. The BSD resistance cassette is shown 
(red) flanked by the tubulin (βα Tub, blue) and actin (Act IR, purple) intergenic sequences. 
AMP: Ampicillin resistance ORF (grey). Sizes are shown (bp). 
6.2.2 Generation of a CDC45-/+ mutant cell line in PCF 
TREU 927 T. brucei 
In order to confirm that the presence of the 12myc epitope tag was not 
interfering with the function of the CDC45 protein it was decided to generate 
the tagged cell line in a CDC45 heterozygous (-/+) background, meaning that all 
of the CDC45 expressed would contain the epitope tag. CDC45 is an essential 
protein in mammals, S. cerevisiae and Xenopus laevis (Hardy, 1997;Zou, 
Mitchell, and Stillman, 1997;Mimura and Takisawa, 1998;Tercero, Labib, and 
Diffley, 2000;Aparicio et al., 2009) and RNAi of T. brucei CDC45 in PCF cells 
leads to cell death (Dang and Li, 2011). Therefore the generation of the tagged 
cell line in a heterozygous background would confirm that the tagged protein is 
functional. 
The CDC45-/+ mutant cell line was generated in PCF TREU 927 T. brucei using a 
classical gene knockout strategy where the entire CDC45 ORF is removed. A 
CDC45 knockout construct, ∆CDC45::PUR (Figure 6-2), was assembled. The 
construct contains regions of the 5’ and 3’ UTRs flanking the CDC45 ORF cloned 
into pBluescript and used as targeting sequence to enable homologous 
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recombination and replacement of the entire CDC45 ORF with an antibiotic 
resistance cassette following transformation. Primers were designed to amplify 
503 bp of the 5’ UTR and 526 bp of the 3’ UTR flanking the CDC45 ORF. The 5’ 
UTR was amplified using primers 37 and 40, which contained XhoI and NruI 
restriction sites, respectively. The 3’ UTR was amplified using primers 41 and 42, 
which contained NruI and XbaI restriction sites, respectively. The two DNA 
fragments were cloned into pBluescript in a three-way ligation using the XhoI, 
NruI and XbaI restriction sites. To allow selection of the construct that has 
integrated into the genome a puromycin (PUR) resistance cassette, prepared by 
restriction digestion with NruI from ∆BRCA2::PUR construct (section 3.2.1), was 
blunt cloned between the flanks using the NruI restriction site. The PUR 
resistance cassette contained mRNA processing signals derived from actin and 
tubulin intergenic sequences, flanking the antibiotic resistance ORF, to allow 
RNA trans-splicing and polyadenylation, respectively. For transformation, the 
construct was excised from pBluescript by restriction digestion with XhoI and 
XbaI, the digested DNA was then ethanol precipitated and approximately 5 µg of 
the resuspended DNA was used for transformation. 
 
Figure 6-2 CDC45 gene deletion construct. 
Restriction map of the construct used for the deletion of CDC45 is shown, relative to the 
CDC45 ORF (top). Sizes of the individual components are shown (bp) and are not to scale. 
Constructs were cloned into pBluescript and excised using the XhoI and XbaI restriction 
sites shown. 5’ UTR and 3’ UTR correspond to un-translated regions upstream and 
downstream of the CDC45 ORF, respectively. βα Tub: βα tubulin intergenic region, Actin IR: 
Actin intergenic region, PUR: puromycin resistance ORF. 
A transformation was carried out in order to generate a CDC45-/+ mutant cell 
line using the ∆CDC45::PUR construct. To do this, PCF wild-type TREU 927 cells 
were transformed and antibiotic resistant transformants were selected by 
placing cells on SDM-79 media supplemented with 1 µg.ml-1 puromycin. 
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The generation of CDC45-/+ mutants was confirmed by PCR analysis performed 
on genomic DNA extracted from six puromycin resistant clones. PCR was 
performed using primers specific to the PUR resistance ORF (primers 144 and 
145) in order to confirm that the cassette was integrated into the genome. 
Integration into the correct locus was checked by PCR using a forward primer 
specific to the PUR resistance ORF (primer 144) and a reverse primer located in 
the 3’ UTR outside of the region cloned in the gene deletion construct (primer 
59). The location of the primers and expected sizes of the PCR products are 
displayed in Figure 6-3A. The agarose gel in Figure 6-3B demonstrates the 
presence of the PUR resistance gene in all of the putative CDC45-/+ mutant 
clones analysed. The PCR with primers 144 and 59 demonstrates that in two cell 
lines (indicated by ‘*’ in Figure 6-3B) the gene deletion construct has integrated 
in the correct location and replaced a CDC45 ORF. The CDC45-/+ mutant clone 
chosen for further analysis is referred to as CDC45-/+ PUR. 
 
 
Figure 6-3 Confirmation of PCF TREU 927 CDC45-/+ mutant cell lines by PCR. 
(A) Primers used to amplify the puromycin resistance ORF (PUR), or a region spanning PUR 
and the CDC45 3’UTR, are indicated (black arrows), with the expected sizes of the resulting 
PCR products shown (bp). (B) An agarose gel of the PCR products obtained using the 
primers, described above, and genomic DNA extracted from wild-type TREU 927 (WT 927) 
and putative CDC45-/+ mutant cell lines. Distilled water (dH2O) was used as a negative 
control. The PCR products produced from the PUR and -/+ allele are indicated (black 
arrows), and size markers are shown (Ladder, kb). ‘*’ indicates CDC45-/+ mutants that are 
confirmed by PCR. 
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6.2.3 Generation of C-terminal 12myc tagged CDC45-/+ 
cell line 
A transformation was next carried out in order to generate a C-terminal 12myc 
tagged CDC45 cell line in the CDC45-/+ background. To do this, the CDC45-/+ 
PUR cell line was transformed with the CDC45 12myc tagging construct (section 
5.3.1) and antibiotic resistant transformants were selected by placing cells on 
SDM-79 media supplemented with 10 µg.ml-1 blasticidin and 0.5 µg.ml-1 
puromycin. The clones obtained from transformation were screened by western 
blot performed on total protein extracted from six blasticidin and puromycin 
resistant clones. The total protein extracts were separated by SDS PAGE on a 3-
8% Tris-Acetate gel before western blotting and probing with anti-myc antiserum 
(Millipore) at a dilution of 1:7000. The western blot in Figure 6-4 demonstrates 
that four of the six putative CDC45-/+ 12myc cell lines contain a protein band of 
the expected size (93 kDa) for CDC45 12myc. Also present is a smaller protein 
band, which could be a degradation product or a post-translationally modified 
CDC45 variant (e.g. phosphorylated); it may also simply result from the 
antiserum binding to non-specific T. brucei proteins, though why then it would 
not be detected in wild-type cells is unclear. One of these clones was taken 
forward for further analysis. Given the efficiency of generating blasticidin and 
puromycin resistant cells that detectably express myc-tagged CDC45, and the 
fact that the cells display no gross growth rate changes (data not shown), it 
seems likely that the C-terminal epitope tag does not critically impair CDC45 
function. However, without checking for the presence of a wild-type CDC45 
allele, this remains to be confirmed. 
 
Figure 6-4 Confirmation of expression of C-terminal 12myc tagged CDC45-/+ by western 
analysis. 
Total protein extract from wild-type TREU 927 (WT 927) and putative 12myc tagged CDC45-
/+PUR cell lines, were separated by SDS-PAGE and western blotted before being probed 
with anti-myc antiserum (1:7000 dilution). The band predicted to correspond with the CDC45 
12myc tagged protein is indicated (black arrow), and size markers are shown (kDa). 
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6.2.4 Co-immunoprecipitation using the CDC45-/+ 12myc 
tagged cell line 
Co-immunoprecipitation using the CDC45-/+ 12myc tagged cell line, and wild-
type TREU 927 cells as a control was next performed. Total protein was 
extracted (section 2.2.4.2) from cells; this is referred to as the input. 
Immunoprecipitation of CDC45 12myc was carried out using anti-myc antiserum 
conjugated to agarose beads (Millipore) as described in section 2.12; protein 
recovered is referred to as the elution. The input and elution protein samples 
were separated by SDS PAGE on 3-8% Tris-Acetate gels, western blotted and first 
probed with anti-BRCA2 antiserum at a dilution of 1:200. The blots were then 
stripped and re-probed with anti-myc antiserum at a dilution of 1:7000. The 
western blot in Figure 6-5 demonstrates that in both the wild-type TREU 927 and 
CDC45-/+ 12myc cell lines a band of the expected size for the BRCA2 protein 
(176 kDa) was present in the input samples (lanes 1 and 2). A band of the 
expected size for CDC45 12myc (93 kDa) was present only in the tagged cell line 
input (lane 2) and elution (lane 4). The elution samples demonstrate that CDC45 
12myc was successfully immunopreciptated from the tagged cell line (lane 4), 
and was not detectable in wild-type cells (lane 3). No BRCA2 protein was 
detected in the elution sample of either cell line, suggesting that an interaction 
was undetectable under these conditions. However, given the unreliable nature 
of the detection of BRCA2 with the anti-BRCA2 antiserum (see previous 
chapters), this could not be considered a definitive experiment. 
 
Figure 6-5 Co-immunoprecipitation analysis of the interaction between CDC45 12myc and 
BRCA2. 
Total protein extracts from wild-type TREU 927 (WT 927) and CDC45-/+ 12myc cell lines were 
subjected to immunoprecipitation using anti-myc antiserum conjugated to agarose beads. 
Input and elution samples were separated by SDS-PAGE and western blotted before being 
probed with anti-myc antiserum (1:7000 dilution) and anti-BRCA2 anti-serum (1:200 
dilution). Size markers are indicated (kDa). 
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6.2.5 Generation of C-terminal double-tagged cell lines in 
PCF TREU 927 T. brucei 
In order to overcome the limitations of the anti-BRCA2 antiserum it was decided 
to generate cell lines in which both BRCA2 and CDC45 were epitope tagged at 
the C-terminus. A construct was assembled to allow the addition of a 6HA 
epitope tag to the C-terminus of BRCA2 at the endogenous locus in the T. brucei 
genome. This 6HA tagging construct was identical to the 12 myc tagging 
construct except the 12myc epitope tag was replaced with a 6HA epitope tag, 
and a bleomycin (BLE) resistance cassette was inserted in place of the BSD 
resistance cassette to allow selection of clones. The cloning of the section of the 
3’ end of the BRCA2 ORF was carried out using the same strategy as for the 
BRCA2 12myc construct (section 5.3.1). Primers 32 and 33 were used to amplify 
491 bp region at the 3’ end of the BRCA2 ORF containing a unique SphI 
restriction site. 
It was also decided to create a positive control for the co-immunoprecipitation 
reaction and test for the functionality of interactions with the epitope tagged 
BRCA2 protein. It has been demonstrated that both mammalian and T. brucei 
BRCA2 and Rad51 interact strongly with each other in vitro (Chapter 5;Sharan et 
al., 1997;Chen et al., 1998;Marmorstein, Ouchi, and Aaronson, 1998). The 
generation of a T. brucei cell line with both BRCA2 and RAD51 C-terminally 
epitope tagged allowed this interaction to act as a positive control for the co-
immunoprecipitation experiment. A construct to allow the addition of a 12myc 
epitope tag to the C-terminus of RAD51 at the endogenous locus in the T. brucei 
genome was generated previously (gift, Rachel Dobson) with a blasticidin (BSD) 
resistance cassette for selection (Figure 6-1). The unique site used for 
linearisation of this construct was BlpI. In a recent study (Dang and Li, 2011), 
endogenously tagged CDC45 with a C-terminal epitope tag consisting of 3 copies 
of the HA epitope was demonstrated to interact with the other two members of 
the CMG complex in T. brucei. This provides some evidence that C-terminal 
epitope tagging if CDC45 does not impair its ability to functionally interact with 
members of the CMG complex, albeit in a slightly different context to that used 
here. However, we cannot rule out that 12myc tagging of CDC45 somehow 
impairs functional interaction with BRCA2, or with other proteins, despite the 
fact that the CDC45+/- 12myc cells grow normally (data not shown). 
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Because of the limitations in the availability of suitable resistance cassettes it 
was decided to generate the two double-tagged cell lines in wild-type PCF TREU 
927 cells, as opposed to heterozygous backgrounds for all tagged proteins. This 
meant that half of the protein expressed in each cell line was epitope tagged as 
only one allele had the tagging construct integrated. The generation of the 
BRCA2 6HA tagged cell line was carried out by the transformation of wild-type 
PCF TREU 927 cells with the linearised BRCA2 6HA construct. Cells were selected 
on SDM-79 media supplemented with 15 µg.ml-1 Zeocin (Invitrogen) and six of the 
resulting clones were chosen. BRCA2 6HA protein expression was confirmed by 
western blot (data not shown), prior to further transformation. One of these 
confirmed cell lines was then subjected to two transformations, with the 
linearised CDC45 12myc construct or the linearised RAD51 12myc construct. For 
each transformation, cells were selected on SDM-79 media supplemented with 10 
µg.ml-1 blasticidin and 10 µg.ml-1 Zeocin, and six of the resulting clones were 
chosen from each transformation. 
6.2.6 Confirmation of C-terminal double-tagged cell lines 
The twelve putative double-tagged cell lines were subject to screening by 
western blot in order to confirm the expression of the two epitope tagged 
proteins in each. Total protein was extracted from wild-type TREU 927 and the 
twelve double-tagged cell lines and separated by SDS PAGE on 3-8% Tris-Acetate 
gels, western blotted and probed with anti-HA antiserum (Sigma) at a dilution of 
1:10000. The blots were then stripped and re-probed with anti-myc antiserum 
(Millipore) at a dilution of 1:7000. The western blots in Figure 6-6 demonstrate 
that all twelve of the tested clones contained correctly expressed BRCA2 6HA 
tagged protein of the expected size (183 kDa). Half of the twelve clones also 
expressed a protein of the expected size for the myc-tagged variants; 55 kDa for 
RAD51 12myc, or 93 kDa for CDC45 12myc. One of each of the double-tagged cell 
lines was chosen for co-immunoprecipitation analysis. 
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Figure 6-6 Confirmation of co-expression of C-terminal epitope tagged proteins in PCF 
TREU 927 T. brucei. 
Total protein extracts from wild-type TREU 927 (WT 927) and the two putative double-tagged 
cell lines (BRCA2 6HA CDC45 12myc and BRCA2 6HA RAD51 12myc) were separated by 
SDS-PAGE and western blotted before being probed with anti-HA antiserum (1:10000 
dilution, top). The blots were stripped and re-probed with anti-myc antiserum (1:7000 
dilution, bottom). The bands produced by BRCA2 6HA, CDC45 12myc, and RAD51 12myc 
proteins are indicated (black arrows), and size markers are shown (kDa). 
6.2.7 Co-immunoprecipitation using C-terminal double-
tagged cell lines 
Co-immunoprecipitation using the two C-terminal double-tagged cell lines, and 
wild-type TREU 927 cells as a control, was performed with anti-myc antiserum as 
described above (section 6.2.4). The co-immunoprecpitation experiment was 
additionally performed using anti-HA antiserum conjugated to agarose beads 
(Roche). The input and elution samples were separated by SDS PAGE on 3-8% 
Tris-Acetate gels, western blotted and probed with anti-HA antiserum at a 
dilution of 1:10000. The blot was then stripped and re-probed with anti-myc 
antiserum at a dilution of 1:7000. 
The western blots in Figure 6-7 show analysis of interaction between BRCA2 and 
RAD51, and also BRCA2 and CDC45. The input samples demonstrate expression of 
tagged proteins of the expected size for the tagged cell lines analysed, but 
absent in wild-type cells. The elution samples demonstrate the successful 
immunoprecipitation of BRCA2 6HA by the anti-HA beads and either RAD51 
12myc or CDC45 12myc by the anti-myc beads. An interaction between either 
RAD51 or CDC45 and BRCA2 could not be detected using the anti-HA 
immunoprecipitation, as evidenced by the blank anti-myc probed elution blot 
(Figure 6-7A). However, an interaction between BRCA2 and RAD51 was detected 
using the anti-myc immunoprecipitation of RAD51 12myc, as evidenced by the 
presence of a band consistent with BRCA2 6HA in the anti-HA probed elution blot 
(Figure 6-7B). In contrast, an interaction between CDC45 and BRCA2 was not 
detected. This could be because the proteins do not interact, or could result 
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from a variety of experimental reasons, the most probable of which is that such 
an interaction is not strong or abundant enough to survive the relatively harsh 
conditions during such a co-immunoprecipitation experiment. 
 
Figure 6-7 Co-immunoprecipitation analysis of the interaction between BRCA2 and CDC45, 
and between BRCA2 and RAD51. 
Total protein extracts from wild-type TREU 927 (WT 927) and the double-tagged cell lines 
(BRCA2 6HA CDC45 12myc, and BRCA2 6HA RAD51 12myc) were immunoprecipitated 
using anti-HA antiserum (A) or anti-myc antiserum (B) conjugated to agarose beads. Input 
and elution samples were separated by SDS-PAGE and western blotted before being probed 
with anti-myc antiserum (1:7000 dilution) and anti-HA anti-serum (1:10000 dilution). Size 
markers are shown (kDa). 
6.2.8 Co-immunoprecipitation after exposure to DNA 
damage 
In order to try and increase the probability of detecting an interaction between 
CDC45 and BRCA2, it was decided to repeat the co-immunoprecipitation 
experiment with protein extracted after the cells had been treated with DNA 
damage. The rationale behind this was that BRCA2-CDC45 interaction in vivo 
may only occur in the presence of replication-blocking lesions, which are only 
present in low abundance during normal growth in culture. Two types of DNA 
damaging agent were therefore chosen; methyl methanesulphonate (MMS) and 
hydroxyurea (HU). MMS is a DNA alkylating agent and may form DNA replication 
fork barriers (Brookes and Lawley, 1961;Reiter et al., 1967;Beranek, 
1990;Sedgwick, 2004). T. brucei mutants of components of the homologous 
recombination machinery, rad51, rad51-3, rad51-5 and brca2, all display 
increased sensitivity to MMS (McCulloch and Barry, 1999;Proudfoot and 
McCulloch, 2005;Hartley and McCulloch, 2008). HU acts by inhibiting 
ribonucleotide reductase, an enzyme involved in deoxyribonucleotide 
triphosphate (dNTP) synthesis, depleting the nucleotide pool and thereby stalling 
DNA replication (Hofer et al., 1997). HU has been used to successfully 
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synchronise bloodstream T. brucei by causing an S-phase block (Forsythe, 
McCulloch, and Hammarton, 2009). Wild-type TREU 927 cells and the two 
double-tagged cell lines were treated with 0.002% MMS for 16 hours, or 0.3 mM 
HU for 16 hours, before protein was extracted as described in section 2.2.4.2. 
Immunoprecipitation using anti-myc antiserum conjugated to agarose beads and 
also anti-HA antiserum conjugated to agarose beads was carried out as described 
in section 6.2.4. The input and elution samples were separated by SDS PAGE on 
3-8% Tris-Acetate gels, western blotted and probed with anti-HA antiserum at a 
dilution of 1:10000. The blot was then stripped and re-probed with anti-myc 
antiserum at a dilution of 1:7000. 
The western blots in Figure 6-8 and Figure 6-9 show analysis of interaction 
between BRCA2 and RAD51, and also BRCA2 and CDC45, after DNA damage with 
HU and MMS, respectively. For both co-immunoprecipitation experiments 
performed, in the presence of MMS or HU, both results are essentially equivalent 
to each other, and to the data presented in Figure 6-7, in the absence of DNA 
damage and despite this increased amount of DNA damage from both 
treatments, an interaction between BRCA2 and CDC45 could still not be 
detected. 
 
Figure 6-8 Co-immunoprecipitation analysis of the interaction between BRCA2 and CDC45, 
and BRCA2 and RAD51 after exposure to hydroxyurea. 
Total protein extracts from wild-type TREU 927 (WT 927) and double-tagged cell lines 
(BRCA2 6HA CDC45 12myc and BRCA2 6HA RAD51 12myc) prepared after treatment with 
hydroxyurea (0.3 mM for 16 hours) were immunoprecipitated using anti-HA antiserum (A) or 
anti-myc antiserum (B) conjugated to agarose beads. Input and elution samples were 
separated by SDS-PAGE and western blotted before being probed with anti-myc antiserum 
(1:7000 dilution) and anti-HA anti-serum (1:10000 dilution). Size markers are indicated (kDa). 
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Figure 6-9 Co-immunoprecipitation analysis of the interaction between BRCA2 and CDC45, 
and BRCA2 and RAD51 after exposure to MMS. 
Protein extracts from wild-type TREU 927 (WT 927) and double-tagged cell lines (BRCA2 
6HA CDC45 12myc and BRCA2 6HA RAD51 12myc) prepared after treatment with MMS 
(0.002% for 16 hours) were immunoprecipitated using anti-HA antiserum (A) or anti-myc 
antiserum (B) conjugated to agarose beads. Input and elution samples were separated by 
SDS-PAGE and western blotted before being probed with anti-myc antiserum (1:7000 
dilution) and anti-HA anti-serum (1:10000 dilution). Size markers are indicated (kDa). 
6.2.8.1 Confirmation of DNA damage 
In order to ensure that the above HU treatment resulted in replication stalling, 
the cells used for the immunoprecipitation were analysed, in parallel, for the 
distribution of cells in the various phases of the cell cycle. This was done by 
analysing DNA content by fluorescent-activated cell sorting (FACS) after 
propidium iodide-staining of the DNA of the cells. Samples from untreated wild-
type PCF TREU 927, and from the two double-tagged cell lines treated with HU, 
were prepared as described in section 2.2.4.2, and a total of 104 cells were 
sorted using detector FL2-A. The FACS plots in Figure 6-10 show that the wild-
type, non HU-treated, cell population gave a characteristic flow cytometry 
profile comprising two peaks; cells in the G1 phase of the cell cycle are 
represented by the peak at position 200, corresponding to 2C DNA content (C 
represents haploid DNA content); and cells with double DNA content (4C) are in 
G2 phase, M phase or cytokinesis and appear as a peak at position 400. S phase 
cells with intermediate DNA contents were detected between the two peaks 
(Chowdhury, Zhao, and Englund, 2008;Forsythe, McCulloch, and Hammarton, 
2009). The double-tagged, HU-treated cell populations gave a flow cytometry 
profile characteristic of cells with an S-phase block, with the majority of cells 
present in a peak between the 200 and 400 position; this indicates that the 
treatment with HU caused stalling of replication and accumulation of cells in this 
cell cycle stage. As MMS is in more routine use in the laboratory during analysis 
Chapter 6  247 
of the sensitivity of DNA repair mutants, it was deemed unnecessary to check its 
effectiveness in this experiment. 
 
Figure 6-10 Flow cytometry profiles of propidium iodide-stained cells after exposure to 
hydroxyurea. 
Histograms show propidium iodide-stained untreated wild-type TREU 927 (WT 927) and HU-
treated (0.3 mM for 16 hours) double-tagged cell lines after flow cytometry analysis. The 
peaks corresponding with cells containing 2C and 4C DNA content are indicated. 
6.2.9 Endogenous N-terminal epitope tagging strategy 
It is possible that the presence of an epitope tag at the C-terminus of either or 
both of BRCA2 and CDC45 could interfere with the proposed interaction between 
the proteins, and this is the reason that an interaction could not be detected. It 
was therefore decided to use a construct that allows the addition of an epitope 
tag to the N-terminus of a gene to generate a second set of cell lines with 
proteins double-tagged, this time at the N-terminus. 
Two constructs that enable the fusion of an N-terminal 12myc or 6HA epitope 
tag at the endogenous locus of a gene of interest were generated by 
modification of an existing construct containing a fluorescent protein and TY 
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epitope tag (pEnT6B;Kelly et al., 2007). Maps of the two constructs are 
displayed in Figure 6-11, and the strategy to enable the N-terminal tagging of T. 
brucei proteins at their endogenous loci is displayed in Figure 6-12. The N-
terminal epitope tagging construct uses a region of the 5’ UTR immediately 
upstream of the ORF and also a region of the 5’ end of the ORF to enable 
homologous recombination and integration into the genome. Selection of clones 
is enabled by the presence of a BSD resistance cassette in the 12myc construct 
and a BLE resistance cassette in the 6HA construct. The resistance ORFs are 
flanked by tubulin and actin processing sequences. After integration of the 
construct, endogenous downstream gene sequences provide polyadenylation 
signals for the tagged gene, while upstream sequences of the integrated 
resistance cassette are used for RNA trans-splicing, meaning that the 5’ UTR is 
non-endogenous. For BRCA2, primers 112 and 113 were used to PCR-amplify 213 
bp of the 5’ end of the BRCA2 ORF; the forward primer contained a SpeI 
restriction site and the reverse primer a unique restriction site (XbaI) to allow 
linearisation of the construct prior to transformation. Primers 114 and 115 were 
used to PCR-amplify 274 bp of the BRCA2 5’ UTR; the forward primer contained 
the same unique restriction site (XbaI) and the reverse primer a BamHI 
restriction site. The DNA fragments were cloned into the 6HA tagging construct 
downstream of the epitope tag in a three-way ligation using the SpeI, XbaI and 
BamHI restriction sites. The same strategy was used to clone the sequences 
specific to RAD51 and CDC45 into the 12myc N-terminal tagging constructs. The 
primers used to amplify the respective 5’ end of ORFs and 5’ UTRs were; 116, 
117 and 118, 119 for RAD51; and 1, 2 and 3, 4 for CDC45, and the unique 
restriction sites used were KpnI and XhoI, respectively. In this manner three 
constructs were assembled to enable the generation of N-terminally tagged 
BRCA2 6HA, RAD51 12myc and CDC45 12myc. For transformation, the constructs 
were linearised by restriction digest using the unique restriction enzymes, the 
digested DNA was then ethanol precipitated and approximately 5 µg of the 
resuspended DNA was used for each transformation. 
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Figure 6-11 Constructs used for N-terminal epitope tagging of T. brucei proteins. 
(A) Construct used for the N-terminal 12myc tagging of CDC45 and RAD51 (only CDC45 is 
shown). 250 bp of the 5’ end of the CDC45 ORF (orange) and 272 bp of the 5’ UTR (light 
blue) were cloned into the SpeI and BamHI restriction sites with a unique restriction site 
between (XhoI). The 12myc epitope tag (green) consists of 12 tandemly repeated copies of 
the c-myc epitope. (B) Construct used for the N-terminal 6HA tagging of BRCA2. 213 bp of 
the 5’ end of the BRCA2 ORF (orange) and 274 bp of the 5’ UTR (light blue) were cloned into 
the SpeI and BamHI restriction sites with a unique restriction site between (XbaI). The 6HA 
epitope tag (green) consists of 6 copies of the HA epitope. In both maps, The BSD or BLE 
resistance cassette (red) is shown flanked by the tubulin (βα Tub, dark blue) and actin (Act 
IR, purple) intergenic sequences. AMP: Ampicillin resistance ORF. Sizes are shown (bp).  
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Figure 6-12 Strategy for N-terminal epitope tagging of T. brucei proteins at their endogenous 
loci. 
A schematic of the N-terminal tagging constructs, described in Figure 6-11, is shown (top). 
Linearisation of the construct using a unique restriction site, between the 3’ end of the ORF 
(orange) and the 5’ UTR (light blue), allows integration into the genome by homologous 
recombination (HR). This produces the endogenous ORF fused with the N-terminal epitope 
tag (green, bottom). 
6.2.10 Generation of N-terminal double-tagged cell 
lines in PCF TREU 927 T. brucei 
Cell lines in which both BRCA2 and CDC45, and BRCA2 and RAD51 were epitope 
tagged at the N-terminus were generated as described in section 6.2.5. The 
generation of CDC45 12myc and RAD51 12myc tagged cell lines was carried out 
first by the transformation of wild-type PCF TREU 927 cells with linearised 
constructs. The expression of tagged protein was confirmed by western blot 
(data not shown). These two confirmed cell lines were then subjected to 
transformation with the linearised BRCA2 6HA construct and six clones were 
chosen from each transformation. The twelve putative double-tagged cell lines 
were subject to screening as described in section 6.2.6. The western blots in 
Figure 6-13 demonstrate that all of the tested clones expressed proteins of the 
expected size for CDC45 12myc or RAD51 12myc (93 kDa and 55 kDa, 
respectively) that were recognised by anti-myc antiserum. All of the twelve 
clones also expressed proteins recognised by anti-HA antiserum of the expected 
size for BRCA2 6HA (183 kDa). 
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Figure 6-13 Confirmation of co-expression of N-terminal epitope tagged proteins in PCF 
TREU 927 T. brucei. 
Total protein extracts from wild-type TREU 927 (WT 927) and the two putative double-tagged 
cell lines (BRCA2 6HA CDC45 12myc and BRCA2 6HA RAD51 12myc) were separated by 
SDS-PAGE and western blotted before being probed with anti-HA antiserum (1:10000 
dilution, top). The blots were stripped and re-probed with anti-myc antiserum (1:7000 
dilution, bottom). The bands produced by BRCA2 6HA, CDC45 12myc, and RAD51 12myc 
are indicated (black arrows), and size markers are shown (kDa). 
6.2.11 Co-immunoprecipitation using N-terminal 
double-tagged cell lines 
Co-immunoprecipitation using the two double-tagged cell lines, and wild-type 
TREU 927 cells as a control was performed, as described in section 6.2.7. 
Additional controls were also performed to ensure that binding had not occurred 
between the epitope-tagged proteins and the antiserum-conjugated beads. Cell 
lines containing a single protein epitope-tagged at the N-terminus were subject 
to immunoprecipitation using antiserum conjugated to agarose beads that were 
specific to the epitope tag not present in the cell line analysed. For example, 
the single-tagged BRCA2 6HA cell line was subject to immunoprecipitation with 
anti-myc antiserum conjugated to agarose beads and the elution sample was 
probed with anti-HA antiserum in order to detect any non-specific binding of 
BRCA2 6HA to the anti-myc beads. The western blots in Figure 6-14 show analysis 
of interaction between BRCA2 and RAD51, and also BRCA2 and CDC45. The input 
samples in Figure 6-14A demonstrate expression of the tagged proteins of the 
expected size for the cell lines analysed. The elution samples in Figure 6-14B 
(anti-HA beads) demonstrate the successful immunoprecipitation of BRCA2 6HA 
(lanes 4 and 5, α-HA). However, interaction between either RAD51 or CDC45 and 
BRCA2 could not be detected, as the anti-myc probed elution blot was blank 
(lanes 4 and 5, α-myc). The control experiments with single tagged RAD51 12myc 
or CDC45 12myc cell lines also did not show any myc-tagged proteins in the 
elution samples (lanes 2 and 3, α-myc), indicating that there was no non-specific 
binding to the anti-HA beads. The elution samples in Figure 6-14C (anti-myc 
beads) demonstrate the successful immunoprecipitation of RAD51 12myc and 
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CDC45 12myc by the anti-myc beads (lanes 3 and 4, α-myc). A possible 
interaction between BRCA2 and RAD51 can be detected, as evidenced by the 
presence of a faint band of the expected size for BRCA2 6HA in the anti-HA 
probed elution blot (lane 4, α-HA), though there was considerable background, 
non-specific binding in this blot. An interaction between CDC45 and BRCA2 was 
not detected (lane 3, α-HA), but the background makes this difficult to be 
certain of. The control experiment with the single tagged BRCA2 6HA cell line 
showed small amounts of HA tagged proteins in the elution sample (lane 2, α-
HA), indicating that there was some non-specific binding to the anti-myc beads 
in this experiment. 
 
Figure 6-14 Co-immunoprecipitation analysis of the interaction between BRCA2 and CDC45, 
and BRCA2 and RAD51. 
Total protein extracts from wild-type TREU 927 (WT 927) and double-tagged cell lines 
(BRCA2 6HA CDC45 12myc, and BRCA2 6HA RAD51 12myc) were immunoprecipitated 
using anti-HA antiserum (B) or anti-myc antiserum (C) conjugated to agarose beads. Input 
(A) and elution (B and C) samples were separated by SDS-PAGE and western blotted before 
being probed with anti-myc antiserum (1:7000 dilution) and anti-HA antiserum (1:10000 
dilution). Size markers are shown (kDa). 
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6.3 In vitro GST pull-down 
Given the lack of convincing evidence for BRCA2-CDC45 interaction in vivo from 
the above experiments, an attempt was next made to recapitulate the 
interaction between T. brucei BRCA2 and CDC45 observed in Oyola et al., 
(2009). To do this, GST pull-down was carried out using proteins over-expressed 
in E. coli. 
6.3.1 Generation of bacterial protein over-expression 
constructs 
The co-expression of two tagged proteins from compatible bacterial over-
expression constructs has successfully been used to detect interaction between 
T. brucei proteins previously (Chapter 5;Dobson et al., 2011). The His BRCA2 C-
term and His 10BRC expression constructs described in section 5.2.1 were used 
in conjunction with CDC45 over-expressed in E. coli using the pGEX-4T-3 
construct. This results in CDC45 being expressed as an N-terminal Glutathione S-
Transferase (GST) fusion; the plasmid also contains an ampicillin (AMP) 
resistance cassette for selection (Figure 6-15). The CDC45 ORF was PCR-
amplified using primers 129 and 130 that contained BamHI and XhoI restriction 
sites, respectively, to allow cloning into pGEX-4T-3. The two empty vectors were 
used to express the His and GST tags (not fused to a protein) for control 
purposes. 
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Figure 6-15 Construct used for N-terminal GST tagging of CDC45 for over-expression in E. 
coli. 
The CDC45 ORF (blue) was cloned into the BamHI and XhoI restriction sites downstream of 
the GST tag (red). AMP: ampicillin resistance ORF(grey). LacI: lac repressor ORF (green). 
Sizes are shown (bp). 
6.3.2 Generation of co-expressing bacterial cultures 
Competent cells of the Rosetta2 E. coli strain were transformed with the 
constructs generated in section 6.3.1 and 5.2 to produce five bacterial cultures. 
The first experimental culture contained the His BRCA2 C-term and GST CDC45. 
The three other cultures were controls, containing one of each of the expression 
constructs (His BRCA2 C-term, His 10BRC and GST CDC45) and the 
complementary empty vector, to control for binding of the T. brucei proteins to 
the His or GST tags. The competent E. coli cells were co-transformed with two 
plasmids and selected on LB agar supplemented with 100 µg.ml-1 ampicillin, 50 
µg.ml-1 kanamycin and 34 µg.ml-1 chloramphenicol. 
6.3.3 GST pull-down using co-expressing bacterial 
cultures 
GST pull-down was carried out as described in section 5.2.3. For unknown 
reasons the expressed GST-tagged CDC45 protein was not able to be detected by 
western blot in these conditions, as previously encountered with GST RAD51 
(section 5.2.3). For this reason eluted GST CDC45 is shown as a coomassie-
stained gel. Analysis of interaction between BRCA2 and CDC45 is displayed in 
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Figure 6-16. The western blot in Figure 6-16A shows input samples probed with 
anti-His antiserum and demonstrates expression of His-tagged proteins of the 
expected sizes for the BRCA2 C-term (100 kDa), 10BRC (66 kDa) and His tag (7 
kDa). Figure 6-16B shows a coomassie stained protein gel of the separated 
elution samples and demonstrates the presence of the GST (28 kDa) and GST 
CDC45 (104 kDa) proteins, indicating they were successfully recovered by the 
GST pull-down approach. The western blot in Figure 6-16C shows the elution 
samples probed with anti-His antiserum to detect the His-tagged BRCA2 variants: 
no signal was detected even with very long exposures (overnight), demonstrating 
that no His-tagged proteins were recovered. This indicates that the BRCA2 C-
term and 10BRC proteins have not bound either GST (lanes 4 and 5) or GST 
CDC45 (lanes 2 and 3), and also that the His tag itself has not bound to GST 
CDC45 (lane 1), although some binding is observed. For this reason, a coomassie 
stained gel of the input and elution samples of the control culture co-expressing 
GST-CDC45 and the His tag is shown in Figure 6-16D, and demonstrates the 
presence of a protein of the expected size for the His tag (7 kDa) in the input 
sample, which is absent from the elution sample, confirming the GST CDC45 has 
not bound non-specifically to the His tag. In addition, no binding between either 
the His BRCA2 C-term or the His 10BRC variant of BRCA2 and GST RAD51 was 
detected (Figure 6-16C) and this acts as a negative control. From these 
experiments, interaction between T. brucei CDC45 and T. brucei BRCA2 is not 
apparent. This was tested for the BRC repeats, for which no such interaction 
might be predicted, and also for the C-terminal ‘half’ of the protein downstream 
of the BRC repeats, which has been suggested to mediate CDC45 binding (Oyola, 
Bringaud, and Melville, 2009). 




Figure 6-16 GST pull-down analysis of the interactions between CDC45 and BRCA2. 
(A) A western blot of the separated input samples probed with anti-His antiserum (1:750 
dilution). His-tagged proteins are indicated (black arrows), and the GST-tagged proteins that 
were co-expressed are indicated (top). (B) A coomassie stained gel of the separated elution 
samples showing GST CDC45 and the GST tag (black arrows). His-tagged proteins that were 
co-expressed are indicated (top). (C) A western blot of the separated elution samples 
probed with anti-His antiserum (1:750 dilution). GST-tagged proteins immunoprecipitated 
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are indicated as are the co-expressed His-tagged proteins (top). (D) A coomassie stained gel 
of the separated input and elution samples from GST CDC45 co-expressed with the His tag 
(black arrows). In each panel size markers are shown (kDa). 
6.4 Summary 
The aim of this chapter was to test the reported interaction between the C-
terminus of T. brucei BRCA2 and CDC45 (Oyola, Bringaud, and Melville, 2009), 
with the longer term goal of investigating the potential mechanism this provided 
for the observed replication phenotype in BSF brca2-/- mutants that was also 
localised to the C-terminus of BRCA2 (Claire Hartley, PhD Thesis, 2008). In vivo 
co-immunoprecipitation was carried out using endogenous C- and N- terminally 
epitope tagged CDC45 and BRCA2. The robust interaction between T. brucei 
BRCA2 and RAD51 was used to ensure that epitope tagging of BRCA2 did not 
impair its ability to functionally interact with RAD51 and subsequent co-
immunoprecipitation between BRCA2 and RAD51 was reliably detected. In 
contrast, no such interaction was observed between BRCA2 and CDC45. The 
induction of DNA damage prior to harvesting cells for co-immunoprecpitation 
was carried out in order to try and increase the probability of detecting an 
interaction between BRCA2 and CDC45, with the assumption that such an 
interaction may only occur in this context. Again, no interaction was found in 
vivo by immunoprecipitation. Next, in vitro GST pull-down was employed using 
full length CDC45 and the C-terminal ‘half’ of BRCA2 expressed in E. coli. Again, 
no interaction was detected. 
Why might the above experiments and those reported by Oyola et al., (2009) be 
in disagreement? It is clearly possible that BRCA2 and CDC45 do, indeed, interact 
in T. brucei and that this interaction is either transient and the in vivo 
approaches therefore too insensitive, or these approaches are disrupted by the 
tagging strategies employed. It is less clear why the GST pull-down approach 
should not reveal an interaction, given that the BRCA2 variants used are clearly 
functional in this context for interaction with RAD51 (Chapter 5). Of course, we 
cannot rule out that the CDC45 expressed in this setting is non-functional, but it 
is in the 2-hybrid approach used by Oyola et al., (2009). Nevertheless, the 
experiments employed by Oyola et al., (2009) expressed only a fragment of 
CDC45, and this was demonstrated to bind to the C-terminus of BRCA2. No 
experiments were performed with full length CDC45, as attempted here. It is 
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clearly possible that this fragment of CDC45 may have folded anomalously, and 
led to a non-physiological and artefactual interaction between BRCA2 and 
CDC45. Nonetheless, immunoprecipitation of T. brucei BRCA2 from cell extracts 
and mass spectrometry identification of interacting proteins could be used to 
test this further. Indeed, this approach may find novel factors that interact with 
BRCA2, some of which may be components of the replication machinery and 
could provide an understanding of the replication phenotype observed in BSF 
brca2-/- mutants.
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7.1 Introduction 
The initial aim of this thesis was to further investigate the role of BRCA2 in the 
regulation of genome stability in T. brucei, extending previous work by Hartley 
and McCulloch (2008). This was achieved by generation of brca2-/- mutants in 
the PCF life cycle stage in both TREU 927 and Lister 427 strains of T. brucei and 
subsequent phenotypic analyses. Investigation of genomic stability in these 
brca2-/- mutant cell lines was performed after prolonged passaging, looking for 
evidence for genome rearrangements by Southern blotting and pulsed field 
agarose gel electrophoresis. Neither of these approaches revealed evidence for 
putative gross chromosomal rearrangements as previously observed in the BSF 
brca2-/- mutants in the Lister 427 strain (Hartley and McCulloch, 2008), which 
meant that genetic dissection of these rearrangements at the sequence level 
was unable to be carried out. Nonetheless, the generation of these mutants 
allowed, for the first time in any organism, the function of multiple BRC repeats 
in a BRCA2 orthologue to be examined by the systematic generation and 
expression of variants of BRCA2 with reduced numbers of BRC repeats. This 
approach was possible due to the unusual BRC repeat expansion present in T. 
brucei BRCA2, where the RAD51-binding repeats are found in a tandem array 
organisation. BRC repeat number variants of T. brucei BRCA2 were examined in 
both the PCF and BSF life cycle stages, in order to try and understand the 
contribution this BRC repeat expansion makes to growth, DNA repair and RAD51 
foci formation, since a function in VSG switching had been previously ruled out 
by the observation that a BRCA2 variant with a single BRC repeat could support 
this process (Hartley and McCulloch, 2008). 
A further aim of this thesis was to define the interactions T. brucei BRCA2 makes 
with some key further factors. Interaction between BRCA2 and RAD51, which is 
considered the central function of BRCA2 orthologues (Holloman, 2011), was 
analysed by in vitro GST pull-down, in vivo immunoprecipitation and 
immunolocalisation of the two proteins. This revealed a surprising level of 
complexity in the interplay between these two HR proteins in T. brucei, both in 
terms of the extent of BRCA2 domains that mediate physical interaction with 
RAD51 and also the dynamics of detectable co-localisation. By related 
approaches, the final chapter of this thesis investigated a putative function for 
T. brucei BRCA2 in DNA replication by attempting to validate a proposed 
Chapter 7  261 
interaction with CDC45 (Oyola, Bringaud, and Melville, 2009). Such a putative 
protein:protein interaction was tested both in vivo and in vitro, however we 
were unable to demonstrate the validity of this interaction.  
7.2 T. brucei BRCA2 functions in the maintenance 
of genome stability in the bloodstream form 
only. 
Analysis of the growth and DNA repair phenotypes of the PCF TREU 927 and PCF 
Lister 427 brca2-/- mutants, and comparison to the relatively severe phenotype 
of the BSF Lister 427 brca2-/- mutants (Hartley and McCulloch, 2008;Claire 
Hartley, PhD thesis, 2008), revealed a striking difference in the consequences of 
the removal of BRCA2 between the two life cycle stages. PCF brca2-/- mutant 
cells, in both parasite strains, were found to be growth impaired and to display 
increased sensitivity to exogenous DNA damage (MMS or phleomycin). However, 
the extent of each of these phenotypes was less severe than when observed in 
BSF brca2-/- mutants (Hartley and McCulloch, 2008). 
A number of reasons can be considered for these life cycle stage differences. It 
is possible that the differences simply result from aspects of growth that impact 
on the assays used. For instance, the underlying growth rate of BSF cells is 
higher than PCF cells in culture (8 hrs relative to 10 hrs, respectively), which 
may result in greater apparent levels of death in the BSF relative to the PCF 
when the mutants are exposed to damage. A number of studies have also 
suggested that cell cycle checkpoints differ between BSF and PCF cells 
(Hammarton et al., 2003;Hammarton, 2007). Though very little is known 
regarding DNA damage checkpoints, if PCF cells did not cease growth after MMS 
or phleomycin treatment to the same extent as BSF cells, this would be manifest 
as lesser apparent killing in the Alamar blue assay employed here. The 
alternative is that the differences reflect variation in genome maintenance 
functions between PCF and BSF cells. It seems unlikely that PCF and BSF cells 
are naturally exposed to differing levels of general DNA damage, which might 
have selected for increased BRCA2-mediated repair activity in the BSF. The only 
potential exception to this may be increased oxidative damage, as the greater 
mitochondrial metabolism in PCF cells relative to BSF cells (Bienen et al., 
1991;Hajduk et al., 1992;Fang and Beattie, 2003) is likely to yield higher levels 
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of reactive oxygen species (ROS), which can damage DNA (Kryston et al., 2011). 
Perhaps, then, some undefined repair activity is upregulated in PCF cells to deal 
with this, and can also contribute to greater repair of MMS- and phleomycin-
induced damage and reduce the impact of BRCA2 loss. BRCA2 has also been 
suggested to play a key role in ensuring the efficient progression of DNA 
replication (Michel et al., 2004;Nagaraju and Scully, 2007;Constanzo, 2011). 
However, as for DNA repair, it seems unlikely that this fundamental mechanism 
could differ substantially between PCF and BSF cells. A final possible explanation 
is that BRCA2 acts in an additional, as yet undefined, function beyond general 
repair and replication maintenance. If such a function assumed greater 
importance in the BSF life cycle stage, more of the available pool of BRCA2 may 
be directed to that function, and less then might be available to tackle the 
increased DNA damage imposed by exogenous MMS or phleomycin. The 
difference in growth rates of PCF and BSF brca2-/- mutants in the absence of 
induced damage is less easy to explain in this scenario, but it may be that such a 
putative role has a significant impact on the general health of BSF cells. Below, I 
consider whether the broader phenotypes detailed in this thesis might offer 
support for any of the above suggestions. In particular, the discussion will focus 
on that proposed role of BRCA2 in the maintenance of genome stability, which is 
only apparent in the BSF, the DNA replication phenotypes observed in brca2-/- 
mutants, and the contribution of BRCA2 to RAD51 subnuclear dynamics, as 
revealed by analysis of the BRC repeat variants and co-localisation.  
brca2-/- mutants in BSF Lister 427 T. brucei display an accumulation of putative 
gross chromosomal rearrangements after prolonged passaging (~ 290 
generations;Hartley and McCulloch, 2008). Work presented here demonstrates 
that these genome rearrangements occur at an earlier time point than previously 
analysed (~ 150 generations). Even more strikingly, this work shows that brca2-/- 
mutants in PCF cells of both TREU 927 and Lister 427 strains do not display 
detectable genome rearrangements, even after passaging (~ 380 and ~ 230 
generations, respectively) to an extent at least equivalent to that in the BSF 
mutants. This work also provides further evidence to suggest that the putative 
GCRs observed in BSF brca2-/- mutants may be specifically targeted to VSGs 
located in the megabase chromosome, although genetic dissection of the 
genome rearrangements is required to confirm this. It was previously reported 
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that detectable GCRs in BSF mutants were only seen in the megabase 
chromosomes, which harbour VSG subtelomere arrays, and not in intermediate- 
and mini-chromosomes, which carry only telomeric VSGs (Hartley and McCulloch, 
2008). Here, probing of the BSF brca2-/- mutants with ingi sequences revealed 
complex banding patterns in Southern blots that showed no variation between 
clones, in contrast to the changes in VSG121 copy number that is observed. 
These data are consistent with ingi being widespread in the T. brucei genome 
(Bringaud et al., 2004;Berriman et al., 2005;Bringaud et al., 2008), but 
demonstrate that ingi are not detectably rearranged during the rearrangements 
that cause visible changes in the subtelomeres of the megabase chromosomes of 
the BSF brca2-/- mutants. 
Is it possible that the above data point to a BSF-specific function for BRCA2 in 
the maintenance of the subtelomeric VSG arrays? If so, quite why the functions 
of BRCA2 in this role would differ between the BSF and PCF life cycle stages so 
dramatically is not known. An obvious explanation could be a requirement for 
antigenic variation in the BSF, which may be inactivated in the PCF. Most VSG 
switching is driven by gene conversion, which means that sequence changes 
normally focus on the recipient DNA molecule, which would be the VSG ES 
(Robinson et al., 1999;Glover, Jun, and Horn, 2011). However, perhaps during 
the process of VSG switching homology searching scans the subtelomeric VSGs to 
a significant extent, and in the absence of BRCA2 this reaction is undermined, 
leading to broad destabilisation of the VSGs. Alternatively, it may be that there 
is a greater level of background, silent VSG gene conversion occurring in the 
subtelomeres than has been appreciated, which is again undermined by the 
absence of BRCA2 and leads to GCRs. This could perhaps explain the extensive 
chromosome size variations observed in T. brucei, which have been localised to 
the VSGs (Callejas et al., 2006). In this regard, it is interesting to consider the 
process of mosaic VSG formation (Thon et al., 1990;Barbet and Kamper, 
1993;Marcello and Barry, 2007), which is not well understood mechanistically, 
and may rely on a novel function for BRCA2 in the BSF.  
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7.3 The BRC repeat expansion is critical for RAD51 
subnuclear dynamics. 
Analysis of variants of T. brucei BRCA2 with 1, 4, 7, 10 and 12 BRC repeats in 
vivo has allowd us to ask why HR in some organisms, such as mammals, plants 
and T. brucei, functions with a BRCA2 protein containing multiple BRC repeats, 
while others, such as C. elegans and U. maydis, utilises an orthologue with a 
single BRC repeat. A similar study by Carreira and Kowalczykowski (2011), relied 
upon in vitro interaction analyses, and suggested that eight BRC repeats of 
human BRCA2 fall into two classes with differing affinities for Rad51 monomers 
and nucleoprotein filaments which co-operate to bring about Rad51 nucleation 
onto ssDNA and filament propagation thereby stimulating DNA strand exchange 
(Carreira and Kowalczykowski, 2011). The question of the need for multiple BRC 
repeats in T. brucei is especially compelling because bioinformatic analysis 
suggest that the BRC repeat expansion is not found in closely related species, 
notably T. vivax and T. congolense, where BRCA2 is predicted to have 1 and 3 
BRC repeats, respectively (Lo et al., 2003). 
This work reveals that the purpose of the BRC repeat expansion in T. brucei is 
more subtle than might have been predicted. Hartley and McCulloch (2008) 
examined T. brucei BSF cells expressing BRCA2 containing only the single, most 
C-terminal BRC repeat and found that they were impaired in the following 
processes: repair of MMS and phleomycin damage, HR and the formation of 
subnuclear RAD51 foci after damage. This thesis shows that those findings paint 
only part of the picture. In both life cycle stages, cells expressing BRCA2 variants 
with 3 or more BRC repeats were capable of repairing MMS and phleomycin 
damage with the same efficiency as wild-type cells. In addition, every BRC 
variant analysed supported growth at wild-type rates. This indicates that the 
BRC repeat expansion is largely dispensable for normal growth and DNA repair. 
Notably, PCF cell lines expressing BRCA2 containing only the most C-terminal 
‘degenerate’ BRC repeat repaired DNA damage as well as wild-type cells, 
showing that even a single BRC repeat can operate in DNA repair. The 
impairment in DNA repair observed by Hartley and McCulloch (2008) is, in fact, 
limited to BSF 1BRC cells, which is the only BRC variant cell line analysed where 
repair of DNA damage is impaired relative to wild-type cells. These data 
indicate, first, that the putatively degenerate C-terminal BRC repeat is 
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functional. Second, they illustrate again that the function of BRCA2 differs 
between PCF and BSF cells. Finally, they suggest that the BRC repeat expansion 
evolved to serve another purpose than general DNA repair, which would make 
sense as it is hard to imagine what aspect of the biology of T. brucei would 
require greater general repair than a close relative such as T. vivax. 
The most striking data on the BRC repeat expansion was obtained when 
analysing the ability of the BRCA2 BRC variant cell lines to form subnuclear 
RAD51 foci after the induction of DNA damage. In both life cycle stages a BRC 
repeat number-dependent increase in the ability to form RAD51 foci was 
observed, with both the number of cells that display detectable RAD51 foci and 
the number of RAD51 foci observed per cell increasing with increasing BRC 
repeat number. This was found for both the PCF cells and BSF cells. However, 
again, life cycle stage differences were found. In the PCF cells, BRCA2 with 1 
BRC repeat was found to be sufficient for RAD51 foci formation to be detectably 
improved relative to brca2-/- cells, though still impaired relative to wild-type 
cells. In contrast, in BSF cells, BRCA2 with 1 BRC repeat was virtually 
indistinguishable from brca2-/- mutant cells, consistent with the findings of 
Hartley and McCulloch (2008), and 3 BRC repeats were required to begin to 
complement the RAD51 foci formation defect in brca2-/- mutant cells. For both 
life cycle stages, it was also apparent that multiple BRC repeats were needed to 
reach the levels of RAD51 foci formation seen in wild-type cells (minimally 10 
BRC repeats and 12 BRC repeats in PCF and BSF, respectively). These data 
indicate a function for the BRC repeat expansion in the regulation of RAD51 foci 
formation and, hence, in RAD51 subnuclear dynamics. 
The above data provide a quantitative link between BRC repeat number and 
BRCA2 function, and suggest that the number of repeats present in the array is 
important. However, it remains unclear why T. brucei BRCA2 possesses this 
unusual BRC repeat expansion, and the disconnection between DNA repair 
efficiency and RAD51 foci formation observed here is perplexing. The 
composition of DNA repair foci is unknown (Lisby and Rothstein, 2009;Bekker-
Jensen and Mailand, 2010), however, they have been shown to contain multiple 
copies of HR proteins including Rad51, BRCA1 and BRCA2, and are thought to be 
repair factories where the high local concentration of repair factors facilitates 
efficient DSB repair (Lisby and Rothstein, 2009;Bekker-Jensen and Mailand, 
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2010). After the induction of DNA damage in mammalian cells, Drosophila and C. 
elegans multiple repair foci are observed microscopically (Mizuta et al., 
1997;Tarsounas, Davies, and West, 2003;Martin et al., 2005;Brough et al., 2008). 
However, it is important to consider that a focus indicates an attempt to repair 
DNA damage, that may not necessarily be successful and also that the repair 
reaction may occur faster than detection can allow (Lisby and Rothstein, 2009). 
The available data rule out that the BRC repeat expansion is needed for the 
normal requirements of DNA repair or for the activation of intact VSGs during 
VSG switching, as a single BRC repeat is sufficient for these functions (Hartley 
and McCulloch, 2008). This work has shown that the ability to form RAD51 foci is 
proportionally linked to the number of BRC repeats present in BRCA2, but 
further work will be needed to understand this. For instance, it would be 
interesting to determine if the BRC repeat number was also related to the 
extent of GCRs observed in the BSF, as this would suggest it has evolved for the 
maintenance of genome stability in BSF cells (section 7.2). It would also be 
interesting to measure the number of lesions induced by damage and see how 
this relates to the number of foci, or whether a single lesion is a site for 
accumulation of increasing amounts of RAD51. Finally, it would useful to detail if 
the unique tandem repeat organisation of the BRC repeats in T. brucei BRCA2 is 
important, or whether multiple BRC repeats in a dispersed arrangement would 
suffice (section 7.4). Is it possible that these data are consistent with the dual 
function of BRCA2 proposed in section 7.2? For instance, is the purpose of the 
BRC repeat expansion in T. brucei BRCA2 to allow the efficient relocalisation of 
RAD51 or BRCA2, or both, from a non-repair function to sites of damage when 
they arise? This would assume that RAD51 or BRCA2 are present in excess to 
accommodate this, and that the non-physiological levels of damage generated in 
these experiments are rapidly repaired, but result in concentrating the proteins 
at damage sites, visible as foci. This is consistent with the absence of evidence 
for an upregulation of RAD51 after DNA damage in T. brucei, as observed in T. 
cruzi and L. major (McKean et al., 2001;Regis-da-Silva et al., 2006). 
7.4 Interactions between T. brucei BRCA2 and 
RAD51 are unusually extensive. 
Mammalian BRCA2 interacts with Rad51 at two well-defined locations: through 
the conserved eight BRC repeat motifs, which function to promote strand 
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exchange (Wong et al., 1997;Chen et al., 1998;Carreira and Kowalczykowski, 
2011), and also through a distinct C-terminal Rad51-binding domain that is 
regulated by cell cycle dependent phosphorylation and may function in DNA 
replication (Esashi et al., 2005;Esashi et al., 2007;Ayoub et al., 2009;Schlacher 
et al., 2011). The data presented here indicate that the interactions between T. 
brucei BRCA2 and RAD51 are more extensive than those observed in mammals, 
and may differ in their details. In vitro GST pull-down analysis indicates that 10 
BRC repeats are required for detectable binding of T. brucei BRCA2 to RAD51, 
which would be consistent with the general picture that BRC repeat number is 
critical for RAD51 interaction (section 7.3). However, the physiological 
significance of this is unclear, as we do not know if the BRC repeat binding 
observed was to RAD51 monomers or to protein filaments (perhaps even 
nucleoprotein filaments). Thus, these experiments do not reveal the function for 
the unusual tandem repeat organisation of the BRC repeats. Nonetheless, this 
requirement for 10 BRC repeats to detect RAD51 binding is in contrast to other 
systems: a single BRC repeat motif isolated from mammalian BRCA2, or the 
naturally occurring single BRC repeat from C. elegans CeBRC-2 or U. maydis 
Brh2, is sufficient for binding to Rad51 in vitro (Wong et al., 1997;Chen et al., 
1998;Kojic et al., 2002;Martin et al., 2005;Petalcorin et al., 2006). 
Analysis of the interaction between the C-terminal ‘half’ of T. brucei BRCA2 and 
RAD51 indicates that a RAD51-binding site exists in the non-conserved C-tail 
region downstream of the DNA/DSS1-binding domain, and that this interaction is 
not regulated by phosphorylation of Serine1523. Thus, though it appears that 
binding between RAD51 and BRCA2 via a C-terminal motif is positionally 
conserved between T. brucei and mammals, the sequence requirements for this 
interaction are not (Esashi et al., 2005;Esashi et al., 2007). Further work will be 
needed to localise this binding site in T. brucei BRCA2 in order to dissect its 
function. 
RAD51 binding was found to occur at a yet further location in T. brucei BRCA2, 
which has not been described in any other organism. This was between the BRC 
repeats and the C-tail and, if it is assumed to result from a single domain, it is 
proposed that the interaction would either localise within the DNA/DSS1-binding 
domain or in the region of BRCA2 between a putatively conserved DMC1 
interaction motif (PhePP) and the start of the DNA/DSS1-binding domain. Again, 
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further work is required to fine map this site of interaction and to understand its 
function. Purification of T. brucei RAD51 and BRCA2, with the aim to set up in 
vitro DNA recombination assays, was attempted during this work but was 
hampered by insolubility of BRCA2 in the bacterial expression systems adopted. 
However, were this to be pursued, especially in the light of the recent successful 
purification of the much lager human BRCA2 protein (Jensen, Carreira, and 
Kowalczykowski, 2010), this would allow biochemical analyses to be conducted 
that might detail how the above interactions influence the mechanism of RAD51 
regulation in HR by BRCA2. 
Immunolocalisation of BRCA2 in T. brucei suggests a complex picture of BRCA2 
subnuclear localisation, with peripheral nuclear ‘rings’ observed in some cells, 
while in others BRCA2 was found in more discrete focal accumulations. Possibly 
the most surprising finding was that overlap between BRCA2 and RAD51 signals 
was observed relatively rarely. In cells without induced DNA damage, RAD51 is 
essentially undetectable by immunofluorescence, whereas BRCA2 signal is 
detectable in > 70% of cells, primarily as ‘foci’ in the nucleus and rings of ‘foci’ 
around the nuclear periphery. After damage, RAD51 foci can be seen and BRCA2 
nuclear peripheral rings were more common, but these signals were found not to 
overlap. RAD51 and BRCA2 were seen only to overlap when each was seen as 
foci, and even here this was only in ~ 50% of cells and in a single focus amongst 
many BRCA2 foci. This appears to contrast with mammals and Drosophila where 
almost complete co-localisation between BRCA2 and Rad51 is observed after 
damage in multiple foci (Mizuta et al., 1997;Tarsounas, Davies, and West, 
2003;Brough et al., 2008). Why the subnuclear localisation between T. brucei 
BRCA2 and RAD51 appears more complex than in any other organism to date, 
remains elusive, and it is not clear if this relates to the apparently greater 
physical interactions between the proteins. Nonetheless, it is intriguing that 
BRCA2 appears to be more readily localised in the T. brucei nucleus than RAD51, 
and that the putative mediator does not always co-localise at sites of RAD51 
foci. It is possible that this is consistent with BRCA2 not simply acting in DNA 
repair, and therefore supporting the proposal that it may have dual roles in the 
biology of T. brucei.  
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7.5 T. brucei BRCA2 does not bind CDC45. 
The report of a putative interaction between the C-terminus of BRCA2 and 
CDC45 in T. brucei (Oyola, Bringaud, and Melville, 2009), coupled with the 
finding that the impaired replication seen in BSF brca2-/- mutants cells could be 
localised to the C-terminus of BRCA2 (Claire Hartley, PhD Thesis, 2008), 
presented a possible novel mechanism for the involvement of BRCA2 in DNA 
replication. brca2-/- mutants in BSF Lister 427 and PCF TREU 927 display defects 
in replication, albeit with differences. BSF brca2-/- mutants display a defect 
which is manifest as an accumulation of cells with either raised kDNA or raised 
nDNA content (Claire Hartley, PhD Thesis, 2008;Oyola, Bringaud, and Melville, 
2009). The PCF TREU 927 brca2-/- mutants analysed here display a predominant 
accumulation of zoids (anucleate cells) which may be due to the lack of a 
mitosis to cytokinesis checkpoint in this life cycle stage (Hammarton, 2007), 
allowing cells that have not completed their nuclear DNA replication to proceed 
through cytokinesis generating zoids. Many approaches were taken in order to 
validate the putative interaction between BRCA2 and CDC45, but none were 
successful. Though it remains possible that the interaction is real, it must be 
sufficiently transient or infrequent to escape detection in the experiments 
performed here. In addition, this meant that the precise mechanism of 
involvement of BRCA2 in DNA replication in T. brucei could not be elucidated, 
and distinct approaches will be needed. 
Very recently, evidence has been published to suggest that in mammalian cells 
the C-terminal Rad51-binding motif of BRCA2 acts to stabilise Rad51 filaments on 
nascent DNA at a stalled replication fork and so prevent degradation of this DNA 
by Mre11 (Hashimoto et al., 2010;Schlacher et al., 2011). It would clearly be 
interesting to investigate if this action is conserved in trypanosomatids, 
especially in light of the extensive interactions between the C-terminus of 
BRCA2 and RAD51 found here (section 7.4). A striking similarity is seen between 
the BRCA2 ‘rings’ observed after immunolocalisation in T. brucei and the 
localisation of the replication origin recognition complex protein (orc1/cdc6) in 
Trypanosoma cruzi (Elias et al., 2002;Calderano et al., 2011). This may suggest 
that BRCA2 does indeed play a role in replication, and in fact this could be the 
non-repair function that has been proposed. However, if correct, it is not clear 
how this could lead to GCRs in BSF cells and not in PCF cells, unless the 
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connection is specific to some aspects of the genome, such as the VSG 
subtelomeres. Exploration of this may reveal a novel mechanism for the function 



















Appendix 2: Alignment of ingi retrotransposons in TREU 927. 
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